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Summary
Genetic programming is an Evolutionary Computing technique, inspired by biological evolu-
tion, capable of discovering complex non-linear patterns in large datasets. Despite the potential
advantages of genetic programming over standard statistical methods, its applications to sur-
vival analysis are at best rare, primarily because of the difficulty in handling censored data.
The aim of this work was to develop a genetic programming approach for survival analysis
and demonstrate its utility for the automatic development of clinical prediction models using
cardiovascular disease as a case study.
We developed a tree-based untyped steady-state genetic programming approach for censored
longitudinal data, comparing its performance to the de facto statistical method —Cox regres-
sion—in the development of clinical prediction models of future cardiovascular events in pa-
tients with symptomatic and asymptomatic cardiovascular disease, using large observational
datasets.
Results showed that Cox regression and the developed genetic programming approach pro-
duced similar results when evaluated in common validation datasets. Despite generally com-
parable performance, albeit in slight favour of the Cox model, the predictors selected for rep-
resenting their relationships with the outcome were quite different and, on average, the models
developed using genetic programming used considerably fewer predictors. The genetic pro-
gramming models were more complex and thus more difficult to validate by domain experts,
however these models were developed in an automated fashion, using fewer input variables,
without the need for domain specific knowledge and expertise required to appropriately per-
form survival analysis.
x Summary
This work has demonstrated the strong potential of genetic programming as a methodology for
automated development of clinical prediction models for diagnostic and prognostic research,
where the primary goal is accurate prediction. In aetiological research, where the primary goal
is to examine the relative strength of association between risk factors and the outcome, then
Cox regression and its variants remain as the de facto approach.
xi
Abstract
Background & Aims Genetic programming is an Evolutionary Computing technique, inspired
by biological evolution, capable of discovering complex non-linear patterns in large datasets.
Genetic programming is a general methodology, the specific implementation of which requires
development of several different specific elements such as problem representation, fitness, se-
lection and genetic variation. Despite the potential advantages of genetic programming over
standard statistical methods, its applications to survival analysis are at best rare, primarily be-
cause of the difficulty in handling censored data. The aim of this work was to develop a genetic
programming approach for survival analysis and demonstrate its utility for the automatic de-
velopment of clinical prediction models using cardiovascular disease as a case study.
Methods We developed a tree-based untyped steady-state genetic programming approach for
censored longitudinal data, comparing its performance to the de facto statistical method—Cox
regression—in the development of clinical prediction models for the prediction of future cardi-
ovascular events in patients with symptomatic and asymptomatic cardiovascular disease, using
large observational datasets. We also used genetic programming to examine the prognostic sig-
nificance of different risk factors together with their non-linear combinations for the prognosis
of health outcomes in cardiovascular disease.
Results These experiments showed that Cox regression and the developed steady-state genetic
programming approach produced similar results when evaluated in common validation data-
sets. Despite slight relative differences, both approaches demonstrated an acceptable level of
discriminative and calibration at a range of times points. Whilst the application of genetic pro-
gramming did not provide more accurate representations of factors that predict the risk of both
symptomatic and asymptomatic cardiovascular disease when compared with existing meth-
xii Abstract
ods, genetic programming did offer comparable performance. Despite generally comparable
performance, albeit in slight favour of the Cox model, the predictors selected for representing
their relationships with the outcome were quite different and, on average, the models developed
using genetic programming used considerably fewer predictors. The results of the genetic pro-
gramming confirm the prognostic significance of a small number of the most highly associated
predictors in the Cox modelling; age, previous atherosclerosis, and albumin for secondary pre-
vention; age, recorded diagnosis of ’other’ cardiovascular disease, and ethnicity for primary
prevention in patients with type 2 diabetes. When considered as a whole, genetic programming
did not produce better performing clinical prediction models, rather it utilised fewer predictors,
most of which were the predictors that Cox regression estimated be most strongly associated
with the outcome, whilst achieving comparable performance. This suggests that genetic pro-
gramming may better represent the potentially non-linear relationship of (a smaller subset of)
the strongest predictors.
Conclusions To our knowledge, this work is the first study to develop a genetic programming
approach for censored longitudinal data and assess its value for clinical prediction in compar-
ison with the well-known and widely applied Cox regression technique. Using empirical data
this work has demonstrated that clinical prediction models developed by steady-state genetic
programming have predictive ability comparable to those developed using Cox regression. The
genetic programming models were more complex and thus more difficult to validate by domain
experts, however these models were developed in an automated fashion, using fewer input vari-
ables, without the need for domain specific knowledge and expertise required to appropriately
perform survival analysis. This work has demonstrated the strong potential of genetic program-
ming as a methodology for automated development of clinical prediction models for diagnostic
and prognostic purposes in the presence of censored data. This work compared untuned ge-
netic programming models that were developed in an automated fashion with highly tuned Cox
regression models that was developed in a very involved manner that required a certain amount
of clinical and statistical expertise. Whilst the highly tuned Cox regression models performed
slightly better in validation data, the performance of the automatically generated genetic pro-
gramming models were generally comparable. The comparable performance demonstrates the
utility of genetic programming for clinical prediction modelling and prognostic research, where
the primary goal is accurate prediction. In aetiological research, where the primary goal is to
Abstract xiii
examine the relative strength of association between risk factors and the outcome, then Cox
regression and its variants remain as the de facto approach.
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Introduction
Prognosis is central to medicine. All diagnostic and therapeutic actions aim to improve pro-
gnosis [286]. Physicians and health policy makers need to make predictions on the prognosis of
a disease in their decision making. Clinical prediction models provide inputs for this decision
making by providing estimates of individual probabilities or risks and benefits [182]. Clinical
prediction models combine a variety of characteristics to predict some diagnostic or prognostic
outcome [286]. Current methods for clinical prediction use traditional statistical techniques,
often using relatively small samples. Generally statistical approaches have inherent restrictions
on the complexity of patterns they can learn and the volume of data they can handle whilst
remaining effective.
Generally, survival analysis is a collection of statistical procedures for the analysis of data in
which the outcome of interest (the survival outcome) is the time to event, which is typically
referred to as survival time [162]. More specifically, survival analysis involves the estimation
of the distribution of the time it takes for an event to happen to a patient based on some set of
features, which are also known as explanatory variables, predictors or covariates. The event
may for example be death, disease incidence, or recurrence. A key characteristic of survival
data is that the follow-up of patients is typically incomplete [286]. For example, some pa-
tients may have been followed for 5 days, some for 15 days, etc, and we may be interested in
predicting 30-day survival. Such incomplete data, is what we call censored data. In essence,
censoring occurs when we have some information about an individual survival times, but we do
not know the survival time exactly in all subjects. Survival is an important long-term outcome
in prognostic research, including medical research areas such as cardiology and oncology.
2 1.1 Motivation
1.1 Motivation
Traditionally the Kaplan-Meier (KM) method, a non-parametric approach, has been used for
exploratory analysis of survival data. Using the KM method survival curves can be generated
for various subgroups (e.g. females versus males) to investigate the effect of explanatory vari-
ables on survival. However, the KM approach is limited as it is unable to consider the effect of
multiple explanatory variables simultaneously. To overcome this limitation, several regression
modelling approaches have been proposed to enable prediction of time to event in the presence
of censored data [287]. Most of these models have come from the long-established statistical
literature such as parametric survival models, including the Weibull, lognormal and Gompertz
models and the semi-parametric Proportional Hazards model proposed by Cox [48]. Hereafter,
these will be jointly referred to as linear statistical methods or models. In medical and epidemi-
ological studies the Cox Proportional Hazards model (or Cox regression) is the most often used
model for survival outcomes.
Alternate methods for survival analysis may be based on machine learning, e.g. Atrifical Neural
Network (ANN). These will be referred to as non-linear statistical methods or models. There
have been several studies that have compared such novel non-linear statistical methods with
their classic linear counterparts for survival outcomes [148, 138, 229, 248]. However the results
are mixed as to whether these non-linear methods offer improved performance. For example
Schwarzer et al. [269] reviewed a substantial number of studies which have used ANNs in
the diagnostic and prognostic classification in cancer, concluding that there is no evidence so
far that application of ANNs represents real progress in the field of diagnosis and prognosis
in oncology. Sargent [269] has also reviewed a number of these comparison studies showing
that the majority have claimed equal performance but could not rule out the possibility of
bias. GP, however, is a relatively new non-linear method that may improve the selection and
transformation of predictors, and it may lead to models with good predictive accuracy in new
patients [22, 89, 136, 238, 297].
GP is an Evolutionary Computation (EC) technique inspired by population genetics, and evol-
ution at the population level, as well as the Mendelian understanding of the structure and mech-
anisms [29, 195, 278]. GP automatically solves complex problems without requiring the user
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to know or specify the form or structure of the solution in advance [239]. This makes GP
well suited to symbolic regression, where in addition to searching for the solution to the com-
plex associations between predictors and outcome, GP also searches for the optimal model
structure. This in turn makes GP well suited to prediction, primarily an estimation problem,
where the mutual correlations between predictors and the outcome are to be estimated. GP has
been shown to work well for recognition of structures in large data sets and has the intrinsic
advantage of automatically selecting a subset of inputs or features during the evolutionary pro-
cess [212, 306].
Because GP has no fixed model structure it can represent complex non-linear associations that
could not be achieved using linear regression techniques, and theoretically achieve higher pre-
dictive accuracy. However, the flexibility of regression models can be greatly enhanced through
the use of factional polynomial, restricted cubic splines and interaction terms, potentially in-
creasing its predictive accuracy [22, 111, 112, 164]. Although it has be emphasised that this
is not normally done, as it complicates interpretation and the correct use of the appropriate
regression methods is quite difficult, as they require extensive statistical knowledge [271].
Despite its potential, critics state that GP is more prone to over-fitting compared to conventional
development methods [136]. An often cited argument against the use of of machine learning
techniques in clinical research, is that modelled relationship between predictors and outcome
can be highly complex and thus difficult to validate by domain experts, sometimes referred to
’black-box’ techniques. However, unlike many machine learning approaches, genetic program-
ming produces an explicit human-understandable model and is not a ’black box’ method. GP
has been used in medical research for classification and, to a lesser extend, prediction. However
its value for prediction on censored data, for survival analysis, has not yet been documented.
1.2 Goals of this Work
The main hypothesis of this research is that the application of GP can provide more accurate
representation of factors that predict the risk of Cardiovascular Disease (CVD) when compared
with existing methods. That is, the development and validation of a GP approach for survival
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analysis would offer improved performance when compared to the de facto statistical methods
for clinical prediction modelling in censored longitudinal data.
There are three main goals of this work. Firstly, to motivate the need for improved clinical risk
prediction methods and models by validating the performance the de facto statistical methods
in a contemporary real-world clinical setting. Secondly, to demonstrate the utility of GP for
the automatic development of clinical prediction models using CVD as case studies. Thirdly,
to apply GP to examine the prognostic significance of different risk factors together with their
non-linear combinations in order to provide more accurate prognosis of health outcomes in
CVD.
1.3 Contributions of this Work
This thesis makes six main contributions:
1. The de facto cardiovascular risk prediction models for T2DM may be unsuitable Us-
ing data from Clinical Practice Research Datalink (CPRD) this work has preformed the
largest, independent, external validation of the de facto cardiovascular risk model for
people with Type II Diabetes Mellitus (T2DM), the UKPDS Risk Engine (UKPDS-RE),
in a diverse and contemporary setting. This work showed poor performance, suggesting
that the UKPDS-RE is not suitable for predicting cardiovascular risk in UK subjects with
T2DM. Considering the widespread application of these prediction models, this work
suggests a need for revised risk equations in T2DM.
2. Developement of a GP approach for survial analysis of censored data GP is a general
methodology, the specific implementation of which requires development of several dif-
ferent specific elements such as problem representation, fitness, selection and genetic
variation. This work has developed a tree-based untyped Steady-state Single-Objective
Genetic Programming (SSOGP) approach for the automated development of clinical pre-
diction models in the presence of censored longitudinal data. Specific GP elements were
developed and implemented, such as fitness functions and search heuristics, to handle
the problem-specific complexities of censored data and facilitate survival analysis.
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3. Generational GP approaches are too computionally expesive for large observational co-
horts This work attempted to implement and evaluate the utility of two broad classes of
GP, steady-state GP common in modern GP systems and the more traditional genera-
tional GP approach. Despite considerable effort, when the developed generational ap-
proaches were applied to the large observational datasets of censored longitudinal data
identified for this work, they failed as a result of requiring more memory that was avail-
able in the computing resources allocated for this work. This serves to demonstrate the
utility of the relatively computationally efficient steady-state GP approach for analysing
large observational cohorts of patients.
4. GP has utility for the automatic development of clinical prediction models in censored
data Using data from the Second Manifestations of ARTerial disease (SMART) study
and from CPRD we have demonstrated that symbolic regression models generated by
the developed SSOGP approach had predictive ability comparable to that of the de facto
statistical method—Cox regression—for the prediction of future cardiovascular events
in patients with symptomatic and asymptomatic CVD. These experiments compared un-
tuned SSOGP symbolic regression models that were developed in an automated fashion
using only basic parameters settings recommended from the GP literature, with highly
tuned Cox regression models that were developed in a very involved manner that re-
quired a certain amount of clinical and statistical expertise. Whilst the highly tuned Cox
regression models performed slightly better in their validation datasets, the performance
of the automatically generated symbolic regression models were generally comparable,
and on average consisting of considerably fewer predictors. Using symptomatic and
asymptomatic CVD as case studies—for secondary and primary prevention clinical set-
tings, respectively—these findings demonstrate the utility of GP as a methodology for
automated development of clinical prediction models for diagnostic and prognostic pur-
poses in the presence of censored longitudinal data.
5. Confirmation of the prognostic significance of certain risk factors in symtomatic CVD
This work has applied GP to examine the prognostic significance of different risk factors
together with their non-linear combinations in predicting cardiovascular outcomes in
patients with symptomatic and asymptomatic CVD. Whilst the application of GP did
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not provide more accurate representations of factors that predict the risk of both symp-
tomatic and asymptomatic CVD when compared with existing methods, GP did offer
comparable performance. Despite generally comparable performance, albeit in slight
favour of the Cox model, the predictors selected for representing their relationships with
the outcome were quite different and, on average, the models developed using GP used
considerably fewer predictors. The results of the GP confirm the prognostic signific-
ance of a small number of the most highly associated predictors in the Cox modelling;
age, previous atherosclerosis, and albumin for secondary prevention; age, recorded dia-
gnosis of ’other’ CVD, and ethnicity for primary prevention in patients with T2DM.
When considered as a whole, GP did not produce a better performing clinical predic-
tion model, rather it utilised fewer predictors, most of which were the predictors that the
Cox regression estimated be most strongly associated with the outcome, whilst achiev-
ing comparable performance. This suggests that GP may better represent the potentially
non-linear relationship of (a smaller subset of) the strongest predictors.
6. In practice GP is robust By implementing SSOGP without model tuning, using only
basic parameters values recommended from general GP literature, observing that it has
performance comparable to the de facto statistical method, we have confirmed the ob-
servations of other authors, that in practice GP is robust and likely to work well over a
wide range of parameter values.
1.4 Overview of this Thesis
The remainder of this work is structured as follows. Chapter 2 describes the wider context
clinical prediction modelling and the UK health system, defining the challenges of predicting
risk in the presence of censored data, and provides motivation for the application of GP for
cardiovascular risk prediction. Chapter 3 surveys and critically assesses the existing research
related to this work. Chapter 4 gives an overview of the essential common themes in the diverse
field of GP and discusses the specific methodological elements that form the developed SSOGP
approach for censored longitudinal data, which are implemented and assessed in the subsequent
experiment chapters. Chapter 5 describes a set of experiments that independently and externally
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validated the performance of the de facto cardiovascular risk prediction model for patients with
T2DM, the UKPDS-RE, using data from CPRD. Chapter 6 describes a set of experiments that
demonstrate the utility of the developed SSOGP approach for the automatic development of
clinical prediction models for risk prediction of future cardiovascular events in patients with
symptomatic CVD using censored survival data from the SMART study. Chapter 7 describes
a set of experiments with a very similar experimental set-up those in the previous chapter, that
demonstrate the utility of the developed SSOGP approach for the automatic development of
clinical prediction models for risk prediction of future cardiovascular events, but uses a much
larger observational cohort of patients from CPRD in a primary prevention clinical setting,
where patients have asymptomatic CVD. Finally in chapter 8, the contributions of this work
are revisited, results are discussed, limitations critically assessed, and opportunities for further
research identified.
1.5 Overview of Related Publications
Here we give an overview of the way in which parts of this thesis have been published.
Chapter 5: External validation of the UKPDS risk engine in incident type 2 diabetes: a
need for new type 2 diabetes-specific risk equations
The content of this chapter is based on research published as an original research article in the
Diabetes Care journal [15] and also published in the proceedings of the 73rd Scientific Sessions
of the American Diabetes Association (ADA 2013) [16].
Chapter 6: Automatic development of clinical prediction models with genetic program-
ming: a case study in the SMART cohort
A large portion of this chapter is published in the proceedings of the 19th Annual International
Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR
2014) [14] and at the time of writing are under review as an original research article in the
Journal of Biomedical Informatics.
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Backgound
We first focus our attention on the wider context clinical prediction modelling and the UK
health system, defining the challenges of predicting risk in the presence of censored data, and
providing motivation for the application of GP for cardiovascular risk prediction.
First we introduce clinical prediction modelling, the prediction cardiovascular risk in patients
with diabetes, and the national health system in the UK. Before introducing the data source
selected for the experiments and its associated clinical coding, we give and overview of study
design and potential sources of data. We then provide an overview of classic statistical ap-
proaches to clinical prediction modelling in the presence of censored data. Before introducing
GP, we give an overview of machine learning in the context of EC. Finally we outline the of
motivation of this thesis.
2.1 Clinical Predciton Modelling
Prognosis is central to medicine. All diagnostic and therapeutic actions aim to improve pro-
gnosis [286]. Physicians and health policy makers need to make predictions on the prognosis
of a disease (of the likelihood of an underlying disease) in their decision making. Traditionally,
predictions were more implicit and medicine more subjective. However we are now in an era
of ’evidence-based medicine’ which is defined as "the conscientious, explicit and judicious use
of current best evidence in making decisions about the care of individual patients" [232, 261].
Evidence based medicine applies scientific method to clinical practice [102]. Another more
recent development is the tendency towards ’shared decision-making’ where physicians and
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patients both actively participate in deciding on choices for diagnostic tests and therapeutic
interventions [47, 286].
Clinical prediction models may provide the evidence-based input for shared decision making,
by providing estimates of individual probabilities or risks and benefits [182]. Clinical predic-
tion models have many names including clinical prediction rules, prognostic models, predictive
risk models, risk scores, risk equations or nanograms [262]. Clinical prediction models com-
bine a number of characteristics (e.g. features related to the patient, the disease, or treatment)
to predict some diagnostic or prognostic outcome [286]. With increasing availability of elec-
tronic patient records the interest in prognostic research will further increase because electronic
records facilitate the application of predictions rules in clinical practice [22].
The aims of clinical prediction modelling fall into two broad categories, obtaining accurate
predictions and obtaining insights into disease mechanisms and pathophysiological processes.
From a modelling perspective this is either accurately predicting the probability or risk of the
outcome or understanding and quantifying the effect of of the risk factors (features) on the
outcome. In this thesis we concern ourselves with the former, obtaining accurate clinical pre-
dictions.
2.2 Cardiovacluar Disease & Diabetes
CVD is a group of disorders of the heart and blood vessels and include coronary heart dis-
ease, cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, congenital
heart disease, deep vein thrombosis, pulmonary embolism, hypertension and heart failure. The
most important behavioural risk factors of heart disease and stroke are unhealthy diet, physical
inactivity, tobacco use and harmful use of alcohol [311]. CVD is the leading cause of death
globally: [311]. An estimated 17.3 million people died from CVD in 2008, representing 30% of
all global deaths. Of these deaths, an estimated 7.3 million were due to coronary heart disease
and 6.2 million were due to cerebrovascular disease. By 2030, almost 23.6 million people will
die from CVD, mainly from heart disease and cerebrovascular disease. These are projected to
remain the single leading causes of death [311].
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Diabetes is on the rise, in the UK and around the world [142, 214, 13, 31, 38, 263, 313].
Forecasting models have shown that the prevalence of diabetes is steadily increasing, and that
diabetes is not a localised chronic condition [159, 312, 199, 26, 228]. Major contributors
to this increase in prevalence are obesity and an ageing population, both of which increase
risk of T2DM. T2DM is a condition that affects 8% of the US population [33] and 4% of
the UK population [70]. Good glucose control is important to reduce the risk of developing
microvascular complications. This is initially achieved through diet and exercise, but glucose-
lowering medication is required in most patients with progressing diabetes.
Asymptomatic patients that are suspected to be at high risk need to be identified by General
Practitioners so they can offer advice about lifestyle changes and initiate preventative treat-
ment. To facilitate this, General Practitioners need tools that can accurately and reliably predict
cardiovascular risk in their patients.
2.3 Cardiovascular Risk
In public health, prediction models may help target preventative interventions to subjects with
relatively high risk of having or developing a disease [286]. Numerous models have been de-
veloped to predict the future occurrence of disease in asymptomatic subjects in the general
population and in specific sub-populations. Arguably, the domain that has seen the most re-
search into the application of prediction models for primary and secondary prevention is CVD.
National policies for the management of both CVD and T2DM advocate the calculation of
CVD risk in order to identify high-risk patients for targeted interventions [264, 295, 245, 66,
216]. Several multivariable risk prediction models (or risk scores) have been developed for
the general, non-diabetic population that also account for diabetes (see chapter 3), but only
a few are specific to T2DM [303]. A minority of of these risk scores have been validated
and tested for their predictive accuracy, with only a few showing a discriminative value of
≥0.80 [303]. The impact of applying these risk scores in clinical practice is almost completely
unknown, but their use is recommended in various national guidelines. Not only are these risks
scores advocated for communicating cardiovascular risk to diabetic patients, they are relied
upon for public health decisions. Evidence that these equations are inadequate could bring into
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question the evidence base underpinning many clinical decisions and public policies about the
management of T2DM.
2.4 National Health Systems: UK perspective
Founded in 1948 the National Health Service (NHS) is the shared name for three of the four
publicly funded healthcare systems in the United Kingdom. The individual systems are NHS
(England), HSENI (Health and Social Care in Northern Ireland), NHS Scotland and NHS
Wales. They provide a comprehensive range of health services, the vast majority of which
are free at the point of use to residents of the United Kingdom. Throughout this document the
’NHS’ or the ’National Health Service’ shall refer to the health systems of England, Scotland
and Wales, ’NHS (England)’ shall refer to the health system in England only. The NHS is the
world’s largest publicly funded health service, employing over 1.7 million staff [219], with a
2011/2012 budget of £106 billion [67].
Appointed by the Prime Minister, the Secretary of State for Health is responsible for the
Department for Health (DoH), which in turn is responsible for the NHS. Strategic Health
Authorities (SHA) enact DoH policy at a regional level, enabling directives and implementing
fiscal policy. SHAs are also responsible for strategic supervision of the NHS trusts such as hos-
pitals, ambulance services, care trusts, mental health services and primary care trusts. Primary
Care Trusts (PCT) provide and/or commission NHS services and form the local management
of the NHS, each with their own budgets and priorities. PCTs are responsible for ≈80% of the
NHS budget funding General Practitioners and prescriptions [108]. However from April 2013,
SHAs and PCTs will be abolished, being, replaced by the NHS Commissioning Board and a
countrywide network of Clinical Commissioning Groups.
Primary care, in contrast to secondary care, refers to local ’frontline’ services acting as a first
point of contact (figure 2.1). A range of independent contractors including General Practi-
tioners, walk-in centres, dentists, pharmacists and optometrists deliver the NHS’ primary care.
Secondary care refers to acute healthcare, emergencies and elective care, which are usually
provided in NHS hospitals.
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Figure 2.1: Figure illustrating primary and secondary care in the NHS. (http:
//www.yas.nhs.uk/AboutUs/YAS_in_the_NHS.html).
General Practitioners are the primary point of contact for patients and are considered as the
’Gatekeepers’ to the NHS. With the exception of a few minority groups such as prisoners
and the armed forces, each resident is allowed to register with a General Practice in the UK.
Homeless people are 40% more likely not to be registered with General Practitioners when
compared with the general population [52]. Patients may also be registered with both private
and NHS General Practices. NHS General Practices provide a range of primary care services
that include treatment of chronic and acute illness, prescribing of medication, referral to spe-
cialist/secondary care, preventative care such as screenings and immunisations, and health edu-
cation such as smoking cessation, lifestyle advice and contraception.
General Practices keep lifetime medical records that include information such as patient demo-
graphics, ’signs, symptoms and diagnoses’, primary care prescriptions (drugs and devices),
immunisations, test results, referrals to specialist / secondary care, feedback from other care
settings and lifestyle information (Body Mass Index (BMI), smoking, alcohol, exercise etc.).
These General Practice records are primarily for General Practice use rather than for research.
The quality, in terms of accuracy, completeness and detail, of these records varies between
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practitioners, between practices and over time. General Practitioners are self-employed with
contractual arrangements with the NHS and performance related pay. Introduced in 2004 the
Quality and Outcomes Framework (QOF) is a payment management and payment system,
which rewards practices for implementing good practice [116]. QOF forms part of the gen-
eral medical services contract, which is voluntary but almost every General Practice takes part.
QOF involves multiple best practice criteria, the level of adherence to which translates into
level of payment to practices. Since the introduction of the QOF in 2004 data quality in Gen-
eral Practice medical records has improved.
2.5 Study Design & Data Sources
Prognostic studies are inherently longitudinal in nature. They are usually carried out in groups
or cohorts of patients, who are followed over time allowing for an event of interest (outcome) to
occur. The cohort is defined by certain criteria, know as selection criteria, such as the presence
of one or more particular characteristics, e.g. having a certain disease, living in a certain geo-
graphic location, or being a certain age. There are several types of cohort studies can be used
for prognostic modelling, including but not limited to retrospective cohort studies, prospective
cohort studies, registry data, and nested case-control studies.
2.5.1 Study Design
In a prospective study, we design the study in advance to achieve some objective, and collect
the data over time according to the study design or protocol. Once complete the data can then
be used for analysis. The investigator is said to age with the study population (hence the term
"prospective study" [305]). Using this design, we can better check specific selection criteria
and use clear and consistent definitions of predictors and outcome, and recored them at pre-
defined time points. Randomised, placebo-controlled clinical trials are a prominent example of
prospective design, considered the ’gold standard’ for assessing the safety and effectiveness of
therapy [292]. They are designed to answer very specific questions about a particular treatment
strategy, disease mechanism and patho-physiological process. In term of data quality, where
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feasible, retrospective cohort studies are therefore generally preferable to retrospective studies.
Prospective cohort studies are sometimes solely set-up for prediction modelling, but a more
common design is that prediction research is done in data from Randomised Clinical Trials
(RCT), or from prospective before-after trials [286]. The strengths are in the well-defined
selection of patients, the prospective recording of predictors, usually with quality check, and
the prospective assessment of outcome. However there are a few key limitations that may
preclude its use for prognostic research.
A key limitation of prospective studies such as RCTs, may be in the selection of patients. Trials
by their very nature select a very specific group of individuals, typically without comorbidity
and/or polypharmacy. Typically stringent selection criteria are used, which may introduce bias,
limiting the generalisability of any models developed on such data. Multi-centre trials help
increase generalisability of findings, but are still contained to same limitation in the study
design. Another challenge is feasibility, the high costs associated with trials often lead to
trials that have relatively short duration and relatively small sample size. Insufficient study
duration can be a problem in some prognostic studies, for example if we are looking to predict
the 10-year risk CVD then data from a prospective that lasted 3 years would be of limited
value. Sample size is key problem for prognostic research and has been discussed previously
(section 2.8.1), Finally, there may also be ethical limitations on prospective designs, such a
comparison group that didn’t receive any treatment for a severe disease. It would unethical
to intentionally deny patients vital treatment, however this may have been observed in patient
records which could be achieved through a retrospective cohort study design.
The most common type of prognostic studies are of the retrospective cohort design, where pa-
tients are identified from patient records within a certain date ranges. These patients are then
followed over time for the outcome, but the investigator looks back in time (hence the term
"retrospective study" [305]). Strengths of a retrospective design include its simplicity, feasibil-
ity and relative cost effectiveness. These strengths are realised by the ease with which existing
patient records can be searched. The low cost allows for relatively long time horizons and large
sample sizes, which can be important for prognostic research, which are often prohibitively ex-
pensive in other study designs. The fact that the data is routinely collected is another strength,
as this ’real-world’ data does not suffer from the same bias that can exist in studies that are
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prospective in nature. This is because the selection criteria in typically not as stringent and the
data is observations from routine practice, generally leading to representative sample and thus
a model and findings with higher generalisability to the target population.
Limitations include correct identification of patients, reliable recording of predictors and out-
comes, and to a lesser extent, sample size. Challenges arise in the correct identification of
patients, which has to be done in retrospect. If certain selection criteria are poorly defined,
ill conceived or insufficient, or some of the information is missing or incorrectly recorded,
this may lead to selection bias. Also the recording of predictors has to have been reliable for
use in prediction modelling. Similarly, the outcome has to reliable. This may be relatively
straightforward for an outcome such as all-cause mortality in cohort that typically would die
in hospital, which may be reasonably well recorded in hospital patient records. However, if
we are interested in death attributed to certain disease or cause, especially if often occurs out-
side of hospital, then the outcomes may need to be verified using additional information from
other sources such the national statistics bureaus like the Office for National Statistics in the
UK. Finally, sample size may be limited in single-centre studies, however this is not usually
a problem in collaborative multi-centre studies. Retrospective cohort studies are often con-
sidered inferior to randomised trials, as, in some cases, they have been shown to overestimate
treatment effects [292]. Conversely however, when RCT data has been used for prognostics
modelling, they often have poor performance in groups of patients that differ from the very
specific group used in the trial. Despite this, retrospective cohort studies, if well designed and
conducted appropriately, can be a valuable and effective approach to determining associations
between specific exposures and outcomes, and are the method of choice when it is not possible
to conduct randomised trials [292]
2.5.2 Electronic Patient Records
The strengths of the retrospective design are further enhanced by the increasing availability
of Electronic Patient Records (EPR) in primary and secondary care. The electronic recording
clinical patient data has come a long way since its inception during the 1980s. In the UK
alone, there are three predominant systems used both for research and for clinical records: the
CPRD [39], The Health Improvement Network (THIN) [294] and QResearch [246, 274].
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Since the 1990s the use of EPRs in the UK has increased, primarily as a result of UK govern-
ment initiatives including the provision of financial incentives for general practice to develop
electronic clinical registers (i.e. QOF) and through the proposed implementation of a single
NHS computer system for EPRs (National Programme for Information Technology, NPfIT).
The UK has a strong reputation of producing quality EPR-based research through publication
of numerous studies, both in the validity and quality of the databases themselves, and in pro-
gnostic and epidemiological research performed using retrospective cohorts developed from
their data [274]. These studies have confirmed the high quality of the data recording in these
primary care databases [157, 289, 296]. Whilst clinical coding practice remains an area from
improvement [100], this has been mitigated to some extend by the linkage with registry, sec-
ondary care and laboratory data [157, 288, 104].
There are several advantages of basing research on a national system of networked data. Firstly,
the use of medical data collected across the UK provides a broadly representative sample. This
is realised by the broad geographical spread individual practice databases across the UK allow-
ing for a broad generalisation of the UK population. Secondly, many patients have complete
data available form 1980, providing an excellent source of longitudinal data for prognostic
research, in some cases providing heath information over the patents lifetime. Finally, the
size (number of patients) of the databases not only enables more complicated question to be
answered with fewer assumptions, but also enables the research into rarer diseases with low in-
cidence rates, that couldn’t be feasibly studied any other way. The CPRD observational dataset
alone consists of longitudinal, anonymous records from 681 primary care practices and over
15 million patients throughout the UK (based on the March 2014 release) [39], with a similar
number of practices (754) and patients (>13m) in QResearch’s EMIS database [246].
Due its merits of feasibility, large sample size and high generalisability, a retrospective obser-
vational cohort design is the preferred study design for experiments conducted for this thesis.
The data source proposed for development of such a cohort is routinely collected data from
UK general practice patient records, linked with other data sources such as secondary care
data and Office of National Statisitcs (ONS) data. This will be achieved using the CPRD
(www.cprd.com). This decision to used CPRD as apposed the other primary care databases is
that Cardiff School of Medicine already has licensed access to CPRD and significant experience
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of using CPRD for high quality research.
2.6 The Clinical Practice Research Datalink
The CPRD (formerly the General Practice Research Database, GPRD) is a computerised data-
base of anonymised longitudinal medical records collated from UK General Practitioners work-
ing in primary care [39]. General Practices using Vision Patient Administration Systems [133]
can contribute data to the CPRD. Practices are paid for contributing to the scheme based on
number of patients and quality of data provided. CPRD is considered by many as the GOLD
standard [39], containing 15.8 million patient records collected continuously since 1987. At
the time of writing, information on approximately 4.8 million active (alive) patients in the UK,
equivalent to about 7% of the UK population, are collected from 681 general practices nation-
wide as detailed in figure 2.2 below.
Figure 2.2: Heat map depicting smoothed estimates of population density (left)
and CPRD coverage (right) in the UK.
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CPRD also has an increasing number of links to secondary care such as Hospital Episode
Statistics (HES), registries and death data. Information collected by CPRD along with some
examples are detailed in Table 2.1 below. The UK Medicines and Healthcare products Regulat-
ory Agency (MHRA) run the CPRD on a non-profit making basis. The MHRA is an Executive
Agency of the DoH. It fulfils a critical public health role in the UK by ensuring that all medic-
ations and medical products meet appropriate standards of safety, quality and efficacy.
Table 2.1: Types of information held in CPRD
Information Examples
Demographics Smoking and drinking status, exercise, etc.
Age, gender, height, weight
Medical symptoms/diagnosis and comments Historical diagnosis
Historical diagnosis
Hospital referrals
All recorded prescriptions (drugs and devices) Strength
Dosage
Referrals Hospitals or specialists
Registration details Dates
Status e.g. transferred out
Status e.g. transferred out Immunisations
Test results
Consultations
Repeat prescription schedules
2.6.1 Clinical Practice Research Datalink Governance
Established in 2006 by the Secretary of State, the Independent Scientific Advisory Committee
(ISAC) is an independent non-statutory advisory body nominated to review the scientific merit
of proposals for research using data from CPRD and safeguard patient confidentiality. ISAC
approval is required for all studies using CPRD data, where destined for publication or for
communication with a third party. ISAC approval is also required for any study that intends to
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use data from a CPRD data linkage scheme.
2.6.2 Data Model
CPRD data is made available through online tools and static databases version created each
month. The CPRD data model illustrated in figure 2.3 consists of the following data tables:
Patient demographics including age, sex
Practice region and collection information
Consultations duration and linkage
Therapy prescribing from general practice
Immunisations vaccination details
Staff General Practitioner, nurse, locum
Clinical medical history and diagnosis
Additional Clinical Details additional information from structured data areas
Referral information about secondary care
Tests structured numerical and qualitative lab results
The Patient table contains basic patient demographics and registration details for the patients.
The Practice table contains details of each practice, including region and collection informa-
tion. The Staff table contains practice staff details, with one record per member of staff. The
Consultation table contains information relating to the type of consultation as entered by the
General Practitioner from a pre-determined list. Consultations can be linked to the events that
occur as part of the consultation via the consultation identifier (consid). The Clinical table
contains medical history events. This file contains all the medical history data entered on the
General Practitioner system, including symptoms, signs and diagnoses. This can be used to
identify any clinical diagnoses, and deaths. Patients may have more than one row of data.
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Figure 2.3: Figure depicting the CPRD data model
The data is coded using Read codes (section 2.7.1), which allow linkage of codes to the med-
ical terms provided. The Additional Clinical Details table contains information entered in the
structured data areas in the General Practitioner’s software. Patients may have more than one
row of data. Data in this file is linked to events in the clinical file through the additional details
identifier (adid). The Referral table contains referral details recorded on the General Practice
system. These files contain information involving patient referrals to external care centres (nor-
mally to secondary care locations such as hospitals for inpatient or outpatient care), and include
speciality and referral type. The Immunisation table contains details of immunisation records
on the General Practitioner system. The Test table contains records of test data on the General
Practitioner system. The data is coded using a Read code, chosen by the General Practitioner,
which will generally identify the type of test used. The test name is identified via the Entity
Type, a numerical code, which is determined by the test result item chosen by the General Prac-
titioner at source. There are three types of test records, involving 4, 7 or 8 data fields (data1
- data8). The data must be managed according to which sort of test record it is. Data can de-
note either qualitative text based results (for example ’Normal’ or ’Abnormal’) or quantitative
results involving a numeric value. The Therapy table contains details of all prescriptions on
the General Practitioner system. This file contains data relating to all prescriptions (for drugs
and appliances) issued by the General Practitioner. Patients may have more than one row of
data. Drug products and appliances are recorded by the General Practitioner using the Multilex
product code system (section 2.7.2).
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Full descriptions of fields in each table are provided in the Appendix [TBC]. All files can be
linked using the encrypted patient identifier (patid). The last three digits of the patient identifier
(patid), and staff identifier (staffid) denote the identifier of the practice (pracid) that the patient,
or staff belongs to. The mapping column references information relating to the use of data in
the field. It specifies lookup references, linkages to other tables, and information on decoding
numerical values. A mapping of ’None’ indicates the existence of raw data in the field. 1.
2.6.3 Data Quality
In large observational databases such as CPRD data quality varies between Practices and over
time. CPRD uses data quality markers to ensure internal consistency of patient data, complete
longitudinal records and complete, continuous, plausible practice level data. There are two
principle data quality markers used in CPRD, a patient ’acceptability’ flag and practice UTS
(’up-to-standard’) date. The patient ’accept’ flag indicates whether the patient record is of an
acceptable quality and integrity. Practice UTS dates refer to the date at which the practice is
of research quality. CPRD data quality is driven by incentivisation, Medico-legal factors and
feedback reports.
2.7 Clinical Coding
A clinical coding system is a coded thesaurus of clinical terms designed to enable users to make
effective use of clinical computer systems. Accurate and consistent coding of clinical data onto
the practice computer clinical system is a vital step in the move towards the Patient Electronic
Health Record and consistent analysis [224]. Several clinical classification systems are relevant
to this research project are described here.
2.7.1 Read Codes
The NHS mandates the use of the Read Clinical Classification Version 3 [221], more commonly
known as Read Codes, in general practice. Read codes are a coded thesaurus of clinical terms
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designed to enable General Practitioners, Practice Nurses and administration staff to make
effective use of clinical computer systems. Read medical codes have been used in the VISION
Patient Administration System since 1995 as a required field for a clinical entry into a patient
record. The Read codes have a hierarchical structure made up of 5 levels of detail in the 5-
character version (5 byte) of the codes and 4 levels in the earlier 4-character version (4 byte).
The characters used are numbers 0 to 9, upper case letters A to Z and lower case letters a to z.
The codes are case sensitive.
Table 2.2: Hierarchical structure of read code for Acute anteroapical infarction
Read Code Term
G.... Circulatory system diseases
G3... Ischaemic heart disease
G30.. Acute Myocardial Infarction (MI)
G301. Other specified anterior MI
G3010 Acute anteroapical infarction
Table 2.3: Hierarchical structure of read code for Allotransplantation of heart
and lung.
Read Code Term
7.... Operations, procedures, sites
79... Heart operations
790.. Heart wall, septum and chamber operations
7900. Transplantation of heart and lung
79000 Allotransplantation of heart and lung
Tables 2.2 and 2.3 give examples of the read code hierarchy. The top level of the hierarchy is
known as the chapter (chapters ’G’ and ’7’ in examples above). Chapters starting with letters
A-Z indicating referring to diagnosis codes and chapters starting with numbers 0 to 9 indicating
process of care codes, in Table 2.2 ’Diagnosis’ and in Table 2.3 ’Operations’. Each successive
level of the hierarchy provides more detail to a concept.
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2.7.2 International Classification of Diseases
The International Classification of Diseases (ICD) is a health care classification system that
provides codes to classify diseases and a wide variety of signs, symptoms, abnormal findings,
complaints, social circumstances, and external causes of injury or disease [319]. Under this
system, every health condition can be assigned to a unique category and given a code, up to six
characters long. Such categories can include a set of similar diseases. The ICD is published
by the United Nations-sponsored World Health Organisation (WHO) and revised periodically
and is currently in its tenth revision ICD-10 which was implemented in 1992. The basic ICD
is a single coded list of three-character categories, each of which can be further divided into up
to 10 four-character subcategories. In place of the purely numeric coding system of previous
revisions, the Tenth Revision uses an alphanumeric code with a letter in the first position and a
number in the second, third and fourth positions. The fourth character follows a decimal point.
Possible code numbers therefore range from A00.0 to Z99.9. Table 2.4 below describes the
structure of ICD-10 code I21.0 for Acute transmural MI of anterior wall.
Table 2.4: Hierarchical structure of ICD-10 code for Acute transmural MI of
anterior wall.
ICD-10 Code Term
I.... Chapter IX: Diseases of the circulatory system
I2... Ischaemic heart diseases (I20-I25)
I21.. Acute MI (I21.0-I21.9)
I21.0 Acute transmural MI of anterior wall
The classification is divided into 21 chapters (see table 2.5 below). The first character of the
ICD code is a letter and each letter is associated with a particular chapter. Each chapter con-
tains sufficient three-character categories to cover its content; not all available codes are used,
allowing space for future revision and expansion. The chapters are described in table 2.5 below.
The desk reference for prescribing by General Practitioners in the UK is the British National
Formulary (BNF) [28] provides information on the selection, prescribing, dispensing and ad-
ministration of medicines. The BNF is arranged into chapters and sections, with some phar-
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maceutical products being a member of more than one BNF chapter. General Practitioners
contributing to CPRD code their selection, prescribing, dispensing and administration of phar-
maceutical products using the Multilex drug knowledge base. Multilex is a proprietary drug ter-
minology used by CPRD that holds clinical and commercial information on more than 75,000
pharmaceutical products and packs [82]. Products within Multilex include all branded pre-
scription medicines, generic medicinal products, Pharmacy and General Sales List medicines,
appliances included in the Drug Tariff, supplementary and specialist dietary foods, diagnostic
and monitoring agents, homeopathic remedies and other NHS products available on prescrip-
tion. UK practices and therefore CPRD use the Read Clinical Classification system, but often
CPRD alone does not hold all the information required for research. In these cases we need to
augment the data in CPRD with data from other sources, such as those provided by the linkage
schemes (discussed later). Many of the additional datasets provided by linkage schemes use
different coding systems, namely the ICD. The Read codes are cross-referenced to ICD-10, but
not ICD-9. However there are challenges as the cross referencing is far from perfect, as in some
cases there is not a one-to-one mapping between conventions. This is further complicated by
the fact that some of data is coded using ICD-9, which does not always have a direct mapping
to ICD-10 or Read. In these cases the expertise of clinicians is still required. Steps are being
made to address this as the NHS National Programme for IT is using the SMOMED Clin-
ical Terms system as the standard terminology in the NHS Care Records Service. SNOMED
Clinical Terms (SNOMED CT) claims to be the most comprehensive, multilingual clinical
healthcare terminology in the world and incorporates all Read (Version 3) terminology via 1:1
mapping [135].
The CPRD holds a wealth of information about primary care but often primary care research
requires information that is not typically captured by general practice. In such cases CPRD data
may need to be augmented with data from other sources. The MHRA aims to optimise CPRD
research outputs by maximally linking person level data from different healthcare domains.
Linkages that are available include:
• HES
• Hospital prescribing
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• Cancer registries
• Myocardial Ischemia National Audit Project (MINAP)
• Office of National Statistics Mortality (death certificates)
• National Bone and Joint Registry (NJR)
• Socio Economic Status (Patient Level)
Data linkage is implemented on a practices level, with practices having the options whether or
not to consent to the CPRD linkage scheme. CPRD has limited linked data available via its
linkage scheme; linkage is only available to English practices consenting to participate in the
scheme, representing 357 (71%) of the 500 English practices in CPRD and 4% of the 8324
practices in England [222]. The CPRD organisation is the custodian of the linked data and in
most cases holds the full datasets. Figure 2.4 below illustrates a typical CPRD data linkage
process. Data provided by these linkage schemes is not part of the base CPRD dataset and
needs to be requested on study-by-study basis through the ISAC by submission and approval
of an ISAC protocol. Granted ISAC protocols relating to the experiments in chapters 5 and 6
of this thesis are detailed in Appendices A and F, respectively.
As indicated above there are several data linkage schemes, those schemes that are directly
relevant to this research, ONS Mortality, HES and Socio-Economic Status (SES) have been
discussed in more detail below.
In the UK death registration is carried out by Local Registration Services in partnership with
the General Register Office. All deaths must be reported to the Register General and sudden
deaths require coroner involvement. The cause of death is recorded on Part I and Part II of the
death certificate. Part I consist for three levels; 1(a)- Disease or condition directly leading to
death; 1(b)- Other disease or condition, if any, leading to 1(a); 1(c)- Other disease or condition,
if any, leading to 1(b). Part II details other significant conditions contributing to the death but
not relating to the disease or death causing it. Cause of death is coded using the ICD coding
system. ICD-9 has been used in the UK since 1979, with ICD-10 introduced in Scotland in
2000 and rest of the UK in 2001. Official death dates are available for 99.9% of English popu-
lation and cause of death is only available since Jan 2001. ONS mortality data is not part of the
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Figure 2.4: Figure depicting a typical CPRD data linkage process
base CPRD dataset, limited to English practices participating in the linkage scheme and needs
to be requested on study-by-study basis through the ISAC. HES are a record-level database
of hospital admissions and outpatient attendances for all NHS trusts in England [223]. HES
holds admission data from 1989 and outpatient data from 2003. The HES dataset consists of
patient, admission, discharge, clinical, speciality, critical care and maternity information. Clin-
ical information is recoded for each episode, with diagnoses coded in ICD-10 and operative
procedures coded using Office of Population Censuses and Surveys, Classification of Surgical
Operations and Procedure (OPCS) Version 4 [220]. HES data is not part of the base CPRD
dataset, limited to English practices participating in the linkage scheme and needs to be reques-
ted on study-by-study basis through the ISAC. CPRD has derived practice-based SES using
the Index of Multiple Deprivation linked to the practice postcode for all four countries of the
UK. SES is also available at ONS small area level (100 houses) using patient postcode. Two
SES scores are available from CPRD; Townsend score and the Index of Multiple Deprivation.
SES data is not part of the base CPRD dataset, limited to English practices participating in the
linkage scheme and needs to be requested on study-by-study basis through the ISAC.
28 2.8 Linear Statistical Methods
2.8 Linear Statistical Methods
Prediction is primarily an estimation problem [286]. For example, what is the risk of dying
over tens years? But prediction is also about testing hypotheses. For examples, how does the
management of blood sugars effect risk of death on patients with diabetes? Or more generally,
what are the important predictors or risk factors associated with a particular disease. Statistical
models may serve to address both estimation and hypothesis testing. In the medical literature
much emphasis has traditionally been given to the identification of predictors.
Statistical models summarise patterns of the data available for analysis. In doing so, it is in-
evitable that assumption need to be made. Testing of underlying assumptions is especially im-
portant if specific claims are made on the effect of a predictor. Statistical models for prediction
can be discerned into three main classes: regression, classification and description. Hereafter,
these will be jointly referred to as linear statistical methods or models. Regression models
are the most widely used statistical models in the medical domain [286]. Statistical modelling
to make predictions encounters various challenges, including dealing model uncertainty and
limited sample size.
2.8.1 Model Uncertainty & Sample Size
Model uncertainly arises from the fact that we usually do not fully pre-specify a model before
we fit it to a dataset [36, 73]. Often, an iterative process is followed with model checking and
model modification. On the other hand, standard statistical methods assume that a model was
pre-specified. In that case, parameter estimates such as regression coefficients, their corres-
ponding confidence intervals, and p-values are largely unbiased [286]. Whenever some part
of the data is used to inform the structure of the model in some way there is potential for bias
to occur, and for underestimation of the uncertainty of the conclusions drawn from the model.
Fortunately, model uncertainty has been actively researched and as a result some statical tool
are available to help study model uncertainty. Statistical resampling methods, namely boot-
strapping help with uncertainty during the development and validation of statistical models.
Sample size is another key challenge in statistical modelling. A sufficient sample size is import-
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ant to assures any scientific question with empirical data. We have to realise that the effective
sample size may often be much smaller than indicated by the total number of subjects in a
study [112]. For example, if we have relatively large number of patients but are interested in
a relativity rare event with low incidence rate, then it is this small number events that is the
effective sample size. Large sample size facilitates many aspects of prediction research. For
multivariate prognostic modelling, a large sample size allows for selection of predictors with
simple automatic procedures such as stepwise feature selection methods (although the value of
such methods is topic of much debate) and reliable testing of model assumptions. Conversely,
with a small sample size we have to be prepared to make stronger modelling assumptions.
When the sample size is very small we can only ask relatively simple questions, while more
complex questions can be addressed with larger sample sizes [286]. Therefore the ambitions
of the research questions may need to be tempered with the effective sample size of the data
available.
2.8.2 Survival Analysis
Suppose that we wanted to study the occurrence of a particular event (or events) in a cohort of
patients. If the time until the event is not of interest, but rather just whether the event occurred or
not, then response could be represented as a simple binary outcome and modelled using logistic
regression. For example, in analysing post- surgery morality, it may not be important whether
patients die 30 days after or two years after the procedure, just that that they perish. However,
typically with long-term and chronic conditions in domains such as cardiology oncology and
endocrinology, the time until event is important. For example, in a study of CVD in patients
with diabetes, whether a patient experienced a cardiovascular event 6 months, or 6 years after
diagnosis ofT2DM is very different. An analysis that simply counted the number of events
would be discarding valuable information and sacrificing statistical power [112].
Generally, survival analysis is collection of statistical procedures for the analysis of data in
which the outcome of interest is time until event, which is often called failure time, survival
time, or event time. More generally, this type of outcome or response is referred to as a survival
outcome, which different to and not to be confused with a survival endpoint. The latter is a
general term used in indicate that the endpoint or event of interest is death, but not necessarily
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that it is time until death that is of interest. Whereas, a survival outcome, survival analysis or
use of a survival model implies that the outcome of interest is time to event only - the event
itself may or may not be survival in the wider sense (i.e death). For example, one may use
a binary survival endpoint (dead/alive) and logistic regression to model post-surgery survival.
Conversely, one may use a survival analysis to model time to non-fatal MI, which would be
using a survival model and thus employing a survival outcome, but in fact have nothing to
do with survival (mortality) in the more general sense. Examples of survival outcomes of
interest include time until cardiovascular death, time until death or MI, or time until incidence
or recurrence of hypertension. More specifically, survival analysis involves the estimation of
the distribution of the time it takes for an event to happen to a patient based some set of features,
which are also known as explanatory variables, predictors, risk factors, features, or covariates.
Censoring
A key characteristic of survival data is that the follow-up of patients is typically incomplete [286].
Survival analysis must address a key analytical problem called censoring. For example some
patients may have been followed 5 days, some for 15 days, etc., and were are interested in
predicting 30-day survival. Patients with such incomplete data are said to be censored, often
referred to as censored observations or censored data. In essence, censoring occurs when we
have some information about an individuals survival time, but we don’t know the survival time
exactly in all subjects.
Using a simple example of censoring from Kleinbaum & Klein [162], consider leukaemia
patients followed until they go out of remission, shown in figure 2.5 as X. If for a given patient,
the study ends while the patient is still in remission (i.e. doesn’t get the event), then the patient’s
survival time is considered censored. We know that for this person, the survival time is at least
as long as the period that the person has been followed, but if the person goes out of remission
(i.e experiences the event) after the study ends, we do not know the complete survival time.
According to Kleinbaum & Klein, 2005 [162], there are generally three reasons why censoring
occurs:
1. a person does no experience the event before the study ends;
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Figure 2.5: Example of censoring in leukemia patients followed until they go out
of remission (source: Kleinbaum & Klein, 2005 [162]).
2. a person is lost to follow-up during the study period;
3. a person withdraws from the study because of death (if death is not the event of in-
terest) or some other reason (i.e. adverse drug reaction or other competing risk)
These situation are graphically illustrated in figure 2.6. The graph describes the experience of
several persons followed over time. An X denotes a person who got the event.
Figure 2.6: Example of different censoring in several leukemia patients followed
over time (source: Kleinbaum & Klein, 2005 [162]).
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Notation, Survial, and Hazard Functions
The two most popular quantitative terms considered in any survival analysis are the survivor (or
survival) function, denoted S(t), and the hazard function, denoted λ(t). The survival function
in the probability that an individual remains event-free longer than some specified time t. The
hazard function λ(t) gives the instantaneous potential per unit time for the event to occur, given
that the individual has remain event-free up to time t [162]. The hazard function is sometimes
referred to as a conditional failure rate and in contrast to the survival function, which focuses
on not experiencing the event, the hazard focuses on the event occurring. It is important to
note that, although it may be helpful to think of the hazard as an instantaneous probability, it is
not a probability as it can take on values greater than one [6]. Thus in some sense the hazard
function can be considered as giving the opposite side of the information given by the survival
function [162]. The distribution of time to a specific event dependent on a set a features or
predictor variables X = {x1, x2, . . . , xk}, can be represented by five closely related functions
given below:
f(t|X) density function (pdf)
F (t|X) cumulative distribution function (cdf)
S(t|X) survival function
λ(t|X) hazard function
Λ(t|X) cumulative hazard function
As with other regression models, X can represent a mixture of binary, categorical, continuous,
spline-expanded, and even ordinal predictors. These interrelated functions can expressed in
Equations 2.1 - 2.5 [112, 162, 45, 6], where T denotes the response variable (usually time to
event), t represents a specified time point, and X refers to a vector of features or explanatory
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variables:
f(t,X) =
∂F (t,X)
∂t
= −∂S(t,X)
∂t
= lim
∆→0
Prob{t ≤ T < t+ ∆, X}
∆
=
λ(t,X)exp
(
−
∫ t
0
λ(u) du
)
= λ(t,X)S(t,X)
(2.1)
F (t,X) = Prob{T < t,X} =
∫ t
0
f(u) du = 1− S(t,X) (2.2)
S(t,X) = Prob{T > t,X} =
∫ ∞
t
f(u) du = exp
(
−
∫ t
0
λ(u) du
)
=
1− F (t,X) = exp[−Λ(t,X)]
(2.3)
λ(t,X) = − ∂logS(t,X)
∂t
=
f(t,X)
S(t,X)
=
lim
∆→0
Prob{t ≤ T < t+ ∆|T > t,X}
∆
(2.4)
Λ(t,X) =
∫ t
0
h(u) du = −logS(t,X) (2.5)
Of the functions considered thus far, the survival function is the most intuitive as it describes
the survival experience in the cohort. Whilst being the less intuitive, the hazard function in
important for several reasons. Firstly, the hazard function is a measure of instantaneous po-
tential, whereas the survival function is a cumulative measure over time. Secondly, it can be
useful when fitting a model to data, specifying the specific model form for parametric model-
ling. Thirdly, it is the vehicle by which the mathematical modelling is performed, that is, most
survival models are expressed in terms of hazard. Whichever quantity is most appealing, the
key point is that by specifying and one of the probability density function, survival function, or
hazard function allows the other two function to be ascertained by using the formula 2.1-6.
Maximum Likelihood Estimation
Whereas unknown parameters in linear regression are estimated using least squares estima-
tion, in logistic regression and survival analysis they are estimated using Maximum Likelihood
Estimation (MLE).
Maximum Likelihood estimates of model parameters are derived by maximising the a likeli-
hood function. The likelihood function is a mathematical expression that describes the joint
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probability of obtaining the data actually observed on the subjects in the study as a function of
the unknown parameters [162].
The natural logarithm of the likelihood, the Log Likelihood (LL), is normally used for conveni-
ence in numerical estimation. The LL is calculated as the sum over all subjects of the distance
between the natural log of the predicted probability p for the binary outcome to the actual
observed outcome y:
LL =
∑
y × log(p) + (1− y)× log(1− p) (2.6)
where y refers to the binary outcome and p to the predicted probability for each subject [286].
A perfectly fitting model would have an LL of zero.
Kaplan-Meier Estimator
As the true form of the survival distribution is seldom known, it is useful to estimate the dis-
tribution without making any assumptions [112]. When censoring is present, S(t) can be es-
timated using the Kaplan-Meier [147] product-limit estimator, a nonparametric method for
survival data, based on conditional probabilities. The KM methods deals with censored data,
and provides attractive graphs on the relationship between predictor values and the outcome
over time [286]. Also, differences between survival curves can be tested statistical significance
using the log-rank test.
The product-limit estimator is a nonparametric maximum likelihood estimator [112]. The for-
mula for the KM product-limit estimator of S(t) is as follows. Let k denote the number of
failures in the sample and let t1, t2, . . . , tk denote unique event times (ordered for ease of cal-
culation). Let di denote the number of failures at ti and ni be the number of subjects at risk at
time ti; that is, ni = number of failure/censoring times > ti. The estimator is then
SKM (t) =
∏
i:ti<t
(1− di/ni) (2.7)
The KM method is often used in prognostic modelling, either to perform univariate analysis
by generating survival curves for various subgroups (e.g. females versus males) to investigate
the effect of predictors on outcome, or to calculate the estimated proportions of subjects that
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remain event-free at a certain time points. However, the KM approach is limited as it cannot
handle continuous predictors, not can it consider the effect of multiple explanatory variables
simultaneously. Because of censoring, logistic regression (a binary variable) is inappropriate.
One could attempt to apply linear regression on event time, but again censoring usually makes
such an analysis meaningless [286]. To overcome this limitation, several regression model-
ling approaches, that allow for multiple predictors, have been proposed to enable prediction
of time to event in the presence of censored data [287]. Most of these models have come
from the long-established statistical literature such as parametric survival models, including
the Weibull, lognormal and Gompertz models and the semi-parametric Proportional Hazards
model proposed by Cox [48].
Parametric Survial Models
The nonparametric KM estimator of S(t) is a very good descriptive statistic for displaying
survival data. However, for the purposes of prognostic modelling, we need to make more
assumptions to allow the data to be modelled in more detail. In this section we discuss a class
of survival models, called parametric models, in which the distributions of the outcome (i.e.
time until event) is specified in term of unknown parameters [162].
Examples of parametric models commonly used in biomedical research include linear regres-
sion, logistic regression, and Poisson regression. With these models, the outcome (i.e. time
until event) is assumed to follow some known distribution, such as the normal, binomial, or
Poisson distribution. What is typically meant is that the outcome is assumed to follow some
family of distributions with unknown distributional parameters that need to estimated. For
example, if we assume an outcome follows a normal distribution, then we know the distribu-
tional family but not the specific or exact distribution. To achieve that we need to estimate
the distributional parameters, typically a shape and scale parameters, which in the case of the
normal distribution would be mean (µ) and variance (σ). For parametric regression models,
the unknown distributional parameters are often estimated from the data, and sometimes the
appropriateness of the choice of distributions family (i.e. the fit to the data) is evaluated using
the data.
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A parametric survival model is a model in which the outcome (i.e. time until event) is assumed
to follow some known distribution. Parametric survival modelling requires choosing one or
more distributions. Common distributions include the Weibull, Exponential (a special case of
Weibull), log-normal, log-logistic, Gompertz, and generalised gamma distributions. Due to
their specific properties, some distributions can accommodate only one type survival regres-
sion formulation (such as the Proportional Hazards (PH) or Accelerated Failure Time (AFT)
specification, discussed in the next sections), whereas other distributions may accommodate
multiple formulations. Machine Learning (ML) is used to estimate the unknown parameters of
S(t) (see section 2.8.2).
Providing the parametric form is correctly specified, there are several advantages in specifying
a functional form for S(t) and estimating any unknown parameters in this function (i.e. para-
metric survival modelling) . Firstly, concise and parsimonious equation and smooth estimates
of S(t), Λ(t), and λ(t), which can be especially useful in prediction modelling. Secondly,
unlike non- and semi-parametric models, fully parametric models enable robust estimation of
expected event times, typically by extrapolation. Due to their nonparametric nature, predic-
tions made by the KM estimator and Cox regression (discussed in section 2.8.2) towards the
end of follow-up are quite unstable, whereas with parametric models they are more robust, as
survival is completely specified by a smooth function over the entire time horizon. In fact,
from a technical view point these approached are only valid for time points in the data where
an event occurred. Thirdly, due to the fully specified functional form, selected quantiles of the
survival distribution can be easily computed. Finally, assuming the parametric form is correctly
specified, more precise estimation of S(t), when compared with nonparametric estimates such
as SKM (t).
Parametric Proportional Hazards Models
The most widely used survival regression specification assumes that the effects of the covari-
ates exp(βX) are multiplicative (i.e. proportional) with respect to hazard λ(t), know as the
proportional hazards assumption (PHA):
λ(t,X) = λ(t)exp(βX) (2.8)
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This regression formulation is called the proportional hazards (PH) model. Analogous to the
PH (parametric and semi-parametric) model for a binary outcome in uncensored data, where
we know whether or not the patient experienced the event in the time horizon of interest, is the
logistic model. Multivariable logistic regression model is is the most widely used statistical
technique nowadays for binary medical outcomes [107, 286, 307]. The PH model is the natural
extension of the logistic model to the survival setting [286]. Indeed, the the PH model is equi-
valent to conditional logistic regression, with conditioning at times where events occur [184].
In the logistic model, we use an intercept in the regression effect, while in the PH model uses
what is referred to as the baseline hazard function, underlying hazard function, average risk
profile, or hazard function for a standatd object.
The λ(t) part of λ(t,X) is the baseline hazard function, which is a subject (i.e patient) with
βX = 0. Any parametric hazard function can be used for λ(t), and as we will see in the next
section, λ(t) can be left completely unspecified without sacrificing the ability to estimate β, by
the use of the semi-parametric Cox Proportional Hazards model (section 2.8.2) [48]. As with
other regression models, the vector of predictor variables X = {x1, x2, . . . , xk} can represent
a mixture of binary, categorical, continuous, spline-expanded, and even ordinal predictors. The
effects of the covariates, the regression effect βX = β0 + β1X1 + β2X2 + . . . + βkXk is
modelled in much the same way as other settings. Depending on whether the distribution of
the underlying hazard function λ(t) has a constant scale parameter, βX may or may not have
an intercept β0. In multiple linear regression, the regression effect βX can be thought of as an
increment in the value of the expected response Y . In binary logistic regression, βX specifies
the log odds that Y = 1, or exp(βX) multiplies the odds that Y = 1. Depending on whether
the baseline hazard function λ(t) has a constant scale parameter, βXmay or may not include
an intercept βo.
The PH model can also be rewritten in terms of the cumulative hazard and survival functions:
Λ(t,X) = Λ(t)exp(βX) (2.9)
S(t,X) = exp[−Λ(t)exp(βX)] = exp[−Λ(t)]exp(βX) (2.10)
Λ(t) is an "underlying" cumulative hazard function. S(t,X), the probability of remaining
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event-free up to time t, given the values of predictors X , can also be written as
S(t,X) = S(t)exp(βX) (2.11)
The regression effect βX is usually centred at the mean values of the predictors and the term
exp(βk) is called a relative hazard function or a hazard ratio, which is the ratio of hazard of
predictor k compared with the baseline hazard (i.e. average risk profile). The hazard ratio is
similar to the odds ratio in logistic regression and arguably the most well known (and often
misunderstood) term in survival analysis, in many cases is the function of primary interest as it
describes the (relative) effects of the predictors.
Note that the regression effect relates the log hazard or log cumulative hazard. In the general
regression notation, the PH model can be linearised with respect to βX , allowing distributional
and regression parts to isolated and checked, using the following identities.
log[λ(t,X)] = log[λ(t)] + exp(βX)
log[λ(t)] + β0 + β1X1 + β2X2 + . . .+ βkXk
(2.12)
log[Λ(t,X)] = log[Λ(t,X)] = log[Λ(t)] + exp(βX)
log[Λ(t)] + β0 + β1X1 + β2X2 + . . .+ βkXk
(2.13)
Accelerated Failure Time Models
Besides the PH survival regression formulation, where effect of predictors is multiplicative with
respect to hazard, other regression formulations can be specified. The AFT model is commonly
used; it assumes that the effect of covariates are multiplicative (i.e. proportional) with respect
to event time or additive with log event time, known as the AFT assumption. The effect of the
predictor is alter the rate at which the subjects proceed along the time axis (i.e. to accelerate or
shorten the time to event [143]). The model is
S(t,X) = ψ
(
log(t)− βX
σ
)
(2.14)
where ψ is any standardised survival distribution function. The parameter σ is called the scale
parameter. The model could also be stated as ψ ∼ [log(T ) − βX]/σ. The Weibull and
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exponential are the only two distributional families that can accommodate both AFT and PH
assumptions.
The interpretation of parameters in different in AFT models from that of PH models. The AFT
assumption is applicable for the comparison of times until event. Whereas, the PH assumption
is applicable for the comparison of hazard. Many parametric survival models are AFT models,
rather than PH model.
Using an example from Kleinbaum & Klein [162], the AFT assumption can be illustrated by
considering the comparison of survival functions among smokers S1(t) and non-smokers S2(t).
The AFT assumption can be expressed as S2(t) = S1(γt) for t ≥ 0, where γ is a constant
called the acceleration factor comparing smokers and non-smokers. In a regression framework
the acceleration factor γ could be reparameterised as exp(β) where β is a parameter to be
estimated from the data. With this parameterisation, the AFT assumption can be expressed as
S2(t) = S1[exp(β)t] or equivalently S2[exp(−β)t] = S1(t) for t ≥ 0.
The AFT assumption can also be expressed in terms of random variables for survival time
rather than the survival function. If T2 is a random variable (from some known distribution)
representing the event time for non-smokers and T1 is a random variable representing event
time for smoker, then the AFT assumption can be expressed T1 = γT2. The logλ and logΛ
transformations of the PH model has the following equivalent for AFT models.
ψ−1[S(t,X)] =
log(t)− βX
σ
(2.15)
letting  denote a random variable from the distribution ψ, the model is also
log(T ) = βX + σ (2.16)
So the property of the response T of interest for regression modelling is log(T ). A one-unit
change in Xj is then most simply understood as a βj change in log event time. The one-unit
change in Xj increases the event time by a factor of exp(βj) [112].
The acceleration factor is a key term of interest obtained from AFT models. It enables the
evaluation of the effect of predictors on time until event, just as the hazard ratio allows the
evaluation of the effect of predictors on hazards . In AFT models the acceleration factor de-
scribes the "stretching out" or contraction of survival functions when comparing one group to
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another [162]. Hence the idea accelerating (or decelerating) toward the event of interest. More
specifically, the acceleration factor is a ratio of survival times corresponding to any fixed value
of S(t) [162].
The idea is graphically illustrated by examining for Group 1 (G1) and Group 2 (G2) show in
figure 2.7. For any fixed value of S(t), the distance of the horizontal line from the S(t) axis to
the survival curve for G = 2 is double the distance to the survival curve for G = 1. Notice that
the median survival time (as well as 25th and 75th percentiles) is double for G = 2. For AFT
models, the ratio of survival times is assumed constant for all fixed values of S(t) [162].
Figure 2.7: Graphical illustration of the AFT assumption and the acceleration
factor γ in the comparison of the survival curves amoung two groups (source:
Kleinbaum & Klein, 2005 [162]).
The Cox Proportional Hazards Model
In medical and epidemiological studies the Cox Proportional Hazards model [48] (or Cox re-
gression) is the most is the most often used model for survival outcomes [112, 286]. Just as in
the fully parametric form of the PH model, the Cox model is analogous to the logistic model
for binary uncensored data, for a survival outcome. Indeed, the Cox model is equivalent to con-
ditional logistic regression, with conditioning at times where events occur [184]. Again, just
as is the case of the logistic model, different variants (some simpler and some more extensive)
exist, which can be seen as special cases or extensions of the Cox model.
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The Cox regression model is often stated in terms of the hazard function cite [307, 286]:
λ(t,X) = λ(t)exp(βX) (2.17)
Note that the Cox model is an example of a PH model where we do not include an intercept
parameter in the regression effect βX = β1x1 + β2x2 + . . .+ βkxkdfd.
It as a semi-parametric method; it makes a parametric assumption concerning the effect of the
predictors in the hazard function (i.e proportionality of effect during follow up), but baseline
hazard function λ(t) is non-parametric meaning that it makes no assumption regarding the
nature of the baseline hazard function itself. The Cox PH model assumes that predictors act
multiplicatively on the hazard function but does not assume that the hazard function is of a
particular form, such as exponential or Weibull. This is an advantage of the model, as in
many situations either the form of the true hazard function is unknown or it is complex. This
is particularly advantageous when the primary the interest of the study is the effect of the
predictors, rather than the shape of λ(t) (which is often the case), as the Cox PH models allows
the analyst to essentially ignore λ(t). Another advantage is that the Cox PH model is less
effected by outliers when compared with parametric methods, due way it used rank ordering of
failure and censoring times.
For estimating and testing regression coefficients, the Cox model is as efficient as paramet-
ric models even when all the assumptions of the parametric model are satisfied [74]. When a
parametric model’s assumptions are not true (i.e. when a Weibull model is used and the distri-
bution of event time does not in fact follow a Weibull distribution and thus the choice of model
is incorrect), the Cox analysis os more efficient that the parametric analysis. For prognostic
modelling we need to predict the risk of the event over time, for example by using the cumu-
lative hazard or survival function. In exactly the same way as in with the general PH model
formulation, the Cox PH can be rewritten in terms of the survival functions:
S(t,X) = S(t)exp(βX) (2.18)
However, in the Cox the non-parametric baseline survival hazard S(t) has not been specified,
it is usually estimated from data using the mean values of the predictors. The baseline survival
is estimated from the non-parametric baseline hazard function as
S(t) = exp[−Λ(t)] (2.19)
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where Λ(t) is the cumulative hazard at time t. The baseline survival in the training data de-
termine the precise time points where we can make prediction for, which is not very natural for
application of the model in new subjects.
Whilst Cox regression and the KM estimator are more flexible than parametric regression mod-
els in their dealing with the baseline hazard function, extrapolation is not readily possible with
Cox or KM analysis because of their non-parametric nature. Predictions at the end of follow-
up are quite unstable with Cox or KM analysis, and are more robust with parametric survival
analysis. For estimation of the effect of predictors, the Cox model is often more suitable than
an exponential or Weibull model. However, log-logistic models have been useful in situations
where predictors worked especially during an early, acute phase of the hazard, which would
show as non-proportional hazards in a Cox model [112]. Note finally that some of the more
flexible methods for binary data have also been extended to survival models, but are not com-
monly used yet (e.g. neural networks) [115, 286].
2.9 Non-linear Statistical Methods
2.9.1 Evolutionary Computation
Other methods for survival analysis are based on Artificial Intelligence (AI) and machine learn-
ing. Hereafter, these will be jointly referred to as non-linear statistical methods or models.
Conventional linear and non-linear regression techniques seek estimate (i.e. optimise) the para-
meters to some pre-specified model structure. In contrast, if a search process works simultan-
eously on both the model structure and model parameters, the technique is called symbolic
regression [167]. Symbolic regression avoids imposing a priori assumptions, and instead in-
fers the model from the data. To obtain the best quality approximation in symbolic regression
we do not specify the size or structural complexity of the model in advance, and no particular
model is provided as a starting point to the algorithm. Instead, initial solutions are formed by
randomly combining mathematical building blocks such as mathematical operators. By not
requiring a specific model to be specified, symbolic regression isn’t affected by human bias,
or unknown gaps in domain knowledge. It attempts to uncover the intrinsic relationships of
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the dataset, by letting the patterns in the data itself reveal the appropriate models, rather than
imposing a model structure that is deemed mathematically tractable from a human perspective.
This approach has, of course, the disadvantages of having a much larger problem space. This
space, referred to as the search space, comprises of all possible solutions to the problem at
hand. In fact, not only is the search space for symbolic regression infinite, but also there are
an infinite number of models that could perfectly fit a finite data set (providing its complexity
isn’t artificially limited in some way). Clearly the search space is clearly too vast for a blind
random search. Therefore some intelligent adaptive way to search the space is required.
In computer science, EC is a subfield of AI and machine learning that borrows liberally from
population biology, genetics and evolution. Algorithms chosen from this collection are known
as Evolutionary Algorithms (EA), which are search techniques based on computer implement-
ations of mechanisms inspired by biological evolution such as reproduction, mutation, recom-
bination, and natural selection. The process of evolution by means of natural selection (descent
with modification) was proposed by Charles Darwin in "On the Origin of Species: By Means
of Natural Selection or the Preservation of Favoured Races in the Struggle for Life" [57] in
1859, to account for the variety of life and its suitability (adaptive fit) for its environment [29].
These evolutionary mechanisms describe how evolution actually takes place through modific-
ation and propagation of genetic material. Evolutionary algorithms are adaptive computational
systems that utilise simplified versions of the processes and mechanisms of evolution, to search
for (approximate) solutions to problems.
An EA is referred to as an Adaptive Strategy and a Global Optimisation technique, because it
can effectively explore very large search spaces without being trapped in local optima. This
makes EA well suited to symbolic regression, where the search space is vast. Also, because
evolutionary algorithms require diversity in order to effectively explore the search space, the
end result is likely to be a selection of high-quality solution, both in model structure and the
corresponding set of parameters.
Most EA s may be divided into generational algorithms, which update the entire sample once
per iteration, and steady-state algorithms, which update the sample a few candidate solutions
at a time [195]. For many specific EA s, there are both generational and steady-state versions
of the algorithm. Based on Luke 20013 [195], we present a basic generational form of an
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evolutionary algorithm in algorithm 2.1. The basic generational EA first generates an initial
starting set of solutions to the problem, know as an initial population, and then iterates through
three procedures. Firstly, each of these solutions, known as individuals, are evaluated to assign
a numerical measure of fitness, which is some measure of quality of the individual solutions
ability to address the problem. Secondly, this fitness information is used to determine how to
breed a new population of children form the current population who act as parents. Thirdly,
the parent and children populations are joined somehow to form the next-generation population,
and the cycles continues. These steps are repeated until a pre-specified stop criterion is satisfied,
usually when a maximum number of generations is reached or when the best individual reached
some defined level of quality (fitness).
Algorithm 2.1 An Abstract Generational Evolutionary Algorithm. [195]
1: P ← Build initial population
2: Best←  .  means "nobody yet"
3: repeat
4: AssessFitness(P )
5: for each individual Pi ∈ P do
6: if Best =  or Fitness(Pi) > Fitness(Best) then
7: Best← Pi
8: end if
9: end for
10: P ← join(P , Breed(P ))
11: until Best is the ideal solution or we have run out of time
12: return Best
2.9.2 Genetic Programming
In its simplest form, representation is the data structure used to define the the solution, i.e. the
individual. However, we can also think of representation as the approach we take constructing,
modifying, and presenting the individual for fitness assessment. In EC there is no single rep-
resentation of an individual. The representation is usually based on the type of problem we are
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tying to address or personal preferences of the investigator. Chronologically we can distinguish
the following main subclasses of EC as:
• Evolutionary Programming (EP) , was developed by Lawrence Fogel [87, 88] in the
early 1960s. EP was originally based on graph representations (specifically finite-state
automata). This family of algorithms are inspired by macro-level or the species-level
process of evolution (phenotype, hereditary, variation) and is not concerned with the
genetic mechanisms of evolution (genome, chromosomes, genes, alleles) [29].
• Evolutionary Strategies (ES) , introduced by Ingo Rechenberg and Hans-Paul Schwe-
fel [249, 250, 163] in the mid 1960s, uses real-valued vectors, typically of fixed length,
mainly for parameter optimisation. It is an almost identical approach to that of Fogel’s
EP which is also inspired by the same species-level process of evolution [29].
• Genetic Algorithms (GA) , invented by John Holland [128] in the 1970s, typically uses
fixed-length bit-strings to encode solutions. The GA is inspired by population genetics
(including heredity and gene frequencies), and evolution at the population level, as well
as the Mendelian understanding of the structure (such as chromosomes, genes, alleles)
and mechanisms (such as recombination and mutation) [29].
A fourth class of evolutionary algorithm was first proposed by Nichael Cramer in 1985 [50].
However, it is John Koza who is credited with the development and popularisation of the field
of GP with though his considerable work and his 1992 monograph on GP [167], the seminal
reference for the field. In his book Koza performs a number of GP experiments, evolving
computer programs to solve a range of problems, including symbolic regression.
The most common form of GP, tree-based GP , uses trees as its representation. Consider the
tree in figure 2.8, containing the mathematical expression max(x + x, x + 3y). This is the
parse tree of a simple program which performs this mathematical operation. There are several
advantages to using parse trees to represent the solution, including, preventing syntax errors,
which could lead to invalid individuals, and the hierarchy in a parse tree resolves any issues
regarding function precedence. Tree-based GP features heavily in n Koza’s seminal work in
the field. However, in addition to trees, there are other important representations that include
graph and linear representations [239, 17].
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Figure 2.8: A symbolic regression parse tree representing max(x + x, x + 3y)
(source: Poli et al., 2008 [239]).
As with GAs, the GP algorithm is inspired by population genetics, and evolution at the pop-
ulation level, as well as the Mendelian understanding of the structure and mechanisms [29].
Genetic algorithms and GP are very similar EA s, their main difference is in their encoding
of the solution, with the former is used in parameter optimisation, while the latter evolves the
structure of the approximation model.
In GP we evolve populations of computer programs or solutions. That is generation by gener-
ation, GP stochastically transforms populations of programs into new, hopefully better, popu-
lations of programs (figure 2.9). GP automatically solves problems without requiring the user
to know or specify the form or structure of the solution in advance [239]. This makes GP well
suited to symbolic regression, where in addition searching for the solution to the complex as-
sociations between predictors and outcome, GP also searches for the optimal model structure.
Which in turn makes GP well suited to prediction, primarily an estimation problem, where
the mutual correlations between predictors and the outcome are to be estimated. GP has been
shown to work well for recognition of structures in large datasets and has the intrinsic advantage
of automatically select a subset of inputs or features during the evolutionary process [212].
Because GP has no fixed model structure it can represent complex non-linear associations that
could not be achieved using linear regression techniques, and theoretically achieve higher pre-
dictive accuracy. However the flexibility of regression models can be greatly enhanced through
the use of factional polynomial, restricted cubic splines and interaction terms, potentially in-
creasing its predictive accuracy [22, 111, 112, 164]. However, it has be emphasised that this is
not normally done as it complicate interpretation and the correct use of the appropriate regres-
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Figure 2.9: Generational GP flowchart (based on Koza [167]). M is the popula-
tion size and Gen is the generation counter. The termination criterion can be the
completion of a fixed number of generations or the discovery of a good-enough
individual (source: Sipper., 2011 [278]).
sion methods is quite difficult, as they require extensive statistical knowledge [271]. Another
characteristic of GP that is advantageous for symbolic regression is the automated selection of
inputs. Not all input (i.e. predictor) variables have a significant effect in the outcome. Typ-
ically in clinical prediction modelling and survival analysis, we start out with a large set for
candidate predictors and only a small subset if these are used in the final (i.e best) model. The
task of identifying this subset is called feature selection, something that GP does inherently and
robustly as part of the evolutionary process. The main drawback of GP for symbolic regression
is its high computational cost, due to the potentially infinite search space. This can be atten-
uated to some degree by limiting the mathematical building blocks provided to the algorithm,
based on existing knowledge of the problem domain and the system that produced the data.
On the other hand, the recent availability of fast multi-core systems has enabled the practical
application of GP in many real-world application areas.
The focus of this thesis is on regression models, which are the most widely used in the med-
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ical domain, for the prediction cardiovascular risk in patients with T2DM. We only consider
situations where there are a limited number of variables, say less than 25. This is in contrast to
other research areas such as genomics (genetic effects), proteomics (protein effects), and meta-
bolomics (metabolite effects). In these areas there often large number of candidate predictors
(features), often >10,000. The application of GP to these types of biomedical problems is an
active research area and experienced a degree of success (see chapter 3). Obtaining predictions
form a model has to be separated from obtaining insights in the disease mechanisms and patho-
physiological processes. Such insights are related to the estimated effects of predictors in a
model. Often predictions models serve the latter purpose too, but the primary aim considered
in this thesis is outcome prediction. However we endeavour to present and interpret and re-
lationships discovered by the final GP system, effectively generating hypotheses on disease
mechanisms and patho-physiological processes.
Our main focus is on the evolution of symbolic expressions (the clinical prediction models)
and we will use a classical GP approach using trees to represent the models or solutions. A
tree-based representation is adopted because it offers many benefits when implementing the
GP algorithm in computer code. In many programming languages, particularly interpreted
functional ones, expressions are internally represented as trees, meaning expression can be
directly evaluated by the interpreter. This potentially enables the whole spectrum of functions
available within a language to be used as inputs of building blocks to the GP system.
2.10 Motivation
The current body of research and a lack of consensus on which risk score is most appropriate
for UK general practice suggests the need for cardiovascular risk models that are closely cal-
ibrated to the contemporary UK T2DM population. Such models would enable physicians and
health policy makers to not only understand the risk of a certain outcome but also understand
the changes in risk resulting from changes in treatment. We investigate the utility of tree-based
GP for survival analysis, more specifically for the prediction of cardiovascular risk in UK pa-
tients with T2DM. To some, GP may not seem to be the best suited or obvious choice for
clinical prediction modelling. Traditional statistic methods are well researched, widely taught,
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widely available, relatively straightforward, and relatively fast to execute. However in addition
to being widely used, they are widely abused, and the correct application of these traditional
statistical models can often require significant statistical knowledge and expertise, as well spe-
cific knowledge of the application domain.
The main advantage of GP is that it performs a global search for a model, contrary to the
local search of most traditional machine learning algorithms [76, 90] and statistical meth-
ods. This gives the potential to discover potentially complex non-linear patterns that could
not be discovered by traditional techniques. Whilst GP is computationally expensive, the
recent availability of fast multi-core systems had attenuated this some degree. Another ad-
vantage of GP is the fact that clinical prediction models can automatically generated without
the, sometimes signifiant, statistical and clinical expertise required in traditional modelling
approaches. Whilst GP is more complicated to validate by clinicians when compared to tra-
ditional statistical approaches, it is not a black-box method and can be validated, unlike some
traditional machine learning algorithms. There have been several studies that have compared
other novel machine learning algorithms with their classic statistical counterparts for survival
outcomes [148, 138, 229, 248, 269, 265], however the results are mixed as to whether these ma-
chine learning methods offer improved performance. GP has been used in medical research for
classification and, to a lesser extent, prediction. However its value for prediction on censored
data, for survival analysis, is not yet been documented.
2.11 Summary Conclusions
We introduced clinical prediction modelling and its role and importance in predicting the risk
of CVD in UK patients with T2DM. As discussed in section 2.4 the structure of the UK NHS
means that UK General Practices are the ’gatekeepers’ to the NHS, and as such primary care
data, especially that which is linked with other sources of data, provides a rich resource for
prognostic research. In section 2.5, we gave an overview of the aspects of design of prognostic
studies, comparing and contrasting trials and observational studies. We outlined that trials by
their very nature select a very specific group of individuals, typically without comorbidity or
polypharmacy. The outcome of interest in this research project is CVD, which typically affects
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older people who in turn typically have comorbidites and polypharmacy. We then argued that
prediction of cardiovascular risk in patients with T2DM would be most appropriately evaluated
using an observational cohort study. In sections 2.5.2 we detail how the strengths of retro-
spective study designs are further enhanced by the increasing availability of electronic patient
records in primary and secondary care. In section 2.6 we described the CPRD and justified its
selection as the suitable dataset for the experiments in this study, and in section 2.7 discussed
the clinical coding conventions that we will to work with in the refining observational cohorts
from CPRD.
In section 2.8, we discussed how time until event is an important outcome in long-term chronic
conditions such as CVD and diabetes. This is because simply defining the outcome as whether
or not the event happened, typically modelled using logistic regression, would be discarding
valuable information and sacrificing statistical power. We also discussed a key characteristic
of time until event data, censoring, and what specific challenges this presents when modelling
such data. We then gave an overview of current linear statistical methods for addressing the
challenges of censored data, a collection of methods referred to survival analysis. Cox Regres-
sion appears to provides the default framework for prediction of long-term chronic outcomes
in the presence of censoring. Kaplan-Meier analysis provides a non-parametric method, but
requires categorisation of all predictors. Parametric survival models are more complicated but
are parsimonious and robust, and are are particularly useful for prediction at the end of, or even
beyond the observed follow-up.
In section 2.9.1 we introduce AI and machine learning for survival analysis and give an over-
view of symbolic regression and the field EC, discussing its strengths and weaknesses. We
discuss how symbolic regression has the potential to discover complex non-linear relationships
between outcome and predictors, that could not be represented using classic linear statistical
approaches.
In section 2.9.2 we introduce GP, a particular algorithm within the collection of techniques
know as EC. In GP we evolve populations of models. That is generation by generation, GP
stochastically transforms populations of models into new, hopefully better, populations of mod-
els We discuss how GP is a relatively recent technique that shows potential, which may improve
the selection and transformation of predictors, and may lead to models with good predictive ac-
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curacy in new patients. We discuss the relative strengths and weaknesses of GP. GP is well
suited to symbolic regression, however its almost infinite search space make this a computa-
tionally extensive approach. However, this has been attenuated by the recent availability of fast
multi-core systems.
Finally in section 2.10, we provided motivation for the thesis. The current body of research
suggests the need for cardiovascular risk models that are closely calibrated to the contemporary
UK T2DM population. GP is a recent approach that has shown potential when used in medical
research for classification and, to a lesser extent, prediction. However its value for prediction
on censored data, for survival analysis, is not yet been documented.
In the next chapter, we will focus on survey and critical assessment of existing research in
relation to this thesis.
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Table 2.5: Chapter structure of the ICD-10 classification system
Chapter Blocks Title
I A00–B99 Certain infectious and parasitic diseases
II C00–D48 Neoplasms
III D50 –D89 Diseases of the blood and blood-forming organs and certain
disorders involving the immune mechanism
IV E00–E90 Endocrine, nutritional and metabolic diseases
V F00–F99 Mental and behavioural disorders
VI G00–G99 Diseases of the nervous system
VII H00–H59 Diseases of the eye and adnexa
VIII H60–H95 Diseases of the ear and mastoid process
IX I00–I99 Diseases of the circulatory system
X J00–J99 Diseases of the respiratory system
XI K00–K93 Diseases of the digestive system
XII L00–L99 Diseases of the skin and subcutaneous tissue
XIII M00–M99 Diseases of the musculoskeletal system and connective tis-
sue
XIV N00–N99 Diseases of the genitourinary system
XV O00–O99 Pregnancy, childbirth and the puerperium
XVI P00–P96 Certain conditions originating in the perinatal period
XVII Q00–Q99 Congenital malformations, deformations and chromosomal
abnormalities
XVIII R00–R99 Symptoms, signs and abnormal clinical and laboratory find-
ings, not elsewhere classified
XIX S00–T98 Injury, poisoning and certain other consequences of external
causes
XX V01–Y98 External causes of morbidity and mortality
XXI Z00–Z99 Factors influencing health status and contact with health ser-
vices
XXII U00–U99 Codes for special purposes
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Chapter 3
Related Work
Next we focus on survey and critical assessment of existing research in relation to this thesis.
First we review and assess the performance of the numerous existing cardiovascular risk scores
for the general population and for patients with T2DM . Before reviewing previous work on
GP in the biomedical and health domain, we review the wider field of machine learning for the
survival analysis. Finally we assess previous work specifically on GP for prognostic research.
3.1 Cardiovascular Risk Scores for the General Popu-
lation
In public health, prediction models may help target preventative interventions to subjects with
relatively high risk of having or developing a disease. Various model have been developed
to predict the future occurrence of disease in asymptomatic subjects in the population. Well
known examples are the Framingham risk functions for cardiovascular disease [314]. The
Framingham risk functions underpin several current policies for preventative interventions. For
example, lipid-lowering therapies are only considered for those with relatively high risk of
cardiovascular disease.
Since the Framingham risk scores were first published in 1976 [144] several other cohort
studies have developed their own risk equations including PROCAM [11], SCORE [46] and
QRISK [124]. These cohort studies differ significantly in terms of study population character-
istics, risk predictors, and outcome [189].
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A systematic review [189] identified 21 risk scores from 18 papers. Five were from Framing-
ham [3, 8, 144, 314], three from the Munster group (PROCAM) [11, 12] and ARIC (Athero-
sclerosis Risk in Communities) [34, 200], two each from QRISK [124, 125, 123] and Reyn-
olds [253, 254], and one each from the Scottish Heart Health Extended Cohort [318], Strong
Heart Study [185], USA-PRC (People’s Republic of China Collaborative Study of Cardiovas-
cular Epidemiology) [320] and NHEFS (National Health and Nutrition Examination Survey
NHANES I Epidemiological Follow-up Study) [93]. Some risk scores used multiple cohorts:
SCORE [46] was derived from a pool of 12 European cohorts, and Progetto CUORE [233]
from a pool of Italian cohorts. Twelve are from North America, eight are European, and one
from China.
The use of routinely collected data from general practice patient records has been proposed
for this research project and the access to CPRD (www.cprd.com) has been agreed for this
purpose. The merit and appropriateness of using this type of routinely collected primary care
data for the development of predictive models for cardiovascular disease has been validated by
the work of Hippisley-Cox et al. [124, 125, 121, 120, 122] in developing QRISK and QRISK2.
QRISK and then later the improved QRISK2 are cardiovascular risk prediction models (or
risk calculators) for the general population. This approach has been further endorsed by the
recommendation from National Institute of Clinical Excellence (NICE) that QRISK2, due its
improved predictive power and better calibration with UK population, be used for predicting
cardiovascular risk in UK general practice [217].
3.2 Cardiovascular Risk Scores for Type 2 Diabetes
People with T2DM have a two-fold increase in the risk of CVD [293, 317]. National policies
for the management of both CVD and T2DM advocate the calculation of CVD risk in order
to identify high-risk patients for targeted interventions [264, 295, 245, 66, 216]. Several mul-
tivariable risk-prediction models have been developed for the general, non-diabetic population
that also account for diabetes, but only a few are specific to T2DM [303]. A systematic review
by Van Dieren et al. [303] identified twelve studies where CVD risk scores were developed
specifically for people with T2DM, and thirty-three were were developed for the general popu-
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lation with diabetes as a risk factor in the model. The majority of these models were developed
from a predominantly white population, and twelve were developed in Asian populations (In-
dia, China, Japan) [303] . Study sample sizes ranged between 698 and 1.5 million subjects.
Of the diabetes-specific models only two have been developed in patients with newly dia-
gnosed T2DM , and they both use data from the United Kingdom Prospective Diabetes Study
(UKPDS) [298]. These two models—one for Coronary Heart Disease (CHD) and the other for
stroke—combine to form the UKPDS-RE [165, 284]. The other study populations composed
of subjects with varying durations of diabetes. The majority of these models predicted 5-year
risk and used and average of eight predictors. The most commonly used predictors were age,
gender, duration of diabetes, HbA1c, and smoking status.
Discriminative ability or discrimination is the ability of a risk score to differentiate between
patients who did and did not experience an event during the study period. This measure can
be quantified by calculating the area under receiver operating characteristic curve (AUC) [107]
(equivalent to the c statistic for a binary outcome), in which a value of 0.5 represents ran-
dom chance, while 1 represents perfect discrimination. Nine of the twelve studies reported
the discrimination of their risk scores, with AUC values ranging from 0.68 to 0.85 [303]. In
terms of AUC, values of 0.7 up to 0.8 indicate acceptable model discrimination [55, 131]. Cal-
ibration refers here to how closely the predicted x-year cardiovascular risk agreed with the
observed x-year cardiovascular risk. Eight of these studies reported measures of calibration
using Hosmer-Lemeshow goodness-of-fit statistic [131], p-values for which were all >0.05, in-
dicating no significant lack of calibration [303]. Only half of these model internally validated
their performance using resampling (e.g. split-sample, cross-validation, bootstrapping) tech-
niques to correct for the overoptimism inherent when evaluating performance of models on the
data in which they were developed.
The majority of models developed for the general population with diabetes as a risk factor
predicted 10-year risk and used an average of eight predictors. The most commonly used pre-
dictors were age, gender, Systolic Blood Pressure (SBP), smoking status, lipid measurements
and diabetes.
Twenty of the 33 studies reported discrimination, with AUC values ranging from 0.65 to
0.86 [303]. Twelve of these studies reported measures of calibration, all with Hosmer-Lemeshow
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p-values > 0.05 [303]. Twelve of the models were internally validated using some form of res-
ampling technique.
According to Van Dieren et al. [303], Thirty studies externally validated 14 different pre-
diction models in patients with T2DM . Nine studies validated two versions of the UK-
PDS risk engine [165, 284], 10 studies validated three versions of the Framingham Prediction
model [3, 314, 9, 8] and nine other prediction models were externally validated only once.
The UKPDS-RE CHD equations [284] have been externally validated in 10 separate stud-
ies [103, 139, 283, 322, 155, 237, 58, 304, 280, 302] which observed moderate discrimination
and poor calibration, overestimating risk. The UKPDS-RE stroke equations [165] were valid-
ated in two separate studies [155, 58] with contrasting results, one reporting moderate discrim-
ination and the other reporting good discrimination and good calibration. The largest of these
studies from the UK used only a small sample (n=798) and from a single locality [283]. The
largest international study had a larger but still relatively small sample size (n=7 502), using
data collated from 20 countries [155]. The versions of the Framingham model by D’Agostino
et al. [3] and by Anderson et al. [9, 8] were externally validated in a cohort with diabetes three
times and the version by Wilson et al. [314] four times. Discriminative ability was moderate,
with poor calibration. Of the risk scores that were only validated once, the Fremantle [58] score
preformed the best with good calibration and discrimination.
Less than a third of the CVD risk scores identified in systematic review by Chamnan et al. [35]
and Van Dieren et al. [303] were externally validated, with varying results. Both the diabetes-
specific and general population risk scores reported good discriminative ability in the data in
which they were developed (apparent and internal validation). However, their discriminative
ability in new, previously unseen cohorts of patients (external validation) varied widely. The
discrimination in models for the general population were generally moderate and the calibration
mostly poor. As suggested by both Chamnan et al. [35] and Van Dieren et al. [303], this could
be explained by differences in the incidence of CVD between patient with and without T2DM
or by the fact that risk models developed in the general population do account for diabetes-
specific risk factors. They argue that this could be overcome by using only diabetes-specific risk
models for patients with diabetes. However, when the diabetes-specific risk models have been
externally validated in new patients, the calibration was also poor with moderate to good calib-
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ration. The more contemporary models such as the DCS [78], Fremmatle [58] and DARTS [72],
appeared to have the best external validity, however these models were only validated once and
therefore more external validation studies are required on different cohorts.
3.3 Genetic Programming in Bioinformatics
GP has long been applied to medicine, biology and bioinformatics. Early work by Hand-
ley [106] and Koza & Andre [169] used GP to make predictions about the behaviour and prop-
erties of biological systems, principally proteins.
Since then GP is has been widely used in biomedical data mining. Often the information
that is of particular medical interest takes the form of very wide datasets, that is datasets with
a relatively large number of columns, inputs or dependent variables [183]. Examples include
chemical analysis using analytical techniques such as Fourier Transform Infrared Spectroscopy
(FTIR), Gas Chromatography-Mass Spectrometry (GCMS), etc [114, 227, 140, 202, 290];
many more from Kell et al. (see below), Single Nuclear Polymorphisms (SNP)s where a typ-
ical data set may contain as many as 300,000 SNPs for 500–1,000 patients [19, 251, 272] and
Affymetrix GeneChip microarray data [62, 80, 117, 126, 130, 174, 187, 190, 323].
Kell and his colleagues in Aberystwyth, and later Manchester, have had great success in apply-
ing GP widely in bioinformatics [5, 59, 79, 98, 97, 94, 94, 141, 153, 152, 154, 151, 273, 301,
316]. Another very active group is that of Moore and his colleagues in Vanderbilt , and later
Dartmouth, [211, 213, 256, 257].
3.4 Genetic Programming in Prognostic Reseach
Albeit to a lesser extent than the biomedical domain, GP has been applied to specifically to
medical diagnosis and prognosis [22, 192, 25, 193, 156]. However with the notable exceptions
of Biesheuvel et al. [22], GP has been applied to data from clinical tests where there are a large
number of readings but few samples, similar to biomedical data mentioned previously. This is
contrary to the dataset proposed for this research project, which will come from general practice
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records, where there are a relatively large number of samples and relatively fewer readings.
This is also preferable in prognostic modelling, as a larger number of samples will increase the
quality of the model, as too do fewer readings or inputs. A systematic literature search over
PubMed, the largest database of biomedical publications, did not identify any applications of
GP for medical diagnosis/prognosis using routinely collected primary or secondary care data,
for which the data would consist of numerous samples in contrast to other types of biomedical
data.
Biesheuvel et al. [22] compare GP and multivariate logistic regression in the development of
a diagnostic prediction model using empirical data from a prospective diagnostic study among
398 patients in secondary care upon diagnosis of Pulmonary Embolism (PE) . Results report
that the AUC of the GP model was significantly larger (0.73; 95%CI: 0.64–0.82) than that of
the logistic regression model (0.68; 0.59–0.77), with comparable calibration or model-fit. The
significantly larger AUC value suggests that GP may be better at discriminating those who
experience the event of interest (for example, PE) versus those who do not. However where
AUC values have been reported in the literature reviewed, most tend to be around 0.6–0.7.
However it is important to stress that improved discrimination of GP in diagnosis of PE reported
by Biesheuvel et al. [22] is only a specific case. The ’no free lunch’ theorem suggests that no
single method will outperform all others on all cases [315]. Therefore it is important to further
evaluate the performance of GP for medical diagnosis and prognosis.
3.5 Genetic Programming for Survival Analysis
The literature reviewed reports an enormous number of applications where GP has been suc-
cessfully used [239]. The literature suggests that the specific GP task required by the project is
that of symbolic regression [17, 167, 239]. Symbolic regression attempts to find a function that
fits the given data points without making any assumptions about the structure of that function.
Since GP makes no such assumption, it is well suited to this sort of discovery task [239]. Sym-
bolic regression was one of the earliest applications of GP [167], and continues to be widely
studied [30, 101, 149, 186].
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Symbolic regression and GP appears to be well suited to classification and regression, and as
discussed in the previous section, it has been successfully applied in clinical prediction model-
ling as an alternative for logistic regression where the data is uncensored [22, 136]. However,
there is a surprising paucity in the literature regarding the application of GP to survival analysis
and censored longitudinal data. There are lots of applications of GP for failure-time, reliabil-
ity analysis, time-series, and other temporal applications in domains such as engineering and
software development [327, 328, 188]. Surprisingly, there were no examples in the reviewed
GP literature that involved the handling of censored longitudinal data, the experimental settings
were such that every entity failed at least once and thus there was no censoring.
Expanding from the GP literature to the broader domain of AI and ML, there have been several
studies, ANNs in particular, that have compared such novel non-linear statistical methods with
their classic linear counterparts for survival outcomes [148, 138, 229, 248], however the results
are mixed as to whether these non-linear methods offer improved performance. For example
Schwarzer et al. [269] reviewed a substantial number of studies which have used ANNs in the
diagnostic and prognostic classification in cancer, concluding that there is no evidence so far
that application of ANNs represents real progress in the field of diagnosis and prognosis in
oncology. Sargent [265] has also reviewed a number of these comparison studies showing that
the majority have claimed equal performance but could not rule out the possibility of bias. GP ,
however, is a relatively recent technique that shows potential, which may improve the selection
and transformation of predictors, and may lead to models with good predictive accuracy in new
patients [22, 89, 136, 238, 297].
3.6 Summary Conclusions
In section 3.1 we introduce and review the large number of cardiovascular risk scores both
for the general population that account for diabetes and for populations with T2DM . These
models and they vary significantly in quality, development and validation methodologies, and
in study population characteristics, risk predictors, and outcome. The degree to which these
models have been assessed for generalisability in new cohorts also varies. The more contem-
porary models seemed to have the best external validity, however it is these models that have
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only been validated once. Therefore more external validation studies are required to assess the
performance of these models in different cohorts of subjects with T2DM . The moderate per-
formance of most prediction model suggests that it is difficult to predict CVD in patients with
T2DM [303].
In section 2.9 we introduce existing AI and machine learning techniques for survival analysis,
which to date have been predominately ANN. We discuss how previous studies comparing the
performance of these non-linear techniques to classic linear statistical approaches, have pro-
duced mixed results and that it remains unclear whether they offer any improved performance.
We also discuss how GP is relatively recent approach with a lot of potential and that has been
successfully applied for the purposes of symbolic regression in what is a well researched area.
In section 3.3 we discuss howGP has been applied with some success to the biomedical & health
domain, often through the use of symbolic regression. However, the bulk of this research has
been in biological domains such as modelling genomic data where there a disproportionally
large number of columns which benefit significantly from the feature selection inherent in the
evolutionary search process. To a lesser extent, GP has been successfully applied for prognostic
research. However, with a small number of notable exceptions ,this has utilised biological data
for prognosis rather than routinely collected longitudinal patient data.
In section 3.4 we discuss the results of out review of the research into the application of GP
for prognostic research. The review did not reveal any research into using GP with routinely
collected longitudinal health care data, which in contrast to biomedical data would have a
relatively large number of rows and fewer columns. There was a single example by Biesheuvel
et al. [22] where longitudinal patient data was used of prognosis, however it was using a small
prospective cohort specifically designed for prognostic research rather than routinely collected
data. The ’no free lunch’ theorem [315] suggests that it is important to further evaluate the
performance of GP for medical diagnosis and prognosis.
From the literature there appears to be only single example where GP has been used for pro-
gnosis in longitudinal patient-level data, however this example applied GP analogous to binary
logistic regression where the outcome is binary. As discussed in section 2.8.2 this would dis-
card valuable information and sacrifice statistical power.
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There appears to have been a number of studies that have used machine learning, predomin-
antly ANNs, for prognostic research where the outcome was time until event (i.e. a survival
analysis). Whilst some of the techniques have been evolutionary in nature, GP was not con-
sidered. Despite the success GP in other areas of the biomedical and health domain, the utility
of GP for clinical prediction modelling in the presence of censored data remain unknown.
In the next chapter we give an overview of the essential common themes in the diverse field
of GP. We introduce a GP framework which later chapters will build upon, offering high-level
overviews of the different elements, whilst also formally defining the specific methodological
elements that will be implemented to form the developed GP approach for survival analysis.
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Chapter 4
Genetic Programming
This chapter is give an overview of the essential common themes in the diverse field of GP. We
introduce a GP framework which later chapters will build upon, offering high-level overviews
of the different elements, whilst also formally defining the specific methodological elements
that will be implemented to form the developed GP approach for survival analysis. After giving
a high-level overview of a basic GP run, we introduce the concepts of solution representation
and search spaces in GP, as well as approaches to define valid regions in these search spaces.
Following on from this, we introduce ideas behind fitness and its role in guiding the GP search,
before defining fitness functions used in this work. Then we introduce the role of GP search
operators and define them. On that basis, we discuss different search strategies and define
the search heuristics that will be used to implement them. Next we discuss the parameters
that control the GP run and offer some guidance on suitable values for these. After which
we discuss uncontrolled intron growth and the phenomenon that is bloat. Finally we discuss
the considerations to be taken into account when implementing GP and define the specific
implementation of GP used in this work, discussing the rationale behind certain choices.
4.1 Introduction
In GP we evolve a population of computer programs. That is, generation by generation, GP
stochastically transforms populations of programs into new, hopefully better, programs (fig-
ure 4.1) [239]. For the context of this thesis a computer program is a symbolic regression
equation, which a mathematical formula representing a clinical prediction model. Just like
biological evolution, GP is a random (or stochastic) process and can never guarantee results.
64 4.1 Introduction
However it is this randomness that enables GP to overcome the some of the pitfalls, i.e. local
optima, that limit deterministic methods.
Figure 4.1: The basic control flow for GP, where survival of the fittest is used to
find solutions (source: Poli at al., 2008 [239]).
Taken from Poli at al., 2008 [239], the basic step in a GP system are shown in Algorithm 4.1.
GP finds out how well a model performs by applying it, and then comparing its behaviour to
some ideal (line 3). For the purposes of this thesis we are interested in in how well a model
predicts the risk of some clinical event . This comparison is quantified to give a numeric value
called fitness. Those models that do well are chosen to breed (line 4) and produce new models
for the next generation (line 5). Genetic variation operations are used to create (i.e. evolve)
new programs from existing ones.
Algorithm 4.1 Genetic Programming
1: Randomly create an initial population of models from the available primitives
(more on this in Section 4.2.1).
2: repeat
3: Execute each model and ascertain its fitness (Section 4.2.2).
4: Select one or two model(s) from the population with a probability based on
fitness to participate in genetic operations (Section 4.3.4).
5: Create new individual model(s) by applying genetic operations with specified
probabilities (Sections 4.3.2 - 4.3.3).
6: until an acceptable solution is found or some other stopping condition is met (e.g.,
a maximum number of generations is reached).
7: return the best-so-far individual .
4.2 Search Spaces & Fitness in Genetic Programming 65
4.2 Search Spaces & Fitness in Genetic Programming
This section provides an introduction to genotypic representations of individual solutions that,
that along with GP search operators, define of the search spaces that GP will explore. We also
introduce measures of quality, or fitness, of solutions in the search space. We discuss fitness in
the context of survival analysis before formally defining the fitness measures that will be used
in this work.
4.2.1 Search Spaces in Genetic Programming
In its simplest form, representation is the data structure used to define the the solution, i.e. an
individual. However, we can also think of representation as the approach we take constructing,
modifying, and presenting the individual for fitness assessment. Since early experiments into
the automatic generation of executable structures [85] a variety of different representations have
been explored including binary string machine code [91], finite state automata [86], generative
grammatical encodings [309, 230, 65] and the dominant tree-based form [166]. Numerous al-
ternative representations have also been proposed, including graph [291], strongly-typed [210],
linear [27], linear-tree [145], and linear- graph [146].
Unsurprisingly given our knowledge of the No Free Lunch theorem [315], with so many differ-
ent representation schemes the GP literature suggests that identifying appropriate representa-
tion schemes for certain type of problems remains an open issue, and as such is an active area of
GP research [231]. There have been novel approaches proposed to address this issue, exploring
the idea that GP can potentially evolve aspects of its own representation, such as Langdon’s
research on evolving data structures [180], Spector’s investigations on autocontructive evolu-
tion [281], which co-evolve the search operators in addition to the individuals [231]. Another
more recent approach is that of GP Hyperheuristics that look to explore search the space of
all alternative algorithms and representations. In their review of open issues in GP O’Neil et
al. [231] comment that Hyperheuristics are demonstrating early potential to outperform classic
GP, and in an exciting twist, theoretical analysis suggests that a Free Lunch may be possible
through their adoption [240, 241]. Whilst there is a diverse landscape of different representa-
tion schemes, the tree-based representation scheme popularised by Koza (1992) [167] remains
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the dominant form and is the focus of this work.
Consider the tree in figure 2.8, containing the symbolic expression max(x+ x, x+ 3y). This
is the parse tree of a simple program which performs this mathematical operation, consisting
of nodes that are elements of a terminal set and a functional set described in table 4.1. The
leaves of the tree are input (predictor) variables or constants forming the terminal set, while the
internal nodes are arithmetic operators that form the functional set. Together the terminal and
functional sets form the primitive set of the GP system.
Figure 4.2: GP syntax tree representing max(x + x, x + 3y) (source: Poli at al.,
2008 [239]).
The functional set can be further subdivided into binary nodes, that take two inputs to produce
an output, and unary nodes that take a single output. The primitive set represents the building
blocks (or genetic material) that will represent the potential solutions to the problem, the indi-
viduals. Over successive generations the search operators (discussed in section 4.3) and fitness
function will be applied to these building blocks to evolve populations of individuals towards a
suitable, hopefully optimal, solution.
By defining the set of primitives, i.e., the functions, input variables, constants, along with the set
of search operators (discussed in section 4.3), we define the search space that GP will explore.
This consists of all possible solutions that can be constructed by the set of search operators in
combining the primitives.
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Table 4.1: Example of primitives in GP terminal and functional sets.
Set Type Kind of Primitive Example(s)
Function Set Arithmetic +, ∗, /
Function Set Mathematical sin, cos, exp
Function Set Boolean AND ,OR,NOT
Function Set Conditional IF − THEN − ELSE
Function Set Looping FOR,REPEAT
Terminal Set Variables x, y
Terminal Set Constants 3, 0.45
Terminal Set 0-arity functions rand , go − left
Constraing Genetic Programming Search Spaces
In order to work correctly functional primitives in GP require an important property called
closure [167]. Closure is required because subtree crossover (described in section 4.3.3 can
mix and join nodes arbitrarily. Koza [167] describes closure as being satisfied when each
function is able to accept the output of any other function or terminal as in an input and remain
syntactically correct. In traditional GAs, closure is not required as the chromosome is not
treated as an executable programme [178].
Closure is the mechanism by which valid GP search spaces are defined. In GP there are two
main approaches to ensure closure and define valid regions in the search space, often referred
to as constraint handling in the EA literature. The first approach is to exclude invalid regions of
the search space. Typically this achieved by constraining the GP system structurally or though
some type system. Examples that fit into this category include simple structural enforcement,
strongly-typed GP, and grammar-based constraints. This class of approaches result in sharp
boundaries or margins in the valid regions of the search space.
The second and most common approach is to suppress invalid regions though fitness penalty
functions, that is invalid individuals are given a significantly reduced fitness value. This kind
of approaches leads to valid regions with softer margins. However, due to some the chal-
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lenges associated with penalty functions [252], different approaches to automatically define
good penalty factors and the development of alternative methods to handle constraints is an
active area of research in GP [40, 41, 42, 49, 207, 279, 171, 252]. Several variations of pen-
alty functions have been proposed in the EA literature including static, dynamic, annealing,
adaptive, co-evolutionary, and death penalties [40, 207]. Alternative methods that have been
proposed include repair functions that attempt to ’repair’ infeasible solutions making them feas-
ible, functions that separate objectives and constraints in MO optimisation settings, and hybrid
approaches that combine other techniques such as Lagrangian multipliers or fuzzy logic.
Both these high-level approaches have their relative strengths and weaknesses, and there are
some important considerations. Excluding invalid regions leads to a smaller search space. It
does necessarily apply that a smaller search spaces mean more tractable problems as sometimes
important intermediate solutions are excluded that assist the search in finding (near-) optimal
solutions. However, if there is domain knowledge that strongly suggests a particular syntactic
constraint on the solution, ignoring it will make is much harder to find a suitable solution.
All the experiments in this thesis utilise untyped GP and closure is partially satisfied by con-
sidering inputs coded as numeric variables. In our GP system implementation, invalid regions
include invalid mathematical operations (e.g. dividing by 0) and solutions that do not repres-
ent time (e.g. do not include the time indicator variable, j in some fashion). Where genetic
operations result in invalid solutions, then fitness penalised by setting the fitness value to∞ (it
the context of a minimisation problem). This approach, often referred to as the death penalty,
effectively rejects individuals and is arguably the easiest way to constrain the search space and
is computationally very cheap. Because invalid solutions have their fitness set to an extreme
value, their fitness does not need to be calculated and no further calculations are required to
quantify the degree invalidity or infeasibility the solutions. A key drawback of this is approach
is that does not exploit any information from the infeasible solutions that may be generated by
GP to inform the search.
There have been a number of publications in the active research area of constraint handling
that suggest that the death penalty in not a good approach. For example, Coit & Smith [43]
compared the death penalty against an adaptive penalty for a problem with a highly-constrained
search space and found that the adaptive penalty approach was superior. Michalewicz [208,
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209, 206] has shown that death penalty is inferior to penalties that are defined in terms of
distance from the feasible region.
However, as small comparative study by Coello Coello [40] suggests that even the use of the
death penalty may be sufficient in some applications, if nothing is known about the problem.
However, its important to note that the same authors report that most comparative studies on
constraint handling techniques in the literature are inconclusive and cite the the "No Free-Lunch
Theorem" of Wolpert & Macready [315], suggesting that its expected that the best constraint
handling techniques for a certain type of problem will tend to exploit specific domain know-
ledge.
Despite the limitations of the death penalty, the justification for its use as the constraint handling
approach for this work was its computationally efficiency and ease of implementation combined
with the fact that little is known about the application of GP to survival analysis. As discussed
in later chapters, the computational expense of applying the developed GP approach to large
clinical datasets was a recurrent challenge, and as pointed out by researches in the field, in some
applications, the problem of finding a feasible solution might be itself NP-hard problem [279].
4.2.2 Genetic Programming Ftiness Functions
Fitness is some numeric measure of quality of each solution within the search space. The fitness
function is the interface between the solution space, and the selection operator, that guides the
GP search to regions or elements of the search space that consist of high quality solutions
that solve (or approximately solve) the problem at hand. In GP, high quality solutions are 1)
accurate, 2) parsimonious, 3) interpretable and 4) generalisable.
Accuracy
In GP, solution accuracy is highly problem dependant. For example a measure of accuracy for
a classification problem would be very different from a metric that would quantify accuracy
in a regression problem. In symbolic regression, the focus of this thesis, accuracy is typically
measured by well-known error measures, which are the differences between observed yˆ and
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expected values y. In GP, commonly used error measures include mean-absolute error (MAE,
Equation 4.1), sum-square error (SSE, Equation 4.2), mean-square error (MSE, Equation 4.3),
root-mean-square error (RMSE, Equation 4.4), and scaled-mean-square error measure (SMSE,
Equation 4.5), where scaling constants a and b are calculated via a least-squares fit. However,
a limitation of these measures is that they cannot be used to compare models across different
datasets because they are dependent on scale. Although slightly more computationally expens-
ive to calculate, R2, the proportion of variance explained by a model, is scale-free. However,
this is constrained by the assumption of linearity in the model, which would be violated if the
data significantly non-linear.
mae(yˆ, y) =
1
n
n∑
i=1
|yˆi − yi| (4.1)
sse(yˆ, y) =
n∑
i=1
(yˆi − yi)2 (4.2)
mse(yˆ, y) =
1
n
n∑
i=1
(yˆi − yi)2 (4.3)
rmse(yˆ, y) =
√√√√ 1
n
n∑
i=1
(yˆi − yi)2 (4.4)
smse(yˆ, y) =
1
n
n∑
i=1
(yˆi − (a+ byi))2 (4.5)
Parsimony
However, solution parsimony is largely problem independent. This can be measured in a num-
ber of ways for abstract genotypes. Typically parsimony measure appropriate to tree-based
GP include tree size and tree depth. Tree size is merely the number of nodes in a (sub) tree.
Tree depth is the minimal number of nodes that must be traversed to get from the root node
of the tree to the selected node. Whilst being intuitive measure complexity, these and many
other metric suffer from their coarse granularity. That is, significantly different trees may end
up with same complexity value using these metrics. To address this issue, Keijzer & Foster
(2007) [150] introduced a measure of tree visitation length, vl, defined in equation 4.6, where
c(t) denotes the number of children of the root of tree t and ti denotes the ith subtree of t [150].
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vl(t) := s(t) +
c(t)∑
i=1
vl(ti) (4.6)
For trees t of fixed size s(t), vl(t) will give smaller values for balanced trees, and larger val-
ues to unbalanced trees. It can be used to steer the GP search towards smaller well balanced
solutions [83].
Interpretability
Solution interpretability is difficult to define explicitly and its utility is highly dependent on the
application domain. For example, with solutions to sales and marketing problems, the applic-
ation domain rarely cares how the solutions works, just that it works to increase profitability.
In our case, the medical domain, interpretability is vital because it enables clinical validation.
A clinical prediction models that is an excellent predictor of some important clinical outcome
(like cardiovascular disease), is highly unlikely to be adopted or given any credibility if domain
experts cannot understand how and why its such a good predictor. Whilst we cannot mathem-
atically quantify it, solution interpretability is certainly correlated with solution parsimony.
Generalisabilty
The generalisabilty of a solution relates to its performance in a dataset other than one in which
it was trained. The phenomenon of overfitting occurs when models learn not only the true pat-
tern in the data, that may generalise to other data with similar characteristics, but also learn
the pattern of the noise which is specific only to the training data. There are many approaches
to evaluating including split sample approaches and resampling approaches, such as bootstrap-
ping and cross-validation. Typically, more parsimonious solutions offer greater generalisability,
although this isn’t always the case.
Multi-objectve Fitness
In some cases it may advantageous to combine two or more different concepts that are on
competition with each other into the fitness function. For example we could combine terms
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solution complexity, and accuracy. Such a fitness function is referred to as a multi-objective
fitness function.
State of the art GP systems are typically Multi-Objective Genetic Programming (MOGP) sys-
tems. In MOGP we optimise with respect to multiple competing fitness measures, f1, f2, ..., fn,
simultaneously. The complexity of solutions is one of the most important things to control dur-
ing a GP. In some cases a significant increase in the complexity of individuals is observed,
without a significant increaser in the fitness of the solutions. This leads to a phenomenon re-
ferred to as bloat (discussed in section 4.6), which can be disastrous for the GP run. Therefore
MOGP provides an important mechanism for controlling complexity, whist simultaneously op-
timising other objectives such as the fitness of solutions
Many different approaches have been proposed to achieve multi-objective optimisation in GP.
The most simple approach is to combine these fitness vectors in a single aggregate scalar
fitness function, such as a weighted sum. This method has been used frequently in GP to
control bloat. By combining program fitness and solution size to form a parsimonious fitness
function one can evolve solutions that satisfy both objectives [167, 326, 325, 324]. There are
many other examples in the literature of linear and semi-linear aggregations of fitness with
other objective vectors [181, 18, 168]. However, these different fitness vectors are typically
on different scales and thus estimating appropriate weights can be non-trivial. Furthermore,
Pareto-optimal (discussed in subsection 4.3.4) solutions may be become unreachable. Typically
in modern MOGP systems the objectives are kept separate, with fitness defined as a vector of
real numbers. These fitness vectors then utilised by multi-objective selection operators, that
operate on the notion of Pareto dominance, which is described in subsection 4.3.4.
Fitness in the Context of Survival Analysis
However, none of the well studied fitness (error) measures discussed thus far are suitable fitness
measures for symbolic regression in the presence of censored survival data. This because unlike
simple linear regression, where these error measures would be appropriate, there is no single
continuous outcome y, with which to compare its distance from a models estimate yˆ. Rather,
in survival problems we have a two-part outcome, with a continuous time until event value and
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a dichotomous event indicator value.
As discussed in section 3.5, there is a surprising paucity in the literature regarding the ap-
plication of GP of survival analysis and censored longitudinal data. Expanding from the
GP literature to the broader domain of AI and ML, there have been some studies, ANNs in
particular, that have evaluated the performance of non-linear methods for survival outcomes
[148, 138, 229, 248, 255, 23, 158, 329, 172, 271]. These applications often utilise either Mar-
tingale residuals [255, 158, 329] or MLE [271] in some manner to develop goodness-of-fit (i.e
fitness) measures in the presence of censored survival data.
The Martingale residual may be thought of as the difference between the observed and expected
number of events for the ith individual. In the context of survival analysis, specifically where
an individual can experience an event only once or not at all, Martingale residuals assess the
relative magnitude of individuals time-to-event in comparison to what it predicted by a fitted
model [277]. Martingale residuals have a mean of 0 across subjects and range between−∞ and
1. Positive residuals indicate that the event occurred and that it occurred earlier that predicted
- that the model "overpredicts". Negative residuals indicate that either the event did not occur
(i.e. event time was censored); or the event occurred later than predicted - that the model
"underpredicts". Equation 4.7 defines Martingale residuals for the i-th individual as:
Mˆi = δi − Λˆ(ti) (4.7)
where δi is the number of events for the i-th subject between time 0 and ti, and Λˆ(ti) is the
expected numbers based on the fitted model.
However there are potential issues or limitations associated with Martingale residuals. As a
consequence of their definition (equation 4.7) Martingale residuals have a maximum of 1, are
skewed towards negative numbers, and individuals that experience the event have, on average,
larger martingale residuals than those with censored event times, which makes it difficult to use
Martingale residuals to identify poorly predicted cases [277].
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4.2.3 Devloping Ftiness Functions for Survival Analysis
Rather than a Martingale-based approach, this section proposes a MLE-based fitness func-
tion—that utilises LL as a goodness-of-fit measure—for survival analysis in censored longitud-
inal data [271]. Where LL (discussed in section 2.8.2) is used to calculate the distance between
the natural log of the predicted probability p for the event to the actual observed outcome y.
In subsection 2.8.2 we introduced survival analysis, and the fundamental quantities used to
assess the risk of event occurrence, and probability of being event-free, at a given time point as
the hazard and survival functions, respectively.
In order to develop a MLE-based GP fitness function for survival data we take advantage of
the fact that the hazard function corresponds to a conditional probability in the discrete time
domain. Below, Equation 4.8 defines the discrete-time hazard function, denoted by h(tij),
which is the conditional probability the individual i will experience the event in time period j,
given that they did not experience it in any earlier time period and the their particular values of
the set of covariates, X , in that time period [277].
hˆ(tij , X) = P [Ti = j|Ti ≥ j,X] (4.8)
This is in contrast to hazard in the continuous-time domain, which represents a rate, and as such
can take values greater than one. The corresponding discrete-time survial function, denoted
Sˆ(tij , X), is defined below in equation 4.9.
Sˆ(tij , X) =
j∏
k=1
hˆ(tik, X) (4.9)
It follows that the original survival analysis problem can be cast into a classification problem
that requires the estimation of a conditional probability. However, to address the problem of
censoring the data needs to pre-processed into the counting process format, where there are
multiple rows per subject, one for each observed discrete-time interval. An example of survival
data in this format is given in table 4.2, where X is the set of P covariates, and x1 represents
a time-independent variable (e.g. gender), and xP a time-varying covariate (e.g. cholesterol).
Note this advantageous feature of the counting time format, that it can inherently represent a
combination of time-varying and static covariates.
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Table 4.2: Example of survival data in the counting process format
PATID (i) Time (j) Event x1 ... xP
01 1 0 1 ... 0
01 2 0 1 ... 1
02 1 0 0 ... 1
02 2 0 0 ... 0
02 3 1 0 ... 1
Now that we have the data in this format we can reformulate h(tij) as the conditional prob-
ability h(tij) = P (EV ENT |X ′), where X ′ is a vector, consisting of the original vector of
covariates (or features), X , plus an additional time period indicator, j.
Now we can estimate P (EV ENT |X ′) using the likelihood and prior ratios with a logistic link
function. Below, equations 4.10 to 4.10 shows the derivation of the logistic link function.
h(tij) =
1
1 + e−ε
(4.10)
In the case where ε is a linear combination of covariates X ′ (including time indicator j), this
represents a logistic regression model, which can be optimised using standard statistical tech-
niques such as Newton-Raphson method. Below, Equation 4.11 defines εlp a linear predictor
for discrete time survival analysis.
εlp = {[α1D1ij + α2D2ij + ...+ αJDJij ] + [β1X1ij + β2X2ij + ...+ βPXPij ]} (4.11)
In this definition Dij is a ’dummy’ time indicator (described in table 4.3), a dichotomy whose
value indexes the time period j in the ith individual, P is the number of predictors (or covari-
ates) and J is the number of observed time periods.
However, if we adopt a more complicated relationship for ε using a symbolic expression, we
can model a non-linear relationship between hazard and covariates. It can be optimised by GP
search operators, using the following likelihood function. Below, Equation 4.12 defines the
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Table 4.3: Example of ’dummy’ time indicators
PERIOD D1 D2 ... DJ−1 DJ
1 1 0 0 0 0
2 0 1 0 0 0
... 0 0 ... 0 0
J − 1 0 0 0 1 0
J 0 0 0 0 1
Likelihood function for the discrete-time hazards model Likelihood.
Likelihood =
n∏
i=1
Ji∏
j=1
h(tij)
EVENT ij (1− h(tij))(1−EVENT ij) (4.12)
Here EVENT ij is a dichotomy representing the event indicator of the ith individual at the jth
time interval. We define n is the number of subjects in training data and Ji as the number
observed time periods (or terms) the ith individual contributes to the likelihood function.
To make optimisation through the GP search operators more computationally tractable, we take
the logarithm of the likelihood to form a fitness function for survival analysis in censored data
of the counting process format. Below, Equation 4.13 defines the fitness function ffsurv.
ff surv = −
n∑
i=1
Ji∑
j=1
EVENT ij log h(tij) + (1− EVENT ij) log(1− h(tij)) (4.13)
The fitness function expresses the joint probability of obtaining the data actually observed on
the subjects in the study as a function of the unknown population parameters.
There are similarities between this and the Martingale-based approaches in the sense that they
both attempt to quantify some distance (or error) between predicted likelihood of events and
observed event outcomes, inherently accounting for censoring. These two approaches differ
in that Martingale approaches use event times and rates (e.g. the cumulative hazard function)
whereas the MLE approach uses conditional probabilities in the discrete time domain.
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This does give the Martingale approach the advantage of not requiring the data to be processed
into discrete time segments, as is required for the MLE approach. However, the Maximum
Likelihood-based method does not appear to suffer from the same biases as the Martingale-
based approaches. This, and the fact that most logistic regression techniques use MLE to
estimate the unknown parameters, were reasons that a MLE-based method was developed for
this work in favour of a Martingale-based one.
4.3 Genetic Programming Search Operators
In GP the evolutionary process is implemented through the application of search operators,
i.e., operators for population initialisation, selection, and variation. These operators define
how the GP system will navigate through the set of possible genotypic solutions. GP departs
significantly from other evolutionary algorithms in the way it implements variation operators,
and the actual implementation of initialisation and variation operators is often specific to the
GP representation scheme being used [239].
This work focuses on the well-known traditional approach to GP popularised by Koza (1998) [167],
which use binary parses trees to represent individual solutions. In subsections 4.3.1-4.3.4 we
introduce initialisation, mutation, recombination, and selection operators, appropriate for tree
representations, that will be employed in our subsequent experiments. We also briefly review
some of the other tree-based search operators, but a full review would be outside the scope of
this work. For a detail review see excellent introductory texts from Poli et al., (2008) [239] and
Banzhaf et al., (1998) [17].
4.3.1 Initialisation Operators
The first step in performing GP is the initialisation of a starting population. This involves
the application of intialisation operators to create a variety of trees for subsequent evolution.
Initialisation may also be used by certain variation operators and search heuristics to generate
new subtrees, as a means of injecting some new genetic material into the population during the
GP run which helps to preserve Population diversity.
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Population diversity is valuable in property in GP. The trees developed can vary in term of
their size, depth, width, and the number of leaf (i.e. terminal) nodes. Whilst the shape of the
initial trees can be lost in a few generations, the diversity of the of the initial population is an
important factor that can effect the quality of the solutions that the GP system can develop. The
initial population provides (the majority of) the building blocks or genetic material that will
be evolved (section 4.3) to (hopefully) find a high quality solution to the problem. Thus if the
diversity of trees in the initial population is low or biased (i.e. they are very similar) then the GP
system has less to work with, conversely if the initial population is diverse the the GP system
and more to work with. Whilst the application of genetic variation operators, either thought
mutation or adding newly initialised individuals, can introduce new, previously unseen genetic
material (discussed in section 4.3), these are typically applied at a low rate and therefore the
(genetic) diversity of the initial population is important.
Random Initialisation
Like most evolutionary algorithms, in GP an initial starting population is typically generated
randomly. The elements of the primitive set (section 4.2.1), the GP building blocks, are com-
bined randomly to produce a initial population of trees.
There are many different approaches to randomly generating this initial population of trees.
In the full method (so named because it generates full trees, i.e. all leaves are at the same
depth) nodes are taken at random from the function set until the maximum tree depth is reached
(beyond that depth, only terminals can be chosen) [239]. Although the full methods generates
trees that are all of the same depth, this doesn’t necessarily mean that all the tress are of the
same size (i.e. the total number of nodes) or shape. This is only the case when the function
set contains only functions with the same arity. The arity of a function is the number of the
arguments accepted by a function. However, even when the function set consists of mixed-
arity functions, the sizes and shapes of the trees generated by the full method tend to be rather
limited [239].
In contrast, the grow method produces irregular trees because the nodes are selected from the
whole primitive (i.e. functions and terminals) set at random throughout the entire tree [17].
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Once a branch has selected a terminal, that branch is ended, even if the maximum tree depth is
reached. If the tree depth is reached by a given branch then a terminal node is selected. A key
limitation of the full and grow initialisation operators is that neither provide a diverse range of
sizes and shapes, and can lead to a uniform set of structures in the initial population because
the routine is the same for all individuals [17].
To prevent this Koza [167] proposed a combination of these two methods, called the ramped
half-and-half method, intended to enhance the population diversity from the outset. Half the
initial population is constructed using full and half is constructed using grow. This is done
using a range of depth limits (hence the term "ramped") to help ensure that we generate trees
having a variety [239]. The ramped half-and-half method most commonly used initialisation
operator in tree-based GP.
Below, Equation 4.14 defines the random initialisation operator, init. Here, P ∈ [0, 1] denotes
the set of probabilities, i.e., real numbers in the interval between 0 and 1. The set of functions
with arity equal to or greater than one is denoted by F>0 [83].
init(n, ps, pv) = I(0, n, ps, pv)
I(i, n, ps, pv) =

f(I(i+ 1, n, ps, pv), . . . , I(i+ 1, n, ps, pv)︸ ︷︷ ︸
arity(f)
) if ru(0, 1) < ps and i < n.
rdu(V ) if ru(0, 1) < pv.
rdu(F0) otherwise.
f = rdu(F>0) (4.14)
Random initialisation creates trees of maximum depth n. A subtree is created with probability
ps at each recursive step. If no subtree is created, an input variable is created with probability
pv, else a constant is created. The full initialisation strategy can be realised by setting ps := 1
and pv := |V |/(|V |+|F0|), the ratio between the number of input variables and the number
of terminals, where only full trees of depth n are created. By setting pv as in the full strategy
and ps := |F>0|/|V |+|F |, the ratio of the number of functions of arity equal to or greater than
one and the number of all functions and input variables, the grow initialisation strategy can be
realised.
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Other Initialisation Operators
Whilst Koza’s ramped half-and-half method is the most common, there are several other ways
of constructing a population (pseudo) random individuals. As stated by Poli et al. (2008) [239],
the shape of the initial trees can be lost within the first few generations and a good initial
population can be crucial to the success of a GP run. The search space often consists of an
infinite number of possible solutions and thus it is impossible to search them all in a uniform
fashion. Therefore any approach to construct an initial population of solutions will be subject
to bias [239].
For example, the ramped half-and-half method tends to produce bushy trees which may on
average be better for some types of problems (such as parity problems), but may not be the best
approach for other types of problems. This is demonstrated by the fact that the ramped half-
and-half method is poor at finding solutions to the Sante Fe ant trail-following problem [176].
Another potential issue is that trees produced by the ramped half-and-half method may just be
too small for some problems. Chellapilla (1997) [37] claims good results are achieved when
the size of the initial trees was more tightly controlled.
Other methods have been proposed that sample trees uniformly based on Alonso’s bijective
algorithm [7, 132, 24, 173]. These more "uniform" initialisations on average tend to produce
more asymmetric trees, in contrast the symmetric trees that are generally constructed by the
ramped half-and-half method. Therefore, uniform sampling and other initialisation methods
may serve as important alternative for certain problems.
Of course, the initial population need not be generated in a random fashion. If something is
known about likely properties of the desired solution, whether produced from a previous GP run
or perhaps constructed by the user, symbolic expressions having these properties can be used
to seed the initial population [4, 129, 175, 179, 308]. However there are some considerations
when seeding an initial population. Just as the shape of the initial trees can be lost within the
first few generation, so can a few high-fitness solutions dominate the population in the first
few generations, leading to rapid loss in genetic diversity. Poli et al. (2008) [239] suggest that
diversity preserving techniques, such as MOGP [234, 270], demes [180], fitness sharing [96]
and the use of multiple seed trees, might be good cures for the problems associated with the
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use of a single seed.
4.3.2 Mutation Operators
Mutation only operates on one individual. Mutation operators were applied in early work in
the evolution of programs [21, 51]. However, Koza, who is credited for popularising the field,
did not use mutation in his seminal work in field [167]. This work has had a wide influence
and mutation is often omitted. However, more recent comparisons of crossover and mutation
suggest that including mutation can be advantageous [239]. Chellapilla (1997) [37] found
that a combination of six mutation operators performed better than previously published GP
work on four simple problems. Harries and Smith (1997) [113] also found that mutation-based
hill climbers outperformed crossover-based GP systems on similar problems. In modern GP
applications mutation is used widely. Whilst its true that you don’t need to use mutation in
GP, there doesn’t appear to be any consensus in field on its relative merits. It has also been
suggested that, when the problem is complex, the relative merits of variation operators are not
only dependent on the problems but also on the actual implementation of the GP system [197].
Subtree Mutation
Below, Equation 4.15 defines the subtree mutation operator, muts. In this definition v ∈ V
denotes an input variable [83].
muts(f(t1, . . . , tn), n, p, pi, ps, pv) =

init(n, ps, pv) if ru(0, 1) < p and ru(0, 1) < pi.
init(0, ps, pv) if ru(0, 1) < p and ru(0, 1) ≥ pi.
f(muts(t1, n, p, pi, ps, pv),
. . . ,muts(tn, n, p, pi, ps, pv)) otherwise.
muts(v, n, p, pi, ps, pv) =

init(n, ps, pv) if ru(0, 1) < p and ru(0, 1) < pi.
init(0, ps, pv) if ru(0, 1) < p and ru(0, 1) ≥ pi.
v otherwise.
(4.15)
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Subtree mutation is the most commonly used mutation operator is tree-based GP,
where a mutation point is randomly selected and the subtree below this point is de-
leted and replaced with a randomly generated subtree or terminal node. The altered
individual is then placed back into the population. The maximum size and shape of
the newly generated subtree can be controlled by the parameters n, ps, and pv, with
the same semantics as equations 4.14. The strength of the mutation operator is con-
trolled by, p, the probability of replacing a subtree of a node with a randomly generated
subtree at each recursion of the tree. The parameter pi is the probability that a newly
generated subtree will be a terminal, controlling the tendency of the operator to grow
or shrink trees. Subtree mutation is described graphically in figure 4.3. The new ran-
domly generated subtrees are typically produced according to the same initialisation
scheme, with the same limitations (e.g. in terms of depth and/or size) as the initial
population.
Figure 4.3: Example of subtree mutation (source: Poli at al., 2008 [239])
Point Mutation
Below, Equation 4.16 defines the point mutation operator mutp. In this definition
v ∈ V denotes an input variable [83].
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mutp(f(t1, . . . , tn), p) =
f
′(mutp(t1, p), . . . ,mutp(tn, p)) if ru(0, 1) < p.
f(mutp(t1, p), . . . ,mutp(tn, p)) otherwise.
mutp(v, p) =
rdu(V ) if ru(0, 1) < p.v otherwise.
f ′ = rdu(Farity(f)) (4.16)
Point mutation analogous to mutation in GA, where bits are flipped. In GP a node in a
tree is selected at random and replaced with randomly selected node of the same arity
and type. This way functions are replaced buy function and variables by variables. The
probability to replace the current node when recursively traversing the tree, denoted p,
controls the strength of the operator. It important to note that point mutation preserves
the shape of the tree.
Constants at Random Mutation
Below, Equation 4.17 defines the constantat at random mutation operator, mutc. In
this definition v ∈ V denotes an input variable. This operator assumes the presence of
numeric constants R ⊆ F0 denotes an input variable [83].
mut c(f(t1, . . . , tn), p, µ, σ) =

f + rn(µ, σ) if ru(0, 1) < p and f ∈ R.
f(mut c(t1, p, µ, σ),
. . . ,mut c(tn, p, µ, σ)) otherwise.
mut c(v, p, µ, σ) = v (4.17)
Here, f ∈ R denotes a real-valued function of arity, i.e., a constant. The constant at
random mutation operator mutates constants by adding random noise drawn from a
Gaussian distribution with mean µ and standard deviation σ. As before, the strength of
the operator is controlled by, p, the probability of mutating a constant at each recursion.
Each change to a constant is considered a separate mutation.
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Other Mutation Operators
In contrast to GA where mutations is simply flipping a bit in a bit string, in GP there are
many different types of mutation operators that can be applied to trees. Often multiple
types of mutation are beneficially used simultaneously [170, 10]. Table 4.4 gives a
brief overview of what types of mutation operators have been used with trees.
Table 4.4: Mutation operators applied in tree-based GP
Operator Name Description of effect
Subtree Subtree exchanged with random subtree [167, 160]
Size-fair subtree Subtree exchanged with random subtree that is, on average,
the same size [160]
Point Single node exchanged with random node of the same
class [203]
Hoist New individual is generated from subtree [161]
Shrink Subtree exchanged with a random terminal [10]
Expansion Terminal exchanged with a random subtree
Permutation Arguments (subtrees) of a node are randomly per-
muted [167, 201]
Constants at random Add noise to constant, according to a Gaussian distribu-
tion [268]
4.3.3 Recombination Operators
GP recombination operators or crossover operators take genetic material form two
selected ’parent’ trees and swaps part of one parent with another, combing them to
form one or two new ’offspring’ trees. In GP the most common form of crossover
is tree-based crossover, often referred to as subtree crossover. Subtree crossover is
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described graphically in figure 4.4. The parents are shown on the left and the offspring
on the right. More specifically:
• Using some selection scheme (described in section 4.3.4, choose two solutions
from the current population to act as parents
• Randomly select a node in each parent to act a crossover point.
• Delete all branches (i.e. the subtree) below the crossover point in each parent
(shaded areas in figure 4.4).
• Recombine (i.e. crossover) the remaining partial trees at their respective cros-
sover points to form a new tree to act as an offspring .
Note, that it is possible to define a version of subtree crossover that can produce two
offspring, but this is not commonly used [239].
Figure 4.4: Example of subtree crossover. Note that the trees on the left are ac-
tually copies of the parents. So, their genetic material can freely be used without
altering the original individuals (source: Poli at al., 2008 [239]).
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Subtree Crossover
Below, Equation 4.18 defines the subtree crossover recombination operator, recs. [83].
recs(t, u) = (tJi 7→ u[j]K, uJj 7→ t[i]K)
i = rdu({0, |t|}) (4.18)
j = rdu({0, |t|})
In this definition, t[i] denotes the ith subtree of tree t, where t[0] = t. The notation
tJi 7→ uK denotes the tree t whose ith subtree has been replaced by tree u. The number
of subtrees of a tree is written as |t|. The subtree crossover operator randomly selects
a crossover point in each parent expression and swaps the corresponding subtrees, re-
turning two offspring trees.
Other Recombination Operators
In this definition of subtree crossover the selection of subtrees, through the selection of
a crossover point, is selected with uniform probability. Uniformly selected crossover
points can lead to the crossover of limited genetic information (i.e. small subtrees) . To
address this the selection of subtrees can be biased so that subtrees containing terminal
are selected with a lower probability than other subtrees. Koza (1992) [167] proposed
a widely used approach of choosing functions 90% and terminals 10% of the time to
counter this problem.
During biological sexual reproduction, the genetic material from the parents appears
in approximately the same place in the child. This is quite different from traditional
tree-based GP crossover, which can move a subtree into a totally different position in
the tree structure. One-point and context preserving are examples of homologous cros-
sover operators, they preserve the position of the genetic material through the use of a
common crossover point in the parent trees. There are many other types of homolog-
ous crossover operators that have also been proposed for tree-based GP [44, 173, 191,
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198, 321]. The prominent crossover operators that are applicable to trees are detailed
in table 4.5.
Table 4.5: Crossover operators applied in tree-based GP
Operator Name Description of effect
Subtree Exchange subtrees between individuals [167]
One-point Exchange subtrees if coordinates match and subtrees have
same shape [177, 242, 244]
Uniform Exchange nodes randomly between individuals, with uni-
form probability [243]
Context preserving Exchange subtrees if coordinates match [69]
Size-fair Exchange subtrees between individuals that are, on average,
the same size [173]
4.3.4 Selection Operators
As mentioned previously, in GP, the the evolutionary process is a search that is facil-
itated through search operators. As part of this search GP uses selection operators to
choose m individuals, from a pool of n individuals, that will be subject to genetic vari-
ation (parent selection), or for transfer into the next generation (survival selection). As
with most EAs, GP employs fitness-based selection, where individuals are selected as
parents or survivors, either deterministically or probabilistically, based on fitness. That
is better solutions are more likely to be selected as parents or survivors, than inferior
solutions. The selection of individuals as parents or survivors is a trade-off between
exploitation of high-quality individuals, and exploration of the search space thought
through the selection of average-quality solutions (which may act as intermediate solu-
tions in the search path later lead to individuals of even higher quality).
As well being either deterministic or probabilistic, search operators can be single-
88 4.3 Genetic Programming Search Operators
objective or multi-objective. Furthermore, search operators can be classified along a
spectrum between non-elitist and elitist, dependent on how they value exploration over
exploitation. There are numerous selection mechanisms, which have been described
many times in the EA literature. A full review of all these approaches is outside the
scope of this thesis, Goldberg (1989) and Luke (2013) [96, 195] provide discussion on
various selection mechanisms.
Single-Objective Selection
The most commonly employed single-objective selection operator in GP is tournament
selection [239]. Figure 4.3 in section 4.4.1 gives a pseudocode implementation of the
tournament selection operator used in this work. In tournament selection a number of
individuals are selected at random from the current population to compete in the tour-
nament. From the pool of competitors, the individual with the best fitness in selected as
the winner of the tournament, and selected for genetic variation. If the genetic operator
to be applied is crossover, two tournaments are used, one for each parent.
A key property of any selection mechanism selection pressure. A system with strong
selection pressure very highly favours fitter individuals, whilst a system with low se-
lection pressure isn’t so discriminating [239]. Tournament selection automatically res-
cales fitness, keeping the selection pressure constant. This is because tournament only
looks at the relative fitness, though ranking the competitors based on fitness, rather
than how much fitter they are. In this way, an exceptionally fit individual cannot im-
mediately swamp the future generation with its children, which would have disastrous
consequences on the GP run due to a drastic reduction in the diversity of genetic ma-
terial available to future generations. Conversely, tournament selection amplifies small
differences in fitness, to prefer better solutions even if they are only marginally better
than the other individuals in the tournament. In tournament selection, the tournament
size parameter allow researchers to adjust the selection pressure, as such control the
degree of elitism.
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A disadvantage of tournament selection is the noise that is introduced thought the ran-
dom selection of individuals for participation in the tournament. This mean that indi-
viduals with average fitness can have some chance of being selected and their offspring
featuring in future generations. Despite this drawback, since tournament selection is
easy to implement, offers some control of elitism, and offers automatic fitness rescal-
ing, it is commonly used in GP.
Multi-Objective Selection
As discussed in subsection 4.2.2 the fitness function acts as an interface between the
solution space and the selection operator, guiding GP though the search space towards
high-quality solutions. In section 4.2.2 we also discussed that it is often highly desir-
able to employ a multi-facetted definition solution quality. Thus a fitness values can
be a vector of different quality elements such as accuracy, parsimony, interpretability,
and generalisability. Single-objective selection operators can only be used with fitness
vectors when an aggregate scalar fitness value (such as a weighted sum) is used. How-
ever, as previously discussed identifying suitable weightings is non-trivial and often
precludes this approach.
A alternate approach that is gaining popularity is to adopt a multi-objective selection
operator than can handle multiple separate quality criteria directly. The most com-
mon forms of multi-objective selection are lexicographic selection and Pareto selec-
tion. Lexicographic selection uses a lexicographical ranking of fitness vectors. Using
the example where accuracy and parsimony are the objectives; lexicographic selection
ranks subjects based on fitness, and where there are individuals that are tied having
the same fitness value, the individual with the lower complexity is assigned the higher
ranking [195].
Pareto selection operators are based on the notion Pareto dominance. Given a set
objectives and two candidate solutions, A and B. A is said to Pareto dominate B if A is
at least as good as B in all objectives, and superior to B in at least one objective. You
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could say that, A is at least as good everywhere and better in something. In Figure 4.5,
an example taken from Poli et al. (2008) [239], individual A dominates (is better than)
individual B along the y axis, but B dominates A along the x axis. Thus there is no
simple ordering between then. This illustrates the notion of a partial order, where there
is no longer a strict linear ordering of solutions. The individual marked ’2’, however
dominates B on both axes and would thus be considered strictly better than B.
Figure 4.5: Two-dimensional example of Pareto optimality and the Pareto front,
where the goal is to maximise along both the x and y axes. Solutions A and B do
not dominate each other. However, solution B is dominated by solution 2. (source:
Poli at al., 2008 [239]).
When A and B are identical in all objectives, or like in our example, if B is better in
some things but A is better in other things, the solutions are said to benon-dominated.
In this case the goal of the search operator is find the Pareto font, this is, the set of all
non-dominated solutions in the search space.
In such a scenario there is said to be no Pareto-optimal set of solutions, but the selection
operator needs to select some set of solutions. To address this we quantify how close
solutions are to the Pareto front. One popular method is Non-Dominated Sorting (NDS)
by Srinivas and Deb (1994) [282], which based on the notion of Pareto front rank. Luke
(2013) [195] offer a nice introduction, describing NDS as "like peeling an onion".
Fitness vectors in Pareto front get a rank of one. They are then removed, the front
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recalculated, and the fitness vectors in this second Pareto font get a rank of two, and so
on. NDS continues to iterate until every fitness vector has a Pareto rank.
Pareto selection operators selects fitness vectors from consecutive Pareto fronts until
the specified number of m fitness vectors are selected. In some cases there may be
more fitness vectors in a given Pareto front than are required. In this case the selection
operator needs to adopt some strategy for choosing a subset of fitness vectors in a
particular Pareto front. The most common strategies are based on crowing distance and
hyper volume contribution, implemented by the NSGA-II [64] and SMS-EMOA [20]
algorithms, respectively.
Pareto-based selection methods have a number of advantages. The main advantage
(and the motivation behind their initial application in GP) is the control of bloat, where
practitioners can manages the trade-offs between solution quality and solution com-
plexity. Of course, dependent of specific problem, the simultaneous optimisation of
other objectives can be advantageous for a GP run. Another advantage is that by
basing selection criteria on multiple objects we can help ensure genetic diversity in
the GP run. MOGP is increasing popular with many state of the art GP using Pareto
selection. All of the experiments in this thesis use multi-objective selection based the
Pareto dominance.
Lexicographic ordering and Pareto dominance are not the only ways to deal with mul-
tiple objectives without combining them into a single scalar fitness function. Alternate
approaches have been proposed that include weaker forms of Pareto dominance and
new methods based on priorities [267] and those which combine Pareto dominance
and lexicographic ordering [196].
Population Diversity Preservation
Although much of the application multi-objective optimisation to GP has been in the
area of bloat control, discussed in section 4.2.2, preserving diversity in the popula-
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tion is another important consideration. As discussed in section 4.3.1, a rapid loss in
genetic diversity can have disastrous consequences for a GP run. Without some mech-
anism to preserve diversity in a population (i.e. promote exploration), searches can
easily converge to solutions that are too small to solve a problem. One such approach
is use a multi-objective search with some measure of diversity as an objective, typ-
ically whilst simultaneously controlling for bloat (parsimony), and optimising fitness
(accuracy) [258]. A particularly successful multi-objective approach by Schmidt and
Lipson (2010) [266], the age-layering technique, uses the notion of the age (how long
the genotype has been in the population) to ensure diversity. Using a multi-objective
search operator, a dynamic variant of the age-layering technique is realised by adding
solution age as an objective to be optimised. Many other approaches to diversity pre-
servation have been proposed by the EA community including demes, random restarts,
crowding, and fitness sharing.
4.4 Search Stratergy
Now that we have introduced the individual components such as primitives, initial-
isation, variation, fitness, and selection, we put them together using an overarching
GP search strategy, or in machine learning terminology, a GP search heuristic. In GP
search heuristics can be classified into two broad groups, generational and steady-state.
With generational search heuristics, the entire populations is updated once per itera-
tion. Whereas with steady-state heuristics, there are no generations per se and only a
few individuals are updated per iteration.
Typically GP is implemented using a steady-state search with tournament selection.
Modern GP systems typically use a multi-objective evolutionary algorithms (MOEA)
as their search heuristic. The majority of today’s best performing GP systems use
steady-state algorithms with Pareto tournament selection. This popularity, whether for
simple teaching examples or complex real-world systems, is that they are relatively
4.4 Search Stratergy 93
simple to implement and allow straight-forward parallelisation. Despite this, simple
steady-state EAs with single-objective tournament selection are widespread [239].
This section describes the set of GP search strategies, group by steady-state and gen-
eration, that have been selected for this study. Search heuristics were selected from
those available from the RGP package [84, 83] within the R statistical programming
language [247], discussed in section 4.7. We implement the popular steady-state heur-
istic with single-objective tournament selection, SSOGP, that is implemented in many
existing GP systems. To explore the utility of a generational approached have chosen
to implement Generational Single-Objective Genetic Programming (GSOGP), and to
explore the utility of multi-objective GP we have implemented Generational Multi-
Objective Genetic Programming (GMOGP). Unfortunately there wasn’t a multi-objective
version of the steady-state search heuristic available in the RGP package at the time of
writing. An overview of the important features and attributes of the search strategies
selected for this work is given in Table 4.6.
Table 4.6: Overview of the important features and attributes of the GP search
heuristics described in this work..
SSOGP GSOGP GMOGP
Optimisation Criteria Fitness Fitness Fitness, Com-
plexity, Age
Selection Framework Steady-state Generational (µ+
λ)
Generational (µ+
λ)
Parent Selection Uniform random Uniform random
or rank-based
Uniform random
or NDS
Variation rec → mut rec → mut rec → mut
Survivor Selection Rank-based Rank-based NDS
Diversity Preservation - - Age-Fitness
Pareto Optimisa-
tion (AFPO)
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4.4.1 Steady-State Single-Objective Genetic Programming
In steady-state GP there are no fixed generational intervals. Instead the population is
updated in a piecemeal fashion rather than all at one time, with a continuous flow of
individuals meeting, mating and producing offspring. The idea is to iteratively breed
a small number of offspring, access their fitness, and, if the they have superior fit-
ness, these offspring replace existing individuals in the same population. The method
is simple to implement and has some efficiency benefits together with benefits from
parallelisation.
"The approach is called steady-state because the genetic operators are applied asyn-
chronously and there is no centralised mechanism for explicit generations. Neverthe-
less it is customary in presenting results with steady-state GP to talk about generations.
In fact steady-state generations are intervals during training which can be said to cor-
respond to generations in a generational GP algorithm. These intervals are often when
fitness is evaluated for the same number of individuals as the population size" [17]
This heuristic has been implemented as a minimal example of the most common and
easy to implement GP search strategy. It is intended to act as baseline for comparison
with more complex single- and multi-objective generational approaches in the devel-
opment of clinical prediction model for censored data.
Algorithm Structure
Here we describe simple single objective steady-state GP as it is implemented in RGP,
which is loosely based on Koza’s original work on GP [167]. In the first step we initial-
ise population pop(0) with µ random individuals, before entering the main evolutionary
loop. Next we randomly choose a variation operator, according to parameter prec . Note
that the choice between recombination and mutation in mutually exclusive, that either
variation operator is applied, but not both. If the variation operator is recombination,
two parents are selected via two independent tournaments, each of size stournament, as
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detailed in the next subsection. If the variation operator is mutation, then one parent
is selected via a single tournament. Next, a single child is created by applying the
variation operator to the parent(s). Then, an individual from the population is selected
for replacement by the new offspring, via a single (negative) tournament, again, of size
stournament . Finally, the newly created child is inserted into the population in place
of the selected individual. This evolutionary process is repeated until the termination
criteria is fulfilled. Pseudocode for this simple steady-state search heuristic is given in
Algorithm 4.2.
Algorithm 4.2 Pseudocode implementation of the SSOGP search heuristic. [83]
1: pop← createIndividuals (number = µ)
2: while termination criterion not met do
3: if randomUniformNumber() ≤ prec then . uniform random numbers [0, 1]
4: mother← tournament(pop, stournament )
5: father← tournament(pop, stournament )
6: child← rec (mother, father)
7: else
8: parent← tournament(pop, stournament )
9: child← mut (parent)
10: end if
11: replaced← negativeTournament(pop, stournament )
12: pop[replaced]← child
13: end while
14: return pop
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Selection Stratergy
Tournament selection is implemented in RGP as follows. First an individual is ran-
domly selected, with a uniform probability and without replacement, from the popu-
lation. This starting individual is designated as the bestIndividual and its fitness the
best fitness. Then iterate the following steps until the number of individual selected
equals stournament . We randomly select another individual from the population, in the
same manner as before, to act as a competitor. If the competitor has a better fitness
than the best individual, then it becomes the bestIndividual and its fitness becomes the
bestFitness, else nothing. We then iterate through the for loop until we have evaluated
stournament individual. Finally, when the loop is finished, we return the bestIndividual.
Negative tournament selection is very much the same process, only that we return in-
dividual with the worst fitness (rather than the best). Note that this is very simple
implementation of single-objective tournament selection, in practice there are much
more complicated variants and extensions. Pseudocode for this tournament and negat-
ive tournament selection is given in Algorithm 4.3.
Diversity Preservation
In the simple single-objective steady-state search heuristic implemented in RGP there
isn’t any mechanism to preserve genetic diversity in the population. However, it could
be extended with minimal effort using external measures such as random restarts, fit-
ness, sharing and crowding. Such extensions have not been implemented in this work
for the sake of simplicity.
Parameters
Table 4.7 details the most important parameters appropriate to the RGP implementation
of SSOGP. Selection of suitable stating parameter was discussed in section 4.5, but the
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Algorithm 4.3 Pseudocode implementation of tourament selection [83]
1: function TOURNAMENT(pop, stournament )
2: bestIndividual← sampleWithoutReplacement(pop, number = 1)
3: bestFitness←∞
4: for i in 1 : stournament do
5: competitor← sampleWithoutReplacement(pop, number = 1)
6: if fit(competitor) < bestFitness then
7: bestFitness← fit(competitor)
8: bestIndividual← competitor
9: end if
10: end for
11: return bestIndividual
12: end function
13: function NEGATIVETOURNAMENT(pop, stournament )
14: worstIndividual← sampleWithoutReplacement(pop, number = 1)
15: worstFitness←∞
16: for i in 1 : stournament do
17: competitor← sampleWithoutReplacement(pop, number = 1)
18: if fit(competitor) > worstFitness then
19: worstFitness← fit(competitor)
20: worstIndividual← competitor
21: end if
22: end for
23: return worstIndividual
24: end function
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important thing to note is the relatively large population size, compared with generation
GP search heuristics.
Table 4.7: Parameters of the SSOGP search heuristic.
Variable (Symbol) Domain Default
Population Size mu (µ) N 300
Tournament Size tournamentSize (stournament ) N 2
Recombination Probability recombinationProbabilty (prec) [0, 1] 0.9
4.4.2 Generational Single-Objective Genetic Programming
GSOGP is a single-objective generational GP search heuristic based the very simple
(µ+λ) ES algorithm, as described by Like (2013) [195]. In this strategy, µ parents are
allowed to breed λ offspring. Then parent and offspring are pooled together, resulting
in a pool of µ + λ parents, from which the best µ are selected for the next generation.
In state of the art GP systems single-objective search heuristics have been superseded
by multi-objective searches, however this search strategy was included mainly as a
baseline for comparison and explore the idea that survival analysis could be solved
using a more simple single-objective approach.
Algorithm Structure
The classic single-objective generational (µ+ λ) evolutionary strategy is implemented
in RGP as follows. First, we initialise population pop(0) with µ random individuals,
before entering the main evolutionary loop. Next, with random uniform probability and
without replacement, we randomly choose 2×λ individuals to act as parents. Then we
take the first λ parents to act as mothers, and the second λ parents as fathers. Next we
create λ offspring by applying the recombination operator to mothers and fathers. Then
we apply mutation operator to the offspring. Next we insert the newly created offspring
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into the population to give us a pool of µ + λ individuals to select from. Finally we
use rank-based selection to select the best µ individuals form the selection pool, to
act as the next generation. This evolutionary process is repeated until the termination
criteria is fulfilled. Pseudocode for this simple generational search heuristic is given
in Algorithm 4.4. Note that for efficiency reasons RGP would also store the fitness of
each individual as it is calculated to avoid recalculating in subsequent iterations.
Algorithm 4.4 Pseudo-code implementation of the GSOGP search heuristic. [83]
1: pop← createIndividuals (number = µ)
2: while termination criterion not met do
3: parents← sampleWithoutReplacement(pop , number = 2× λ)
4: mothers← parents [1 : λ]
5: fathers← parents [ (λ+ 1) : 2× λ]
6: children← mutpop (recpop(mothers , fathers))
7: selectionPool← parents ∪ children
8: survivors← selGSOGP (selectionPool , number = µ)
9: pop← survivors
10: end while
11: return pop
Selection Stratergy
In RGP the selection operator selGSOGP implements the rank-based selection scheme.
Individuals are ranked according to their fitness, and the n highest ranked (best) indi-
viduals are selected. This is very simple version of this selection scheme. There are
extensions where individuals are assigned a selection probability as a function of their
rank in the population. There are a number of such functions proposed, with the linear
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and exponential being the most common. For the sake of simplicity these extensions
to the rank-based selection scheme were not implemented in this study.
Diversity Preservation
As with previous single-objective search strategy, there is no mechanism to preserve
genetic diversity implemented in RGP for this search heuristic.
Parameters
Table 4.8 details the most important parameters appropriate to the RGP implementation
of GSOGP. Note that λ should be a multiple of µ and follow the constraint λ ≤ (µ
2
).
Table 4.8: Parameters of the GSOGP search heuristic.
Variable (Symbol) Domain Default
Population Size mu (µ) N 100
Children per Generation mu (λ) N 50
4.4.3 Generational Multi-Objective Genetic Programming
GMOGP is a generational multi-objective GP search heuristic, based on a classical
generational (µ + λ) strategy discussed previously. This approach combines the ideas
of multi-objective GP, to control bloat (solution complexity) whilst optimising solu-
tions fitness. A third objective is also added, age, that assists in preserving genetic di-
versity. This heuristic has been implemented to explore the idea that a multi-objective
generational approach can offer improvements over the less complex single-objective
approaches in the development of clinical prediction model for censored data.
4.4 Search Stratergy 101
Algorithm Structure
The classic multi-objective generational (µ + λ) evolutionary strategy is implemented
in RGP as follows. First, we apply the initialisation operator to initialise population
pop(0) with µ random individuals, before entering the main evolutionary loop. Next,
according to the parent selection probability Ppsel, 2× λ parents are selected either by
Pareto selection, or by uniform random sampling without replacement. Then we take
the first λ parents to act as mothers, and the second λ parents as fathers. Next we create
λ offspring by applying the recombination operator to mothers and fathers. Then we
apply mutation operator to the offspring. Next we create ν new individuals using the
initialisation operator. Then we insert the newly created offspring and newly created
individuals into the population to give us a pool of µ + λ + ν individuals to select
from. Finally we use the Pareto selection operator to select the best µ individuals form
the selection pool, to act as the next generation. This evolutionary process is repeated
until the termination criteria is fulfilled. Pseudocode for this simple generational search
heuristic is given in Algorithm 4.5
Selection Stratergy
In RGP the selection operator selGMOGP is a Pareto search operator based on NDS with
three objectives; fitness, solution complexity, and age (discussed in next paragraph).
Crowding distance in the event that there are ties during the NDS. This selection
strategy is a kin to the selection strategy of the well-established NSGA-II Evolutionary
Multi-Objective Algorithms (EMOA), discussed in section 4.3.4.
Diversity Preservation
GMOGP implements elements of Schmidt & Lipson (2010) Age-Fitness Pareto Op-
timisation (AFPO) algorithm for preserving genetic diversity and avoiding premature
convergence [266]. In each generation, ν newly initialised individuals are inserted into
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Algorithm 4.5 Pseudo-code implementation of the GMOGP search heuristic. [83]
1: pop← createIndividuals (number = µ)
2: while termination criterion not met do
3: if randomUniformNumber() ≤ ppsel then
4: parents← selGMOGP ( pop , number = 2× λ)
5: else
6: parents← sampleWithoutReplacement ( pop , number = 2× λ)
7: end if
8: mothers← parents [1 : λ]
9: fathers← parents [ (λ+ 1) : 2× λ]
10: children← mutpop (recpop (mothers , fathers ) )
11: newIndividuals← create Individuals ( number = ν )
12: selectionPool← parents ∪ children ∪ newIndividuals
13: survivors← selGMOGP ( selectionPool , number = µ)
14: pop← survivors
15: end while
16: return pop
the population to maintain genetic diversity. These new randomly generated individu-
als will on average be of low fitness and therefore quickly dominated by older, fitter
individuals before having a chance evolve through a series of variation steps. This
problem is mitigated by the introduction of genetic age , G, as defined as follows [83]:
age(gnew) = 0,
age[mut(g)] = age(g) + 1,
age[rec(gA, gB)] = max [age(gA), age(gB)],
(4.19)
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where gnew is a new genotype just inserted into the selection pool, and g, gA, and
gB are individuals already existing in a population. New individuals are assigned an
age of 0, whilst every mutation operation increments an individuals age by one, and
for every recombination operation an individuals age is taken as the largest of its two
parent. Solution age is implemented as an objective to minimised, along with solution
complexity and fitness
This enables dynamic age-layering of the population, where younger individuals are
given a chance to evolve independently of other older, likely fitter and less complex,
individuals until they are of the same genetic age (i.e. have undergone a similar amount
of variation). It is the hope that his approach will preserve genetic diversity during the
GP run, and thus promote exploration of the search, with the ultimate aim of discover-
ing new local optima or even the global optimum.
Parameters
Table 4.9 details the important parameters appropriate to the RGP implementation of
GMOGP. Setting the boolean search heuristic parameters Complexity Control and Age
Layering to false will disable the bloat control and diversity preservation objectives,
respectively. As in the GSOGP search heuristic and for the same reason, these para-
meters are subject to the following constraint of λ ≤ [µ
2
]
.
Table 4.9: Parameters of the GMOGP search heuristic.
Variable (Symbol) Domain Default
Population Size mu (µ) N 100
Children per Generation lambda (λ) N 50
New Individuals per Generation nu (ν) N0 50
Age Layering ageLayering B true
Parent Selection Probability parentSelectionP (ppsel ) [0, 1] 1
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4.4.4 Termination and Solution Designation
A GP run finishes when a specified termination criterion is satisfied. The termination
criterion may be a maximum number of generations, maximum run-time, or may be
some problem specific success predicate, such as a target fitness. When the run is
finished some method of designating the result of the run is applied. Typically, the
best-so-far individual is identified and designated as the result of the run, although
additional individuals and data may be returned as necessary or appropriate to the
problem. The RGP package supports the implementation of time, iterations and fitness
based termination criterion.
4.5 Genetic Programming Parameters
GP parameters refer to parameters that control the GP run, sometimes referred to as
tuning parameters, which are typically defined as a preparatory step. There can be a
large number of different parameters than can be used to control a GP run dependant
on the complexity of the GP system. There are no hard and fast rules about the optimal
control parameters that should be used, as these depend too much on the details of the
application. A challenge with GP is that, despite having being around for some time,
it is a relatively young field and the effects of using various combinations of parameter
values is not yet well understood for many applications domains [17]. In their practical
advise on GP, Banzhaf et al. (1998) [17] and Poli et al. (2008) [239] both report that
in practice GP is robust and likely to work well over a wide range of parameter values
and, as a consequence, you do not necessarily need to spend a long time tuning GP for
it work adequately [239, 17].
An important, arguably the most important, control parameter in GP is population size.
Other control parameters include genetic variation rates, the maximum solution size,
maximum number of generations, and other details of the run. In this section we will
discuss these typical control parameters, what is know about their effects , and some
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rules of thumb on their use from the literature. However, much of what is known about
GP parameters is anecdotal and based on experience of researchers in the field [17].
4.5.1 Population Size
Population size, denoted as µ, is important for a number of reasons. Larger populations
take more time and consume more computational resources when evolving a genera-
tion. Also, larger populations typically have greater genetic diversity, which increase
the search space that can be explored, which in turn may reduce the number of evalu-
ations required for finding a solution. Poli, et al. (2008) [239] suggest that, as a rule
one prefers to have the largest population size that your system can handle gracefully;
normally, the population size should be at least 500, and people often use much larger
populations.
Banzhaf, et al. (1998) [17] report that positive results have been achieved with popula-
tion sizes ranging from µ = 10 to µ = 1, 000, 000 individuals, and that in between 10
and 100, 000 individuals they observed a near-linear improvement in performance of
the GP system. The authors also state that µ = 1, 000 is usually an acceptable starting
point for smaller problems and that the population size should grow as the problem
grows more difficult. The authors offer a rule of thumb for dealing with more com-
plex problems, that if sufficiently difficult, then the population size should start at and
µ = 10, 000 individuals and be increased if the other parameters exert heavy selection
pressure.
Population size should also be governed by the number of available training cases, with
a large number of training cases requiring an increase in µ. Banzhaf, et al. (1998) [17]
recommend using 1, 000 ≤ µ ≤ 10, 000 individuals for between 10 and 200 fitness
cases, and µ > 10, 000 for more than 200 training cases. Koza reports his experience
with population size, using 50 ≤ µ ≤ 10, 000 in his book [167], but reports µ = 500
individuals as his most common setting.
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4.5.2 Maximum Number of Generation
Some authors suggest limiting the number of generations to 50, arguing that nothing
much happens after the fiftieth generation and if a solution hasn’t been found by then,
its unlikely to found in a reasonable amount of time [239]. However other authors
such as Banzhaf et al.(1998) [17] report that they have observed interesting evolution
as late as generation 1000, even interesting development occurring as late a generation
10,000.
4.5.3 Primitive Set
Banzhaf et al. [17] offer some rules of thumb for the selection function and terminal
sets that they claim have served them well:
• Make the terminal and function sets as small as possible. Larger sets usually
mean longer search time
• Its not important to have (all) custom functions in the function set: the system
often evolves its own approximations.
• It is very important, however, that the function set contains functions capable of
permitting non-linear behaviour, such as if-then functions, boolean operators on
numbers, and sigmoid squashing functions
• The function set should be adapted to the problem in the following way: prob-
lems that are expected to be solved by smooth curves should use function sets
that can generate smooth curves, and problems that are expected to be solved by
other types of functions should have at least one representative of these functions
in the function set.
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4.5.4 Genetic Variarion Rates
The correct balance of crossover and mutations rates is a topic that is wide open in
GP, and as such is typically problem specific. Much if the literature suggests that as
a starting point, probabilities for applying genetic operations should be very high for
crossover (Pc = 0.9) and very small for mutation (Pm = 0.1), with the mutations rate
Pm increased if the results are unsatisfactory. However Poli et al. [239] , and Banzhaf
et al. [17] suggest that a different balance (Pc = 0.5, Pm = 0.5) may lead to better
results for harder problems.
4.5.5 Selection Pressure
Selection pressure is another parameter to consider. In tournament selection, the tour-
nament size allow researchers to adjust the selection pressure. A small tournament
size causes a low selection pressure and a large tournament size causes high selection
pressure. Banzhaf et al. [17] report that they have had very good experiences with low
selection pressure, with tournaments of 4 individuals regularly performing well.
4.5.6 Maximum Solution Size
Poli et al. [239] propose that as a rule of thumb, one should try to estimate the size
of the minimum possible solution (using the terminals and functions given to GP) and
add some percentage (e.g., 50-200%) as a safety margin. Whereas Banzhaf et al. [17]
propose that the maximum depth of the trees or the program size should be set such that
the programs can contain about ten times the number of nodes as the expected solution
size. To allows for error in predicting the solution and for intron growth (discussed in
sections 4.6).
Typically the initial solution size should be very small compared with the maximum
solution size. This enables good solutions to be built up piece by piece using blocks
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of in inheritance. However, if this approach is not successful for complex problems,
larger initial solutions can be used to add some complexity at the beginning of the GP
run to help avoid local optima. A commonly use approach to create a random initial
population using the ramped half-and-half approach (discussed in sections 4.3.1), with
a depth range of 2 − 6. These maximum permitted size of initial solutions will be
dependent upon the number of the functions, the number of terminals and the arities
of the functions. However, evolution will quickly move the population away from its
initial distribution [239].
4.6 Bloat: Survival of the Fattest
Most representation schemes in GP, including tree-based GP, allow for variable length
solutions. One interesting problem with evolving variable length solutions is the in-
crease of the size of individuals (or solutions) over time. Early on researchers noticed
that very often the average size (number of nodes) of the solutions in a population, after
a certain number of generations in which it was largely static, at some point would start
growing at a rapid pace. Typically the increase in program size was not accompanied
by any corresponding increase in fitness [275, 239]
This phenomenon, is commonly referred to as bloat. Bloated trees contain a lot of sub-
trees that don’t do anything at all, analogous to superfluous steps in an equation that can
be simplified. These subtrees were dubbed introns, like their DNA counterparts [194].
Bloat should not be confused with growth. There are times, such as at the beginning of
the run where the starting population typically consists of relatively small individuals,
where we would expect to see progressive increase in solution size. The distinction
between growth and bloat is that for growth we would expect significant increase in
size to be associated with a significant increase in fitness. We should therefore define
bloat as solution growth wihtout (significant) return in terms of fitness.
Bloat is not only surprising, but a real problem for GP. Bloated individuals take longer
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to evaluate and use, consume more memory, can be hard to interpret, may exhibit poor
generalisation, and are typically far from optimal. Over the years, many theories have
been proposed to explain various aspects of bloat, and while great strides have been
made, we still lack a single, universally-accepted unifying theory to explain the broad
range of empirical observations [239].
Lacking a firm understanding of bloat, GP practitioners have still be faced with the
reality of counteracting bloat in their GP runs. As a result a number of ad-hoc, yet
effective, approaches have been devised to control bloat. Bloat control has become
a very active research area, with several different theories on why bloat occurs and
proposed methods for controlling bloat [275, 175, 179, 204, 259, 260]. A review of all
these approaches is outside the scope of this thesis. However, we briefly discuss some
of the most important.
• Size and Depth Limits
• Anti-bloat Genetic Operators
• Anti-Bloat Selection
The earliest and simplest way to constrain the size of individuals is by placing hard
bounds on the maximum allowable size or depth of individuals generated by genetic
initialisation and variation operators. This can work in several different ways. Many
implementations of this kind of approach generate an offspring and check its size or
depth, if its within the pre-specified limits then the offspring enters into the next popu-
lation, else one of the parents is enters. This type of approach does indeed ensure that
solutions grow too large, but has some significant disadvantages. That is, the popula-
tion is often made up if individuals that almost violate the bounds, which is typically
not desired. This problem can be addressed by, rather than return a parent, either
classing that evolutionary step as a failure and repeat it, or by returning the oversize
offspring but settings fitness to 0. t also well known that depth limits leads to trees
that tend to be bushy that are near the depth limit, whereas size limits tend to produce
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stringy trees that are close to the size limit. If limits are used they need to be defined in
such a way that they do the job of controlling bloat, but at the same time don’t constrain
the search space so such that suitable quality solutions cannot be found. In section 4.5
we discuss some of the guidance from GP authors on the practical specification of these
parameter values.
Bloat can also be controlled by using genetic operators that, directly or indirectly, have
an effect on bloat. More recent operators (discussed in sections 4.3.3 and 4.3.2) in-
clude size fair crossover and size fair mutation, which work by constraining choices
made during the genetic operation to actively prevent growth. Older methods include
mutation operators such as hoist mutation and shrink mutaion, which help control the
average tree size in the population whilst ensuring that new genetic material is intro-
duced.
More recently the trend has been towards penalising large individuals by somehow
modulating their selection probability based on their size. This is called the parsimony
pressure method, which is perhaps the simplest and most frequently used method to
control bloat in GP. It works but subtracting a values that based on size from the
fitness values of a given individual. Bigger solutions have more subtracted, and thus
lowered fitness, which in turn lead to a lower chance of being selected as parents for
the next generation. The value to subtract, the penalty, is a function of fitness, size, and
a constant known as the parsimony coefficent. Some authors have demonstrated some
benefits of modifying the value of the parsimony coefficient during the GP run, but
most implementation keep this value constant. Recent methods also include the use of
multi-objective optimisation to control bloat, which typically involves some modified
selection mechanism based on the Pareto criterion.
Several variations and extensions of Pareto selection that help control bloat have been
proposed in the GP literature. For example, niching via fitness sharing has been pro-
posed to better cover the Pareto front through the inclusion of preference information
to focus the selection procedure towards specific regions of the Pareto front [96, 119].
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Different applications and variants of Pareto tournament selection [119, 225, 77] as
well as the use of other multi-objective optimisation techniques [1, 60, 61] have been
developed that control for bloat and/or solutions complexity. Controlling bloat while
at the same time maximising fitness turns the evolution of programs into either a
multi-objective optimisation problem or, at least, into a constrained optimisation prob-
lem [239].
4.7 Implementation
In this section we discuss some of the important consideration when implementing a
GP system. We also give an overview of different options including existing GP im-
plementations, as well as options for implementing a GP system from scratch. Finally
we introduce the specific GP implementation used for this work and offer justification
for implementation choices made.
4.7.1 Implemeting Genetic Programming
When implementing GP there are two main approaches; using existing GP implement-
ations, or implementing a GP system from scratch. There advantages and disadvant-
ages to both options. Implementing from scratch is an excellent way to ensure that
you know exactly how the algorithms are implemented and are (typically) easier to
customise. However, the downside is the programming expertise required and the need
to thoroughly test the system’s behaviour. Using an existing implementation is faster
and good implementations are often robust, throughly tested, efficient, and well doc-
umented. However, heavy customisation can be complicated, with lengthly trial and
error, requiring the user to delve into the source code. Also, must but not all existing
GP implementation are publicly available, some are commercial and as such come at
price. According to Poli et al. (2008), good publicly available GP implementations
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include: Lil-GP, ECJ, Open Beagle and GPC++. The most prominent commercial
implementation remains Discipulus.
As discussed in chapters 2 and 3, the utility of GP for clinical prediction modelling in
the presence of censored data remain unknown. This indicated that significant custom-
isation of the GP implementation was required. For this reason we decided against us-
ing an existing implementation of GP, instead opting to build the system from scratch.
This was motivated not only by the requirement of heavy customisation by the desire
to have full control of the mechanisms involved in the developed GP system.
How GP trees are implemented will obviously depend a great deal on the programming
languages and libraries used. Whilst the earliest GP system were implemented in Lisp,
people have since coded GP is a huge range of different languages, including C/C++,
Java, JavaScript, Perl, Prolog, Mathematica, Pop-11, MATLAB, Fortran, Occam and
Haskell [239]. Languages that provide dynamic lists as fundamental data types and
appropriate libraries will of course make it easier to implement expression tress and
the necessary GP operations.
4.7.2 The R Programming Language
R is a free cross-platform software environment for statistical computing and graphics.
It is a GNU project which is similar to the S language and environment which was
developed at Bell Laboratories (formerly AT&T, now Lucent Technologies) by John
Chambers and colleagues [247]. R provides a wide variety of statistical and graphical
techniques, and is highly extensible. R can be easily extended via libraries, referred to
as packages, with more than 5,800 additional packages and 120,000 functions (as of
June 2014) available at the Comprehensive R Archive Network (CRAN).
R expressions are internally represented as trees. This makes using R expressions
to represent trees a logical choice. R supports the direct manipulation of expression
trees through the same syntax for manipulating nested lists, making implementation of
4.7 Implementation 113
GP operators in R simple, succinct, and easy for proficient R users to understand. R
supports computing on the language, which greatly simplifies symbolic computation
inherent in most GP operations.
As previously discussed, a drawback of building a GP system from scratch is the re-
quirement of proficiency in a suitable programming language. R is no exception with a
relatively steep learning curve. A key disadvantage of R is its performance for compu-
tationally expensive tasks, of which GP is an example. This arises from two aspects of
R, memory and processing. R requires all objects to loaded into memory (RAM),which
can be prohibitive on standard-performance computers and large datasets. R is an in-
terpreted language, which provides great flexibility for exploratory data analysis and
statistical analysis. However, as an interpreted language R does not offer high per-
formance for computationally expensive tasks, natively working in serial using only a
single processing unit. To address this a number of R packages have been developed to
address these weakness, such as methods that efficiently manage memory and support
parallel computation.
R is freely available and thought its open-source development model, R has an extens-
ive collection packages. As one might expect from a statistical programming language,
R has excellent core capabilities for data processing, analysis, statistics, and visualisa-
tion. But, though its extensive collection of packages, also provides advanced special-
ist capabilities for experimental design, machine learning, optimisation, EC, parallel
computing, and many others.
4.7.3 RGP: Implementing Genetic Programming in R
Whilst a number of different R packages are typically used in even simple project, there
were two packages that offered a significant amount of the functionality required to
implement the GP system for this study. These R packages were the publicly available
RGP and EMOA packages.
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The RGP package by Flash et al (2014) [84, 83] provides implementations of the ini-
tialisation, recombination and mutation operators described in sections 4.3.1, 4.3.2, and
4.3.3, respectively. RGP provides implementation of the single- and multi-objective
selection operators described in section 4.3.4. With the multi-objective optimisation
being realised through the emoa package, which provides functionality such as NDS,
Crowding Distance (CD), etc [205]. In addition to search operators, RGP also imple-
ments the single- and multi-objective search heuristics described in sections 4.4.1 to
4.4.3. The are also optimised variants of these operators written in C available. See the
CRAN package documentation on CRAN for more details [84].
For all experiments in this work it was decided to implement a GP system from scratch
using the R statistical programming language and associated packages relevant to GP,
namely RGP and EMOA. The ease of extensibility and customisation were a driving
factor in this choice, as a significant amount of development was required to imple-
ment GP for survival analysis. The RGP and EMOA, packages provide a substantial
amount of functionality required to implement our GP system using R. However, in
implementing a GP system for survival analysis there was significant amount of R
development required, mainly with respect to the implementation a suitable fitness
function for censored data and modification of search operators and heuristics to work
with data in the counting process format required by this problem domain, as discussed
in section 4.2.2. Another driving factor in using R to implement our GP system was
the rich functionality and flexibility that R provides in the ancillary aspects of the GP
system, such experimental design, data processing, and the analysis and visualisation
of GP results.
4.8 Summary Conclusions
In the first section (4.1) of this chapter we introduced GP, presenting it as an abstract
EA for stochastically exploring a vast multidimensional search space.
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In section 4.2 we introduced the building blocks of GP , the primitives, and saw how
they are combined to produce genotypic representations of individual solutions, that
along with GP search operators, define of the search spaces that GP will explore. We
also introduced measures of quality, or fitness, of solutions in the search space. We
discussed that measures of quality can be multi-facetted, leading to multi-objective fit-
ness. We discussed some of the issues that are presented by censored data and survival
analysis, before we defined the fitness measures that will be implemented in this study.
Then in section 4.3 we discussed how the evolutionary process is implemented in GP
through the application of search operators, illustrating how these operators define how
the GP system will navigate through the set of possible genotypic solutions. We intro-
duced and formally defined initialisation, mutation, recombination, and selection op-
erators, appropriate for tree representations, that will be employed in our subsequent
experiments.
In section 4.4 we introduced the set of GP search strategies, grouped by steady-state
and generation, that had been selected for this study. We formally defined these search
heuristics, including single and multi-objective versions, where appropriate. We also
discussed genetic diversity and how its preservation during the GP run is important to
its success. We also introduced approaches to control solution complexity and preserve
genetic diversity using multi-objective search strategies.
In section 4.5 we look at some of the basic parameters that control a GP run; we sum-
marise the literature to try to understand the effects of these parameters, attempting to
offer some ’rules of thumb’ on selecting reasonable stating values for these parameters.
In section 4.6 we talk about the phenomenon of intron growth and bloat, how this
causes problems in GP, and relate this back to section 4.4 by discussing how certain
implementations of genetic operators can counteract this issue.
Finally, in section 4.7 we discussed some of the important consideration when imple-
menting a GP system, giving an overview of different implementation options. Then
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we defined the specific GP implementation used for this work and justified the imple-
mentation choices made.
In the next chapter, using an observational cohort of patients extracted from CPRD, we
will independently and externally validate the performance of the de facto cardiovas-
cular risk prediction model for patients with T2DM.
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Chapter 5
Experiment 1: External validation of
the UKPDS risk engine in incident
type 2 diabetes
Next we perform our first set of experiments that aims to address one of the main goals
of this work - to motivate the need for improved clinical risk prediction methods. This
is achieved by independently and externally validating the performance of the de facto
cardiovascular risk prediction model for patients with T2DM using a contemporary
observational cohort of patients extracted developed from CPRD.
Objective To evaluate the performance of the UKPDS-RE for predicting the 10-year
risk of cardiovascular disease endpoints in an independent cohort of UK patients newly
diagnosed with type 2 diabetes.
Research Design and Methods This was a retrospective cohort study using routine
healthcare data collected between April 1998 and October 2011 from around 350 UK
primary-care practices contributing to the CPRD. Participants comprised 79,966 pa-
tients aged between 35 and 85 years (388 269 person years) with 4,984 cardiovascular
events. Four outcomes were evaluated: first diagnosis of CHD, stroke, fatal CHD, and
fatal stroke.
Results Accounting for censoring , the observed versus predicted ten-year event rates
were as follows: CHD 6.1% vs 16.5%, fatal CHD 1.9% vs 10.1%, stroke 7.0% vs
10.1%, and fatal stroke 1.7% vs 1.6%, respectively. The UKPDS-RE showed moder-
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ate discrimination for all four outcomes, with the concordance-index values ranging
from 0.65 to 0.78.
Conclusions The UKPDS stroke equations showed calibration ranging from poor to
moderate; however, the CHD equations showed poor calibration and considerably
overestimated CHD risk. There is a need for revised risk equations in type 2 diabetes.
5.1 Introduction
National policies for the management of both CVD and type 2 diabetes advocate the
calculation of CVD risk in order to identify high-risk patients for targeted interven-
tions [264, 295, 245, 66, 216]. Several multivariable risk-prediction models (or risk
scores) have been developed for the general, non-diabetic population that also account
for diabetes, but only a few are specific to type 2 diabetes [303]. Only two of these
have been developed in patients with newly diagnosed type 2 diabetes, and they both
use data from the UKPDS [298]. These two models—one for CHD and the other for
stroke—combine to form the UKPDS-RE [165, 284].
International and national clinical guidelines recommended using the UKPDS-RE for
predicting cardiovascular risk [216, 134, 32, 218]. Not only is the UKPDS-RE ad-
vocated for communicating cardiovascular risk to diabetic patients [295], it has been
relied upon for public health decisions [310, 71, 95, 2]. Evidence that these equa-
tions are inadequate could bring into question the evidence-base underpinning many
clinical decisions and public policies about the management of type 2 diabetes. Two
systematic reviews of external validations of type 2 diabetes cardiovascular risk pre-
diction models [303, 35] reported poor calibration of the UKPDS-RE CHD equations
in 10 separate studies [103, 139, 283, 322, 155, 237, 58, 304, 280, 302] and differing
findings for the stroke equations in two separate studies [155, 58]. The largest of these
studies from the UK used only a small sample (n=798) and from a single locality [283].
The largest international study had a larger but still relatively small sample size (n=7
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502), using data collated from 20 countries [155].
The purpose of this study was to carry out an external evaluation of the performance
of the UKDPS-RE on a large, relatively contemporary dataset of UK-resident patients
newly diagnosed with type 2 diabetes.
5.2 Research Design and Methods
This study was carried out using data from CPRD and linked data from the Office for
National Statistics and Hospital Episode Statistics. Ethical approval for the study was
granted by the CPRD Independent Scientific Advisory Committee on 6th September
2012, protocol number 12_084R (Appendix A).
The CPRD observational data set consists of longitudinal, anonymous records from
nearly 700 primary-care practices and more than 11 million patients throughout the
UK (based on the January 2012 release) [39]. The computerised data, recorded in
the course of routine healthcare by general practitioners and associated staff, included
demographic and lifestyle information, medical history, clinical investigations, drug
prescriptions, and hospital referrals. Diagnoses in CPRD are recorded using the Read
code classification and have been validated in a number of studies, showing a high
positive predictive value [118].
Additionally, 357 of the English practices contributing to the data set, representing
about 45% of CPRD patients, participate in a linkage scheme by which registered pa-
tients are anonymously linked, through a trusted third party, to other, independent data
sets [92]. These include hospital-admission data, collated nationally for England as the
Hospital Episode Statistics (HES) [68], and mortality data, collated by the Office for
National Statistics (ONS) [226]. HES provides details of all National Health Service
(NHS) inpatient admissions in England since 1997, including primary and contribut-
ory causes coded using the ICD-10 classification. ONS provides details of all deaths
in England with immediate and antecedent causes coded using the ICD-9 and ICD-10
120 5.2 Research Design and Methods
classifications. The CPRD dataset and its associated linked datasets are described in
more detail in section 2.6.
For this study, a single cohort of patients with incident type 2 diabetes, registered with
practices between 1998 and 2011, was identified from the CPRD data set as described
below. In order to improve ascertainment of cardiovascular events, only patients whose
records linked to the HES and ONS mortality datasets were included, with the former
providing details of diagnoses and procedures related to inpatient episodes, and the
latter providing both the date and cause(s) of death. The HES data also provided the
ethnicity information required for the study. Patients aged between 35 and 84 years at
diagnosis were included in the study. As the original UKPDS-RE was based on a cohort
aged <65 years, a sensitivity analysis was performed. Patients were excluded if they
had on-going or recent CVD (as defined by the UKPDS study criteria), implausible
or improbable dates, or missing or indeterminate sex or smoking status. Patients that
were HES eligible but had no records in the linked HES data were excluded (n=1727).
Patients whose ethnicity was not recorded (n=29,199) were presumed Caucasian and
combined with the Caucasian group.
5.2.1 Selection of type 2 diabetes patients
Patients were considered for selection if they had a clinical (Read or ICD-10) code
indicative of diabetes mellitus in their CPRD or linked HES records. As not all clinical
codes for diabetes distinguish between type 1 diabetes and type 2 diabetes, and some
patient histories may erroneously have contained both type 1 and type 2 diabetes codes,
these patients were categorized as having type 2 diabetes if they met one or more of
the following criteria:
• Clinical codes exclusively indicative of type 2 diabetes
• At least one clinical code indicative of type 2 diabetes (regardless of others in-
dicative of type 1 or non-specific diabetes) and at least one prescription for an
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oral hypoglycaemic agent (OHA)
• Prescription of two or more classes of OHA
• Diagnoses of both type 1 and type 2 diabetes and an age of diagnosis older than
35 years.
Any patient with evidence of diabetes secondary to other causes was excluded. The
date of diabetes incidence was defined as the date of either first diagnosis or first pre-
scription of a diabetes medication, whichever was earlier. A ’wash-in’ period of 365
days was applied to exclude non-incident type 2 diabetes cases.
5.2.2 Outcome measures
The primary outcomes comprised the four cardiovascular events evaluated by the UKPDS-RE:
CHD, fatal CHD, stroke, and fatal stroke. To aid comparison, the definition of the out-
comes in the CPRD cohort was the same as the definitions from the UKPDS [298,
165, 284]. CHD was defined as the occurrence of fatal or non-fatal myocardial infarc-
tion (MI) or sudden death [298]. In patients with multiple CHD events, only the first
event was considered. No distinction was made between ischaemic and haemorrhagic
strokes. In patients with multiple strokes, only the first stroke was considered. Deaths
from causes other than the defined outcomes of interest were treated as censored. Oc-
currence of clinical events of interest in CPRD were observed from GP-recorded dia-
gnoses, diagnoses recorded during a hospital admission, or cause of death.
5.2.3 Input variables
Values for the input variables required for the UKPDS-RE were taken from CPRD
observations around the time of diabetes incidence. Table 5.1 shows the baseline char-
acteristics at the time of incident diabetes. Baseline smoking status was the value re-
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corded closest to diabetes incidence, preferring values recorded prior to diabetes incid-
ence; for systolic blood pressure, glycated haemoglobin A1c (HbA1c), total cholesterol,
and high density lipoprotein (HDL) cholesterol, the baseline value was the average of
biochemical readings recorded in the first two years. The numbers of readings used in
deriving these two-year averages were also recorded for use as input parameters (re-
gression dilution) in the UKPDS-RE [284]. Atrial fibrillation was deemed present at
baseline if a prior diagnosis or record of a CHADS2 test existed (CHADS2: congestive
heart failure, Hypertension, Age ≥ 5 years, Diabetes mellitus, prior Stroke or transient
ischemic attack).
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Table 5.1: Characteristics of patients in the CPRD cohort and UKPDS study. Values are at baseline and are numbers (per-
centages) unless otherwise stated.
Females Males
Characteristic CPRD UKPDS CPRD UKPDS
n 36,746 1,879 43,220 2,643
Age (years), mean (SD) 62.6 (12.3) 52.7 (8.7) 60.3 (11.6) 51.5 (8.8)
Ethnicity (%)
Caucasian/Not recorded 35,452 (96.5) 1,603 (85.0) 42,009 (97.2) 2,151 (81.0)
Afro-Caribbean 404 (1.1) 153 (8.1) 350 (0.8) 201 (7.6)
Asian-Indian 890 (2.4) 141 (7.4) 861 (2.0) 2,91 (11.0)
Smoking status (%)
Non-smoker 19,684 (54) — 16,207 (37) —
Former smoker 10,715 (29) — 18,173 (42) —
Current smoker 6,347 (17) 474 (25) 8,840 (20) 898 (34)
Systolic blood pressure (mmHg), mean (SD)* 139 (14) 139 (21) 139 (13) 133 (18)
HbA1c (%), mean (SD)* 7.0 (1.2) 6.9 (1.5) 7.1 (1.2) 6.6 (1.4)
Total cholesterol (mmol/l), mean (SD)* 5.0 (0.9) 5.7 (1.1) 4.7 (0.9) 5.2 (1.0)
HDL cholesterol (mmol/l), mean (SD)* 1.37 (0.32) 1.18 (0.27) 1.17 (0.27) 1.06 (0.23)
Total/HDL cholesterol ratio, mean (SD)* 3.85 (1.03) — 4.16 (1.11) —
* Mean of values in the first two years from baseline (HbA1c, systolic blood pressure, and cholesterol)
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Multiple imputation was used to replace missing values for systolic blood pressure,
HbA1c, total cholesterol, HDL cholesterol, and the number of biochemical readings
used in their two-year averages. Multiple imputation is a technique that offers substan-
tial improvements over value replacement approaches based on complete cases or cases
matched for age and sex [137]. It involves creating multiple copies of the data and im-
puting the missing values with plausible values randomly selected from their predicted
distribution. Here, we used the Multivariate Imputation by Chained Equations (MICE)
library in the R [247] statistical programming language to generate five imputed data-
sets. Rubin’s rules were then used to combine the results from analyses on each of
the imputed values, producing estimates and confidence intervals that incorporate the
uncertainty of imputed values.
5.2.4 Statistical analysis
For each of the four outcomes, the 10-year estimated risk was calculated for every
patient in the CPRD cohort using the UKPDS-RE [165, 284]. Observed 10-year risks
were generated using the Kaplan-Meier method, by decile of predicted risk and by
five-year age group. The predictive performance of the UKPDS-RE on the cohort was
assessed by examining measures of calibration and discrimination.
Calibration refers here to how closely the predicted 10-year cardiovascular risk agreed
with the observed 10-year cardiovascular risk. This was assessed for each decile of
predicted risk—ensuring 10 equally sized groups—and each five-year age group, by
calculating the ratio of predicted to observed cardiovascular risk separately for males
and for females. Plotting observed proportions versus predicted probabilities, where a
45◦ line denoted perfect discrimination, enabled the calibration of the risk-score pre-
dictions to be visually assessed.
Discrimination is the ability of the risk score to differentiate between patients who did
and did not experience an event during the study period. This measure was quantified
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by calculating a concordance index (C-index), in which a value of 0.5 represents ran-
dom chance, while 1 represents perfect discrimination. All statistical analyses were
carried out in R (v2.15.2) [247].
5.3 Results
We identified 79,966 eligible cases, who contributed 383,025, 388,269, 381,833, and
388,004 person years of observed follow-up for CHD, fatal CHD, stroke, and fatal
stroke, respectively. The incidence rates for cardiovascular events in the CPRD co-
hort were 59.2 (95% CI 56.8–61.6), 16.8 (15.5–18.1), 71.2 (68.5–73.2), and 15.2
(14.0–16.5) per 1000 person years for CHD, fatal CHD, stroke, and fatal stroke, re-
spectively. The median durations of follow-up were 4.2 years (inter-quartile range
[IQR] 2.0–7.2), 4.3 (2.1–7.3), 4.2 (2.0–7.2), and 4.3 (2.1–7.3), respectively. The pro-
portions of cases followed for 10 years or more were 8.5%, 8.8%, 8.4%, and 8.8%,
respectively. Table 5.1 details the characteristics of these patients at or in the first two
years from diabetes diagnosis (baseline). People recruited to the UKPDS were a very
unusual group of people with type 2 diabetes, and this is reflected in the baseline char-
acteristics. For instance, the mean age at baseline for females in the UKPDS was 53
years versus 63 years in general clinical practice (table 5.1).
5.3.1 Missing data
Complete data on age, ethnicity, smoking status, atrial fibrillation status, systolic blood
pressure (SBP), HbA1c, total cholesterol, and HDL cholesterol were available for 70%
of females (n=43 741) and 74% of males (n=54 710). Most patients (n=120 572;
88.3%) had missing data on no more than two risk factors (table 5.2). For specific
covariates, the proportion of missing data was as follows: HDL cholesterol (26.2%
in females, 23.6% in males), SBP (4.1% in females, 3.7% in males), HbA1c (8.1%
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in females, 12.0% in males), and total cholesterol (9.5% in females, 12.3% in males)
(table 5.3).
Table 5.2: Risk factors used in UKPDS Risk Engine models
Risk Factor CHD Stroke
Sex X X
Age (at diagnosis, in years) X X
Ethnicity X
Smoking status (at diagnosis) X X
Atrial fibrillation X
Systolic blood pressure (mmHg) X X
HbA1c (%) X
Total: HDL cholesterol ratio X X
Duration diabetes (days) X X
Table 5.3: Completeness of data
No. of risk factors not recorded No. (%) of females No. (%) of males
(per patient) (n=36 746) 9n= 43 220)
0 (complete data) 43,741 (70) 54,710 (74)
2 10,337 (17) 11,784 (16)
3 2,326 (4) 2,410 (3)
4 723 (1) 644 (1)
5 3,670 (6) 2,970 (4)
6 37 (0) 35 (0)
7 1,648 (3) 1,598 (2)
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5.3.2 Discrimination and calibration
A visual illustration of the agreement between mean observed risk and the mean pre-
dicted risk, grouped by decile of predicted risk for each of the four UKPDS-RE out-
comes is shown in Figure 5.1. Presenting these data in an alternative way, figure 5.2
shows the agreement between the observed risk and the predicted risk by five-year
age and sex-specific groups for each of the outcomes. Both the CHD models were
clearly miscalibrated—notably for males (overestimating event rates by 174% and
466%, compared with 160% and 398% in females, for CHD and fatal CHD, respect-
ively) and most notably for fatal CHD (overestimating event rates by 440%). There was
a clear and consistent over-prediction of risk across all deciles of predicted risk, and
across all age and sex-specific groups. The disagreement between observed proportions
and predicted risks increased in subsequent deciles of risk and in the older age groups
(figures 5.1 and 5.2). The stroke model overestimated event rates by 29% and 58% in
females and males, respectively, and the fatal-stroke model underestimated event rates
by 20% in males and overestimated these rates by 11% in females. The stroke models
showed modest agreement between observed and predicted risk grouped by decile of
risk, with the exception of the final, 10th decile for the stroke model in both males
and females (figures 5.1 and 5.2). Both the stroke and the fatal-stroke models showed
modest agreement across all age groups, with some divergence towards the latter age
ranges (70–85 years), most noticeably for males in the stroke model. The fatal-stroke
model slightly under-predicted risk for the later age groups, whereas the stroke model
tended to over-predict risk for these latter age groups.
Table 5.4 summaries the performance of the four UKPDS-RE models in predicting
the 10-year risk in type 2 diabetes patients who were initially free of CVD. The
UKPDS-RE overestimated the risk of CHD, fatal CHD, and stroke by 169%, 440%,
and 44%, respectively, and underestimated the risk of fatal stroke by 5%. According
to the C-index all models were found to have acceptable model discrimination, with
the exception of the CHD model in males (C-index=0.65), which was found to have
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Figure 5.1: Observed versus predicted 10-year risk by sex and outcome
modest discrimination. The C-index values for females and males, respectively, were
as follows: for the CHD model, 0.71 and 0.65; for the fatal-CHD models, 0.78 and
0.74; for the stroke models, 0.73 and 0.71; and for the fatal-stroke models, 0.77 and
0.78. All the models showed better discrimination in females, with the exception of
fatal stroke, and better discrimination (and variability in estimates) in fatal outcomes
in both females and males. Of all the models evaluated, fatal stroke demonstrated the
best prognostic separation, with discrimination results ranging from acceptable to good
(0.77 and 0.78 in females and males, respectively), whereas CHD exhibited the worst
prognostic separation, most noticeably in males, with discrimination results ranging
from modest to acceptable (0.71 and 0.65).
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Figure 5.2: Observed and predicted 10-year risks by age group, sex, and outcome
(solid lines represent observed proportions and dashed predicted risk).
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Table 5.4: Summary of UKPDS-RE performance in predicting 10-year cardiovascular risk
CHD Fatal CHD Stroke Fatal Stroke
Females Males Females Males Females Males Females Males
n 36,746 43,220 36,746 43,220 36,746 43,220 36,746 43,220
Event rates (%)
Observed 6.14 1.88 7.00 1.69
(95% CI) 5.82–6.45 1.70–2.06 6.67–7.33 1.52–1.86
4.59 7.44 1.54 2.16 7.28 6.77 1.92 1.50
(4.18–5.01) (6.97–7.90) (1.29–1.79) (1.91–2.42) (6.77–7.79) (6.34–7.20) (1.65–2.19) (1.28–1.72)
Predicted 16.51 10.14 10.10 1.60
(95% CI) (16.43–16.59) (10.07–10.20) (10.00–10.20) (1.58–1.62)
11.94 20.39 7.66 12.24 9.38 10.71 1.53 1.67
(11.86–12.02) (20.31–20.48) (7.60–7.73) (12.18–12.30) (9.28–9.47) (10.61–10.81) (1.51–1.54) (1.65–1.68)
Discrimination (%)
C-index 0.71 0.65 0.78 0.74 0.73 0.71 0.77 0.78
(95% CI) (0.69–0.73) (0.63–0.66) (0.75–0.81) (0.72–0.77) (0.72–0.75) (0.70–0.72) (0.74–0.80) (0.76–0.81)
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This validation study showed that the risk equations that constituted the UKPDS-RE
were poorly calibrated and significantly overestimated CHD risk. The stroke equations
showed calibration ranging from poor to moderate. All the UKPDS-RE equations
showed moderate discrimination, with slightly better discrimination for fatal events.
This finding was concordant with several other much smaller, external validation stud-
ies (<8,000 subjects) that also showed poor calibration and overestimation of CHD
risk by the UKPDS-RE [103, 139, 283, 322, 155, 237, 58, 304, 280, 302]. To date,
this is the largest study, with around 80,000 patients, and the most comprehensive ex-
ternal validation of cardiovascular-risk prediction in a diverse and more contemporary
population with type 2 diabetes.
The relatively poor performance of the UKPDS-RE may be explained, at least in part,
by the differences in the baseline profiles of the UKPDS and CPRD populations. These
plausibly include: the epidemiological setting, changes in life expectancy, changes in
smoking habits, the presence or absence of co-morbidities, temporal changes in dia-
betes management, and changes in the general quality of care. Other plausible explan-
ations include the possible harm of overly aggressive treatment with sulfonylureas and
insulin in the early stages of the disease [54].
The CPRD cohort used in this study was drawn from the UK general-practice, and
identified 79,966 patients aged 35–85 years newly diagnosed with type 2 diabetes and
registered between 1998 and 2011. The data used to derive the UKPDS-RE risk equa-
tions originated from a randomised trial of 5102 UK patients aged 25–65 years newly
diagnosed with type 2 diabetes and recruited between 1977 and 1991 (followed up until
1997) [298]. The CPRD cohort comprised patients aged 35–85 for two reasons: pa-
tients aged under 35 were excluded to reduce misclassification of type 1 diabetes, and
patients aged 66–85 were included to reflect the fact that NICE guidelines recommend
using the UKPDS-RE for all ages [295]. Of the 79,966 patients in the CPRD cohort,
31,179 (39%) were outside the 25–65 age range, and a sensitivity analysis suggested
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that the inclusion of older subjects aged 65–85 did not significantly affect calibration
or discrimination.
A number of the UKPDS trial’s exclusion criteria—namely, macrovascular complic-
ations, ketonuria, nephropathy, severe retinopathy, malignant hypertension, uncorrec-
ted endocrinopathy, and severe concurrent illness—were not applied to the CPRD co-
hort because their presence would not preclude the use of the UKPDS-RE in clinical
practice [298]. It is important to note that, by the nature of trial selection criteria,
UKPDS recruits were more likely to be of lower risk, suggesting that the UKPDS-RE
would be expected to underestimate risk when applied to the CPRD cohort. Over-
all, the UKPDS-RE overestimated cardiovascular risk in the CPRD cohort, suggesting
that—in spite of the additional exclusion criteria—the UKPDS patients were at higher
risk.
A potential difference in the rigour of ascertainment of primary outcomes between
UKPDS and CPRD warrants consideration. In this study, we deliberately limited se-
lection to those designated by CPRD as being of research quality, with data linked to
HES and ONS mortality data during their entire follow-up period. These criteria com-
bine to make case ascertainment among the highest of any observational data sources.
Even prior to the introduction of HES-linked data in CPRD, the predictive value of GP-
recorded diagnoses of acute MI in the General Practice Research Database (forerunner
to CPRD) exceeded 90% [105].
The secular differences between the UKPDS sample and the current CPRD cohort may
have played an important role. The advent of routine diabetes screening in primary
care in the UK has almost certainly led to earlier diagnosis of type 2 diabetes than was
available at the time of UKPDS recruitment. This is supported by an absolute 2% fall
in average incident HbA1c among UK patients with newly diagnosed type 2 diabetes
between 1991 and 2012 [127], although the mean HbA1c at specific regimen initiation
did not change at all [53]. As such, patients in the UKPDS cohort are likely to have
had more advanced diabetes at the point of diagnosis, with correspondingly greater
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vascular morbidity.
Over the same period, the diagnosis of MI has evolved from one based solely on clinical
symptoms to one that may involve increasingly sophisticated serological and imaging
components, such that the severity of MI on admission may plausibly have been re-
duced. Post-MI care has also improved over the period, and consequently death rates
subsequent to MI have fallen. This may partially explain why the UKPDS-RE overes-
timated fatal CHD, but it does not account for the same discrepancy in non-fatal CHD,
which by this rationale could be regarded as conservative.
Another explanation for the disagreement in the observed and predicted risk estimates
may be the progressive increase in the use of effective medication for hypertension and
dyslipidaemia over the past 20 to 30 years. Of the CPRD patients at baseline (i.e. type 2
diabetes incidence), 22.4% were taking lipid-lowering medication, 49.2% were taking
antihypertensive treatment, and 13.7% were taking some form of antiplatelet therapy
at baseline. By contrast, the UKPDS was conducted at a time when the number of
patients taking such medications was much lower. For example, of the UKPDS patients
at baseline, 0.3% used lipid-lowering therapy, 12% used antihypertensive therapy, and
1.6% used more than one aspirin daily. Furthermore, during the period of follow up,
less than 2% of UKPDS patients took lipid-lowering therapy at any stage compared
with 75.3% of the CPRD cohort [299].
Other changes are also apparent. Only 19% of the CPRD patients were current smokers
at baseline, compared with 30% in the UKPDS. The high relative-risk reduction in
CHD afforded by statin therapy (subsequent to UKPDS) could have had the effect of
reducing the amount of risk that was then potentially modifiable by other interventions
such as new glucose-lowering therapies. The benefits of statin therapy are believed to
extend beyond their effect on lipid profiles. This is plausible, given that UKPDS-RE
considerably overestimated the risk of CHD but not that for stroke. On the other hand,
the specific risk markers targeted by these drugs, such as cholesterol, blood pressure,
and glucose control are still accounted for within the UKPDS-RE, so the magnitude if
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the discrepancy remains difficult to explain. The principal difference between the CHD
and stroke models is the presence of HbA1c as an input parameter in the former. The
poor calibration of CHD in this study brings into question the role of glucose control
in predicting macrovascular complications. In sensitivity analysis—where decile of
observed HbA1c was used as the subgroup criterion—there was no gradient in observed
risk of CHD, contrary to widespread expectation (figure 5.3). If corroborated, this
would have a significant impact on current clinical management guidelines for type 2
diabetes. Our findings might also suggest that, in contemporary practice, the ’benefit’
of glucose control (i.e., reduction in CHD risk) is being overstated and consequently is
having an undue influence on the diagnosis and treatment of type 2 diabetes.
Figure 5.3: Observed and predicted 10-year risks by HbA1c, sex, and outcome
(solid lines represent observed proportions and dashed predicted risk).
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The overestimation of cardiovascular risk by the UKDPS-RE may also lead to unne-
cessary targeting of patients for preventative strategies. Accurate estimation of abso-
lute risk is important not only for communicating information on prognosis to patients
and practitioners but also for estimating the potential risk-benefit balance, and cost
effectiveness of therapy. For example, NICE guidelines for the management of type
2 diabetes recommend using the UKPDS-RE and a specified risk threshold to identify
patients not considered to be at high cardiovascular risk for lipid-lowering therapy with
statins. Due to the considerable overestimation of cardiovascular risk observed in this
study, use of the UKPDS-RE in clinical practice may lead potentially to harmful over-
treatment of patients with type 2 diabetes.
5.4.1 Strengths and limitations of the study
A major strength of this study was the size and representativeness of the cohort. Its
limitations are the high levels of missing data for HbA1c, total cholesterol, and HDL
cholesterol. Omitting cases with missing data and performing a complete-case analysis
would have potentially introduced bias into the study. However, the issue of missing
data has been addressed by using established methods of multiple imputation. We
assumed that people with missing ethnicity data were white. This may have biased the
findings to some small degree, but it is unlikely to have impacted substantially on our
findings.
Measurement error in identifying the CVD outcomes will have been present in the
analysis, but this study has endeavoured to apply the UKPDS study’s definitions of
the cardiovascular outcomes as far as possible in selecting appropriate medical codes
[298]. Moreover, we have supplemented the clinical information recorded in the CPRD
with linked but independent secondary-care data from HES, which included details
of primary and additional diagnoses for inpatient episodes, and with cause-specific
mortality data extracted from death certificates from the ONS. It is therefore unlikely
that measurement error is a large source of bias.
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Restricting cohort membership to patients from the subset of English practices particip-
ating in the linkage scheme between CPRD and HES/ONS should not have introduced
significant bias: patient characteristics have been found to be similar between linked
and non-linked practices [118]. In order to provide data on ethnicity only those HES
eligible patients with a hospital contact were included in our cohort. This excluded
only 2% of patients but these patients were presumably healthier than the overall co-
hort.
Here we have attempted to validate the UKPDS-RE as a prognostic tool in a cohort of
newly diagnosed subjects. We did not evaluate its performance with respect to CVD
risk among patients with established type 2 diabetes. As the CHD and stroke models
each include duration of diabetes as an input parameter, exploration of the utility of
UKPDS-RE among prevalent cases of type 2 diabetes is an important future objective.
5.5 Conclusions
The four UKPDS risk equations constituting the UKPDS-RE showed a reasonable abil-
ity to identify high-risk patients (discrimination) but were generally poor at quantifying
the absolute risk (calibration). The UKPDS-RE CHD risk equations consistently over-
estimated absolute risk, whereas the UKPDS-RE stroke equations performed relatively
well. However, when considered as a whole, the UKPDS-RE was unsuitable for pre-
dicting CVD risk in UK subjects with newly diagnosed type 2 diabetes. Our findings
suggest that the use of UKPDS-RE in clinical practice will lead to over-estimation of
CVD risk in patients with newly diagnosed T2DM. This in turn is likely to lead to
selection of preventative treatments, for which, for some patients, the balance of risks
may outweigh the benefits. Considering the widespread application of these prediction
models in clinical practice, drug reimbursement, and public health decision-making,
we suggest that there is a need for revised risk equations in type 2 diabetes. Using the
clinical setting of CVD in patients with T2DM to motivate, these findings add support
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to the hypothesis that there is a need for improved clinical risk prediction methods.
In the next chapter, we will perform our second set of experiments to demonstrate the
utility of genetic programming for the automatic development of clinical prediction
models for risk prediction of future cardiovascular events in patients with symptomatic
cardiovascular disease using data from the Second Manifestations of ARTerial disease
study.
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Chapter 6
Experiment 2: A case study in
symptomatic cardiovascular disease in
the general population using the
SMART cohort
Next we perform our second set of experiments to test the main hypothesis—that ap-
plication of GP can provide more accurate representation of factors that predict the
risk of CVD when compared with existing methods—by assessing the utility of the
developed GP approach for the automatic development of clinical prediction models
for risk prediction of future cardiovascular events in patients with symptomatic cardi-
ovascular disease using data from the SMART study.
GP is a general methodology, the specific implementation of which requires develop-
ment of several different specific elements such as problem representation, fitness, se-
lection and genetic variation. Here we implement the specific GP elements developed
in chapter 4 to form a GP approach for clinical prediction modelling in the presence
of censored survival data, and assess its performance and examine the prognostic sig-
nificance of different risk factors when compared with the de facto statical method in
empirical data from the clinical setting of secondary prevention.
Background & Aims Genetic programming is an Evolutionary Computing methodo-
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logy, inspired by biological evolution, capable of discovering complex non-linear pat-
terns in large data sets. Despite the potential advantages of genetic programming over
standard statistical methods, its applications to survival analysis are at best rare, primar-
ily because of the difficulty in handling censored data. The aim of this study was to
demonstrate the utility of genetic programming for the automatic development of clin-
ical prediction models using asymptomatic cardiovascular disease as a case study.
Study Design and Setting We compared genetic programming against the commonly
used Cox regression technique in terms of development and performance of a cardi-
ovascular risk score using data from the SMART study, a prospective cohort study
designed to identify predictors of future cardiovascular events in patients with symp-
tomatic cardiovascular disease. The event predicted was a composite cardiovascular
event, comprising of cardiovascular death, non-fatal stroke, and myocardial infarction.
The predictive ability of both models was assessed in terms of discrimination and cal-
ibration.
Results A total of 3,873 patients were enrolled in the study 1996-2006, aged 19-82
years with a total of 460 cardiovascular events. The study cohort was split 70:30 into
derivation and validation sets, used for model fitting and assessment of performance of
both the genetic programming and Cox regression models. The discrimination of both
models was comparable, albeit in favour in genetic programming; at time points t=1,
3, and 5 years the C-index was 0.65, 0.76, 0.74, and 0.66, 0.70, 0.70, for the genetic
programming and Cox regression models, respectively. At the same time points, the
calibration of both models was also comparable, but with the Cox modelling better
calibrated to the validation data.
Conclusions Using empirical data, we demonstrated that a prediction model developed
automatically by genetic programming has predictive ability comparable to that of
manually ’tuned’ Cox regression. The genetic programming model was more com-
plex but was developed in a fully automated fashion, used fewer predictors as inputs,
and did not require the expertise needed for survival analysis. Genetic programming
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demonstrated potential as a methodology for the automated development of clinical
prediction models for diagnostic and prognostic purposes.
6.1 Introduction
The objective of this study was to develop a tree-based untyped genetic programming
approach for censored longitudinal data, comparing it to multi-variable Cox regression
in the development of a clinical prediction model for the occurrence of vascular events
in patients with symptomatic cardiovascular disease, using data from a prospective co-
hort study. Four models were developed, three using symbolic regression (GMOGP,
GSOGP and, SSOGP) and another using multi-variable Cox regression, and their per-
formance was evaluated in terms of discrimination and calibration in a validation data
set.
As discussed in chapter 4, there are a great number of different operators and parameter
settings, independent of a particular GP search strategy, that can be used in modern GP
systems. The purpose of the experiments in this chapter are to demonstrate the utility of
GP for clinical prediction modelling in the presence of censored survival data. As such,
we have endeavoured to use ’out of the box’, untuned GP, adopting commonly used
operators and parameter settings recommended by the literature for the data and type
of problem at hand. In this way aim to demonstrate its practical utility by comparing
untuned GP, that does not require significant specialist expertise, with highly tuned Cox
regression, which does require significant statistical expertise to be applied correctly.
Whilst there have been successful applications of genetic programming to regression
and classification problems, we believe that this is the first study to have used genetic
programming for survival analysis. This serves to demonstrate the utility of genetic
programming for the automated development of clinical prediction models.
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6.2 Patients and Methods
This study was carried out using data from the SMART study. Details of the ongo-
ing prospective cohort study at the University Medical Centre Utrecht, the Nether-
lands, designed to identify predictors of future cardiovascular events in patients with
symptomatic cardiovascular disease have been described previously [276]. Briefly,
we consider 3,873 patients who were enrolled in the study between September 1996
and March 2006. Patients were enrolled when presenting at hospital, with follow-up
starting from study inclusion. Patients had a clinical manifestation of atherosclero-
sis, defined as transient ischaemic attack, ischaemic stroke, peripheral atrial disease,
Abdominal Aortic Aneurysm (AAA), or coronary heart disease. After informed con-
sent, patients underwent a standardised vascular screening, including a health ques-
tionnaire for clinical information, laboratory assessment, and anthropometric meas-
urements at enrolment. During follow-up patients were biannually asked to fill in a
questionnaire on hospitalisations and outpatient clinic visits. When a possible event
was reported by a participant, correspondence and relevant data were collected (dis-
charge letters, laboratory radiology results). Based on all obtained information, every
event was audited by three physicians from different departments.
The primary outcome was any cardiovascular event, comprising of cardiovascular death,
non-fatal stroke and non-fatal myocardial infarction (table 6.1). Combing predictor
events is a common approach in cardiovascular research to increase statistical power [286].
A cardiovascular event occurred in 460 patients during follow-up.
For our study we a priori selected 25 candidate predictors based on previous pro-
gnostic studies (Framingham, SCORE). These 25 candidate predictors included risk
factors traditionally associated with future events (hyperhomocysteinemia, Intima Me-
dia Thickness (IMT) and creatinin level), demographics (age and sex) and risk factors
for vascular events in the general population (smoking, alcohol use, BMI, diastolic and
systolic blood pressure, lipids and diabetes). Indicators to the location of symptomatic
vascular disease (cerebral, coronary, peripheral atrial disease or AAA) and markers of
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Table 6.1: Definitions of fatal and non-fatal vascular events in the SMART study
Event Definition
Ischaemic stroke Definite: Relevant clinical features that have caused an in-
crease in impairment of at least one grade on the modified
Rankin scale, accompanied by a fresh ischaemic infarction
on a repeat brain-scan
Probable: Clinical features that have caused an increased
impairment of at least one grade on the modified Rankin
scale; without a fresh ischaemic infarction on a repeat brain-
scan
Myocardial infarction Fatal or non-fatal myocardial infarction: at least two of the
following criteria:
1. chest pain for at least 20 min, not disappearing after ad-
ministration of nitrates
2. ST-elevation > 1 mm in two following leads or a left
bundle branch block on the ECG
3. CK elevation of at least two times the value of CK and a
MB-fraction > 5% of the total CK
Vascular death Sudden death: Unexpected cardiac death occurring within 1
h after onset of symptoms, or within 24 h given convincing
circumstantial evidence
Death from ischaemic stroke
Death from intracerebral haemorrhage (haemorrhage on
CT-scan)
Death from congestive heart failure
Death from myocardial infarction
Death from rupture of AAA
Vascular death from other cause, such as sepsis following
stent placement
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the extent of atherosclerosis (homocysteine, glutamine, creatinin, albumin, IMT and
presence of carotid artery stenosis, table 6.5) were also considered as it is conceivable
that they are relevant to predict future events in patients with symptomatic vascular dis-
ease. We note that the primary focus of these models is achieving accurate predictions
rather than insight into the predictor effects.
6.2.1 Methods
The data set was split, randomly, into two parts: a derivation set of approximately
66.67% (2582 patients) and a validation set of approximately 33.33% (1291 patients).
The derivation set was used for model development (both by Cox regression and by
genetic programming) and the validation set to access the performance of the two mod-
els. The aim for both models was to predict the absolute risk of occurrence of vascular
events (stroke, myocardial infarction or cardiovascular death). Given the available
follow-up, 1-, 3-, and 5-year risks could be assessed. With respect to sample size in the
derivation set, the balance of 313 events and 25 predictors is reasonable, (table 6.5). At
least 10-20 events per candidate predictor have been proposed in previous guidelines
for the sensible development of predictions models [112, 236, 285, 286].
Multiple imputation is a technique that offers substantial improvements over value re-
placement approaches based on complete cases or cases matched for age and sex [137].
It involves creating multiple copies of the data and imputing plausible values randomly
selected from their predicted distribution. Here, we used multiple imputation to re-
place missing values for smoking status, packyears, alcohol, BMI, diabetes, SBP,
Dyastolic Blood Pressure (DBP), Total Cholesterol (TC), High-density Lipoprotein
Cholesterol (HDL), Low-density Lipoprotein Cholesterol (LDL), triglycerides, homo-
cysteine, glutamine, creatinine, albumin, IMT and carotid artery stenosis (table 6.5),
generating five imputed data sets. The first set of imputations were used for further
analysis (’single imputation’). Although multiple imputation is preferable from a the-
oretical view point, single imputation was considered more practical and sufficient to
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obtain reasonable predictions [286]. Final models were also constructed with multiply
imputed data sets to check for any relevant differences in point estimates, and widening
of confidence intervals.
Cox Regression
The SMART data set, like many others in cardiology and oncology, is an example of
censored data, often referred to as a survival outcome. In medical and epidemiological
studies the Cox Proportional Hazards model (or Cox regression) is the most often used
model for survival outcomes [48]. Analogous to this model for a binary outcome in
uncensored data, where we know whether or not the patient experienced the event in
the time horizon of interest, is the logistic model. Multi-variable logistic regression
model is is the most widely used statistical technique nowadays for binary medical
outcomes [107, 286, 307]. The Cox PH model is the natural extension of the logistic
model to the survival setting [286].
In the derivation set, we fitted a Cox regression model using a similar modelling
strategy that described by Steyerberg [286] in the development of a clinical predic-
tion model on the SMART study data set. Briefly, the we first fitted a full main effects
model. Biologically implausible values were set to missing (prior to imputation) and
extreme values truncated at the 1st and 99th centile. To enhance the flexibility of the
Cox regression and enable fairer comparison with the (unrestricted) genetic program-
ming, we considered continuous predictors (e.g. age, creatinine, blood pressure) for
transformation. Several transformations were considered in adding polynomials, frac-
tional polynomial terms, transformations (e.g. log, square root, exponential), restricted
cubic splines (with varying number of knots) and linear coding (i.e categorisation).
To further enhance a fair comparison with genetic programming, we considered inter-
action effects between predictors. Key limitations of the Cox PH model include the
assumption of proportional hazards - that hazard functions in the different strata are
proportional over time, assumptions of linearity and additivity which are implicit in re-
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gression’s linear combinations, and the fact that the baseline hazard is never specified
(although this last one may be advantage in some cases). All model assumptions relev-
ant to the Cox proportion hazards model were tested. A reduced model was obtained
by applying a backwards selection procedure, with Akaike information criterion (AIC)
as the stopping criterion.
Internal validation of the model was performed using a bootstrapping re-sampling pro-
cedure [22, 75, 111]. Random samples were drawn (with replacement) from the de-
rivation set with 200 replications, and the backwards selection of predictors for the
reduced model repeated each time. Bootstrapping yielded an estimate of optimism of
the reduced models as expressed by the concordance (C) statistic, which for a bin-
ary outcome is identical to the area under the receiver operating characteristic (ROC)
curve. A shrinkage factor was derived from the bootstrap estimates to re-calibrate the
model to adjust for optimism. The re-calibrated model was applied to the validation set
to estimate its discrimination and calibration in an independent sample. All analyses
were carried out in R (v3.0.1) [247].
Symbolic Regression
For the experiments in this chapter we implemented three untyped tree-based GP mod-
els using steady-state single-objective (SSOGP), generational singe-objective (GSOGP)
and, generational multi-objective (GMOGP) search strategies, discussed in sections 4.4.1 -
4.4.3, to fit symbolic regression models to the data to estimate discrete hazard, thus
predicting the risk for cardiovascular events. Here the outcome is discrete hazard rate
which is the conditional probability that an individual will experience the event during
time interval [t-∆/2, t+∆/2), given they are event-free at the beginning of the interval,
as opposed to continuous hazard rate in the Cox regression. We have modelled survival
in discrete time, as opposed to continuous time, to take advantage of the discrete-time
survival fitness function (Equation 4.13) detailed in section 4.2.3, which enables GP
to be applied to censored survival data. An advantage of this model is that it’s not
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constrained by the assumption of proportional hazards and is better suited to any non-
linear interactions between explanatory variables. However, the data need to prepos-
sessed into the ’counting process format’, which results in multiple observations per
subject, representing the discrete time segments for which they were observed.
Symbolic regression was performed using the RGP package in the R statistical pro-
gramming language, with the SSOGP, GSOGP and, GMOGP search heuristics using
the parameter settings detailed in tables 6.2 - 6.4. The choice of these starting paramet-
ers was driven by the size of the training data available, the perceived relative complex-
ity of the problem and, the recommendation and guidelines from authors in the field of
GP which are discussed in section 4.5. Wherever possible we have opted for the most
common or default operators and parameter settings, opting not to tune the parameters.
The default RGP function set (+,−,÷,×, sin, cos, tan,√, exp, log) was used to en-
able the representation of potential non-linear relationships present in the training data.
Koza’s [167] ramped half-and-half random initialisation method, the most commonly
used initialisation operator in tree-based GP, was used with a maximum tree depth of
63. The GP approach utilised is untyped with the search space constrained by the use
of fitness penalties. Specifically, the ’death penalty’ is used where invalid solutions,
such invalid mathematical operations (e.g. dividing by 0), have their fitness value set
to ∞ giving them the lowest possible fitness (section 4.2.1). As discussed in sec-
tion 4.5, some authors propose that as a rule of thumb to specifying the maximum tree
depth, one should try to estimate the size of the expected solution size and add some
percentage as a safety margin. For this experiments we calculated, when transform-
ing categorical predictors into ’dummy’ variables (i.e. n-1 dummies per categorical
predictors, where n is the number of levels), that the expected solution depth would
be 21 based on the expected solution being modelled as a regression model with 19
predictors. Based on this we estimated a maxdepthsize = 21 × 3% = 63. In most
real-world GP applications only a fixed compute time budget is available. Therefore,
the expiration of a fixed time compute budget was chosen as the termination criterion.
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The compute time budget for these experiments was set to 12 hours wall-time and
these experiments were run on a single thread on an Intel Westmere 2.8GHz CPU with
48 GB of memory. Because larger population sizes tend to increase genetic diversity,
because this problem is a relatively difficult one and, the data has a relatively large
number of training cases, we wanted to use the largest population size that the GP sys-
tem could handle gracefully. Based on observations from practitioners (see section 4.5)
in the filed we opted for an initial population size of µ = 1, 000. The most commonly
used mutation and recombination operators in tree-based GP, Subtree Mutation (Equa-
tion 4.15) and Subtree Crossover (Equation 4.18), were selected for this experiment
with the default RGP parameter settings. Because this is relatively hard problem we
have opted genetic variation rates of 0.5 and 0.5 for crossover (Prec) and mutation
(1 − Prec), respectively. For the SSOGP search heuristic implemented in these exper-
iments we have opted for a low selection pressure (tournamentsize = 4) because, as
discussed in section 4.5, authors have have very good experiences with low selection
pressure, with tournaments of 4 individuals regularly performing well.
Table 6.2: Parameters of the SSOGP search heuristic.
Variable (Symbol) Domain Setting
Population Size mu (µ) N 1,000
Tournament Size tournamentSize (stournament ) N 4
Recombination Probability recombinationProbabilty (prec) [0, 1] 0.5
Table 6.3: Parameters of the GSOGP search heuristic.
Variable (Symbol) Domain Setting
Population Size mu (µ) N 1,000
Children per Generation mu (λ) N 500
We did not perform internal validation in the genetic programming approach using a
bootstrap as we did with the Cox regression, because it would not have been possible
to convert it into a shrinkage factor in the same way as we would for a Cox regression.
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Table 6.4: Parameters of the GMOGP search heuristic.
Variable (Symbol) Domain Setting
Population Size mu (µ) N 1,000
Children per Generation lambda (λ) N 500
New Individuals per Generation nu (ν) N0 500
Age Layering ageLayering B true
Parent Selection Probability parentSelectionP (ppsel ) [0, 1] 1
The genetic programming system is a stochastic process, with each run potentially
yielding models with differing complex structures (i.e. symbolic regression). As a
result regression coefficients do not exist in genetic programming models in the same
way that they do in regression models. Instead the training data was split 2/3:1/3 into
training and holdout sets, using a stratified random split to ensure proportionate number
of events. The first 2/3, the training set, was used for training to induce a population
of prediction models. The remaining 1/3, the holdout set, was used at the end of
the genetic programming run to calculate the fitness of the population of models and
thus determine the fittest or ’best of run’ model to be returned as the output of the
genetic programming system. In this way the final genetic programming model was
selected based on its fit to unseen data using a sample other than which it was trained
or developed.
To understand variable selection in the genetic programming and enable comparison
with bootstrapped backwards selection of the Cox model, the genetic programming
system was executed 25 times to produce 25 ’suggested’ models. For each iteration
the training data was randomly (stratified) split 2:1. The final genetic programming
model was applied to the validation data set to assess its performance, in terms of
discrimination and calibration in an independent sample. All analyses were carried out
in R version 3.1.2 [247].
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Comparison of both methods
The four clinical prediction models, one obtained from Cox progression and three from
symbolic regression (SSOGP, GSOGP and, GMOGP), were evaluated in terms of over-
all survival curves, discrimination and calibration in the validation data set. The models
were used to predict the discrete hazards h(t) at t = 1, 3, and 5 years. Model were first
evaluated visually by comparing the survival probabilities S(t) predicted by the models
with estimates obtained using the KM method. The agreement between these curves
and the KM estimates were assessed visually.
Discrimination is the ability of the risk score to differentiate between patients who did
and did not experience an event during the study period. This measure was quantified
by calculating a concordance statistic (C-statistic), proposed by Harrell et al. [109,
110, 111, 300] which is a rank-based measure for censored survival data. The C-
statistic is equivalent of the AUC measure [107] for survival data, in which a value of
0.5 represents random chance and 1 represents perfect discrimination. The C-Statistic
was evaluated considering truncation of the survival/censoring times at t=1, 3, and 5
years.
Calibration refers here to how closely the predicted x-year cardiovascular risk agreed
with the observed x-year cardiovascular risk. Model calibration was assessed using cal-
ibration plots and the generalisation of the Hosmer-Lemeshow test statistic for survival
data [56]. This was assessed by grouping subjects into g equally sized groups, with the
same cardinality, based on quantiles of predicted S(t), where t is a fixed time point,
and calculating the ratio of predicted to observed cardiovascular risk. For each of the g
groups, plotting observed proportions (KM) versus predicted probabilities (model) en-
abled the calibration of the model predictions to be visually assessed. The closer the g
points are to the 45 degree line connecting (0,0) to (1,1), the better is the calibration. To
obtain the χ2 statistic, the model predicted number of events was calculated, for each
group, as the product of the group size by the average predicted incidence 1 − S(t).
The results were then compared to the observed number of events in the corresponding
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groups calculated as the product of the group size by the KM estimate of 1−S(t). This
leads to a statistic which, under the null hypothesis of numerical agreement between
predicted and observed number of deaths, has a χ2 distribution. Calibration was eval-
uated by grouping subjects according to the predicted S(t) at t = 1, 3, and 5 years. All
analyses were carried out in R version 3.1.2.
6.3 Results
6.3.1 Descriptives
There were no major differences in the baseline characteristics of the patients between
the derivation and validation sets (table 6.5). Data were available on 9,636 and 4,895
person-years collected during a median follow-up of 3.3 (range, 0-9 years) and 3.3
years (0-9 years) for the derivation and validation sets, respectively. In the derivation
set a total of 313 events occurred, corresponding to 1-, 3-, and 5-year cumulative incid-
ences of 4.1%, 8.9% and 15.0% respectively. In the validation set a total of 147 events
occurred, corresponding to 1-, 3-, and 5-year cumulative incidences of 3.8%, 8.1% and
12.0% respectively.
6.3.2 Model Derivation
Prior to modelling extreme values in IMT, BMI, lipids (cholesterol, HDL, LDL, trigly-
cerides), homocysteine and creatinine were truncated at the 1st and 99th centile. In-
dicators to the location of symptomatic vascular disease (cerebral, coronary, peripheral
atrial disease or AAA) were optimally combined into a single variable (or sumscore),
with each condition contributing one point except AAA that contributed 2 points. Us-
ing univariate cox models there was no significant difference between the sumscore
(χ2 119; 1 d.f.) and using the separate terms (χ2 123; 4 d.f.) however there was a
saving of 3 degrees of freedom from the sumscore.
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Table 6.5: Baseline characteristics of patients in the SMART cohort, by derivation
and validation sets (n=3,873).
N Test set Training set Test Statistic
N = 1291 N = 2582
Cardiovascular event 3873 11% ( 147) 12% ( 313) χ21 = 0.45, P = 0.51
1
Gender : Female 3873 25% ( 320) 25% ( 656) χ21 = 0.18, P = 0.68
1
Age years 3873 52 60 68 52 60 68 F1,3871 = 0.03, P = 0.862
Smoking : Never 3873 18% ( 235) 18% ( 458) χ23 = 5.6, P = 0.13
1
Former 69% ( 885) 71% (1826)
Current 12% ( 158) 11% ( 286)
NA 1% ( 13) 0% ( 12)
Packyears years 3852 5.2 18.2 33.8 6.1 19.5 34.5 F1,3850 = 0.79, P = 0.382
Alcohol : Never 3873 20% ( 255) 19% ( 496) χ23 = 1.1, P = 0.77
1
Former 11% ( 141) 10% ( 267)
Current 69% ( 885) 70% (1804)
NA 1% ( 10) 1% ( 15)
Body mass index Kg/m2 3870 24 26 29 24 26 29 F1,3868 = 3, P = 0.0842
Diabetes : 0 3873 76% ( 983) 78% (2004) χ22 = 1.1, P = 0.59
1
1 23% ( 294) 21% ( 552)
NA 1% ( 14) 1% ( 26)
Systolic blood pressure, automatic mm Hg 2650 127 140 155 127 139 153 F1,2648 = 1.4, P = 0.232
Diastolic blood pressure, automatic mm Hg 2652 73 79 86 73 79 86 F1,2650 = 0.01, P = 0.92
Systolic blood pressure, by hand mm Hg 2375 128 140 158 125 139 155 F1,2373 = 3.8, P = 0.0522
Diastolic blood pressure, by hand mm Hg 2374 75 82 90 74 82 90 F1,2372 = 0.2, P = 0.652
Total cholesterol mmol/L 3855 4.4 5.2 5.9 4.3 5.1 5.9 F1,3853 = 2.6, P = 0.112
High-density lipoprotein cholesterol mmol/L 3843 0.95 1.15 1.40 0.97 1.18 1.43 F1,3841 = 3.8, P = 0.052
Low-density lipoprotein cholesterol mmol/L 3657 2.5 3.1 3.8 2.4 3.0 3.8 F1,3655 = 3.2, P = 0.0732
Triglycerides mmol/L 3845 1.1 1.6 2.3 1.1 1.5 2.2 F1,3843 = 4.1, P = 0.0422
Cerebral 3873 30% ( 387) 29% ( 760) χ21 = 0.12, P = 0.73
1
Coronary 3873 56% ( 724) 56% (1436) χ21 = 0.08, P = 0.78
1
Peripheral 3873 24% ( 308) 24% ( 632) χ21 = 0.18, P = 0.67
1
Adominal aortic aneurysm 3873 10% ( 134) 11% ( 282) χ21 = 0.26, P = 0.61
1
Homocysteine (µ)mol/L 3410 10 13 16 10 13 16 F1,3408 = 2.5, P = 0.112
Glutamine (µ)mol/L 3854 5.3 5.8 6.5 5.3 5.7 6.5 F1,3852 = 0.94, P = 0.332
Creatinin mL/min 3856 78 89 102 78 89 101 F1,3854 = 0.62, P = 0.432
Albumin : No 3873 75% ( 969) 75% (1928) χ23 = 1.1, P = 0.78
1
Micro 17% ( 221) 17% ( 434)
Macro 3% ( 33) 3% ( 81)
NA 5% ( 68) 5% ( 139)
Intima media thickness mm 3775 0.75 0.88 1.05 0.75 0.88 1.07 F1,3773 = 0.24, P = 0.632
Presence of carotid artery stenosis : 0 3873 79% (1020) 79% (2038) χ22 = 0.91, P = 0.63
1
1 18% ( 236) 19% ( 486)
NA 3% ( 35) 2% ( 58)
a b c represent the lower quartile a, the median b, and the upper quartile c for continuous variables. N is the number of non–
missing values. Numbers after percents are frequencies. NA represent missing values. Tests used:1Pearson test; 2Wilcoxon
test
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The full Cox regression model consisted of 14 predictors, several of which had lim-
ited contributions. Predictors that had a relatively large effect were age, location of
symptomatic vascular disease (sum score), albumin, and the marker of renal damage,
creatinine. The coding of predictors that gave the best representation for age and cre-
atinine were (AGE − 50)2 and log(CREAT), respectively. We also tested interactions
between predictors but the resultant interactions were not considered relevant enough
to include any interaction terms in the final model. The proportionality of hazards was
tested using an overall test which was not significant. We judged our sample size to
large enough to allow for some model reduction (313 events and a full model with 17
degrees of freedom), facilitating easier practical application and clinical interpretation.
We applied a backwards step-wise selection procedure, using AIC as the stopping rule,
to achieve a reduced Cox model. The reduced step-wise selected model was found to
be optimal with 9 predictors (table 6.6). Predictors with relatively weaker effects (al-
cohol, diabetes, gender, smoking status, and stenosis) were excluded from the reduced
model.
Bootstrapping of the reduced model yielded an estimate of required shrinkage for the
coefficients in the step-wise selected model of 0.91, suggesting that each coefficient
should be reduced by 9% to obtain a re-calibrated model that corrects for optimism.
This shrinkage factor was applied to the reduced backwards step-wise model and con-
sidered the calibrated ’final’ Cox regression model (table 6.7). All analyses were re-
peated with the multiply imputed data sets, with largely similar results.
Based on the parameter settings detailed in section 6.2.1, the generational approaches
failed to complete within the allocated 12 hour fixed time budget because they ex-
ceeded the maximum memory allocation (42Gb). This is likely to be due to the in-
creased computational expense of the generational approach to GP, when compared
to the computationally cheaper steady-state approach. The experiments were repeated
with a range of different parameter settings that effect the memory requirements, such
as population size and max depth of solutions, but unfortunately these all exceeded the
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Table 6.6: Cox regression coefficients in the full model, and stepwise selected
model (using AIC).
Predictor Full Stepwise
Age AGE 0.0011 0.0011
Albumin ALBUMIN=Macro 0.5289 0.5371
ALBUMIN=Micro 0.5227 0.5184
Alcohol ALCOHOL=Current 0.0234
ALCOHOL=Former −0.1854
Body mass index BMI −0.0383 −0.0359
Creatinin CREAT 0.5992 0.5282
Diabetes DIABETES 0.0783
High-density lipoprotein cholesterol HDL −0.4619 −0.4096
Previous atherosclerosis (sum score) HISTCAR2 0.2980 0.2895
Homocysteine HOMOC 0.0169 0.0182
Intima media thickness IMT 0.5145 0.5879
Gender SEX=Female 0.1754
Smoking SMOKING=Current 0.0798
SMOKING=Former 0.0427
Presence of carotid artery stenosis STENOSIS 0.1815
Systolic, by hand SYSTH 0.0037 0.0041
available memory and failed. From here on we will discuss only the results from the
SSOGP symbolic regression models.
Figure 6.1 describes the run statistics for the 25 GP SSOGP runs performed on the
different stratified re-samples of the derivation data set. The figure depicts the evol-
ution of the different GP run’s best fitness (bestFit) and complexity, quantified using
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Table 6.7: Association of each predictor with cardiovascular events in the calib-
rated final Cox model.
Low High ∆ Effect S.E. Lower 0.95 Upper 0.95
AGE 52.00 68.0 16.00 0.32 0.08 0.16 0.48
Hazard Ratio 52.00 68.0 16.00 1.38 1.18 1.61
BMI 24.03 28.7 4.69 -0.15 0.08 -0.31 0.00
Hazard Ratio 24.03 28.7 4.69 0.86 0.73 1.00
SYSTH 127.00 156.0 29.00 0.11 0.07 -0.04 0.25
Hazard Ratio 127.00 156.0 29.00 1.11 0.96 1.29
HDL 0.96 1.4 0.47 -0.18 0.09 -0.34 -0.01
Hazard Ratio 0.96 1.4 0.47 0.84 0.71 0.99
HISTCAR2 1.00 5.0 4.00 1.05 0.27 0.52 1.59
Hazard Ratio 1.00 5.0 4.00 2.87 1.67 4.91
HOMOC 10.50 15.9 5.40 0.09 0.05 -0.02 0.19
Hazard Ratio 10.50 15.9 5.40 1.09 0.98 1.21
CREAT 78.00 101.0 23.00 0.12 0.05 0.04 0.21
Hazard Ratio 78.00 101.0 23.00 1.13 1.04 1.24
IMT 0.75 1.1 0.32 0.17 0.07 0.04 0.30
Hazard Ratio 0.75 1.1 0.32 1.19 1.04 1.35
ALBUMIN — Micro:No 1.00 2.0 0.47 0.14 0.21 0.74
Hazard Ratio 1.00 2.0 1.60 1.23 2.09
ALBUMIN — Macro:No 1.00 3.0 0.49 0.24 0.02 0.96
Hazard Ratio 1.00 3.0 1.63 1.02 2.61
mean visitation length (meanVisLen), over time. Time is represented as iterative or
evolutionary steps (stepNo), where an evolutionary step is each time that tournament
selection is performed and new individuals are generated and considered for inclusion
in the population. The ’final’ symbolic regression model is the individual the best (i.e.
lowest) fitness at the end of all 25 GP runs. We can see that there is significant vari-
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ation in the best fitness and complexity of the individuals developed by the different GP
runs. However, in general the improvement in best fitness appears to level out towards
the over time in all runs, suggesting that the selected fixed time compute budget of 12
hours wall time is acceptable. A range of different run statistics for all 25 SSOGP runs
are detailed in Appendix B.
The final model produced by genetic programming model included 6 predictors: age
(AGEn), sum score of previous atherosclerosis (HISTCAR2n), gender (SEXfemale.n),
IMT (IMTn), homocysteine (HOMOCn), and albumin (ALBUMINNo.n), in addition
to the discrete time indicator (tj), which is present in all the genetic programming
models to represent the jth time interval. The final prediction model generated by ge-
netic programming is presented in figure 6.2, which is a binary parse tree representing
Equation 6.1.
λˆ(tj, X) =Prob(T = tj|T ≥ tj, X) = 1
1 + e−Xβˆ
, where
Xβˆ =(tj − (0.441 + tj)) ∗ exp(sin(sin(ALBUMINNo.n)))∗
exp((HOMOCn + AGEn)/tan(1.889)) ∗ cos((tan(SEXfemale.n)
+ (HOMOCn + AGEn))/exp(cos((tan(tan(exp(HISTCAR2n)))
+ sin(IMTn) + sin(IMTn))/tan(1.886)))) ∗ 2.487− exp(cos(
HISTCAR2n/tan(tan(−1.813))/tan(tan(tan(0.739)))))
(6.1)
The other 24 prediction model generated by genetic programming are presented in
Appendix C.
The genetic programming approach was applied 25 times, each time trained and tested
on a different stratified re-sample of the derivation data set. This leads to a pool 25
different ’best of run’ models, each of which may have selected different subset of pre-
dictors as inputs and as such may have differing levels of performance. In this pool of
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Figure 6.1: Selected runs statisitcs for the 25 SSOGP runs in the SMART experi-
ments.
genetic programming models, the mean number of predictors used was 6 (IQR: 5—8).
The backwards step-wise selection procedure used in the Cox modelling was also re-
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Figure 6.2: The final model developed by genetic programming, presented as a
binary tree.
peated 25 times, using bootstrap re-sampling to better understand the frequencies at
which different subsets of predictors were selected. In the pool of 25 backwards se-
lected Cox models the mean number of predictors used was 9 (IQR: 8—10). There
was a reasonable association between the estimated effect of a predictor according in
the reduced backwards step-wise model and the frequency of the selection when the
step-wise selection was repeated in the bootstrap procedure (table 6.8).
Generally the features selected by repeating the GP were far more variable than the
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Table 6.8: Number (proportion) of times predictors were selected duting the 25
repititions of Cox regression backwards step-wise selection procedure and genetic
programming.
Predictor Cox Regression Genetic Programming
Age AGE 25 (1.00) 19 (0.76)
Gender SEX 11 (0.44) 5 (0.20)
Smoking SMOKING 5 (0.20) 10 (0.40)
Alcohol ALCOHOL 3 (0.12) 11 (0.44)
Body mass index BMI 19 (0.76) 4 (0.16)
Systolic, by hand SYSTH 14 (0.56) 6 (0.24)
High-density lipoprotein cholesterol HDL 18 (0.72) 8 (0.32)
Diabetes DIABETES 10 (0.40) 1 (0.04)
Previous atherosclerosis (sum score) HISTCAR2 25 (1.00) 20 (0.80)
Homocysteine HOMOC 19 (0.76) 13 (0.52)
Creatinine CREAT 22 (0.88) 7 (0.28)
Albumin ALBUMIN 22 (0.88) 23 (0.92)
Presence of carotid artery stenosis STENOSIS 10 (0.40) 10 (0.40)
Intima media thickness IMT 23 (0.92) 12 (0.48)
features selected by the Cox regression stepwise selection procedure (table 6.8). This
is to be be expected as GP is a stochastic system, where as the stepwise procedure is
deterministic, only giving variable results because we are repeating the procedure on
different bootstrap resamples of the derivation data set.
Despite this, the predictors that were estimated to have the largest effect in the final
stepwise selected Cox model which were also selected with the high frequency in boot-
strapped stepwise selection—age, previous atherosclerosis, and homocysteine—were
selected (relatively) frequently when GP was repeated. Interestingly, stepwise selection
also often selected BMI, HDL, creatinine, albumin and, IMT as predictors, however,
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these featured in a relatively low proportion of the GP models. However, albumin and
IMT did feature in the best performing ’final’ GP model. Conversely, the ’final’ GP
model featured gender as a predictor, a predictor that was estimated to have small effect
and was selected in low proportion of Cox models by the stepwise selection procedure.
6.3.3 Model Validation
Using the validation data set, the average performance of the 25 ’best of run’ predic-
tion models automatically generated by GP was compared with the calibrated final Cox
model. Graphical comparisons of the S(t) values produced by each model with those
obtained by the KM method in the validation set are shown in figure 6.3. As can be
seen from this figure, both the Cox and GP models produced similar values that had
good agreement with the KM estimates in the earlier years. However, this agreement
deteriorated in the latter years, where the KM estimates have high variability, as indic-
ates by the large error bars. This high variation my be explained by the fact that with a
median follow-up time of 3.3 years, there are far fewer events and number of subjects
in the latter time periods. Whilst agreement deteriorated in the latter time-points, both
models had generally acceptable overall agreement.
The discriminative performance in the validation set, according to the C-statistic, of
the models at different time points is shown in table 6.9 and figure 6.4. From the
C-statistic estimates we can see that a satisfactory performance of >0.6 was reached
in both models, at all time points. There was generally comparable discriminative
performance of both models, at all time points, albeit in favour of the Cox model. Both
models demonstrated better performance at time t = 3 years, which may be explained
by the 3.3 median follow up time in the validation set.
The calibration plots evaluated by grouping subjects according to quantiles of predicted
risk (1 − S(t)) at t = 1, 3, and 5 years are shown in figure 6.5. The corresponding
χ2 statistics and p-values are shown in table 6.10. From the graphical inspection of
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Figure 6.3: Average survival curves for the Cox regression and genetic program-
ming models. The error bars represent ±2 standard errors of the KM estimates.
Table 6.9: C-statistic estimates by model at t=1, 3, and 5 years
Time (years) Cox PH Regression Genetic Programming
1 0.66 0.59
3 0.70 0.69
5 0.70 0.64
the calibration plots we can see that there was no tendency to systematically over- or
under-predict at any of the time points in either the Cox or GP models. The genetic
programming model was less calibrated than the Cox model, confirmed by the higher
χ2 values in table 6.10 at times t = 3 and t = 5, whereas it was better calibrated at time
t = 1. Calibration in both models was worst at time t = 5, and best in the Cox and GP
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Figure 6.4: C-statistic estimates by model for t=1, 3 and 5 years
Table 6.10: χ2 statistic for the comparison between observed versus expected (ac-
cording to the model) number of events in groups of patients defined according to
the predicted 1− S(t) at t=1, 3, and 5 years.
Time (years) Cox Regression Genetic Programming
t χ2 p-value χ2 p-value
1 7.93 0.541 5.18 0.818
3 4.89 0.844 9.99 0.352
5 10.32 0.325 16.17 0.063
models at times t = 3 and t = 1, respectively. However the Homser-Lemeshow test
statistic, detailed in table 6.10, suggested that there was only a statistically significant
lack of calibration in the GP model at time point t = 5.
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Figure 6.5: Calibration plots for the Cox regression and genetic programming
models, at t=1, 3, and 5 years..
6.4 Discussion
This study showed that Cox regression and GP produced similar results when evaluated
in a common validation data set. After re-calibration the discriminative ability of the
GP model in the validation set was slightly larger than that of the Cox model at two
time points, compared with the Cox model model, which was marginally better at
only one time point. Despite slight relative differences, both models demonstrated an
acceptable level of discriminative ability (C-index >0.6) at all times points. The GP
model had relatively poorer calibration when compared with the Cox model. The Cox
model demonstrated no statistically significant lack of calibration at any time point,
however the GP did demonstrate a statistically significant lack of calibration at the
latter time point only.
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Despite generally comparable performance, albeit in favour of the Cox model, the
predictors selected for representing their relationship with the outcome were quite dif-
ferent. The final reduced Cox model used 9 predictors, in contrast to 6 predictors used
in the GP. The GP model used significantly fewer predictors, further confirmed by
repeating the the GP and the stepwise selection procedure used in the Cox modelling,
resulting in mean numbers of predictors of 6 (IQR: 5—8) and 9 (IQR: 8—10), respect-
ively.
Predictors that were estimated to have larger contributions to the final Cox model and
that frequently selected during stepwise selection—age, previous atherosclerosis, and
homocysteine—were selected in the final GP model, with age and previous atheroscler-
osis selected at (relatively) high frequency when the GP was repeated. However, others
predictors that had large to moderate contributions to the final Cox model—BMI, creat-
inine, and HDL—did not features in the final GP model and were selected infrequently
when GP was repeated. Interestingly, gender did not have much of contribution to the
final cox model yet it was selected relatively infrequently by GP and featured in the
final GP model. There were other predictors —albumin and IMT —where the pic-
ture was less clear, and whilst they had large to moderate contributions to the final
Cox model and featured in the final GP model, they were selected at low frequencies
when GP was repeated. Whilst these results confirm the prognostic significance of a
small number of the most highly associated predictors in the Cox modelling, symbolic
regression model did not estimate such a large number predictors to be strongly asso-
ciated with the outcome, associated strongly enough for inclusion in the model at least,
whilst achieving comparable performance.
These results suggest that GP may better represent the potentially non-linear relation-
ship of (a smaller subset of) the strongest predictors. To test the first part of this hypo-
thesis—that GP can represent the potential non-linear relationships that exist between
predictors—the shape of the predictor effects were plotted to evaluate whether or not
the effects were non-linear in nature. Using the ’final’ GP model, the effects of each
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predictor’s values were plotted against log hazard, whilst the other values were held
at their reference values. Reference values were the modal class for binary variables
and the mean of continuous variables. Figure D.1 of appendix D illustrates that the
the ’final’ model developed by GP is modelling non-linear effects for the continuous
predictors age, initma media thickness and homocysteine.
To test the second part of this hypothesis—that GP can better represent these rela-
tionships between predictors using fewer variables—we repeated the GP runs with
exactly the same experimental set-up, but restricting the inputs to predictors that were
selected with a relatively high frequency (>0.5) in the original GP run of the primary
experiment. The covariates included age, previous atherosclerosis, homocysteine, and
albumin. This produced very similar results (detailed in appendix E) both in terms
of calibration and discrimination. Both these findings support the hypothesis that GP
may better represent the potentially non-linear relationship of (a smaller subset of) the
strongest predictors.
Whilst considerable effort was made to relax the linearity of the Cox regression, through
transformation of predictors, the nature of the approach relies on linear combinations of
predictors. The fact that GP required fewer predictors to achieve similar performance
may have an advantage in practical application of the developed clinical prediction
model. The acquisition of information that forms the inputs to such a model can be
prohibitively onerous in routine clinical practice. Therefore a prediction model that re-
quires fewer inputs, especially if the information relating to these inputs is in practice
recorded easily and to a good quality, would considerably increase adoption and utility.
This work has limitations introduced by its use of data from the SMART study, a
study from a secondary prevention setting, designed to predict the risk of subsequent
cardiovascular events in patients with already presenting with clinical CVD. Through
its use of the SMART study data this work has demonstrated the utility of GP in a
secondary prevention setting, however, there are limitations in the generalisability of
these findings to the other clinical settings of cardiovascular risk prediction. Indeed,
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secondary prevention in stable cardiovascular patients is not the most common clinical
setting for the application of cardiovascular risk prediction models in routine practice.
6.5 Conclusion
To our knowledge, this is the first empirical study to assess the value of GP for clinical
prediction purposes compared to the well-known and widely applied Cox PH regres-
sion technique. Using data from the SMART study we demonstrated that a symbolic
regression model developed by SSOGP has predictive ability comparable to that of Cox
regression for the prediction of future cardiovascular events in a secondary prevention
setting, i.e in patients with symptomatic cardiovascular disease. These experiments
compared an untuned SSOGP symbolic regression model that was developed in an
automated fashion using basic parameter values recommended from the GP literature,
with a highly tuned Cox regression model that was developed in a very involved man-
ner that required a certain amount of clinical and statistical expertise.
Whilst the highly tuned Cox regression model performed marginally better in the val-
idation data, both in terms of calibration and discrimination, the performance of the
automatically generated prediction model was generally comparable.
These findings demonstrate the utility of GP as a methodology for automated develop-
ment of clinical prediction models for diagnostic and prognostic purposes, where the
primary goal is accurate prediction. These findings also confirm the prognostic signi-
ficance of age, previous atherosclerosis, homocysteine, and to a lesser extent albumin
and IMT, for cardiovascular risk in patients with symptomatic CVD. Finally, further
validation is required to assess the utility of GP for automated development of new
clinical prediction models in other clinical and environmental settings.
In the next chapter we discuss a series of experiments using a very similar method-
ology and experimental set-up to those used in this chapter. However, the developed
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GP approach is applied to different dataset refined from CPRD in a primary preven-
tion setting in patients with T2DM, rather than the secondary prevention setting in the
general population used in this chapter. We look to see if we observe similar results to
this chapter and further demonstrate the utility of GP for clinical prediction modelling
in censored survival data in different clinical setting.
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Chapter 7
Experiment 3: A case study in
asymptomatic cardiovascular disease
in type 2 diabetes using CPRD
Next we perform our third and final set of experiments—which have a very similar
experimental set-up those in the previous chapter—to further test our main hypothesis
that application of GP can provide more accurate representation of factors that predict
the risk of CVD when compared with existing methods, but this time using a different
clinical setting and datasource.
We assess the utility of the developed SSOGP approach for the automatic development
of clinical prediction models for risk prediction of future cardiovascular events, assess-
ing its performance and examining the prognostic significance of different risk factors
when compared with the de facto statical method in a much larger observational cohort
of patients from CPRD in a primary prevention clinical setting, where patients have
asymptomatic CVD.
Background & Aims The aim of this study was to demonstrate the utility of genetic
programming for the automatic development of clinical prediction models using symp-
tomatic cardiovascular disease in patients with T2DM as a case study.
Study Design and Setting We compared genetic programming against the commonly
used Cox regression technique in terms of development and performance of a cardi-
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ovascular risk score using data from CPRD to refine a retrospective observations cohort
of T2DM patients with asymptomatic cardiovascular disease. The event predicted was
a composite cardiovascular event, comprising of cardiovascular death, non-fatal stroke,
and myocardial infarction. The predictive ability of both models was assessed in terms
of discrimination and calibration.
Results The study cohort consisted of 63,496 patients with T2DM, registered with
practices between 1999 and 2011, aged 35-85 years with a total of 14,804 cardiovas-
cular events. The study cohort was split 70:30 into derivation and validation sets, used
for model fitting and assessment of performance of both the genetic programming and
Cox regression models. The discrimination of both models was comparable, albeit in
favour in Cox regression; at time points t=2, 5, and 8 years the C-index was 0.69, 0.65,
0.67, and 0.71, 0.70, 0.70, for the genetic programming and Cox regression models,
respectively. At the same time points, the calibration of both models was also compar-
able, with no significant lack calibrated to the validation data.
Conclusions Using empirical data, we have confirmed the findings of the previous
chapter in a new clinical context—primary prevention—demonstrating that a predic-
tion model developed automatically by genetic programming has predictive ability
comparable to that of manually ’tuned’ Cox regression. The genetic programming
model was more complex but was developed in a fully automated fashion, used sig-
nificantly fewer predictors as inputs, and did not require the expertise needed for sur-
vival analysis. Genetic programming demonstrated potential as a methodology for the
automated development of clinical prediction models for diagnostic and prognostic
purposes.
7.1 Introduction
CVD is the leading cause of mortality and a major cause of morbidity globally and in
the UK. Asymptomatic patients that are suspected to be at high risk need to be identi-
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fied by general practitioners so they can offer advice about lifestyle changes and initiate
preventative treatment. To facilitate this, general practitioners need tools that can ac-
curately and reliably predict cardiovascular risk in their patients. National policies for
the management of both CVD and type 2 diabetes advocate the calculation of CVD
risk in order to identify high-risk patients for targeted interventions [264, 295, 245,
66, 216]. As discussed in chapter 3, several multivariable risk-prediction models have
been developed for the general, non-diabetic population that also account for diabetes,
but only a few are specific to type 2 diabetes [303].
In chapter 5 we carried out an external validation of the performance of the UKPDS-RE
on a large, relatively contemporary retrospective cohort of UK-resident patients with
T2DM from CPRD. Results showed that the UKPDS-RE had a reasonable ability to
identify high-risk patients (discrimination) but were generally poor at quantifying the
absolute risk (calibration). Our findings suggested that the use of UKPDS-RE in clin-
ical practice will lead to over-estimation of CVD risk in patients with newly diagnosed
T2DM. Considering the widespread application of these prediction models in clin-
ical practice, drug reimbursement, and public health decision-making, we suggest that
there is a need for revised risk equations in T2DM.
The objective of this study was to compare the GP approach for censored longitudinal
data developed in section 6.2.1, with multi-variable Cox regression in the development
of a clinical prediction model for the occurrence of vascular events in a large, relatively
contemporary dataset of UK-resident patients with T2DM. Models were developed
using SSOGP and multi-variable Cox regression, and their performance was evaluated
in terms of discrimination and calibration in a validation data set.
The experiments in this chapter differ from chapter 6 in terms of the clinical setting
and the cohort of patients. In the previous experiment we assessed the developed GP
approach in the clinical setting of secondary prevention, where we are predicting sub-
sequent cardiovascular events in patients with a clinical diagnosis of CVD, using data
from a prospective cohort study designed to identify predictors of future cardiovascular
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events in patients with symptomatic CVD. In this chapter we evaluate the developed
GP approach in the primary prevention setting, where we are predicting the risk of
a primary cardiovascular event in a much larger retrospective observational cohort of
patients with T2DM from UK general practice.
7.2 Patients and Methods
This study was carried out using data from CPRD and linked data from the ONS and
HES. Ethical approval for the study was granted by the CPRD Independent Scientific
Advisory Committee on 9th October 2012, protocol number 12_111R (Appendix F).
The CPRD dataset and its associated linked datasets have been described previously in
sections 2.6 and .
This study considers a prospective open cohort of CVD-free patients with T2DM in
the January 2013 build of CPRD, over 14 years from 1997 to 2011, aged 30-85 years
at index date and registered with practices participating in CPRD-HES/ONS linkage to
ensure accurate cause of death, ethnicity and socioeconomic status. For each patient,
the start of follow-up is defined as the latest of: patient registration date, practice Up-
To-Standard (UTS) date, start of HES coverage, and start of ONS coverage; the index
date is then calculated as the start of follow-up plus 365 days wash-in (see below). End
of follow-up is defined as the earliest of: patient transfer-out date (where not internal),
ONS death date, practice last-data-collection date, patient HES linkage date, end of
HES coverage, and end of ONS coverage. In addition, the ONS SES linkage period
must overlap the follow-up period by at least one day.
Patients were excluded from the cohort that have any one of the following criteria: a
recorded diagnosis of cardiovascular or cerebrovascular disease prior to the index date;
any temporary residence status; interrupted periods of registration with the practice;
no valid Index of Multiple Deprivation (SES); were taking statins at index; implaus-
ible or improbable dates; or recorded risk factor values out of plausible range. Patients
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were selected that were eligible for linkage schemes with the HES, ONS mortality data
and Index of Multiple Deprivation data throughout their respective period of follow-
up. This should provide accurate ascertainment of ethnicity, socioeconomic status, and
cause of death. Issues with ethnicity data where within the non-missing data there are
a large proportion of ethnicities recorded as ’unknown’ will be addressed by recoding
the ’unknown’ responses as ’white’, with the rationale that, assuming the study popu-
lation is comparable with the UK population, 93% or more of people without ethnicity
recorded would be expected to be from a white ethnic group.
Patients were considered for selection if they had a clinical (Read or ICD-10) code
indicative of diabetes mellitus in their CPRD or linked HES records. As not all clinical
codes for diabetes distinguish between type 1 diabetes and type 2 diabetes, and some
patient histories may erroneously have contained both type 1 and type 2 diabetes codes,
these patients were categorised as having type 2 diabetes if they met one or more of
the following criteria:
• Clinical codes exclusively indicative of type 2 diabetes
• At least one clinical code indicative of type 2 diabetes (regardless of others in-
dicative of type 1 or non-specific diabetes) and at least one prescription for an
Oral Hypoglycaemic Agent (OHA)
• Prescription of two or more classes of OHA
• Diagnoses of both type 1 and type 2 diabetes and an age of diagnosis older than
35 years.
Any patient with evidence of diabetes secondary to other causes was excluded. The
date of diabetes incidence was defined as the date of either first diagnosis or first pre-
scription of a diabetes medication, whichever was earlier. A ’wash-in’ period of 365
days was applied to exclude non-incident T2DM cases.
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The primary outcome is first CVD event either before or at death, with CVD being
defined here as coronary heart disease (including myocardial infarction and angina) or
cerebrovascular disease (including stroke and transient ischemic attack). A wash-in
of 365 days is applied to ensure no prior history of CVD. Either a diagnosis of CVD
or an intervention to treat CVD—such as an angioplasty or coronary bypass—will
be considered an event. These events will be recorded as Read codes in the CPRD
Clinical or Referral tables; as ICD-10 or OPCS codes in HES diagnosis or procedure
tables, respectively; or as ICD-10 or ICD-9 codes in the OPCS cause-of-death data.
Lists of the relevant codes are supplied as part of the approved ISAC protocol for this
study (Appendix F).
For our study we a priori selected 23 candidate predictors—values for which were
taken from CPRD observations around the index date—based on previous prognostic
studies (e.g UKPDS). These 23 candidate predictors included indicators of baseline
comorbidity (Charleston Index, no. general practitice attendances in year prior, treated
hypertension, durations of diabetes, a recorded diagnosis of the following; some other
form of CVD not defined in the outcome, renal disease, rheumatoid arthritis, atrial
Fibrillation), demographics (age, gender, self assigned ethnicity, and quintiles of the
Index of Multiple Deprivation) and risk factors for vascular events in the general popu-
lation (smoking status, BMI, SBP, and lipids). Treated hypertension is defined as dia-
gnosis of hypertension and at least one current prescription of at least one antihyper-
tensive agent(e.g. thiazide, Beta-blocker, calcium channel blocker, or Angiotensin-
Converting-Enzyme (ACE) inhibitor). Prescribed related drugs (lipid-lowering, ACE,
Angiotensin Receptor Blockers (ARB), Beta-blocker, and Anti-Platelet Therapy (APT)
therapies), table 6.5) were also considered as it is conceivable that they are relevant to
predict future events in patients with asymptomatic vascular disease. We note that the
primary focus of these models is achieving accurate predictions rather than insight into
the predictor effects.
Multiple imputation was considered to replace missing values for ethnicity, smoking
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status, BMI, SBP, TC, HDL, LDL and triglycerides. However, the proportions of
missing data exceeded what can be reliably imputed using even the more advanced
multiple imputation techniques. Instead categorical predictors were given an addi-
tional ’missing’ categories and continuous predictors were categorised into clinical
meaningful categories, also with an additional ’missing’ category. In the clinical con-
text of primary prevention thus level of missing data for many predictors in question
is not unexpected, as they would not normally be recorded unless the general practi-
tioner already suspects some above average risk of CVD. Whilst, to some degree, in
categorising the continuous predictors that have missing values we discard some of the
information, this loss is outweighed by the loss of not including these predictors at all,
or in removing observations with these missing values (complete case analysis) as this
would considerably reduce the sample size and in turn the power to detect the patterns
in the data.
7.2.1 Methods
The data set was split, randomly, into two parts: a derivation set of approximately
66.67% (42,331 patients) and a validation set of approximately 33.33% (21,165 pa-
tients). The derivation set was used for model development (both by Cox regression
and by genetic programming) and the validation set to access the performance of the
two models. The aim for both models was to predict the absolute risk of occurrence
of vascular events (stroke, myocardial infarction or cardiovascular death). Given the
available follow-up, 2-, 5-, and 8-year risks could be assessed. With respect to sample
size in the derivation set, the balance of 9,878 events and 23 predictors is reasonable,
(table 6.5). At least 10-20 events per candidate predictor have been proposed in previ-
ous guidelines for the sensible development of predictions models [112, 236, 285, 286].
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Cox Regression
In the derivation set, we fitted a Cox regression model using a similar modelling
strategy that was described in chapter 6 in the development of a clinical prediction
model in the cohort developed from the CPRD data set. Briefly, the we first fitted a
full main effects model. Biologically implausible values were set to missing (prior
to imputation) and extreme values truncated at the 1st and 99th centile. To enhance
the flexibility of the Cox regression and enable fairer comparison with the (unrestric-
ted) genetic programming, we considered continuous predictors (e.g. age, duration
of diabetes) for transformation. Several transformations were considered in adding
polynomials, fractional polynomial terms, transformations (e.g. log, square root, ex-
ponential), restricted cubic splines (with varying number of knots) and linear coding
(i.e categorisation). To further enhance a fair comparison with genetic programming,
we considered interaction effects between predictors.
Key limitations of the Cox PH model include the assumption of proportional hazards
- that hazard functions in the different strata are proportional over time, assumptions
of linearity and additivity which are implicit in regression’s linear combinations, and
the fact that the baseline hazard is never specified (although this last one may be ad-
vantage in some cases). All model assumptions relevant to the Cox proportion hazards
model were tested. A reduced model was obtained by applying a backwards selection
procedure, with Akaike information criterion (AIC) as the stopping criterion.
Internal validation of the model was performed using a bootstrapping re-sampling pro-
cedure [22, 75, 111]. Random samples were drawn (with replacement) from the de-
rivation set with 200 replications, and the backwards selection of predictors for the
reduced model repeated each time. Bootstrapping yielded an estimate of optimism of
the reduced models as expressed by the concordance (C) statistic, which for a bin-
ary outcome is identical to the area under the receiver operating characteristic (ROC)
curve. A shrinkage factor was derived from the bootstrap estimates to re-calibrate the
model to adjust for optimism. The re-calibrated model was applied to the validation set
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to estimate its discrimination and calibration in an independent sample. All analyses
were carried out in R (v3.0.1) [247].
Symbolic Regression
For the experiments in this chapter we implemented the same tree-based SSOGP ap-
proached as in the previous SMART experiments chapter (discussed in chapters 4
and 6) to fit symbolic regression models to the data to estimate discrete hazard, thus
predicting the risk for cardiovascular events. Findings from the previous experiments
in the SMART study data (chapter 6) found that the GSOGP and, GMOGP search
strategies were too computationally expensive for the computing resources available.
As the CPRD cohort used in these experiments is considerably larger than that of the
SMART cohort, and thus more computationally expensive, the generational GP ap-
proached were not considered in this experiment.
Symbolic regression was performed using the RGP package in the R statistical pro-
gramming language, with the SSOGP search heuristic using the same parameter set-
tings as the previous experiments, detailed in table 7.1.
Briefly, the default RGP function set (+,−,÷,×, sin, cos, tan,√, exp, log) was used
to enable the representation of potential non-linear relationships present in the train-
ing data. Koza’s [167] ramped half-and-half random initialisation method was used
with a maximum tree depth of 156, which was calculated as a function of the expected
solution depth of 52. The GP approach utilised is untyped with the search space con-
strained by the use of fitness penalties. Specifically, the ’death penalty’ is used where
invalid solutions, such invalid mathematical operations (e.g. dividing by 0), have their
fitness value set to∞ giving them the lowest possible fitness (section 4.2.1).
Again, as in the previous experiments, expiration of a fixed time compute budget was
chosen as the termination criterion. The compute time budget for these experiments
was set to 12 hours wall-time and these experiments were run on a single thread on an
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Intel Westmere 2.8GHz CPU with 48 GB of memory.
Table 7.1: Parameters of the SSOGP search heuristic.
Variable (Symbol) Domain Setting
Population Size mu (µ) N 1,000
Tournament Size tournamentSize (stournament ) N 4
Recombination Probability recombinationProbabilty (prec) [0, 1] 0.5
We did not perform internal validation in the genetic programming approach using a
bootstrap as we did with the Cox regression, because it would not have been possible
to convert it into a shrinkage factor in the same way as we would for a Cox regression.
The genetic programming system is a stochastic process, with each run potentially
yielding models with differing complex structures (i.e. symbolic regression). As a
result regression coefficients do not exist in genetic programming models in the same
way that they do in regression models. Instead the training data was split 2/3:1/3 into
training and holdout sets, using a stratified random split to ensure proportionate number
of events. The first 2/3, the training set, was used for training to induce a population
of prediction models. The remaining 1/3, the holdout set, was used at the end of
the genetic programming run to calculate the fitness of the population of models and
thus determine the fittest or ’best of run’ model to be returned as the output of the
genetic programming system. In this way the final genetic programming model was
selected based on its fit to unseen data using a sample other than which it was trained
or developed.
To understand variable selection in the genetic programming and enable comparison
with bootstrapped backwards selection of the Cox model, the genetic programming
system was executed 25 times to produce 25 ’suggested’ models. For each iteration
the training data was randomly (stratified) split 2:1. The final genetic programming
model was applied to the validation data set to assess its performance, in terms of
discrimination and calibration in an independent sample. All analyses were carried out
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in R version 3.1.2 [247].
Comparison of both methods
The two clinical prediction models, one obtained from Cox progression and three from
symbolic regression (SSOGP), were evaluated in terms of overall survival curves, dis-
crimination and calibration in the validation data set. The models were used to predict
the discrete hazards h(t) at t = 2, 5, and 8 years. Model were first evaluated visually
by comparing the survival probabilities S(t) predicted by the models with estimates
obtained using the KM method. The agreement between these curves and the KM
estimates were assessed visually.
Discrimination was assessed using the concordance statistic (C-statistic) [109, 110,
111, 300], which was evaluated considering truncation of the survival/censoring times
at t=2, 5, and 8 years.
Model calibration was assessed using calibration plots and the generalisation of the
Hosmer-Lemeshow test statistic for survival data [56]. Calibration was evaluated by
grouping subjects according to the predicted S(t) at t = 2, 5, and 8 years. All analyses
were carried out in R version 3.1.2.
7.3 Results
7.3.1 Descriptives
There were no major differences in the baseline characteristics of the patients between
the derivation and validation sets (table 7.2). Data were available on 255,478 and
126,937 person-years collected during a median follow-up of 5.33 (range, 0-13 years)
and 5.25 years (0-13 years) for the derivation and validation sets, respectively. In
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the derivation set a total of 9,834 events occurred, corresponding to 2-, 5-, and 8-
year cumulative incidences of 6.8%, 17.0% and 26.0% respectively. In the validation
set a total of 4,970 events occurred, corresponding to 2-, 5-, and 8-year cumulative
incidences of 6.8%, 17.0% and 27.0% respectively.
7.3.2 Model Derivation
Prior to modelling extreme values in continuous predictors were truncated at the 1st
and 99th centile. Categorical predictors with missing values were given an additional
’missing’ categories and continuous predictors with missing values were categorised
into clinical meaningful categories, also with an additional ’missing’ category.
The full Cox regression model consisted of 23 predictors, some of which had limited
contributions. Predictors that had a relatively large effect were age, ethnicity, gender,
smoking status, SES, no. of general practitioner contacts in previous year, recorded
diagnosis of ’other’ CVD, atrial fibrillation, BMI, SBP, lipids, ACE/ARB therapy, and
APT therapy. The proportionality of hazards was tested using an overall test which was
not significant. We judged our sample size to large enough to allow for some model
reduction (9,834 events and a full model with 39 degrees of freedom), facilitating easier
practical application and clinical interpretation. We applied a backwards step-wise
selection procedure, using AIC as the stopping rule, to achieve a reduced Cox model.
The reduced step-wise selected model was found to be optimal with 20 predictors
(table 7.3). Predictors with relatively weaker effects (treated hypertension, LDL, and
duration of T2DM) were excluded from the reduced model.
Bootstrapping of the reduced model yielded an estimate of required shrinkage for the
coefficients in the step-wise selected model of 0.99, suggesting that each coefficient
should be reduced by 1% to obtain a re-calibrated model that corrects for optimism.
This shrinkage factor was applied to the reduced backwards step-wise model and con-
sidered the calibrated ’final’ Cox regression model (table 7.4).
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Table 7.2: Baseline characteristics of patients in the CPRD cohort, by derivation
and validation sets (n=63,496).
N Test set Training set Test Statistic
N = 21165 N = 42331
Cardiovascular event 63496 23% ( 4970) 23% ( 9834) χ21 = 0.5, P = 0.48
1
Age (at baseline) years 63496 52 62 71 52 62 71 F1,63494 = 0.19, P = 0.662
Ethnicity : Mssn 63496 18% ( 3816) 18% ( 7673) χ23 = 0.44, P = 0.93
1
Nn-W 8% ( 1638) 8% ( 3219)
Unkn 15% ( 3174) 15% ( 6371)
Whit 59% (12537) 59% (25068)
Gender : Feml 63496 47% ( 9909) 47% (19736) χ21 = 0.22, P = 0.64
1
Smoking status : Crrn 63496 19% ( 3940) 19% ( 7999) χ23 = 1.4, P = 0.71
1
Frmr 23% ( 4837) 23% ( 9754)
Nevr 51% (10738) 50% (21290)
Mssn 8% ( 1650) 8% ( 3288)
Index of Multiple Deprivation quintiles : 1 63496 18% (3741) 18% (7804) χ24 = 6.2, P = 0.19
1
2 22% (4695) 22% (9197)
3 20% (4315) 20% (8603)
4 21% (4456) 21% (8898)
5 19% (3958) 18% (7829)
Charlson index : 0 63496 3% ( 560) 3% ( 1130) χ24 = 4.8, P = 0.31
1
1 66% (13900) 65% (27595)
2 19% ( 3979) 19% ( 8254)
3 9% ( 1800) 8% ( 3540)
4 4% ( 926) 4% ( 1812)
No. GP attendances year prior 63496 5 9 15 5 9 15 F1,63494 = 0.04, P = 0.852
Recorded diagnosis of Other CVD 63496 17% ( 3695) 18% ( 7499) χ21 = 0.64, P = 0.42
1
Treated hypertension 63496 39% ( 8280) 39% (16316) χ21 = 2, P = 0.16
1
Renal disease 63496 7% ( 1498) 7% ( 3028) χ21 = 0.12, P = 0.73
1
Rheumatoid arthritis 63496 1% ( 297) 2% ( 652) χ21 = 1.8, P = 0.18
1
Atrial Fibrillation 63496 3% ( 615) 3% ( 1301) χ21 = 1.4, P = 0.24
1
Duration of T2DM days 63496 17 49 106 17 49 106 F1,63494 = 0.02, P = 0.92
Body mass index Kg/m2 45656 26 29 33 26 29 33 F1,45654 = 0.79, P = 0.372
Systolic blood pressure mm Hg 51930 130 140 150 130 140 150 F1,51928 = 0, P = 0.952
Total cholesterol mmol/L 37817 4.2 4.9 5.7 4.2 4.9 5.7 F1,37815 = 0.5, P = 0.482
High-density lipoprotein cholesterol mmol/L 23071 1.0 1.2 1.4 1.0 1.2 1.4 F1,23069 = 2.5, P = 0.112
Low-density lipoprotein cholesterol mmol/L 18470 2.1 2.7 3.4 2.1 2.6 3.4 F1,18468 = 0.49, P = 0.482
Triglycerides mmol/L 27390 1.2 1.7 2.5 1.2 1.7 2.5 F1,27388 = 0.46, P = 0.52
Lipid lowering Tx 63496 31% ( 6624) 31% (13224) χ21 = 0.02, P = 0.88
1
ACE/ARB Tx 63496 35% ( 7349) 34% (14596) χ21 = 0.36, P = 0.55
1
Beta-blockers Tx 63496 14% ( 2902) 13% ( 5401) χ21 = 11, P < 0.001
1
Anti-Platelet Tx 63496 20% ( 4262) 20% ( 8516) χ21 = 0, P = 0.95
1
a b c represent the lower quartile a, the median b, and the upper quartile c for continuous variables. N is the number of non–
missing values. Numbers after percents are frequencies. NA represent missing values. Tests used:1Pearson test; 2Wilcoxon test.
Tx represents therapy.
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Table 7.3: Cox regression coefficients in the full model, and stepwise selected
model (using AIC).
Predictor Full Stepwise
ACE/ARB Tx ACEARB=1 0.1008 0.1088
Atrial Fibrillation AF=1 0.2032 0.1992
Age (at baseline) AGE 0.0445 0.0441
Anti-Platelet Tx APT=1 0.2634 0.2605
Beta-blockers Tx BETAB=1 0.0811 0.0857
Body mass index BMIf=O/P- −0.1166 −0.1174
BMIf=Obes −0.0613 −0.0630
BMIf=Un/N −0.0528 −0.0547
Charlson index CHARLS 0.0346 0.0342
No. GP attendances year prior CONT 0.0106 0.0106
Recorded diagnosis of Other CVD CVD.other=1 0.2548 0.2516
Ethnicity ETHNICf=Nn-W 1.4759 1.4617
ETHNICf=Unkn 1.2071 1.1957
ETHNICf=Whit 1.3145 1.3031
High-density lipoprotein cholesterol HDLf=Best −0.0675 −0.0664
HDLf=Bttr −0.1135 −0.1110
HDLf=Mssn 0.0454 0.0715
Treated hypertension HYPER=1 0.0164
Low-density lipoprotein cholesterol LDLf=Mssn 0.0269
LDLf=NrOp 0.0355
LDLf=Optm −0.0811
Lipid lowering Tx LLT=1 −0.0449 −0.0512
Rheumatoid arthritis RA=1 0.1194 0.1195
Renal disease RENAL=1 0.1069 0.1041
Systolic blood pressure SBPf=Hy/N −0.0739 −0.0767
SBPf=Mssn 0.0077 0.0070
SBPf=NrmH −0.0805 −0.0825
Index of Multiple Deprivation SES_5 0.0533 0.0528
Gender SEX=Feml −0.2142 −0.2124
Smoking status SMOKf=Frmr −0.2166 −0.2134
SMOKf=Mssn −0.1548 −0.1506
SMOKf=Nevr −0.2705 −0.2670
Duration of T2DM T2DM.dur 0.0000
Total cholesterol TCf=BrdH 0.1012 0.1162
TCf=High 0.1870 0.1996
TCf=Mssn 0.0862 0.0909
Triglycerides TRIGf=Dsrb −0.0736 −0.0760
TRIGf=High 0.0631 0.0643
TRIGf=Mssn 0.0254 0.0328
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Table 7.4: Association of each predictor with cardiovascular events in the calib-
rated final Cox model.
Low High ∆ Effect S.E. Lower 0.95 Upper 0.95
AGE 52 71 19 0.8378000 0.019885 0.7988200 0.8767700
Hazard Ratio 52 71 19 2.3113000 2.2229000 2.4031000
SES_5 2 4 2 0.1055100 0.015017 0.0760730 0.1349400
Hazard Ratio 2 4 2 1.1113000 1.0790000 1.1445000
CHARLS 1 2 1 0.0342070 0.012211 0.0102730 0.0581410
Hazard Ratio 1 2 1 1.0348000 1.0103000 1.0599000
CONT 5 15 10 0.1058000 0.012740 0.0808310 0.1307700
Hazard Ratio 5 15 10 1.1116000 1.0842000 1.1397000
ETHNICf — Mssn:Whit 4 1 -1.3031000 0.053376 -1.4077000 -1.1985000
Hazard Ratio 4 1 0.2716900 0.2447000 0.3016500
ETHNICf — Nn—W:Whit 4 2 0.1585700 0.040632 0.0789350 0.2382100
Hazard Ratio 4 2 1.1718000 1.0821000 1.2690000
ETHNICf — Unkn:Whit 4 3 -0.1074100 0.028978 -0.1642000 -0.0506120
Hazard Ratio 4 3 0.8981600 0.8485700 0.9506500
SEX — Feml:Male 1 2 -0.2123800 0.021353 -0.2542400 -0.1705300
Hazard Ratio 1 2 0.8086500 0.7755100 0.8432200
SMOKf — Crrn:Nevr 3 1 0.2669500 0.028446 0.2112000 0.3227100
Hazard Ratio 3 1 1.3060000 1.2352000 1.3809000
SMOKf — Frmr:Nevr 3 2 0.0535600 0.026013 0.0025756 0.1045400
Hazard Ratio 3 2 1.0550000 1.0026000 1.1102000
SMOKf — Mssn:Nevr 3 4 0.1163900 0.037252 0.0433750 0.1894000
Hazard Ratio 3 4 1.1234000 1.0443000 1.2085000
CVD.other — 1:0 1 2 0.2516000 0.026515 0.1996300 0.3035700
Hazard Ratio 1 2 1.2861000 1.2210000 1.3547000
RENAL — 1:0 1 2 0.1040500 0.042783 0.0202000 0.1879100
Hazard Ratio 1 2 1.1097000 1.0204000 1.2067000
RA — 1:0 1 2 0.1195100 0.073803 -0.0251380 0.2641600
Hazard Ratio 1 2 1.1269000 0.9751700 1.3023000
AF — 1:0 1 2 0.1992400 0.049470 0.1022800 0.2962000
Hazard Ratio 1 2 1.2205000 1.1077000 1.3447000
BMIf — Mssn:Obes 2 1 0.0629870 0.033153 -0.0019920 0.1279700
Hazard Ratio 2 1 1.0650000 0.9980100 1.1365000
BMIf — O/P—:Obes 2 3 -0.0544540 0.029073 -0.1114400 0.0025290
Hazard Ratio 2 3 0.9470000 0.8945500 1.0025000
BMIf — Un/N:Obes 2 4 0.0082777 0.034289 -0.0589270 0.0754830
Hazard Ratio 2 4 1.0083000 0.9427800 1.0784000
SBPf — Hy/N:Hypr 1 2 -0.0766970 0.050911 -0.1764800 0.0230880
Hazard Ratio 1 2 0.9261700 0.8382100 1.0234000
SBPf — Mssn:Hypr 1 3 0.0070265 0.033982 -0.0595770 0.0736310
Hazard Ratio 1 3 1.0071000 0.9421600 1.0764000
SBPf — NrmH:Hypr 1 4 -0.0824550 0.026521 -0.1344400 -0.0304740
Hazard Ratio 1 4 0.9208500 0.8742100 0.9699900
TCf — Dsrb:Mssn 4 1 -0.0909320 0.034001 -0.1575700 -0.0242920
Hazard Ratio 4 1 0.9130800 0.8542100 0.9760000
TCf — BrdH:Mssn 4 2 0.0252240 0.034996 -0.0433660 0.0938140
Hazard Ratio 4 2 1.0255000 0.9575600 1.0984000
TCf — High:Mssn 4 3 0.1086300 0.039523 0.0311700 0.1861000
Hazard Ratio 4 3 1.1148000 1.0317000 1.2045000
HDLf — Poor:Mssn 4 1 -0.0715470 0.039955 -0.1498600 0.0067627
Hazard Ratio 4 1 0.9309500 0.8608300 1.0068000
HDLf — Bttr:Mssn 4 2 -0.1825500 0.059112 -0.2984000 -0.0666910
Hazard Ratio 4 2 0.8331500 0.7420000 0.9354800
HDLf — Best:Mssn 4 3 -0.1379300 0.052705 -0.2412300 -0.0346290
Hazard Ratio 4 3 0.8711600 0.7856600 0.9659600
TRIGf — BrdH:Mssn 4 1 -0.0327550 0.048791 -0.1283800 0.0628740
Hazard Ratio 4 1 0.9677800 0.8795200 1.0649000
TRIGf — Dsrb:Mssn 4 2 -0.1088000 0.041304 -0.1897600 -0.0278510
Hazard Ratio 4 2 0.8969100 0.8271600 0.9725300
TRIGf — High:Mssn 4 3 0.0315420 0.042669 -0.0520870 0.1151700
Hazard Ratio 4 3 1.0320000 0.9492500 1.1221000
LLT — 1:0 1 2 -0.0511850 0.028526 -0.1070900 0.0047251
Hazard Ratio 1 2 0.9501000 0.8984400 1.0047000
ACEARB — 1:0 1 2 0.1088200 0.023102 0.0635440 0.1541000
Hazard Ratio 1 2 1.1150000 1.0656000 1.1666000
BETAB — 1:0 1 2 0.0856990 0.028756 0.0293370 0.1420600
Hazard Ratio 1 2 1.0895000 1.0298000 1.1526000
APT — 1:0 1 2 0.2605300 0.026711 0.2081800 0.3128900
Hazard Ratio 1 2 1.2976000 1.2314000 1.3674000
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Figure 7.1 describes the run statistics for the 25 SSOGP runs performed, based on the
parameter settings detailed in section 7.2.1, on the different stratified re-samples of the
derivation data set. The figure depicts the evolution of the different GP run’s best fitness
(bestFit) and complexity, quantified using mean visitation length (meanVisLen), over
time. Time is represented as iterative or evolutionary steps (stepNo), where an evol-
utionary step is each time that tournament selection is performed and new individuals
are generated and considered for inclusion in the population. The ’final’ symbolic re-
gression model is the individual the best (i.e. lowest) fitness at the end of all 25 GP
runs. We can see that there is significant variation in the best fitness and complexity of
the individuals developed by the different GP runs. However, in general the improve-
ment in best fitness appears to level out towards the over time in all runs, confirming
that the selected fixed time compute budget of 12 hours wall time is acceptable. A
range of different run statistics for all 25 SSOGP runs are detailed in Appendix G.
The final symbolic regression model produced by SSOGP included 7 predictors: age
(AGEn), recorded diagnosis of ’other’ CVD (CVD.other.n), lipid-lowering therapy
(LLTn), ethnicity (ETHNICf), SBP(SBPf), LDL (LDLf), and triglycerides (TRIGf),
in addition to the discrete time indicator (tj), which is present in all the genetic pro-
gramming models to represent the jth time interval. The final prediction model gen-
erated by genetic programming is presented in figure 7.2, which is a binary parse tree
representing Equation 7.1.
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Figure 7.1: Selected runs statisitcs for the 25 SSOGP runs in the CPRD experi-
ments.
λˆ(tj, X) =Prob(T = tj|T ≥ tj, X) = 1
1 + e−Xβˆ
, where
Xβˆ = cos(sin(sin(ETHNICfMssn.n ∗ −2.599 + sin(LDLfOptm.n∗
(LDLfOptm.n ∗ −4.092 + tan(cos(CVD .other .n + sin(
ETHNICfMssn.n ∗ −2.599 + sin(LDLfOptm.n ∗ (LDLfOptm.n∗
− 4.092 + tan(cos(CVD .other .n + sin(sin(ETHNICfMssn.n∗
− 2.599 + sin(LDLfOptm.n ∗ (LDLfOptm.n ∗ −3.631 + tan(cos(
CVD .other .n + LLTn)) + sin(TRIGfBrdH .n + tan(1.449)))) + sin(
2.057))))) + sin(time.d ∗ −0.733 + sin(SBPfHyN .n)))) + sin(2.0566
∗ −2.599)))) + sin(sin(sin(LDLfOptm.n ∗ −4.092 + tan(cos(
CVD .other .n +−0.733))))))) + sin(ETHNICfMssn.n ∗ −2.599+
sin(sin(LDLfOptm.n ∗ (LDLfOptm.n ∗ −4.092 + tan(cos(
CVD .other .n + sin(sin(exp(sin(SBPfNrmH .n)) + sin(2.057)))))
+ sin(−4.092)))) + sin(2.057))))) ∗ (2.057 ∗ −2.599 + sin(AGEn)+
sin(ETHNICfMssn.n ∗ −2.599 + sin(LDLfOptm.n ∗ (
LDLfOptm.n ∗ −4.092 + tan(cos(CVD .other .n + sin(AGEn)))+
sin(time.d ∗ −0.733 + ETHNICfMssn.n))) + sin(sin(−4.092))))
(7.1)
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Figure 7.2: The final model developed by genetic programming, presented as a
binary tree.
The other 24 prediction model generated by genetic programming are presented in
Appendix H.
The genetic programming approach was applied 25 times, each time trained and tested
on a different stratified re-sample of the derivation data set. This leads to a pool 25
different ’best of run’ models, each of which may have selected different subset of
predictors as inputs and as such may have differing levels of performance. In this pool
of genetic programming models, the mean number of predictors used was 5 (Inter-
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Quartile Range (IQR): 4—7). The backwards step-wise selection procedure used in
the Cox modelling was also repeated 25 times, using bootstrap re-sampling to better
understand the frequencies at which different subsets of predictors were selected. In
the pool of 25 backwards selected Cox models the mean number of predictors used was
20 (IQR: 19—21). There was a reasonable association between the estimated effect
of a predictor according in the reduced backwards step-wise model and the frequency
of the selection when the step-wise selection was repeated in the bootstrap procedure
(table 7.5).
Generally the features selected by repeating the GP were far more variable than the
features selected by the Cox regression stepwise selection procedure (table 7.5). This
is to be be expected as GP is a stochastic system, where as the stepwise procedure is
deterministic, only giving variable results because we are repeating the procedure on
different bootstrap resamples of the derivation data set. Despite this, the predictors that
were estimated to have the largest effect in the final stepwise selected Cox model which
were also selected with the high frequency in bootstrapped stepwise selection—age, re-
corded diagnosis of ’other’ CVD, and ethnicity—were selected (relatively) frequently
when GP was repeated. Interestingly, stepwise selection also often selected ACE/ARB
therapy, atrial fibrillation, APT therapy, Beta-blocker therapy, BMI, Charlson index,
No. GP attendances year prior, HDL, diagnosis of renal disease, SBP, SES, gender,
smoking status, TC, and triglycerides as predictors, however, these featured in a low
proportion of the GP models. However, SBP and triglycerides did feature in the best
performing ’final’ GP model. Conversely, the final GP model featured lipid-lowering
therapy and LDL as predictors, predictors that was estimated to have small effect s and
were selected in low proportion of Cox models by the stepwise selection procedure.
7.3.3 Model Validation
labelsubsec:cprd_validation Using the validation data set, the average performance of
the 25 ’best of run’ prediction models automatically generated by genetic programming
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Table 7.5: Number (proportion) of times predictors were selected duting the 25
repititions of Cox regression backwards step-wise selection procedure and genetic
programming.
Predictor Cox Regression Genetic Programming
ACE/ARB Tx ACEARB 25 (1.00) 1 (0.04)
Atrial Fibrillation AF 25 (1.00) 4 (0.16)
Age (at baseline) AGE 25 (1.00) 20 (0.80)
Anti-Platelet Tx APT 25 (1.00) 9 (0.36)
Beta-blocker Tx BETAB 23 (0.92) 0 (0.00)
Body mass index BMIf 22 (0.88) 0 (0.00)
Charlson index CHARLS 23 (0.92) 2 (0.08)
No. GP attendances year prior CONT 25 (1.00) 1 (0.04)
Recorded diagnosis of Other CVD CVD.other 25 (1.00) 19 (0.76)
Ethnicity ETHNICf 25 (1.00) 20 (0.80)
High-density lipoprotein cholesterol HDLf 20 (0.80) 4 (0.16)
Treated hypertension HYPER 6 (0.24) 1 (0.04)
Low-density lipoprotein cholesterol LDLf 14 (0.56) 7 (0.28)
Lipid lowering Tx LLT 13 (0.52) 3 (0.12)
Rheumatoid arthritis RA 16 (0.64) 0 (0.00)
Renal disease RENAL 24 (0.96) 2 (0.08)
Systolic blood pressure SBPf 24 (0.96) 2 (0.08)
Index of Multiple Deprivation SES_5 25 (1.00) 1 (0.04)
Gender SEX 25 (1.00) 3 (0.12)
Smoking status SMOKf 25 (1.00) 9 (0.36)
Duration of T2DM T2DM.dur 14 (0.56) 0 (0.00)
Total cholesterol TCf 25 (1.00) 5 (0.20)
Triglycerides TRIGf 25 (1.00) 7 (0.28)
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was compared with the calibrated final Cox model. Graphical comparisons of the
S(t) values produced by each model with those obtained by the KM method in the
validation set are shown in figure 7.3. As can be seen from this figure, both the Cox
and genetic programming models produced similar values that had good agreement
with the KM estimates in the earlier years. However, this agreement deteriorated in
the latter years, where the KM estimates have high variability, as indicates by the large
error bars. This high variation my be explained by the fact that with a median follow-
up time of 5.2 years, there are far fewer events and number of subjects in the latter
time periods. Whilst agreement deteriorated in the latter time-points, both models had
generally acceptable overall agreement.
Figure 7.3: Average survival curves for the Cox regression and genetic program-
ming models. The error bars represent ±2 standard errors of the KM estimates.
The discriminative performance in the validation set, according to the C-statistic, of the
models at different time points is shown in table 7.6 and figure 7.4. From the C-statistic
estimates we can see that a satisfactory performance of >0.6 was reached in both mod-
els, at all time points. There was generally comparable discriminative performance of
both models, with the Cox model showing marginally better discrimination at all time
points.
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Figure 7.4: C-statistic estimates by model for t=1, 3 and 5 years
The calibration plots evaluated by grouping subjects according to quantiles of predicted
risk (1 − S(t)) at t = 2, 5, and 8 years are shown in figure 7.5. From the graphical
inspection of the calibration plots we can see that there was no tendency to system-
atically over- or under-predict at any of the time points in either the Cox or genetic
programming models. Again from visual inspection, the genetic programming model
appeared to be marginally less calibrated than the Cox model, however, both models
demonstrated comparable performance with significant lack of calibration at any time
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Table 7.6: C-statistic estimates by model at t=2, 5, and 8 years
Time (years) Cox PH Regression Genetic Programming
2 0.713 0.656
5 0.703 0.621
8 0.701 0.631
point.
The corresponding χ2 statistics and p-values are shown in table 7.7 for completeness
only. As with any statistical test, the power increases with sample size; this can be
undesirable for goodness of fit tests because in very large data sets, small departures
from the proposed model will be considered significant. Because of the very large
sample sizes studied here, a statistically significant Hosmer-Lemeshow statistic (as
detailed in table 7.7) is not considered informative with respect to calibration [81, 235].
Figure 7.5: Calibration plots for the Cox regression and genetic programming
models, at t=2, 5, and 8 years..
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Table 7.7: χ2 statistic for the comparison between observed versus expected (ac-
cording to the model) number of events in groups of patients defined according to
the predicted 1− S(t) at t=2, 5, and 8 years.
Time (years) Cox Regression Genetic Programming
t χ2 p-value χ2 p-value
2 1589 < 0.001 1575 < 0.001
5 4612 < 0.001 4146 < 0.001
8 8236 < 0.001 6937 < 0.001
7.4 Discussion
This study showed that Cox regression and GP produced similar results when evaluated
in a common validation data set. After re-calibration the discriminative ability of the
Cox model in the validation set was slightly larger than that of the GP model at all time
points. Despite slight relative differences, both models demonstrated an acceptable
level of discriminative ability (C-index >0.6) at all times points. The GP model had
marginally poorer calibration when visually compared with the Cox model. However,
both models demonstrated no significant lack of calibration at any time point.
Despite generally comparable performance, albeit in favour of the Cox model, the
predictors selected for representing their relationship with the outcome were quite dif-
ferent. The final reduced Cox model used 20 predictors, in contrast to 7 predictors used
in the GP model. The GP model used significantly fewer predictors, further confirmed
by repeating the the GP and the stepwise selection procedure used in the Cox model-
ling, resulting in mean numbers of predictors of 5 (IQR: 4—7) and 20 (IQR: 19—21),
respectively.
Predictors that were estimated to have larger contributions to the final Cox model and
that frequently selected during stepwise selection—age, recorded diagnosis of ’other’
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CVD, and ethnicity—were selected in the final GP model and with (relatively) high
frequency when the GP was repeated. However, others predictors that had large to
moderate contributions to the final Cox model—ACE/ARB therapy, atrial fibrillation,
APT therapy, Beta-blocker therapy,BMI, Charlson index, No. GP attendances year
prior, HDL, diagnosis of renal disease, SBP, SES, gender, smoking status, TC, and
triglycerides —were selected infrequently when GP was repeated. However, SBP and
triglycerides did feature in the best performing ’final’ GP model. Conversely, the final
GP model also featured lipid-lowering therapy and LDL as predictors, predictors that
was estimated to have small effect s and were selected in low proportion of Cox mod-
els by the stepwise selection procedure. Whilst these results confirm the prognostic
significance of a small number of the most highly associated predictors in the Cox
modelling, symbolic regression model did not estimate such a large number predictors
to be strongly associated with the outcome, associated strongly enough for inclusion
in the model at least, whilst achieving comparable performance.
As with the experiments in the previous chapter, these results suggest that GP may bet-
ter represent the potentially non-linear relationship of (a smaller subset of) the strongest
predictors. To test the first part of this hypothesis—that GP can represent the poten-
tial non-linear relationships that exist between predictors—the shape of the predictor
effects were plotted to evaluate whether or not the effects were non-linear in nature.
Using the ’final’ GP model, the effects of each predictor’s values were plotted against
log hazard, whilst the other values were held at their reference values. Reference values
were the modal class for binary variables and the mean of continuous variables. Fig-
ure I.1 of appendix I illustrates that the the ’final’ model developed by GP is modelling
non-linear effects for the continuous predictor age (which was the only continuous
predictor in the model, all the others were binary).
To test the second part of this hypothesis—that GP can better represent these relation-
ships between predictors using fewer variables—we repeated the GP runs with exactly
the same experimental set-up, but restricting the inputs to predictors that were selected
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with a relatively high frequency (>0.5) in the original GP run of the primary experi-
ment. The covariates included age, recorded diagnosis of other CVD, and ethnicity.
This produced very similar results (detailed in appendix J) both in terms of calibra-
tion and discrimination. Both these findings support the hypothesis that GP may better
represent the potentially non-linear relationship of (a smaller subset of) the strongest
predictors.
Whilst considerable effort was made to relax the linearity of the Cox regression, through
transformation of predictors, the nature of the approach relies on linear combinations of
predictors. The fact that GP required fewer predictors to achieve similar performance
may have an advantage in practical application of the developed clinical prediction
model. The acquisition of information that forms the inputs to such a model can be
prohibitively onerous in routine clinical practice. Therefore a prediction model that re-
quires fewer inputs, especially if the information relating to these inputs is in practice
recorded easily and to a good quality, would considerably increase adoption and utility.
This work has limitations introduced by its use of data from CPRD to refine a cohort
of patients, a cohort from a primary prevention setting, designed to predict the risk of
primary cardiovascular events in patients withT2DM who have presented with clinical
CVD. Through its use of the CPRD data this work has demonstrated the utility of GP
in a primary prevention setting, however, there are limitations in the generalisability
of these findings to the other clinical settings of cardiovascular risk prediction. How-
ever, its important to note primary prevention in asymptotic cardiovascular patients is
arguably the most common clinical setting for the application of cardiovascular risk
prediction models in routine practice.
7.5 Conclusion
Using data from CPRD we demonstrated that a symbolic regression model developed
by SSOGP has predictive ability comparable to that of Cox regression for the predic-
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tion of future cardiovascular events in patients with T2DM in a primary prevention
setting, i.e in T2DM patients with asymptomatic cardiovascular disease. These experi-
ments compared an untuned SSOGP symbolic regression model that was developed in
an automated fashion using basic parameter values recommended from the GP literat-
ure, with a highly tuned Cox regression model that was developed in a very involved
manner that required a certain amount of clinical and statistical expertise. Whilst the
highly tuned Cox regression model was better calibrated to validation data and the un-
tuned genetic programming model had better discriminative ability, the performance of
the automatically generated prediction model was generally comparable. These find-
ings confirm those of the previous experiments and demonstrate the utility of GP as a
methodology for automated development of clinical prediction models for diagnostic
and prognostic purposes, where the primary goal is accurate prediction. These findings
also confirm the prognostic significance of age, recorded diagnosis of ’other’ CVD, and
ethnicity, and to a lesser extent SBP and triglycerides, for cardiovascular risk in T2DM
patients with asymptomatic CVD.
In the next chapter the hypotheses and goals of this thesis are revisited and contri-
butions discussed in light of the results of this work. These results are summarised,
discussed, and put into context. Limitations of this work are critically assessed and
opportunities for further research identified.
196 7.5 Conclusion
197
Chapter 8
Discussion & Conclusions
The previous chapters have described the wider context clinical prediction modelling
and the UK health system, defining the challenges of predicting risk in the presence
of censored data, and providing motivation for the application of GP for cardiovas-
cular risk prediction. Then we surveyed and critically assessed the existing research
related to this thesis. Next we gave an overview of the essential common themes in
the diverse field of GP and discussed the specific methodological elements that formed
the developed GP approach for censored longitudinal data, which was implemented
and assessed in the subsequent experiment chapters. Then we performed our first set
of experiments that independently and externally validated the performance of the de
facto cardiovascular risk prediction model for patients with T2DM, the UKPDS-RE,
using data from CPRD. The results of these experiments showed poor performance,
suggesting that the UKPDS-RE is not suitable for predicting cardiovascular risk in UK
subjects with T2DM and that there is a need for revised risk models in T2DM. Next we
discussed our second set of experiments that demonstrated the utility of the developed
GP approach for the automatic development of clinical prediction models for risk pre-
diction of future cardiovascular events in patients with symptomatic cardiovascular
disease using censored survival data from the SMART study. Finally, we discussed our
third and final set of experiments with a very similar experimental set-up those in the
previous chapter, that demonstrated the utility of the developed GP approach for the
automatic development of clinical prediction models for risk prediction of future car-
diovascular events, but used a much larger observational cohort of patients from CPRD
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in a primary prevention clinical setting, where patients have asymptomatic CVD.
In this chapter the hypotheses and goals of this thesis are revisited and contributions
discussed in light of the results of this work. These results are summarised, discussed,
and put into context. Limitations of this work are critically assessed and opportunities
for further research identified.
8.1 Contributions of this Work
This thesis makes six main contributions:
1. The de facto cardiovascular risk prediction models for T2DM may be unsuitable
Using data from CPRD this work has preformed the largest, independent, ex-
ternal validation of the de facto cardiovascular risk model for people with T2DM,
the UKPDS-RE, in a diverse and contemporary setting. This work showed poor
performance, suggesting that the UKPDS-RE is not suitable for predicting car-
diovascular risk in UK subjects with T2DM. Considering the widespread ap-
plication of these prediction models, this work suggests a need for revised risk
equations in T2DM.
2. Developement of a GP approach for survial analysis of censored data GP is
a general methodology, the specific implementation of which requires devel-
opment of several different specific elements such as problem representation,
fitness, selection and genetic variation. This work has developed a tree-based
untyped SSOGP approach for the automated development of clinical prediction
models in the presence of censored longitudinal data. Specific GP elements were
developed and implemented, such as fitness functions and search heuristics, to
handle the problem-specific complexities of censored data and facilitate survival
analysis.
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3. Generational GP approaches are too computionally expesive for large observa-
tional cohorts This work attempted to implement and evaluate the utility of two
broad classes of GP, steady-state GP common in modern GP systems and the
more traditional generational GP approach. Despite considerable effort, when
the developed generational approaches were applied to the large observational
datasets of censored longitudinal data identified for this work, they failed as a
result of requiring more memory that was available in the computing resources
allocated for this work. This serves to demonstrate the utility of the relatively
computationally efficient steady-state GP approach for analysing large observa-
tional cohorts of patients.
4. GP has utility for the automatic development of clinical prediction models in cen-
sored data Using data from the SMART study and from CPRD we have demon-
strated that symbolic regression models generated by the developed SSOGP
approach had predictive ability comparable to that of the de facto statistical
method—Cox regression—for the prediction of future cardiovascular events in
patients with symptomatic and asymptomatic CVD. These experiments com-
pared untuned SSOGP symbolic regression models that were developed in an
automated fashion using only basic parameters settings recommended from the
GP literature, with highly tuned Cox regression models that were developed in a
very involved manner that required a certain amount of clinical and statistical ex-
pertise. Whilst the highly tuned Cox regression models performed slightly better
in their validation datasets, the performance of the automatically generated sym-
bolic regression models were generally comparable, and on average consisting
of considerably fewer predictors. Using symptomatic and asymptomatic CVD
as case studies—for secondary and primary prevention clinical settings, respect-
ively—these findings demonstrate the utility of GP as a methodology for auto-
mated development of clinical prediction models for diagnostic and prognostic
purposes in the presence of censored longitudinal data.
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5. Confirmation of the prognostic significance of certain risk factors in symtomatic
CVD This work has applied GP to examine the prognostic significance of differ-
ent risk factors together with their non-linear combinations in predicting car-
diovascular outcomes in patients with symptomatic and asymptomatic CVD.
Whilst the application of GP did not provide more accurate representations of
factors that predict the risk of both symptomatic and asymptomatic CVD when
compared with existing methods, GP did offer comparable performance. Des-
pite generally comparable performance, albeit in slight favour of the Cox model,
the predictors selected for representing their relationships with the outcome were
quite different and, on average, the models developed using GP used consider-
ably fewer predictors. The results of the GP confirm the prognostic significance
of a small number of the most highly associated predictors in the Cox modelling;
age, previous atherosclerosis, and albumin for secondary prevention; age, recor-
ded diagnosis of ’other’ CVD, and ethnicity for primary prevention in patients
with T2DM. When considered as a whole, GP did not produce a better perform-
ing clinical prediction model, rather it utilised fewer predictors, most of which
were the predictors that the Cox regression estimated be most strongly associ-
ated with the outcome, whilst achieving comparable performance. This suggests
that GP may better represent the potentially non-linear relationship of (a smaller
subset of) the strongest predictors.
6. In practice GP is robust By implementing SSOGP without model tuning, us-
ing only basic parameters values recommended from general GP literature, ob-
serving that it has performance comparable to the de facto statistical method, we
have confirmed the observations of other authors, that in practice GP is robust
and likely to work well over a wide range of parameter values.
As stated in the introduction, the main hypothesis of this research is that the applic-
ation of GP can provide more accurate representation of factors that predict the risk
of cardiovascular disease when compared with existing methods. This work repres-
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ents a successful first attempt at evaluating this hypothesis. The results of this work
may not be able to confirm conclusively whether GP offers a more accurate repres-
entation of factors that predict the risk of cardiovascular disease when compared with
Cox regression. However, they can confirm that GP offers comparable accuracy, whilst
developing clinical prediction models in an automated fashion that require fewer pre-
dictors.
Specifically, in-line with main goals of this work described in the section 1.2, this
work has provided evidence that the de facto cardiovascular risk prediction models
for T2DM may be unsuitable - motivating the need for improved clinical risk predic-
tion methods and models for survival outcomes in contemporary populations. It has
also demonstrated the utility of GP for the automatic development of clinical predic-
tion models and examined the prognostic significance of different risk factors together
with their non-linear combinations, using two different CVD case studies. This work
has successfully achieved these three main goals in contributions one, four, and five,
respectively.
8.2 Discussion
GP is a general methodology, the specific implementation of which requires develop-
ment of several different specific elements such as problem representation, fitness, se-
lection and genetic variation. In chapter 4 we developed a tree-based untyped SSOGP
approach for the automated development of clinical prediction models in the presence
of censored longitudinal data. Specific GP elements were developed and implemented,
such as fitness functions and search heuristics, to handle the problem-specific complex-
ities of censored data and facilitate survival analysis. In fact, single and multi-objective
generation GP approaches (GSOGP and GMOGP) were also developed. However, the
utility of these approaches could not be assessed because when implemented using our
experimental set-up, these generational approaches proved too memory intensive for
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the computing resources available (42Gb memory).
Problem representation was addressed by taking advantage of the fact that the hazard
function corresponds to a conditional probability in the discrete time domain, casting
the original survival analysis problem into a classification problem that required the
estimation of a conditional probability. However, to address the problem of censor-
ing the data needed to be pre-processed into the counting process format, with mul-
tiple rows per subject, one for each observed discrete-time interval. A suitable fitness
measure was developed for symbolic regression in the presence of censored survival
data based on ML estimation to calculate the distance between the natural log of the
predicted probability of the event to the actual observed outcome. The developed fit-
ness function expresses the joint probability of obtaining the data actually observed
on the subjects in the study as a function of the unknown population parameters. In
the absence of suitable existing GP system, the developed GP approach was imple-
mented from scratch using the R statistical programming language. However, it was
only implemented from scratch in the general sense, i.e. we did not use an existing
GP system. Existing GP- and EA-specific R packages provided a significant amount
of problem-agnostic functionality required to implement our GP system. However,
in implementing a GP system for survival analysis there was significant development
required, mainly with respect to the implementation a suitable fitness function for cen-
sored data, modification of search operators, and heuristics to work with the specific
problem representation and associated counting process data format.
In chapter 5 we evaluated the performance of the de facto cardiovascular risk for people
T2DM, the UKPDS-RE, for predicting the 10-year risk of CVD in a cohort of UK pa-
tients from CPRD newly diagnosed with T2DM. At the time of writing, this work is the
largest, independent, external validation of the UKPDS-RE, in a diverse contemporary
setting. The four UKPDS risk equations constituting the UKPDS-RE showed a reas-
onable ability to identify high-risk patients (discrimination) but were generally poor
at quantifying the absolute risk (calibration). The UKPDS-RE CHD risk equations
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consistently overestimated absolute risk, whereas the UKPDS-RE stroke equations
performed relatively well. However, when considered as a whole, the UKPDS-RE
was unsuitable for predicting CVD risk in UK subjects with newly diagnosed T2DM.
These findings suggest that the use of UKPDS-RE in clinical practice will lead to
over-estimation of CVD risk in patients with newly diagnosed T2DM. This in turn is
likely to lead to selection of preventative treatments, for which, for some patients, the
balance of risks may outweigh the benefits. Considering the widespread application
of these prediction models in clinical practice, drug reimbursement, and public health
decision-making, these results suggest that there is a need for revised risk equations in
T2DM.
In chapters 6 and 7 we compared the performance of the de facto statistical method
for survival analysis, Cox regression, with the developed SSOGP approach in the de-
velopment of clinical prediction models for the prediction of future cardiovascular
events in patients with symptomatic and asymptomatic cardiovascular disease, using
data from the SMART study and CPRD, respectively. Both these experiments showed
that Cox regression and the developed SSOGP approach produced similar results when
evaluated in common validation datasets. Despite slight relative differences, both ap-
proaches demonstrated an acceptable level of discriminative and calibration at a range
of times points.
Whilst the application of GP did not provide more accurate representations of factors
that predict the risk of both symptomatic and asymptomatic CVD when compared with
existing methods, GP did offer comparable performance. Despite generally compar-
able performance, albeit in slight favour of the Cox model, the predictors selected for
representing their relationships with the outcome were quite different and, on average,
the models developed using GP used considerably fewer predictors. The results of the
GP confirm the prognostic significance of a small number of the most highly associated
predictors in the Cox modelling; age, previous atherosclerosis, and albumin for sec-
ondary prevention; age, recorded diagnosis of ’other’ CVD, and ethnicity for primary
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prevention in patients with T2DM. When considered as a whole, GP did not produce
a better performing clinical prediction model, rather it utilised fewer predictors, most
of which were the predictors that the Cox regression estimated be most strongly asso-
ciated with the outcome, whilst achieving comparable performance. This suggests that
GP may better represent the potentially non-linear relationship of (a smaller subset of)
the strongest predictors.
Whilst considerable effort was made to relax the linearity of the Cox regression, through
transformation of predictors, the nature of the approach relies on linear combinations
of predictors. The fact that symbolic regression required fewer predictors to achieve
similar performance may have an advantage in practical application of the developed
clinical prediction model. The acquisition of information that forms the inputs to such
a model can be prohibitively onerous in routine clinical practice. Therefore a predic-
tion model that requires fewer inputs, especially if the information relating to these
inputs is in practice recorded easily and to a good quality, would considerably increase
adoption and utility.
Unlike other machine learning algorithms, GP in not a ’black box’ method and provides
a mathematical formula as its output. However, the model structure in the GP model
is typically more complex than that of the Cox regression model. This hinders the
interpretation of the (relative) effects of predictors on the outcome and if the primary
objective of the modelling is to understand these effects, such as in aetiologic research,
then Cox regression and other related approaches still remain the first choice. How-
ever, if the primary goal of the research is accurate risk prediction, then GP has some
utility when compared with its regression counterpart. GP offers advantages that in-
clude its ability to learn complex non-linear relationships that may exist in the data,
it is not confined by the statistical assumptions that underpin Cox regression (such as
proportional hazards), its inherent feature selection, and that GP models are developed
in automated fashion.
An advantage of Cox regression was its ability to be calibrated using all available
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data by applying a shrinkage factor - an measure of the models optimism (or over-
fitting) - estimated though bootstrapping or penalised regression methods. Whereas
with GP we cannot estimate a shrinkage factor in the same way and need validation
sample. This suggests that in cases where the data is scarce, Cox regression may be a
better approach. In contrast where there the data is large, possibly with a large number
of predictors and potential interactions effects, GP would have a distinct advantage.
Whilst interaction effects can be modelled using regression techniques, this can be
onerous and require a degree of expertise.
The considerable statistical and clinical expertise required in the development of ap-
propriate clinical predictions should not be understated. Problems with step-wise fea-
ture selection methods are another concern; including biased R2 values, confidence
intervals for effects and predicted values that are falsely narrow, biased regression
coefficients that need shrinkage, and severe problems in the presence of collinearity.
Both Cox regression and step-wise selection are widely used, and widely abused, in
prognostic and aetiologic research. Whilst fitting models using these techniques is
relatively straightforward and intuitive, sometimes they are applied blindly without ap-
propriate testing of the underlying assumptions. Whilst Cox regression is a powerful
tool, its correct application requires a certain amount of statistical rigour and expertise
from the researcher, and cannot be used in certain data if its underpinning assumptions
are violated. Another weakness of Cox model is that it does not explicitly define the
underlying baseline hazard, which means that technically its predictions are only valid
at the time points observed in the data and that it may not appropriate for extrapolation
to non-observed time points. It should be noted, however, that other regression meth-
ods for survival analysis, such as parametric survival models, can define the baseline
hazard and are appropriate for extrapolation. However parametric modelling of sur-
vival is even more involved than Cox modelling, requiring greater technical expertise,
and as such features far less in published aetiologic research.
The main weakness of the GP approach is that the data need to be converted into the
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counting process format, which leads to large data sets and longer executions times. So
whilst methodologically GP works better on large data sets, in practice the long execu-
tion times can make its use prohibitive. However, this weakness can addressed though
parallel processing. GP is a method that can be described as "naturally parallelizable",
and as such can adapted to execute in parallel across multiple machines or processors.
Finally, the GP model has a number of parameters that need to be specified a priori.
These parameters include the size of the population, the building block of models such
as mathematical operators, how many runs to perform, the rates at which to apply
genetic variation such as crossover and mutation, and parameters such as maximum
tree depth that control the complexity, and thus potential of over fitting, of final GP
model. Often the choice of these parameters in based on trail and error, model tuning,
or from the literature. Model tuning refers to repeating the same experiment many
times whilst simultaneously varying multiple parameters and quantifying relationship
between them and the quality of resultant models to understand which parameters are
important.
However, there are little or no literature on the relative importance of specific para-
meters of survival analysis. Model tuning was outside of the scope of this work, but
further research is warranted into characterising the association of GP parameters and
performance in a survival analysis setting. In the absence of modelling tuning and suit-
able literature, we used arbitrarily selected model parameters that were in an order of
magnitude with widely accepted starting parameters of GP applied in other settings.
8.3 Critical Assessment
There are typically a number of limitations of when using real-world observational
data, and the experiments in this thesis are no exception. Data have been collated from
routine clinical practice, thus there are missing and erroneous data, coding imperfec-
tions, lack of standardisation of biochemical measures (such as lipid profiles), vari-
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ations between biochemical test centres and measurements are taken with varying peri-
odicity. Measurement error in identifying the CVD outcomes will have been present
in the analysis, but this work has endeavoured to select appropriate medical codes for
the cardiovascular endpoints involved, consulting clinical expertise whenever possible.
Certain covariates of interest such as smoking status, BMI, lipids, family history of
CVD, etc, may not be recorded consistently. There are also limitations with ethnicity
data where even within the non-missing data there are a large proportion of ethnicit-
ies recorded as ’unknown’. Removal or exclusion of patients with missing data may
introduce bias into the study; this was addressed by using multiple imputation tech-
niques to impute missing values or modelling as categorical variables with a missing
level/category, where appropriate. There are also limitations in specifying covariates or
predictors a priori as there is potential to miss important factors and relationships that
exist with variables not considered. There are limitations on the split-sample validation
approach where predictive accuracy estimates, although unbiased, can be imprecise.
There are also limitations inherent in the classic statistical modelling techniques used
in this work, each of which have their own set of assumptions, such as non-informative
censoring, linearity, additively, proportionality, etc., that need to be satisfied in order
to order to take a given approach. Violation of such statistical assumptions may have
precluded the use of certain techniques and/or consideration of all covariates.
A key strength of the experiments in this thesis have been the size of the datasets util-
ised and study design adopted. We have used real-world observation medical datasets
with a retrospective cohort study design to minimise the selection bias by using real
patient data, observed in routine clinical practice, that has not been subject to the se-
lection biases inherent in other types of data and study designs, such those associated
with RCT data. We have used relatively large datasets which are important to give
adequate statistical power to detect the associations with the outcome, something even
more important in the context of CVD, where generally events are quite rare and thus
large sample sizes are required. However, the strength of the these large datasets has in-
troduced key challenges from the resultant increase in computational expense required
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to analyses them. Potentially, smaller datasets could have been used, or subsets of the
selected datasets, however this was not done because of the resultant loss of statistical
power to detect the associations between the predictors and the outcome, which in the
context of this thesis are rare cardiovascular events.
The choice of implementation language, the R statistical programming language, did
not help with computational issues, as a key disadvantage of R is its performance for
computationally expensive tasks. However, it was felt that the disadvantages of the
Rs computational inefficiency were outweighed by the advantages of how it intern-
ally represents expressions as trees, supporting direct manipulation of expression trees
through the same syntax for manipulating nested lists, making implementation of GP
operators in R simple, succinct, and easy for proficient R users to understand.
The computational issues from the size of the data were further exasperated by re-
quirement, by the fitness function and other elements of the approach developed for
this work, to have the data in the counting process or long format. This meant that
rather than requiring one row per subject, multiple rows per subject—one for each
time segment for which the subject was observed—were required. This requirement
significantly increases the size of the data and the number of fitness cases that needed
to be evaluated, in turn, significantly increasing the computational expense of the ana-
lysis.
Another limitation is the use of the death penalty for constraining the search space.
The literature suggests that this approach is generally not the best and that, in the
first instance, measures that penalise individuals based on some degree of invalidity or
infeasibility are superior. The rationale was that the death penalty is computationally
cheap when compared to other methods and that due to the nature of the experiments
in this that computational expense had become an important consideration.
At the outset it was the intention to evaluate steady-state and generational, as well
as single- and multi-objective approaches to symbolic regression for clinical predic-
tion modelling of censored survival data. Whilst Steady-state Multi-Objective Genetic
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Programming (SMOGP) was not supported in the R packages selected for this work,
SSOGP, GSOGP and, GMOGP were. However, during the experiments the genera-
tional approaches (GSOGP and GMOGP), were unsuccessful due to the fact that they
exceeded the available memory when applied to the large datasets selected for the ex-
periments. As a result, only models developed using SSOGP we able to be evaluated
in this work. The fact that only single-objective GP was evaluated in a key limitation
of this thesis.
Using only a simple single-objective steady-state search heuristic (i.e. SSOGP) there
wasn’t any mechanism to preserve genetic diversity in the population. A multi-objective
search heuristic would have helped with controlling the size and complexity of the
solutions developed and thus controlling bloat, however this has been controlled for to
a lesser degree, buy constraining the maximum depth of new individuals or subtrees
developed from the initialisation and variation operators. A SMOGP search heuristic
was not developed from scratch, for which a significant amount of work would have
been required to integrate it with the existing R packages used for the problem agnostic
elements, as it would have been beyond the scope of this work.
Another limitation of examining only steady-state GP is the noise that is introduced
thought the random selection of individuals in tournament selection. Meaning that
individuals with average fitness can have some chance of being selected and their off-
spring featuring in future generations. However, steady-state GP is far more compu-
tationally efficient, which was major consideration when analysing large observation
datasets. This is reflected in the fact that whilst this work attempted to evaluate single
and multi-objective generational approaches, they were too computationally expensive
to be used the large datasets identified for this thesis. The fact that the utility of gener-
ational GP approaches for clinical prediction modelling in censored survival data was
not evaluated is another limitation of this work.
In this work we have chosen to consider the most common type of GP, untyped tree-
based GP. A limitation of this work is that we have not characterised the utility of
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other types of GP, such as linear or graph-based GP. Evaluating other types of GP
was considered outside the scope of this work as we wanted to access the utility of the
most accessible and most researched type of GP with basic parameters settings, rather
than evaluate more specialised forms of GP where the literature may be more sparse.
For this thesis we enforced closure and defined the valid search space through fitness
penalisation, which is a computationally less efficient approach, as many invalid solu-
tions would have been created and not considered by giving them the lowest possible
fitness. A more efficient approach may have been to implement a typed GP system to
explicitly define the valid search space and avoid the evaluation of invalid solutions.
However, this does not mean that the not excluding invalid search spaces would have
lead to better solutions, as these invalid regions can form an important intermediate
steps towards a (near-)optimal solutions, just that in this case a more computationally
efficient GP implementation would have reduced the required resources and possibly
enabled a wider range of experiments to be performed.
Another limitation of this work is that it did not characterise the association of GP
parameters and performance in a survival analysis setting. This is because model tun-
ing was outside of the scope of this work. In the absence of modelling tuning and
suitable literature, we used arbitrarily selected model parameters that were in an order
of magnitude with widely accepted starting parameters of GP applied in other settings.
However, the literature suggests that in practice GP is robust and likely to work well
over a wide range of parameter values.
8.4 Further Work
A key weakness of the GP approach for censored data presented in this work is that the
data needed to be converted into the counting process format, which leads to even lar-
ger data sets, longer executions times and increased memory requirements. So whilst
methodologically GP works better on large data sets, in practice the long execution
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times can make its use prohibitive. Further work is required to reduce the computa-
tional expense of GP, both in terms of reducing execution times and in the reduction of
hardware requirements. Speeding up GP runs and reducing memory requirements—so
that analyses on large datasets could be done on standard commodity hardware in an
amount of time in the same order of magnitude as classical regression methods—would
make GP far more accessible to a broader audience, facilitate, and expedite research
into extensions and applications of GP in the big data era.
Reduction in the computational expense of GP may enable another area of potential
further work, the characterisation of the utility of generation GP approaches for clinical
prediction modelling in the censored data. In this work using large medical datasets,
the memory requirements of the generational search heuristics exceeded the available
computing resources, even using compute nodes with 42Gb of memory. Although bey-
ond the scope of this work, these issues of execution time and hardware requirements
can addressed though parallel processing. GP is a method that can be described as
’naturally parallelisable’, and as such can adapted to execute in parallel across multiple
machines or processors. The landscape of big data analytics has changed dramatically
in the last few years, a trend that looks set to continue for some years to come, with
exciting new technologies such as Hadoop and Spark facilitating highly distributed
computing on commodity hardware.
Also, an approach for performing GP on censored survival data that does not require
the data to be pre-processed into the long format would be advantageous in terms of re-
ducing the computation expense. However, it must be noted that although not explored
in this work, the long format enables the analysis of time-varying covariates which
can be highly advantageous when answering certain prognostic research questions, an-
other potential avenue for further research. The development of other fitness measures
and constraint handling approaches specific to survival analysis would be an important
area for further research. It would be very interesting to compare their performance
and understand how these effect the search and the resultant solutions.
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Another area of further work would be assess the impact of using a multi-objective
steady-state GP on the performance of clinical prediction models developed on cen-
sored survival data. It would be interesting to understand how controlling genetic
diversity and bloat though additional jointly-optimised objectives would effect the per-
formance of the survival models developed by GP, and whether they could outperform
the de facto statistical methods for survival analysis.
Whilst this work supports the observations of other authors, that GP is robust and works
well on a range parameter settings, further work is required to characterise relation-
ship between GP run parameters and the performance of the resulting survival models.
Model tuning was outside of the scope of this work, however, characterising the re-
lative effects of GP parameter settings on the performance of the developed clinical
prediction models may have a number of benefits. By understanding which parameters
do not drive performance we could potentially reduce the computational expense by
constraining some aspect of the experimental design or search space, such as reducing
the number of fitness evaluations or reducing the number and average size of individu-
als. By understanding the near-optimal GP parameter settings for the development of
clinical prediction models in censored survival data, GP may be able to provide more
accurate representation of factors that predict the risk of cardiovascular disease and
demonstrate improved performance when compared with existing methods.
Finally, further work is required to assess the utility of the developed GP approach for
automated development of new clinical prediction models in other clinical and envir-
onmental settings, preferably comparing their performance against more established
risk prediction models currently used in routine clinical practice (for example QRISK
2 [125] and SCORE [46] for primary prevention of CVD, the GRACE score [99, 63] in
acute coronary syndromes and, euroSCORE [215] in Cardiac surgery). Further work
will also be required to identify the most appropriate clinical parameters required for
GP risk modelling in order to optimise their predictive power in the relevant setting
and to ensure that these required measures are not only practical to measure at scale in
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routine clinical practice but also cost effective.
8.5 Conclusions
To our knowledge, this work is the first empirical study to assess the value of GP for
clinical prediction purposes compared to the well-known and widely applied Cox PH
regression technique. Using real-world data this work has demonstrated that symbolic
regression models developed by SSOGP have predictive ability comparable to that of
Cox regression models. The symbolic regression models were more complex and thus
more difficult to validate by domain experts, however these models were developed
in an automated fashion, using considerably fewer input variables, without the need
for domain specific knowledge and expertise required to appropriately perform sur-
vival analysis. GP has demonstrated strong potential as a methodology for automated
development of clinical prediction models for diagnostic and prognostic purposes.
This work compared untuned SSOGP symbolic regression models that were developed
in an automated fashion with highly tuned Cox regression models that were developed
in a very involved manner that required a certain amount of clinical and statistical
expertise. Whilst the highly tuned Cox regression models performed slightly better
in validation data, the performance of the automatically generated prediction models
were generally comparable. The comparable performance demonstrates the utility of
GP for clinical prediction modelling and prognostic research, where the primary goal
is accurate prediction. In aetiological research, where the primary goal is to examine
the relative strength of association between risk factors and the outcome, then Cox
regression and its variants remain as the de facto approach.
In hypothesis-driven research, the user formally specifies some idea—the hypothesis—a
priori and uses data to prove (or disprove) this idea. In contrast, with a data-driven ap-
proach the user does not formally specify a hypothesis a priori, but uses the data to
discover patterns and relationships, thus generating hypotheses. Frequentist statist-
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ical approaches for clinical prediction modelling (such as Cox regression) are typically
hypothesis-driven. Typically the user specifies the variables of interest and the general
model form (e.g. Cox regression) a priori . There are ways in which these methods can
be more data-driven, such as considering a broad set of variables and using stepwise
feature selection procedures to select the subset of important predictors. However, as
discussed previously in this chapter, there are problems with stepwise feature selection
procedures and this is only partially data-driven, the general model form has already
been specified a priori and limited to linear combinations of predictors. In contrast GP
is a data-driven approach, it automatically solves problems without requiring the user
to know or specify the form or structure of the solution in advance. In addition to ef-
ficiently searching for potentially complex non-linear associations between predictors
and outcome, GP also searches for the optimal model form (or structure) and—intrinsic
to its evolutionary process—automatically selects a subset of features.
In an era of evidence-based medicine and shared decision-making, medicine and health-
care is becoming increasingly data-driven, so too increases its overlap with the field
of computer science. With increasing amounts of medical data becoming available
through EPR systems and consumer-facing wearables, the opportunity for computer
science to significantly reduce the burden of disease continues to grow. Computer
science can be used to extract knowledge from large datasets and use it to ultimately
improve both the services provided and the quality outcomes for the patient. For ex-
ample, accurate risk prediction models can extracted from the data for a potentially
unlimited number of disease and therapeutic areas, helping to understand in advance
what course of action is more likely to have the desired outcome and how to spend
resources effectively. Models can be automatically and efficiently retrained and recal-
ibrated to reflect new tests, new interventions, new patients, and any other updates to
the underlying data. This becomes more advantageous as both the volumes of medical
data and efficient mechanisms for data collection continue to increase. Therefore, auto-
matically generated and updated models are more likely to remain relevant and valid
for longer, and thus be more cost-effective to develop and maintain, when compared
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with hand-crafted models. Routine application of automated clinical prediction mod-
els could be used to screen entire populations and offer timely targeted interventions to
those identified to be at risk, thus having potential economic and quality of life impact
for society.
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Appendix A
ISAC Protocol: UKPDS-RE Validation
   
ISAC v1.0: 27/03/2012 
ISAC APPLICATION FORM   
PROTOCOLS FOR RESEARCH USING THE CLINICAL PRACTICE RESEARCH DATALINK (CPRD) 
 
ISAC use only: 
Protocol Number 
Date submitted 
 
............................. 
............................. 
IMPORTANT 
If you have any queries, please contact ISAC Secretariat: 
ISAC@cprd.com 
 
1. Study Title  
Comparison of cardiovascular outcomes observed in patients with type 2 diabetes and those 
predicted by the UKPDS Risk Engine 
2. Does this protocol describe a purely observational study using CPRD data (this may include the review of 
anonymised free text)? 
 
Yes    No   
 
3. Does this protocol seek access to data held under the CPRD Data Linkage Scheme? 
 
Yes    No   
 
4. If you are seeking access to data held under the CPRD Data Linkage Scheme, please select the source(s) of linked 
data being requested. 
 
 Hospital Episode Statistics   Cancer Registry Data                MINAP                                                       
 ONS Mortality Data    Index of Multiple Deprivation/ Townsend Score  
 Mother Baby Link                 Other: (please specify)  
 
 
 
 
5. If you are seeking access to data held under the CPRD Data Linkage Scheme, have you already discussed your 
request with a member of the Research team?  
 
Yes    No*   
 
*Please contact the CPRD Research Team on +44 (20) 3080 6383 or email kc@cprd.com to discuss your 
requirements before submitting your application. 
 
6. Does this protocol involve requesting any additional information from GPs?  
 
Yes*    No   
 
 * Please indicate what will be required:  
   Completion of questionnaires by the GPψ     Yes      No   
 Provision of anonymised records (e.g.  hospital discharge summaries)  Yes      No   
 Other (please describe)        
 
ψ Any questionnaire for completion by GPs needs to be approved by ISAC before being sent out for completion.   
 
 
GUIDANCE ON ANSWERING QUESTIONS 2-3: 
These questions must be completed by all applicants.  You should note the following:   
 
(i) If you have answered NO to question 2, you may need to seek separate ethics approval from an NHS 
Research Ethics Committee for this study. The ISAC will provide advice on whether this may be 
needed. 
 
 (ii) If you have answered YES answered to question 2 above and you will be using data obtained from the 
CPRD Group at the MHRA (question 3), this study does not require separate ethics approval from an 
NHS Research Ethics Committee.  
 
If you will be using data obtained from EPIC, you will need to consult the data provider regarding their 
arrangements for obtaining ethics approval for the study.  
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NB: Answering YES to question 2 means that the answers to questions 8-10 should all be NO. If any of the answers 
below are YES please review your answer to question 2 as it should be NO. 
 
7. Has this protocol been peer reviewed by another Committee? 
 
Yes*    No   
 
* Please state in your protocol the name of the reviewing Committee(s) and provide an outline of the review process 
and outcome. 
8. Does the study involve linking to patient identifiable data from other sources? 
 
Yes     No   
 
9. Does this study require contact with patients in order for them to complete a questionnaire? 
 
Yes     No   
 
10. Does this study require contact with patients in order to collect a sample? 
 
Yes*    No   
 
* Please state what will be collected 
 
   
11. Type of Study (please tick one box below) 
 
Adverse Drug Reaction  Drug Use   Disease Epidemiology 
Pharmacoeconomic   Drug Effectiveness  Other    
 
12. Data source  (please tick one box below) 
 
CPRD :        
 
Sponsor has on-line access   Purchase of ad hoc dataset  
Commissioned study    
Other        (please specify)    
 
13. Financial Sponsor of study 
 
Pharmaceutical Industry (please specify)    Academia(please specify)  Cardiff 
University 
Government / NHS (please specify)     None    
Other (please specify)      
 
14. This study is intended for: 
 
Publication in peer reviewed journals   Presentation at scientific conference  
Presentation at company/institutional meetings  Other      
 
15. Principal Investigator (full name, job title, organisation & e-mail address for correspondence regarding this 
protocol) 
Christian Bannister, MSc, Postgraduate Researcher, Cardiff University, bannisterca@cf.ac.uk 
 
16. Affiliation (full address) 
Cardiff University School of Medicine, Primary Care & Public Health, Cardiff Medicentre, Heath Park, Cardiff, CF14 4UJ 
17. Type of Institution (please tick one box below) 
 
Academia  Research Service Provider  Pharmaceutical Industry  
NHS  Government Departments  Others    
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18. Experience/expertise available  
 
Please complete the following questions to indicate the experience/expertise available within the team of researchers 
actively involved in the proposed research, including  analysis of data and interpretation of results 
 Previous GPRD/CPRD Studies  Publications using GPRD/CPRD data 
 
None                               
1-3                                
> 3                                
          Yes                              No 
Is statistical expertise available within the research team?       
                           If yes, please outline level of experience   The research team has statistical 
expertise appropriate to use of large datasets for epidemiological research. Additional expertise can be sought from 
colleagues within Cardiff School or Medicine as required. 
 
Is experience of handling large data sets (>1 million records)  
available within the research team?          
                           If yes, please outline level of experience   CP and CC and SJJ have extensive 
experience of using large routine NHS datasets including HES, GRPD and THIN. 
 
Is UK primary care experience available within the research team?       
                           If yes, please outline level of experience   The team has experience of using 
primary care data form a variety of studies.  Specific clinical assistance can be sought if required from colleagues from 
the department of Primary Care and Public Health within Cardiff School of Medicine 
19. Other collaborators (if applicable: please list names and affiliations of all collaborators) 
Dr. Chris Poole 
Senior Lecturer in Evaluation of Medicines, Cardiff University 
Sara Jenkins-Jones, MSc 
Postgraduate Researcher, Cardiff University 
Professor Craig Currie 
Professor of Applied Pharmacoepidemiology, Cardiff University 
 
20. Protocol’s Author (if different from PI) 
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PROTOCOL CONTENT CHECKLIST 
 
All protocols using CPRD data which are submitted for review by ISAC must contain information on the 
areas detailed in the instructions.  If you do not feel that a specific area required by ISAC is relevant for 
your protocol, you will need to justify this decision to ISAC.  
 
Applicants must complete the checklist below to confirm that the protocol being submitted includes all the 
areas required by ISAC, or to provide justification where a required area is not considered to be relevant 
for a specific protocol.  Protocols will not be circulated to ISAC for review until the checklist has been 
completed by the applicant.  
 
Please note, your protocol will be returned to you if you do not complete this checklist, or if 
you answer ‘no’ and fail to include justification for the omission of any required area. 
 
 Included in 
protocol? 
 
Required area Yes No If no, reason for 
omission 
Lay Summary (max.200 words)   
 
 
Background    
Objective, specific aims and rationale    
Study Type 
Hypothesis Generating 
Hypothesis Testing 
 
 
 
  
 
 
 
 
 
Study Design    
Sample size/ power calculation  
(Please provide detailed justification of  
sample size in the protocol) 
   
Study population  
(including estimate of expected number of  
relevant patients in the CPRD) 
 
 
 
 
 
 
Selection of comparison group(s) or controls   N/A to this study 
Exposures, outcomes and covariates    
Data/ Statistical Analysis 
Hypothesis Generating 
Hypothesis Testing 
 
 
 
 
 
 
 
 
 
Patient/ user group involvement †   N/A to this study 
Limitations of the study design, data sources  
and analytic methods 
   
Plans for disseminating and communicating 
study results 
   
 
† It is expected that many studies will benefit from the involvement of patient or user groups 
in their planning and refinement, and/or in the interpretation of the results and plans for 
further work. This is particularly, but not exclusively true of studies with interests in the 
impact on quality of life.   Please indicate whether or not you intend to engage patients in any 
of the ways mentioned above. 
 
ISAC strongly recommends that researchers using CPRD consider registering as a NRR data provider in 
order that others engaged in research within the UK can be made aware of current works. The National 
Research Register (NRR) is a register of ongoing and recently completed research projects funded by, 
or of interest to, the United Kingdom's National Health Service. Information on the NRR is available on 
www.nrr.nhs.uk . 
 
Please Note: Registration with the NRR is entirely voluntary and will not replace information 
on ISAC approved protocols that are published in summary minutes or in the ISAC annual 
report.   
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Lay summary 
The UK Prospective Diabetes Study (UKPDS) was a clinical trial designed to show the long-
term benefits of controlling both blood sugar and blood pressure in individuals newly 
diagnosed with type 2 diabetes (T2DM).  The UKPDS Risk Engine was developed from the 
trial data and calculates the absolute risk of coronary heart disease and stroke for individuals 
diagnosed with T2DM.   The UKPDS Risk Engine is widely utilised in the economic 
evaluation of various T2DM-related interventions across the world as well as in the UK.   
 
A growing number of trials have failed to demonstrate the causal relationship between lower 
blood glucose and improved outcomes, some even suggesting that there is a harmful effect of 
lowering blood sugar too aggressively.  Therefore the benefits of improved glycaemic control 
predicted by models such as the UKPDS Risk Engine may be overestimated. 
 
The purpose of this epidemiological study is to compare observed cardiovascular outcomes 
with those predicted by the UKPDS Risk Engine in a representative population of people 
with T2DM managed according to routine standard of care. This study of real-life data should 
give a better understanding of the applicability of the UKPDS Risk Engine to the general 
population of people with T2DM.  
 
Introduction 
Diabetes is on the rise, in the UK and around the world1-7.  Forecasting models have shown 
that the prevalence of diabetes is steadily increasing, and that diabetes is not a localised 
chronic condition8-12.  Major contributors to this increase in prevalence are obesity and an 
ageing population, both of which increase risk of type 2 diabetes (T2DM).  Understanding the 
costs and effectiveness of healthcare delivery in diabetes is of clear importance to health 
services.   
 
There are many different predictive risk models for diabetes used in health economics, such 
as the UKPDS Risk Engine13, the UKPDS Outcomes Model14 and the Center for Outcomes 
Research Diabetes Model15.  All these models are based on epidemiological data derived 
from the UKPDS23.  As such, while assumptions may hold true in a clinical setting with a 
specific population of individuals who have specific risk factors used in the UKPDS, these 
models may not accurately reflect the actual incidence, prevalence, mortality and costs 
related to the late complications of diabetes in the general population today or after a given 
duration16. 
 
Moreover, models derived from UKPDS epidemiological data13-15 include estimates of 
reduced mortality and cardiovascular events associated with a reduction in HbA1c for 
patients with T2DM.  However, a growing number of large randomised, controlled trials have 
failed to demonstrate a causal relationship between clinically important reductions in HbA1c 
and improved outcomes16-20.  
 
The recent Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial21 and  
retrospective cohort study assessing survival as a function of HbA1c22 even suggests potential 
harm associated with aggressive glycaemic control in this patient population.  The benefits of 
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improved glycaemic control for people with T2DM may therefore be overestimated in these 
models. 
 
Another important factor is the manner in which the UKPDS Risk Engine13 is used in health 
economics. The risk engine was designed to predict the future risk of specific cardiovascular 
events in patients newly diagnosed with T2DM over a specified time horizon.  However, the 
model is often used at other stages of the care pathway, not just at the beginning as intended, 
with the assumption that the model performs the same at any level of treatment 
intensification.  The validity of this assumption is far reaching as many T2DM interventions 
have been evaluated in this way for use by the NHS and other health services worldwide. 
 
A review of previous work carried to externally validate the UKPDS risk engine revealed that 
the risk engine has been previously validated on prospective cohorts; 10,137 from 
Norfolk[23] ; 428 from Poole[24]; 1,622 from Germany and the Netherlands[25]; 1,482 from 
the Netherlands[26] and 7,067 from China[27].   However none of these studies have 
validated the UKPDS risk engine on a UK-wide prospective cohort, nor have any studies 
evaluated its performance at different stages of the diabetes care pathway. 
 
In the light of new research that challenges our understanding of the impact of glycaemic 
control on long-term outcomes in T2DM, this study requests approval to use GPRD data in 
evaluating the appropriateness of the UKPDS Risk Engine and the assumption that the Risk 
Engine can be used at any stage of the T2DM treatment pathway. 
 
Objective 
The purpose of the proposed study is to characterise the appropriateness of the UKPDS Risk 
Engine for the prediction of cardiovascular events for individuals with T2DM from the 
general population. 
 
Methods 
Data source     
GPRD 
 
Study type 
The study will be hypothesis testing with regard to cardiovascular risk in patients with 
T2DM. 
 
Study design 
The study will use a retrospective cohort design. 
 
Study population and cohorts 
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The aim of the study is not to replicate the UKPDS, but to access the appropriateness of using 
the UKPDS Risk Engine (developed using data from the UKPDS) in the UK T2DM 
population.  We achieve this by adopting selection criteria to develop a cohort of incident 
cases of T2DM, with no recent history of myocardial infarction (MI), angina or heart failure 
from GPRD and test the performance of the risk engine on this cohort.  
 
The study comprises of a single cohort of incident cases of type 2 diabetes registered with 
practices between 1991 and 2011.  A wash-in of 365 days has been applied to exclude non-
incident T2DM patients (see table 1, item 5).  Patients will be selected who have had a 
diagnosis of type 2 diabetes with no frank diagnoses of diabetes secondary to other causes 
e.g. gestational or iatrogenic. Subjects will be classified as type 2 diabetes on the basis of 
frank differential diagnosis. More specifically, patients will be classified as having T2DM if 
they have a diagnosis of diabetes and one or more of the following: 
1. More than one diagnostic record exclusively for type 2 diabetes OR  
2. Prescription of two or more differing classes of OAD OR  
3. A diagnostic code indicative of T2DM (regardless of conflicting diagnoses of type 1 
or non-specific diabetes) plus a prescription for an OAD. 
Patients diagnosed before the age of 35 with no OAD and a prescription for insulin were 
classified as type 1 and hence excluded.  In the absence of such a diagnosis, a prescription 
history including exposure to oral hypoglycaemic agents (assignment to T2DM if >6 separate 
OHA prescriptions) where the age at incident diabetes event is greater than 40 years of age.   
 
Patients will be selected that have linkage with Hospital Episode Statistics (HES) data and 
Office for National Statistics (ONS) mortality data.  This will provide the ethnicity and cause 
of death information required for this study as well as more accurate ascertainment of 
cardiovascular events.  This will possibly result in some data loss (see table 1) as the data that 
is eligible for HES and/or ONS linkage is a subset of the data available through GPRD.   
 
Stage Description Lost Remaining 
1 GPRD patients with T2DM of status 'accept' (GPRD 
quality indicator) 
N/A 490,084 
2 Omit patients in 1 with unknown dates of first 
diagnosis or first prescription 
14,096 475,988 
3 Omit patients in 2 where year of DM presentation* > 
year of birth or > 2011 
1 475,987 
4 Omit patients in 3 where year of DM presentation* < 
1991 
44,462 431,525 
5 Omit patients in 4 where wash-in from registration to 
DM presentation* < 365 days 
106,406 325,119 
6 Omit patients in 5 where sex is neither male nor female 24 325,095 
7 Omit patients in 6 where age at DM presentation* < 21 4,838 320,257 
9 Omit patients in 7 not having smoking status at baseline 
(DM presentation*) 
8,897 311,360 
8 Omit patients in 7 who are ineligible for HES linkage 180,205 131,155 
10 Omit patients in 9 not having ethnicity of types 1, 2, or 
3 (see 'Model Covariates' section) 
26,512 104,643 
11 Omit patients in 10 who are ineligible for ONS 
Mortality linkage (and hence cause of death) 
778 103,865 
*DM Presentation refers to the earlier of two dates; date of first DM diagnosis or date of first prescription of DM drugs 
Table 1: Sample data loss from inclusion/exclusion criteria  
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Sample size and power calculation  
The UKPDS risk engine was developed on 4,540 patients from the UKPDS and is 
conservatively assumed as the minimum sample size for this study.  This minimum number 
of subjects is easily achievable, where we estimate that >100,000 suitable subjects with 
incident of T2DM are available in GPRD; even with ‘acceptable quality status’ (see table 1).  
 
Outcomes 
The primary outcomes are the four cardiovascular events predicted by the UKPDS Risk 
Engine are coronary heart disease (CHD), fatal CHD, stoke and fatal stroke. This study 
proposes to use the same endpoints to ensure that we are predicting the same events.  Using 
ICD-9and ICD-10, Table 2 below details the exact coding of the endpoints used in UKPDS28 
risk engine that are proposed for this study.  For hard endpoints of stroke and CHD we will 
be reliant on data from HES and ONS.  For HES we will consider patients admitted as 
emergencies with a primary diagnosis of the relevant event.  For ONS we will consider 
deaths with a primary or contributory cause of death of stoke or CHD. 
 
Endpoint ICD -10 Codes ICD-9 Code 
CHD I21-I25, I46.1 410-414.9 798.9 (fatal or non-fatal 
MI and Sudden death) 
Fatal CHD I21-I25, I46.1 410-414.9 798.9 (fatal MI or 
Sudden death) 
Stroke I60-I69 430-438.9 (fatal or non-fatal 
Stroke) 
Fatal Stroke I60-I69 430-438.9 (fatal Stroke) 
Table 2:  ICD-9 and ICD-10 coding of cardiovascular endpoints used in UKPDS and 
proposed for study. 
   
CHD is defined as the occurrence of fatal or non-fatal myocardial infarction (MI) or sudden 
death.28 In patients with multiple CHD events, only the first event is considered in this study.  
Stroke is defined as a neurological deficit with symptoms or signs lasting 1 month or more.28 
No distinction was made between ischemic, embolic, and hemorrhagic strokes. In patients 
with multiple strokes, only the first stroke is considered here.  Death from causes other than 
the defined outcomes of interest will be treated as censored.  
 
 
Model covariates 
Covariates are those required by the UKPDS Risk Engine as inputs, as follows: 
AGE  Age in years (over 20 years) at diagnosis 
SEX   F for female; M for male  
ETHNIC 1 for Caucasian, 2 for Afro-Caribbean; 3 for Asian-Indian   
SMOK  0 for never, 1 for past, 2 for current smoker of tobacco in any form, at index of 
each care pathway 
DUR  Duration of diabetes (positive integer) 
AF  Presence of Atrial Fibrillation (Y for yes, N for no) 
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SBP  Systolic blood pressure (mmHg), mean of values for years 1 and 2 
A1C   HbA1c (%), mean of values for years 1 and 2   
TC  Total cholesterol, mean of values for years 1 and 2 (mmol/l) 
HDL  HDL cholesterol, mean of values for years 1 and 2 (mmol/l) 
H  No of readings for HbA1c used in calculating mean value used 
BP  No of readings for SysBP used in calculating mean value used 
CHOL  No readings TC/HDL used in calculating mean value used 
 
To improve model stability HbA1c, SysBP, TC and HDL will be taken as mean values one 
year apart 
 
Data/statistical analysis 
The UKPDS Risk Engine will be evaluated with a series of diagnostic plots, comparing 
survival probabilities for the study population calculated by the UKPDS Risk Engine with 
survival probabilities for the study population calculated by non- parametric methods. A 
version of the UKPDS Risk Engine has been obtained for this purpose, with the permission of 
the Diabetes Trails Unit at the University of Oxford.  The non-parametric method proposed is 
the life-table method with one-year intervals, which also provides 95% confidence 
intervals29.  The life-table method, also known as Actuarial Estimate of survivor function is a 
technique for estimating the survival function S(t) of censored data.  The life-table method is 
analogous to the Kaplan-Meier estimate of the survival function, but with the life-table 
method intervals can predefined and uniform (e.g. 1-year), whereas with Kaplan-Meier time 
intervals are defined by event times.  A more detailed explanation is outlined in appendix A. 
This methodology is the same used in the development and evaluation of the UKPDS Risk 
Engine13 and should therefore aid comparison.  Declining secular trends in diabetes mortality 
and all-cause mortality in the general population shall be addressed by performing a 
sensitivity analysis using 5-year periods.  Where appropriate missing data shall be handled 
using multiple imputation.  Multiple imputation is a powerful technique that offers substantial 
improvements over the biased and flawed value replacement approaches based on complete 
cases or cases matched for age and sex[30-31].  It involves creating multiple copies of the data 
and imputing the missing values with sensible values randomly selected from their predicted 
distribution. We propose to use the Multivariate Imputation by Chained Equations (MICE) 
approach.   
 
In order to evaluate the performance of the UKPDS Risk Engine at various stages of the 
diabetes care pathway, four levels of glycaemia treatment levels have been defined: 
1. Diet	  and	  lifestyle	  modification	  
2. Metformin	  monotherapy	  
3. Metformin	  in	  combination	  with	  other	  oral	  hypoglycaemic	  agents	  (OHA)	  
4. Insulin–based	  therapy	  (with	  or	  without	  OHAs)	  
 
The UKPDS Risk Engine will be evaluated using all available patients in the study 
population as they enter each of the pre-defined treatment pathways, this will be carried out 
for each of the four outcomes.  The behaviour of the UKPDS Risk Engine at each of these 
treatment stages will be compared and contrasted with the parametric life-table method using 
diagnostic plots as described above. 
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Limitations of the study design, data sources and analytic methods 
This study has a number of limitations. GPRD collates data from routine practice, thus there 
are missing data, there are coding imperfections, and there is no standardisation of measures 
such as HbA1c. The normal ranges for HbA1c do vary between biochemical test centers 
(unless test is specifically reported as DCCT−aligned), and measurements are taken with 
varying periodicity. We consider these limitations may introduce noise into the study but 
have no reason to suspect they will introduce bias. Duration of diabetes is an important 
covariate but one which must be treated with caution.  
 
 
Plans for disseminating and communicating study results 
Findings from this study will be disseminated through scientific meetings and peer-reviewed 
manuscript(s). 
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Appendix A:  Life-Table Method 
The life-table estimate of the survivor function, also known as the Actuarial estimate of the 
survivor function, is obtained by first dividing the period of observation into a series of time 
intervals.  These intervals need not necessarily be of equal length but often are.  
Suppose that the jth of m such intervals, j=1, 2,…, m, extends from time t’j to t’j+1, and let dj 
and cj denote the number of deaths and number of censored survival times, respectively, in 
this time interval.  Also let nj be the number of individuals who are alive, and therefore at risk 
of death, at the start of the jth interval.  We now make the assumption that the censored 
survival times occur uniformly throughout the jth interval, so that the average number of 
individuals who are at risk during this interval is 
 
j!n = jn − jc2  
 
This assumption is sometimes known as the actuarial assumption. 
 
In the jth interval, the probability of death can be estimated by dj/n’j, so that the 
corresponding survival probability is (n’j-dj)/n’j.  Now consider the probability that an 
individual survives beyond time t’k, k=1, 2, …, m, that is, until some time after the start of the 
kth interval.  This will be the product of the probabilities that an individual survives beyond 
the start of kth interval and through each of the k-1 preceding intervals, and so the life-table 
estimate of the survivor function is given by 
 
*S (t) = jn ' − jd
jn '
"
#
$
$
%
&
'
'
j=1
k
∏  
 
For t’k<= t < t’k+1, k=1, 2. …, m.  A graphical estimate of the survivor function will then be a 
step-function with constant values of the function in each time interval. 
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Appendix B
Run statistics: SMART experiments
The full range of run statistics for the 25 GP runs in the SMART experiments in
chapter 6
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Figure B.1: The full range of runs statisitcs for the 25 SSOGP runs in the SMART
experiments in chapter 6.
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Appendix C
Final Models: SMART experiments
The final 25 models developed by SSOGP the SMART experiments in chapter 6,
presented as a binary trees
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Appendix D
Predictor Effects: SMART
experiments
Plots of the effects of predictor values on log hazard in the ’final’ GP model in the
SMART experiments in chapter 6
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Figure D.1: Plots of the effects of predictor values on log hazard in the ’final’ GP
model in the SMART experiments in chapter 6.
263
Appendix E
Results: SMART experiments
(secondary analysis)
Results of the additional experiments that repeat the SMART experiments in chapter 6,
but only on the subset of covariates that were selected with a relatively high frequency
(> 0.5) in the main experiment.
Figure E.1: Average survival curves for the Cox regression and genetic program-
ming models. The error bars represent ±2 standard errors of the KM estimates.
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Figure E.2: C-statistic estimates by model for t=1, 3 and 5 years
Table E.1: C-statistic estimates by model at t=1, 3, and 5 years
Time (years) Genetic Programming (superset) Genetic Programming (subset)
1 0.59 0.59
3 0.69 0.70
5 0.64 0.64
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Figure E.3: Calibration plots for the Cox regression and genetic programming
models, at t=1, 3, and 5 years..
Table E.2: χ2 statistic for the comparison between observed versus expected (ac-
cording to the model) number of events in groups of patients defined according to
the predicted 1− S(t) at t=1, 3, and 5 years.
Time (years) Genetic Programming (superset) Genetic Programming (subset)
t χ2 p-value χ2 p-value
1 5.18 0.818 3.44 0.944
3 9.99 0.352 12.13 0.206
5 16.17 0.063 21.88 0.009
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ISAC Protocol: CPRD Experiments
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ISAC APPLICATION FORM 
PROTOCOLS FOR RESEARCH USING THE CLINICAL PRACTICE RESEARCH DATALINK (CPRD) 
 
ISAC use only: 
Protocol Number 
Date submitted 
 
............................. 
............................. 
IMPORTANT 
If you have any queries, please contact ISAC Secretariat: 
ISAC@cprd.com 
 
1. Study Title  
Developing a new cardiovascular risk score for the UK general population 
 
2. Principal Investigator (full name, job title, organisation & e-mail address for correspondence regarding this 
protocol) 
Christian Bannister, MSc, Postgraduate Researcher, Cardiff University, bannisterca@cf.ac.uk 
 
3. Affiliation (full address) 
Cardiff University School of Medicine, Primary Care & Public Health, Cardiff Medicentre, Heath Park, Cardiff, CF14 4UJ 
4. Protocol’s Author (if different from the principal investigator) 
 
 
5. Type of Institution (please tick one box below) 
 
Academia  Research Service Provider  Pharmaceutical Industry  
NHS  Government Departments  Others    
 
6. Financial Sponsor of study 
 
Pharmaceutical Industry (please specify)    Academia(please specify)  Cardiff 
University 
Government / NHS (please specify)     None    
Other (please specify)      
 
7. Data source  (please tick one box below) 
 
      
 
Sponsor has on-line access   Purchase of ad hoc dataset  
Commissioned study    
Other      (please specify)   
 
8. Has this protocol been peer reviewed by another Committee? 
 
Yes*    No   
 
* Please state in your protocol the name of the reviewing Committee(s) and provide an outline of the review process 
and outcome. 
 
9. Type of Study (please tick all the relevant boxes which apply) 
 
Adverse Drug Reaction/Drug Safety  Drug Use   Disease Epidemiology  
Drug Effectiveness   Pharmacoeconomic          Other    
 
10. This study is intended for: 
 
Publication in peer reviewed journals   Presentation at scientific conference  
Presentation at company/institutional meetings  Other     Form 
chapter(s) of PhD thesis 
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11. Does this protocol also seek access to data held under the CPRD Data Linkage Scheme? 
 
Yes    No   
 
 
12. If you are seeking access to data held under the CPRD Data Linkage Scheme, please select the 
source(s) of linked data being requested. 
 
 Hospital Episode Statistics   Cancer Registry Data*               MINAP                                                       
 ONS Mortality Data    Index of Multiple Deprivation/ Townsend Score  
 Mother Baby Link    Other: (please specify)  
 
 
 
*Please note that applicants seeking access to cancer registry data must provide consent for publication 
of their study title and study institution on the UK Cancer Registry website. Please contact the CPRD 
Research Team on +44 (20) 3080 6383 or email admin@cprd.com to discuss this requirement further. 
 
 
13. If you are seeking access to data held under the CPRD Data Linkage Scheme, have you already 
discussed your request with a member of the Research team?  
 
Yes    No*   
 
*Please contact the CPRD Research Team on +44 (20) 3080 6383 or email admin@cprd.com to discuss 
your requirements before submitting your application. 
 
Please list below  the name of the person/s at the CPRD with whom you have discussed your request. 
 Tarita Murray Thomas (MHRA/CPRD Enquiry Reference: OCR9669) 
 
14. Does this protocol involve requesting any additional information from GPs?  
 
Yes*   No   
 
 * Please indicate what will be required:  
   Completion of questionnaires by the GPψ     Yes      No   
 Provision of anonymised records (e.g.  hospital discharge summaries)  Yes      No   
 Other (please describe)        
 
ψ Any questionnaire for completion by GPs or other health care professional must be approved by ISAC 
before circulation for completion.   
15. Does this protocol describe a purely observational study using CPRD data (this may include the 
review of anonymised free text)? 
 
Yes*   No**   
 
* Yes: If you will be using data obtained from the CPRD Group, this study does not require separate 
ethics approval from an NHS Research Ethics Committee. 
** No: You may need to seek separate ethics approval from an NHS Research Ethics Committee for this 
study. The ISAC will provide advice on whether this may be needed. 
 
16. Does this study involve linking to patient identifiable data from other sources? 
 
Yes    No   
 
17. Does this study require contact with patients in order for them to complete a questionnaire? 
 
Yes    No   
 
N.B. Any questionnaire for completion by patients must be approved by ISAC before circulation for 
completion.   
18. Does this study require contact with patients in order to collect a sample? 
 
Yes*   No   
 
* Please state what will be collected    
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19. Experience/expertise available  
 
Please complete the following questions to indicate the experience/expertise available within the team of researchers 
actively involved in the proposed research, including  analysis of data and interpretation of results 
 Previous GPRD/CPRD Studies  Publications using GPRD/CPRD data 
 
None      
1-3       
> 3       
          Yes                              No 
Is statistical expertise available within the research team?       
                           If yes, please outline level of experience   The research team has statistical 
expertise appropriate to use of large datasets for epidemiological research. Additional expertise can be sought from 
colleagues within Cardiff School of Medicine as required. 
 
 
Is experience of handling large data sets (>1 million records)  
available within the research team?          
                           If yes, please outline level of experience   The research team have extensive 
experience of using large routine NHS datasets including HES, GRPD and THIN. 
 
Is UK primary care experience available within the research team?       
                           If yes, please outline level of experience   The team has experience of using 
primary care data form a variety of studies.  Specific clinical assistance can be sought if required from colleagues from 
the department of Primary Care and Public Health within Cardiff School of Medicine 
 
20.  References relating to your study 
 
Please list up to 3 references (most relevant) relating to your proposed study. 
 
1 Anderson KM, Odell PM, Wilson PWF, KannelWB. Cardiovascular disease risk profiles.Am Heart J 1991;121(1 
pt 2):293-8.  
2 Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J,Minhas R, Sheikh A, et al. Predicting cardiovascular risk 
in England andWales: prospective derivation and validation of QRISK2. BMJ 2008;336:1475-82, 
doi:10.1136/bmj.39609.449676.25.  
3 Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J,MayM, Brindle P. Derivation and validation of QRISK, 
a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 
2007;335:136, doi:10.1136/bmj.39261.471806.55.  
 
21. List of all investigators/collaborators (please list the names, affiliations and e-mail addresses* of all collaborators, 
other than the principal investigator) 
Sara Jenkins-Jones, MSc 
Postgraduate Researcher, Cardiff University  
s.jenkins-jones@cs.cardiff.ac.uk 
 
Professor Craig Currie 
Professor of Applied Pharmacoepidemiology, Cardiff University 
currie@cardiff.ac.uk 
 
*Please note that your ISAC application form and protocol must be copied to all e-mail addresses listed above at the time of 
submission of your application to the ISAC mailbox. Failure to do so will result in delays in the processing of your application. 
 
 
 
 
 
270 8.5 Conclusions
   
bannisterca@cardiff.ac.uk  4 
 
PROTOCOL CONTENT CHECKLIST 
In order to help ensure that protocols submitted for review contain adequate information for protocol evaluation, 
ISAC have produced instructions on the content of protocols for research using CPRD data. These instructions 
are available on the CPRD website (www.cprd.com/ISAC). All protocols using CPRD data which are submitted for 
review by ISAC must contain information on the areas detailed in the instructions.  IF you do not feel that a 
specific area required by ISAC is relevant for your protocol, you will need to justify this decision to ISAC.  
 
Applicants must complete the checklist below to confirm that the protocol being submitted includes all the areas 
required by ISAC, or to provide justification where a required area is not considered to be relevant for a specific 
protocol.  Protocols will not be circulated to ISAC for review until the checklist has been completed by the 
applicant.  
 
Please note, your protocol will be returned to you if you do not complete this checklist, or if you 
answer ‘no’ and fail to include justification for the omission of any required area. 
 
 Included in 
protocol? 
 
Required area Yes No If no, reason for omission 
Lay Summary (max.200 words)   
 
 
Background    
Objective, specific aims and rationale    
Study Type 
Descriptive 
Hypothesis Generating 
Hypothesis Testing 
 
 
 
 
 
  
 
 
 
 
Study is primarily hypothesis 
testing 
Study Design    
Sample size/power calculation  
(Please provide justification of  
sample size in the protocol) 
   
Study population  
(including estimate of expected number of  
relevant patients in the CPRD) 
 
 
 
 
 
 
Selection of comparison group(s) or controls    
Exposures, outcomes and covariates 
Exposures are clearly described  
Outcomes are clearly described 
 
 
 
 
 
 
 
 
Data/ Statistical Analysis Plan 
There is plan for addressing confounding  
There is a plan for addressing missing data 
 
 
 
 
 
 
 
 
Patient/ user group involvement †   n/a 
Limitations of the study design, data sources  
and analytic methods 
   
Plans for disseminating and communicating study 
results 
   
 
† It is expected that many studies will benefit from the involvement of patient or user groups in 
their planning and refinement, and/or in the interpretation of the results and plans for further 
work. This is particularly, but not exclusively true of studies with interests in the impact on quality 
of life.   Please indicate whether or not you intend to engage patients in any of the ways mentioned 
above. 
 
ISAC strongly recommends that researchers using CPRD consider registering as a NRR data provider in order that 
others engaged in research within the UK can be made aware of current works. The National Research 
Register (NRR) is a register of ongoing and recently completed research projects funded by, or of interest to, 
the United Kingdom's National Health Service. Information on the NRR is available on www.nrr.nhs.uk .  
Please Note: Registration with the NRR is entirely voluntary and will not replace information on 
ISAC approved protocols that are published in summary minutes or in the ISAC annual report.   
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Lay summary 
Cardiovascular disease (CVD) is the leading cause of mortality and a major cause of morbidity 
globally and in the UK.  National policies support targeting of interventions to reduce risk of 
cardiovascular disease among high-risk patients.  General practitioners use validated risk prediction 
models to identify these high risk patients. Numerous multivariate risk models have been developed to 
estimate a patient’s risk of cardiovascular disease based on key known risk factors.   
 
Until recently in the UK, the National Institute for Clinical Excellence (NICE) recommended the 
long-established Framingham equation for cardiovascular risk prediction.  Published reviews have 
suggested that Framingham may over-estimate risk by up to 50% in contemporary northern European 
populations.  NICE have now ceased recommendation of any single model, leaving practitioners to 
decide which model to use. The purposes of the proposed study is develop a new model to predict 
cardiovascular risk that is more closely calibrated to the UK general population and to validate its 
performance against current risk models used in UK general practice. 
 
Introduction 
Cardiovascular disease (CVD) is a group of disorders of the heart and blood vessels and include 
coronary heart disease, cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, 
congenital heart disease, deep vein thrombosis, pulmonary embolism, hypertension and heart failure. 
The most important behavioral risk factors of heart disease and stroke are unhealthy diet, physical 
inactivity, tobacco use and harmful use of alcohol[1]. CVD is the leading cause of death globally: [1]. 
An estimated 17.3 million people died from CVD in 2008, representing 30% of all global deaths. Of 
these deaths, an estimated 7.3 million were due to coronary heart disease and 6.2 million were due to 
cerebrovascular disease.  By 2030, almost 23.6 million people will die from CVD, mainly from heart 
disease and cerebrovascular disease. These are projected to remain the single leading causes of 
death[1]. 
 
Asymptomatic patients that are suspected to be at high risk need to be identified by General 
Practitioners so they can offer advice about lifestyle changes and initiate preventative treatment.  To 
facilitate this, General Practitioners need tools that can accurately and reliably predict cardiovascular 
risk in their patients.  National policies now support targeting of interventions to reduce risk of 
cardiovascular disease among high-risk patients[2-5].  There are numerous risk models that have been 
developed to predict the risk of cardiovascular outcomes for a 10-year time horizon based using key 
known risk factors.  Such models include the Framingham Risk Score[6] and the Reynolds Risk 
Score[7], both developed from US data.  The SCORE risk function was developed using data from 
various European countries[8]; ASSIGN originated from Scottish data[9]; while QRISK2[10-12] and the 
Joint British Society (JBS)[13] models were computed from UK data.  Framingham is the most 
commonly used model in the UK[6] but has some well-documented limitations; namely that it is poorly 
calibrated to an ethnically diverse population such as the UK[14]. Framingham may perform well in 
ethno-demographically similar populations to its source but may over-estimate risk by up to 50% in 
contemporary northern European populations[20].   
 
Thus far the models discussed have all been examples of validated 10-year risk models with an 
absolute risk threshold of 20% specified by the NICE[3].  Patients with a 10-year score above 20% are 
considered high risk and targeted for primary prevention measures.   Applying this 20% risk threshold 
for intervention may not identify younger patients who, because of their age, have a low absolute 10-
year risk but who have a high relative risk compared with their peers[16]. This is because age has such 
a dominant effect in calculating absolute cardiovascular risk. Some argue that younger patients with 
an adverse risk profile may have more to gain during their lifetime if interventions are started at a 
younger age rather than waiting until they cross the 20% threshold[17-20].  However lifetime risk 
models predict the cumulative risk of the event of interest over the remainder of the patient’s life[21] 
and may provide a more appropriate assessment of future risks, particularly for younger ages[16-19].  
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There is currently only a single published model[16] that predicts lifetime risk of cardiovascular disease 
derived from contemporary UK data, and no mention of such models in UK guidelines. 
 
A recent systematic review of cardiovascular risk models[37] reported that in none of the 21 risk scores 
reviewed was the effect of treatment fully assessed or adjusted for.  The review suggests that two 
treatment effects need to be considered: (1) prior treatment (started before enrolment in the study) and 
(2) subsequent treatment started during study follow-up (treatment drop-ins). None of the risk scores 
addressed the effect of subsequent treatment[37].   
 
The current body of research and a lack of consensus on which risk score is most appropriate for UK 
general practice suggests the need for cardiovascular risk models that are closely calibrated to the 
contemporary UK population and can adequately account for treatment effects.  Such models would 
enable GPs to not only understand the risk of a certain outcome but also understand the changes in 
risk resulting from changes in treatment. Models that could adequately account for treatment effects 
would be a first, making a contribution to this body of research and avoid some of limitations of the 
existing models. The proposed study requests approvals to use Clinical Practice Research Datalink 
(CPRD) data to derive and validate new cardiovascular risk scores that, whilst accounting for 
treatment effects, provide accurate estimates of cardiovascular risk in patients from different ethnic 
groups in the UK general population. 
 
Objective 
The objective of the proposed study is to develop and validate new cardiovascular risk algorithms 
that, whilst accounting for treatment effects, provide accurate estimates of cardiovascular risk in 
patients from different ethnic groups in the UK general population. 
 
Methods 
Data source     
CPRD with linked HES, ONS and Census datasets. 
Study type 
The study will be primarily hypothesis testing with regard to cardiovascular risk in the general 
population. 
 
Study design 
The study will use a prospective open cohort design. 
Study population and cohorts 
The study proposes a single open cohort from the general population, over 14 years from 1997 to 
2011.  To ensure completeness of recording of morbidity and prescribing data, practices in CPRD that 
have been ‘Up-To-Standard’ (UTS) for at least one year will be considered eligible for inclusion.  An 
open cohort of all patients, aged 35-74 years at index date, drawn from all patients registered with 
eligible practices from 1 January 1997 to 31 December 2011.  Index date will be the latest of the 
following dates: mid-year estimate of 35th birthday, date of registration with the practice, practice 
UTS date, and the beginning of the study period (1 January 1997). In addition we will only include 
patients in the analysis once they have a minimum of one year’s complete data after the UTS date. 
 
Patients will be excluded from the cohort that have any one of the following criteria: a recorded 
diagnosis of cardiovascular or cerebrovascular disease prior to the index date; any temporary 
residence status; interrupted periods of registration with the practice; no valid Townsend Score; were 
taking statins at index; implausible or improbable dates; or recorded risk factor values out of plausible 
range.  A ‘wash-in’ period of 365 days will be applied prior to the index to further ensure excluding 
prior history of cardiovascular or cerebrovascular disease and that patients weren’t taking statins at 
baseline.  Patients will be selected that are eligible for linkage schemes with the Hospital Episode 
Statistics (HES), Office of National Statistics (ONS) mortality data and Index of Multiple 
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Deprivation/ Townsend Score data throughout their respective period of follow-up.  This should 
provide accurate ascertainment of ethnicity, socioeconomic status, and cause of death.  Issues with 
ethnicity data where within the non-missing data there are a large proportion of ethnicities recorded as 
‘unknown’ will be addressed by recoding the ‘unknown’ responses as ‘white’, with the rationale that, 
assuming the study population is comparable with the UK population, 93% or more of people without 
ethnicity recorded would be expected to be from a white ethnic group.  Linkage with MINAP was 
considered but its merits were thought to be outweighed by the reduction in cohort size and study 
period from linkage scheme eligibility constraints.  Table 1 below provides an estimate of expected 
number of eligible patients for this study. 
 
Stage Description Lost Remaining 
1 CPRD patients with status 'accept' (CPRD quality indicator) n/a 11,801,879 
2 Omit patients in 1 where ineligible for required linkage 
schemes 
9,537,894 2,263,985 
3 Omit patients in 2 where age at eligibility for entry into study 
between 35 and 74 
133,242 2,130,743 
4 Omit patients in 3 where date at eligibility for entry between 
'1997-01-01' and '2011-12-31' 
1,165,441 965,302 
5 Omit patients in 4 taking statins at baseline 287,641 677,661 
6 Omit patients in 5 with CVD at baseline 18,143 659,518 
7 Omit patients using a 'wash-in' of 365 days for 5 and 6 24,669 634,849 
Table 1:  Attrition from cohort selection criteria indicating expected numbers of eligible patients 
 
Sample size and power calculation  
A sample size calculation has not been carried a priori as this the study does not intend to take a 
sample per se but rather to use all available data in GPRD that meets the selection criteria.    
 
Selection of comparison group(s) or controls  
A split-sample (or cross-validation) approach will be taken for model development, 70% of the 
eligible patients shall be randomly allocated to a training set and 30% will be randomly allocated to a 
test set.  Based on estimates of study cohort size from table 1, expected numbers of patients in the 
training and test sets would be 444,394 and 190,455 respectively.  Data from the training set will be 
used to derive the new risk score and the test used to validate it.  Although this method provides some 
assurance that the model will ‘overfit’ the data, this approach is not an adequate surrogate for external 
validation.  
 
Outcomes 
Primary outcome measure is first recorded diagnosis of cardiovascular disease recorded by the general 
practice either before or at death or via their linked ONS death certificate within the study period. 
Cardiovascular disease is defined as coronary heart disease (myocardial infarction, angina), stroke or 
transient ischaemic attacks in the term cardiovascular disease but not peripheral vascular disease.  
Read code definitions will be used for case identification of coronary heart disease and 
cerebrovascular disease in general practice records.  ICD-9 and ICD-10 codes will be used for case 
identification in HES data and on ONS death certificates.  For HES we will consider patients admitted 
as emergencies with a primary diagnosis of the relevant event.  For ONS we will consider deaths with 
a primary or contributory cause of death of coronary heart disease or cerebrovascular disease.  A 
preliminary set of outcome codes for this study have been included as appendix A.   
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Model covariates 
Covariates proposed for model derivation include the following (where appropriate these risk factors 
will be modelled as time-independent, time-dependent or both): 
1. Age (years)  
2. Self assigned ethnicity (white/not recorded, Indian, Pakistani, Bangladeshi, other Asian, black 
African, black Caribbean, Chinese, other including mixed) 
3. Sex (male v female) 
4. Smoking status (current smoker, non-smoker (including ex-smoker)) 
5. SBP (continuous) 
6. Lipid Profile: 
a. Total serum cholesterol (continuous) 
b. High-density lipids (continuous) 
c. Low-density lipids (continuous) 
d. Triglycerides  (continuous) 
e. Ratio of total serum cholesterol: HDL cholesterol (continuous) 
7. BMI (continuous) 
8. Family history of CHD in first-degree relative under 60 years (yes/no) 
9. Townsend deprivation score (output area level 2001 census data evaluated as a continuous 
variable) 
10. Treated hypertension (diagnosis of hypertension and at least one current prescription of at 
least one antihypertensive agent-e.g. thiazide, β blocker, calcium channel blocker, or 
angiotensin converting enzyme inhibitor) (yes/no) 
11. T2DM (yes/no) 
12. Renal disease (yes/no) 
13. Atrial fibrillation (yes/no) 
14. Rheumatoid arthritis (yes/no) 
15. Charleston Index (categorical) 
16. No. GP attendances in year prior 
17. Angiotensin-converting-enzyme inhibitor or angiotensin receptor blockers (yes/no) 
18. β -blockers (yes/no) 
19. Anti-Platelet Therapy (yes/no) 
20. Statin therapy  (categorical) 
21. Other Lipid-lowering therapies (yes/no) 
22. Other cardiovascular disease (yes/no) 
 
Prior treatment effects will be accounted for by time-independent covariates capturing status at 
baseline.  Where appropriate, subsequent treatment effects will be accounted for by time-dependent 
covariates in two forms: ever exposed (e.g. was the patient exposed to therapy x at any time during 
the study period) and cumulative effect (e.g. over how many time periods, if any, was the patient 
exposed to therapy x during the study period).  
 
Data/statistical analysis 
Descriptive data on the study population shall be evaluated to determine the comparability of the 
randomly assigned training and test groups and evaluate the likelihood of any selection bias or 
confounding.  Baseline characteristics will also be evaluated to help determine the generalisability of 
the study population to other populations.   Declining secular trends in cardiovascular mortality and 
all-cause mortality in the general population shall be addressed by performing a sensitivity analysis 
using 5-year periods.  Where appropriate missing data shall be handled using multiple imputation.  
Multiple imputation is a powerful technique that offers substantial improvements over the biased and 
flawed value replacement approaches based on complete cases or cases matched for age and sex[22-23].  
It involves creating multiple copies of the data and imputing the missing values with sensible values 
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randomly selected from their predicted distribution. We propose to use the Multivariate Imputation by 
Chained Equations (MICE) approach.   
 
All the risk scores mentioned thus far[6-13] have been developed using regression techniques, namely 
survival analysis.   The study proposes two regression approaches for the derivation of a new 
cardiovascular risk model, the long-established survival model methods and a newer regression 
method called symbolic regression.   
 
 
Survival Analysis 
The study proposes the use of survival models (such as Cox proportional hazards or parametric 
survival models) on the training dataset to estimate the coefficients associated with each potential risk 
factor for the prediction of the outcome of interest (first recorded diagnosis of cardiovascular disease) 
for men and women separately.  We have proposed a set of potential variables a priori but will 
consider these variables for inclusion in the model using significance tests and models will be 
compared using likelihood measures such as Akaike Information Criterion (AIC). The proportional 
hazards assumptions will be checked for each variable and tested for any non-linear relation between 
continuous independent variables and the outcome.  Covariate interactions effects will also be 
considered for inclusion in the model. If there are missing values for key predictors then multiple 
imputation will be performed.   
 
The coefficients (i.e. weights for the new cardiovascular disease risk equation) from the final survival 
model, built using the training dataset, will be used to obtain the predicted risk scores for all patients 
in the previously unseen test dataset.  These predicted risk scores from the test dataset shall then be 
used to evaluate its performance of the final model in terms of calibration and discrimination.  
Calibration refers to how closely the predicted risk of cardiovascular disease agrees with the observed 
risk for a certain period.  This will be assessed for each tenth of predicted risk, ensuring 10 equally 
sized groups, and for each 5 year age band by calculating the ratio of predicted to observed risk of 
cardiovascular disease separately for men and for women. Calibration of the risk score predictions 
will be assessed by plotting observed proportions versus predicted probabilities. Calibration measures 
such as Brier Score (adjusted version for censored data)[24] and R2 statistic[26] will also be calculated.  
Discrimination is the ability of the risk score to differentiate between patients who experience a 
cardiovascular event during the study and those who do not. This shall be measured using the D 
statistic[25] and Area Under the Receiver Operating Characteristic (ROC) Curve statistic[27].  As in the 
training set, missing values in the test dataset will be imputed as required.   
 
Symbolic Regression 
Genetic programming (GP) is an evolutionary computation technique that automatically solves 
problems without requiring the user to know or specify the form or structure of the solution in 
advance. At the most abstract level GP is a systematic, domain-independent method that allows 
computers to solve problems automatically starting from a high-level statement of the problem [28].  
 
Symbolic regression attempts to find a function that fits the given data points without making any 
assumptions about the structure of that function. Since GP makes no such assumption, it is well suited 
to this sort of discovery task[28]. Symbolic regression was one of the earliest applications of GP[29], and 
continues to be widely studied[30-33].  Although computationally intensive, GP is well suited to large 
datasets such as CPRD with the ability to handle a large number of variables and/or cases, inherently 
performing feature selection (i.e. selection of which variables should be included in the models) 
leading to parsimonious models. The data and analysis steps that are proposed for the survival models 
will be the same for the symbolic regression. The only difference will be that the model itself, the risk 
equation, will be developed using the symbolic method. 
 
Model Comparisons  
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We propose to compare the performance of the derived survival and symbolic regression models on 
the test dataset.  We shall calculate the predicted cardiovascular risk for each patient in the test dataset 
using the developed survival and symbolic regression models.  We shall then calculate the mean 
predicted risk for each model and the observed risk from the data.  We shall then compare the 
predicted and observed risk by 10th of predicted risk for each score.  Observed risk will be obtained 
using Kaplan-Meier estimates.  We also propose to use the 20% risk threshold as specified by NICE 
guidelines [3] to calculate and compare the proportions of patients that would be classified as at ‘high-
risk’ by each model. 
 
Limitations of the study design, data sources and analytic methods 
This study has a number of limitations. CPRD collates data from routine practice, thus there are 
missing and erroneous data, coding imperfections, lack of standardisation of biochemical measures 
(such as lipid profiles), variations between biochemical test centres and measurements are taken with 
varying periodicity.  Certain covariates of interest such as smoking status, BMI, lipids, family history 
of CVD may not be recorded consistently within CPRD. There are limitations to the size of the cohort 
available for consideration as only a subset of CPRD patients are eligible for the data linkage schemes 
required.  There are also limitations with ethnicity data where even within the non-missing data there 
are a large proportion of ethnicities recorded as ‘unknown’.  Limitations arise from recording the 
‘unknown’ responses as ‘white’, with the rationale that, assuming the study population is comparable 
with the UK population, 93% or more of people without ethnicity recorded would be expected to be 
from a white ethnic group.  Removal or exclusion of patients with missing data may introduce bias 
into the study; this can often be addressed by using multiple imputation techniques to impute missing 
values where appropriate.  There are also limitations in specifying input variables a priori as there is 
potential to miss important factors and relationships that exist with variables not considered.  There 
are limitations on the split-sample validation approach where predictive accuracy estimates, although 
unbiased, can be imprecise.  There are also limitations inherent in all statistical modeling techniques 
each of which have their own set of assumptions, such as non-informative censoring, linearity, 
additively, proportionality, etc., that need to be satisfied in order to order to take a given approach.  
Violation of such statistical assumptions may preclude the use of certain techniques and/or 
consideration of all covariates.  The proposed survival analysis approach has many such assumptions 
that will need to be satisfied whereas the Symbolic regression via GP has no such limitations.  The 
computational expense such as available memory and processing speed (and thus time) may also be 
another limiting factor where certain techniques, main effects and n-way interaction effects cannot be 
considered within such computational constraints.  The GP approach to symbolic regression is 
considered computationally expensive whereas survival analysis is computationally cheap in 
comparison. There may also be bias introduced due to QOF incentivisation, where general practices 
are paid according to the reporting under certain criteria, which will be explored using sensitivity 
analyses.  
 
Plans for disseminating and communicating study results 
Findings from this study will be disseminated through scientific meetings, peer-reviewed 
manuscript(s) and form part of a PhD thesis. 
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11610	   7920300	   CHD	   Saphenous	  vein	  graft	  replacement	  of	  four+	  coronary	  arteries	  
7137	   7920y00	   CHD	   Saphenous	  vein	  graft	  replacement	  of	  coronary	  artery	  OS	  
51515	   7920z00	   CHD	   Saphenous	  vein	  graft	  replacement	  coronary	  artery	  NOS	  
9414	   7921.00	   CHD	   Other	  autograft	  replacement	  of	  coronary	  artery	  
7134	   7921.11	   CHD	   Other	  autograft	  bypass	  of	  coronary	  artery	  
44561	   7921000	   CHD	   Autograft	  replacement	  of	  one	  coronary	  artery	  NEC	  
19413	   7921100	   CHD	   Autograft	  replacement	  of	  two	  coronary	  arteries	  NEC	  
10209	   7921200	   CHD	   Autograft	  replacement	  of	  three	  coronary	  arteries	  NEC	  
42708	   7921300	   CHD	   Autograft	  replacement	  of	  four	  of	  more	  coronary	  arteries	  NEC	  
61310	   7921y00	   CHD	   Other	  autograft	  replacement	  of	  coronary	  artery	  OS	  
7609	   7921z00	   CHD	   Other	  autograft	  replacement	  of	  coronary	  artery	  NOS	  
31556	   7922.00	   CHD	   Allograft	  replacement	  of	  coronary	  artery	  
32651	   7922.11	   CHD	   Allograft	  bypass	  of	  coronary	  artery	  
70111	   7922000	   CHD	   Allograft	  replacement	  of	  one	  coronary	  artery	  
57241	   7922100	   CHD	   Allograft	  replacement	  of	  two	  coronary	  arteries	  
45886	   7922200	   CHD	   Allograft	  replacement	  of	  three	  coronary	  arteries	  
45370	   7922300	   CHD	   Allograft	  replacement	  of	  four	  or	  more	  coronary	  arteries	  
59423	   7922y00	   CHD	   Other	  specified	  allograft	  replacement	  of	  coronary	  artery	  
48767	   7922z00	   CHD	   Allograft	  replacement	  of	  coronary	  artery	  NOS	  
19402	   7923.00	   CHD	   Prosthetic	  replacement	  of	  coronary	  artery	  
36011	   7923.11	   CHD	   Prosthetic	  bypass	  of	  coronary	  artery	  
92419	   7923000	   CHD	   Prosthetic	  replacement	  of	  one	  coronary	  artery	  
66664	   7923100	   CHD	   Prosthetic	  replacement	  of	  two	  coronary	  arteries	  
66236	   7923200	   CHD	   Prosthetic	  replacement	  of	  three	  coronary	  arteries	  
67761	   7923300	   CHD	   Prosthetic	  replacement	  of	  four	  or	  more	  coronary	  arteries	  
19193	   7923z00	   CHD	   Prosthetic	  replacement	  of	  coronary	  artery	  NOS	  
33461	   7924.00	   CHD	   Revision	  of	  bypass	  for	  coronary	  artery	  
52938	   7924000	   CHD	   Revision	  of	  bypass	  for	  one	  coronary	  artery	  
67554	   7924100	   CHD	   Revision	  of	  bypass	  for	  two	  coronary	  arteries	  
31540	   7924200	   CHD	   Revision	  of	  bypass	  for	  three	  coronary	  arteries	  
101569	   7924300	   CHD	   Revision	  of	  bypass	  for	  four	  or	  more	  coronary	  arteries	  
63153	   7924500	   CHD	   Revision	  of	  implantation	  of	  thoracic	  artery	  into	  heart	  
97953	   7924y00	   CHD	   Other	  specified	  revision	  of	  bypass	  for	  coronary	  artery	  
57634	   7924z00	   CHD	   Revision	  of	  bypass	  for	  coronary	  artery	  NOS	  
37682	   7925.00	   CHD	   Connection	  of	  mammary	  artery	  to	  coronary	  artery	  
28837	   7925.11	   CHD	   Creation	  of	  bypass	  from	  mammary	  artery	  to	  coronary	  artery	  
33718	   7925000	   CHD	   Double	  anastomosis	  of	  mammary	  arteries	  to	  coronary	  arteries	  
48822	   7925011	   CHD	   LIMA	  sequential	  anastomosis	  
92233	   7925012	   CHD	   RIMA	  sequential	  anastomosis	  
31519	   7925100	   CHD	   Double	  implant	  of	  mammary	  arteries	  into	  coronary	  arteries	  
44723	   7925200	   CHD	   Single	  anast	  mammary	  art	  to	  left	  ant	  descend	  coronary	  art	  
51507	   7925300	   CHD	   Single	  anastomosis	  of	  mammary	  artery	  to	  coronary	  artery	  NEC	  
22647	   7925311	   CHD	   LIMA	  single	  anastomosis	  
68123	   7925312	   CHD	   RIMA	  single	  anastomosis	  
68139	   7925400	   CHD	   Single	  implantation	  of	  mammary	  artery	  into	  coronary	  artery	  
37719	   7925y00	   CHD	   Connection	  of	  mammary	  artery	  to	  coronary	  artery	  OS	  
56990	   7925z00	   CHD	   Connection	  of	  mammary	  artery	  to	  coronary	  artery	  NOS	  
96804	   7926.00	   CHD	   Connection	  of	  other	  thoracic	  artery	  to	  coronary	  artery	  
62608	   7926000	   CHD	   Double	  anastom	  thoracic	  arteries	  to	  coronary	  arteries	  NEC	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67591	   7926200	   CHD	   Single	  anastomosis	  of	  thoracic	  artery	  to	  coronary	  artery	  NEC	  
60753	   7926300	   CHD	   Single	  implantation	  thoracic	  artery	  into	  coronary	  artery	  NEC	  
72780	   7926z00	   CHD	   Connection	  of	  other	  thoracic	  artery	  to	  coronary	  artery	  NOS	  
47788	   7927.00	   CHD	   Other	  open	  operations	  on	  coronary	  artery	  
18903	   7927000	   CHD	   Repair	  of	  arteriovenous	  fistula	  of	  coronary	  artery	  
19164	   7927100	   CHD	   Repair	  of	  aneurysm	  of	  coronary	  artery	  
61592	   7927200	   CHD	   Transection	  of	  muscle	  bridge	  of	  coronary	  artery	  
48206	   7927300	   CHD	   Transposition	  of	  coronary	  artery	  NEC	  
51702	   7927400	   CHD	   Exploration	  of	  coronary	  artery	  
5744	   7927500	   CHD	   Open	  angioplasty	  of	  coronary	  artery	  
95382	   7927y00	   CHD	   Other	  specified	  other	  open	  operation	  on	  coronary	  artery	  
41757	   7927z00	   CHD	   Other	  open	  operation	  on	  coronary	  artery	  NOS	  
2901	   7928.00	   CHD	   Transluminal	  balloon	  angioplasty	  of	  coronary	  artery	  
5703	   7928.11	   CHD	   Percutaneous	  balloon	  coronary	  angioplasty	  
18670	   7928000	   CHD	   Percut	  transluminal	  balloon	  angioplasty	  one	  coronary	  artery	  
33735	   7928100	   CHD	   Percut	  translum	  balloon	  angioplasty	  mult	  coronary	  arteries	  
42462	   7928200	   CHD	   Percut	  translum	  balloon	  angioplasty	  bypass	  graft	  coronary	  a	  
86071	   7928300	   CHD	   Percut	  translum	  cutting	  balloon	  angioplasty	  coronary	  artery	  
41547	   7928y00	   CHD	   Transluminal	  balloon	  angioplasty	  of	  coronary	  artery	  OS	  
732	   7928z00	   CHD	   Transluminal	  balloon	  angioplasty	  of	  coronary	  artery	  NOS	  
24888	   7929.00	   CHD	   Other	  therapeutic	  transluminal	  operations	  on	  coronary	  artery	  
22828	   7929000	   CHD	   Percutaneous	  transluminal	  laser	  coronary	  angioplasty	  
33650	   7929100	   CHD	   Percut	  transluminal	  coronary	  thrombolysis	  with	  streptokinase	  
40996	   7929111	   CHD	   Percut	  translum	  coronary	  thrombolytic	  therapy-­‐	  streptokinase	  
66583	   7929200	   CHD	   Percut	  translum	  inject	  therap	  subst	  to	  coronary	  artery	  NEC	  
19046	   7929300	   CHD	   Rotary	  blade	  coronary	  angioplasty	  
8942	   7929400	   CHD	   Insertion	  of	  coronary	  artery	  stent	  
42304	   7929500	   CHD	   Insertion	  of	  drug-­‐eluting	  coronary	  artery	  stent	  
93618	   7929600	   CHD	   Percutaneous	  transluminal	  atherectomy	  of	  coronary	  artery	  
6182	   7929y00	   CHD	   Other	  therapeutic	  transluminal	  op	  on	  coronary	  artery	  OS	  
31679	   7929z00	   CHD	   Other	  therapeutic	  transluminal	  op	  on	  coronary	  artery	  NOS	  
34965	   792A.00	   CHD	   Diagnostic	  transluminal	  operations	  on	  coronary	  artery	  
19681	   792A000	   CHD	   Percutaneous	  transluminal	  angioscopy	  
43446	   792A100	   CHD	   Intravascular	  ultrasound	  of	  coronary	  artery	  
56905	   792Ay00	   CHD	   Diagnostic	  transluminal	  operation	  on	  coronary	  artery	  OS	  
61248	   792Az00	   CHD	   Diagnostic	  transluminal	  operation	  on	  coronary	  artery	  NOS	  
33620	   792B.00	   CHD	   Repair	  of	  coronary	  artery	  NEC	  
22020	   792B000	   CHD	   Endarterectomy	  of	  coronary	  artery	  NEC	  
94783	   792B100	   CHD	   Repair	  of	  rupture	  of	  coronary	  artery	  
93432	   792B200	   CHD	   Repair	  of	  arteriovenous	  malformation	  of	  coronary	  artery	  
69247	   792By00	   CHD	   Other	  specified	  repair	  of	  coronary	  artery	  
44585	   792Bz00	   CHD	   Repair	  of	  coronary	  artery	  NOS	  
55598	   792C.00	   CHD	   Other	  replacement	  of	  coronary	  artery	  
55092	   792C000	   CHD	   Replacement	  of	  coronary	  arteries	  using	  multiple	  methods	  
93828	   792Cy00	   CHD	   Other	  specified	  replacement	  of	  coronary	  artery	  
70755	   792Cz00	   CHD	   Replacement	  of	  coronary	  artery	  NOS	  
34963	   792D.00	   CHD	   Other	  bypass	  of	  coronary	  artery	  
3159	   792Dy00	   CHD	   Other	  specified	  other	  bypass	  of	  coronary	  artery	  
33471	   792Dz00	   CHD	   Other	  bypass	  of	  coronary	  artery	  NOS	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31571	   792y.00	   CHD	   Other	  specified	  operations	  on	  coronary	  artery	  
10603	   792z.00	   CHD	   Coronary	  artery	  operations	  NOS	  
45960	   8B27.00	   CHD	   Antianginal	  therapy	  
240	   G3...00	   CHD	   Ischaemic	  heart	  disease	  
24783	   G3...11	   CHD	   Arteriosclerotic	  heart	  disease	  
20416	   G3...12	   CHD	   Atherosclerotic	  heart	  disease	  
1792	   G3...13	   CHD	   IHD	  -­‐	  Ischaemic	  heart	  disease	  
241	   G30..00	   CHD	   Acute	  myocardial	  infarction	  
13566	   G30..11	   CHD	   Attack	  -­‐	  heart	  
2491	   G30..12	   CHD	   Coronary	  thrombosis	  
30421	   G30..13	   CHD	   Cardiac	  rupture	  following	  myocardial	  infarction	  (MI)	  
1204	   G30..14	   CHD	   Heart	  attack	  
1677	   G30..15	   CHD	   MI	  -­‐	  acute	  myocardial	  infarction	  
13571	   G30..16	   CHD	   Thrombosis	  -­‐	  coronary	  
17689	   G30..17	   CHD	   Silent	  myocardial	  infarction	  
12139	   G300.00	   CHD	   Acute	  anterolateral	  infarction	  
5387	   G301.00	   CHD	   Other	  specified	  anterior	  myocardial	  infarction	  
40429	   G301000	   CHD	   Acute	  anteroapical	  infarction	  
17872	   G301100	   CHD	   Acute	  anteroseptal	  infarction	  
14897	   G301z00	   CHD	   Anterior	  myocardial	  infarction	  NOS	  
8935	   G302.00	   CHD	   Acute	  inferolateral	  infarction	  
29643	   G303.00	   CHD	   Acute	  inferoposterior	  infarction	  
23892	   G304.00	   CHD	   Posterior	  myocardial	  infarction	  NOS	  
14898	   G305.00	   CHD	   Lateral	  myocardial	  infarction	  NOS	  
63467	   G306.00	   CHD	   True	  posterior	  myocardial	  infarction	  
3704	   G307.00	   CHD	   Acute	  subendocardial	  infarction	  
9507	   G307000	   CHD	   Acute	  non-­‐Q	  wave	  infarction	  
10562	   G307100	   CHD	   Acute	  non-­‐ST	  segment	  elevation	  myocardial	  infarction	  
1678	   G308.00	   CHD	   Inferior	  myocardial	  infarction	  NOS	  
30330	   G309.00	   CHD	   Acute	  Q-­‐wave	  infarct	  
17133	   G30A.00	   CHD	   Mural	  thrombosis	  
32854	   G30B.00	   CHD	   Acute	  posterolateral	  myocardial	  infarction	  
29758	   G30X.00	   CHD	   Acute	  transmural	  myocardial	  infarction	  of	  unspecif	  site	  
12229	   G30X000	   CHD	   Acute	  ST	  segment	  elevation	  myocardial	  infarction	  
34803	   G30y.00	   CHD	   Other	  acute	  myocardial	  infarction	  
28736	   G30y000	   CHD	   Acute	  atrial	  infarction	  
62626	   G30y100	   CHD	   Acute	  papillary	  muscle	  infarction	  
41221	   G30y200	   CHD	   Acute	  septal	  infarction	  
46017	   G30yz00	   CHD	   Other	  acute	  myocardial	  infarction	  NOS	  
14658	   G30z.00	   CHD	   Acute	  myocardial	  infarction	  NOS	  
27951	   G31..00	   CHD	   Other	  acute	  and	  subacute	  ischaemic	  heart	  disease	  
23579	   G310.00	   CHD	   Postmyocardial	  infarction	  syndrome	  
15661	   G310.11	   CHD	   Dressler's	  syndrome	  
36523	   G311.00	   CHD	   Preinfarction	  syndrome	  
4656	   G311.11	   CHD	   Crescendo	  angina	  
39655	   G311.12	   CHD	   Impending	  infarction	  
1431	   G311.13	   CHD	   Unstable	  angina	  
19655	   G311.14	   CHD	   Angina	  at	  rest	  
61072	   G311000	   CHD	   Myocardial	  infarction	  aborted	  
8.5 Conclusions 285
   
bannisterca@cardiff.ac.uk  19 
 
55137	   G311011	   CHD	   MI	  -­‐	  myocardial	  infarction	  aborted	  
7347	   G311100	   CHD	   Unstable	  angina	  
17307	   G311200	   CHD	   Angina	  at	  rest	  
34328	   G311300	   CHD	   Refractory	  angina	  
18118	   G311400	   CHD	   Worsening	  angina	  
11983	   G311500	   CHD	   Acute	  coronary	  syndrome	  
54251	   G311z00	   CHD	   Preinfarction	  syndrome	  NOS	  
39449	   G312.00	   CHD	   Coronary	  thrombosis	  not	  resulting	  in	  myocardial	  infarction	  
9413	   G31y.00	   CHD	   Other	  acute	  and	  subacute	  ischaemic	  heart	  disease	  
9276	   G31y000	   CHD	   Acute	  coronary	  insufficiency	  
68357	   G31y100	   CHD	   Microinfarction	  of	  heart	  
39693	   G31y200	   CHD	   Subendocardial	  ischaemia	  
21844	   G31y300	   CHD	   Transient	  myocardial	  ischaemia	  
27977	   G31yz00	   CHD	   Other	  acute	  and	  subacute	  ischaemic	  heart	  disease	  NOS	  
4017	   G32..00	   CHD	   Old	  myocardial	  infarction	  
16408	   G32..11	   CHD	   Healed	  myocardial	  infarction	  
17464	   G32..12	   CHD	   Personal	  history	  of	  myocardial	  infarction	  
1430	   G33..00	   CHD	   Angina	  pectoris	  
20095	   G330.00	   CHD	   Angina	  decubitus	  
18125	   G330000	   CHD	   Nocturnal	  angina	  
29902	   G330z00	   CHD	   Angina	  decubitus	  NOS	  
12986	   G331.00	   CHD	   Prinzmetal's	  angina	  
11048	   G331.11	   CHD	   Variant	  angina	  pectoris	  
36854	   G332.00	   CHD	   Coronary	  artery	  spasm	  
25842	   G33z.00	   CHD	   Angina	  pectoris	  NOS	  
66388	   G33z000	   CHD	   Status	  anginosus	  
54535	   G33z100	   CHD	   Stenocardia	  
7696	   G33z200	   CHD	   Syncope	  anginosa	  
1414	   G33z300	   CHD	   Angina	  on	  effort	  
32450	   G33z400	   CHD	   Ischaemic	  chest	  pain	  
9555	   G33z500	   CHD	   Post	  infarct	  angina	  
26863	   G33z600	   CHD	   New	  onset	  angina	  
12804	   G33z700	   CHD	   Stable	  angina	  
28554	   G33zz00	   CHD	   Angina	  pectoris	  NOS	  
28138	   G34..00	   CHD	   Other	  chronic	  ischaemic	  heart	  disease	  
5413	   G340.00	   CHD	   Coronary	  atherosclerosis	  
1655	   G340.11	   CHD	   Triple	  vessel	  disease	  of	  the	  heart	  
1344	   G340.12	   CHD	   Coronary	  artery	  disease	  
3999	   G340000	   CHD	   Single	  coronary	  vessel	  disease	  
5254	   G340100	   CHD	   Double	  coronary	  vessel	  disease	  
6331	   G341.00	   CHD	   Aneurysm	  of	  heart	  
27484	   G341.11	   CHD	   Cardiac	  aneurysm	  
2155	   G341000	   CHD	   Ventricular	  cardiac	  aneurysm	  
67087	   G341100	   CHD	   Other	  cardiac	  wall	  aneurysm	  
59193	   G341200	   CHD	   Aneurysm	  of	  coronary	  vessels	  
91774	   G341300	   CHD	   Acquired	  atrioventricular	  fistula	  of	  heart	  
41677	   G341z00	   CHD	   Aneurysm	  of	  heart	  NOS	  
36609	   G342.00	   CHD	   Atherosclerotic	  cardiovascular	  disease	  
7320	   G343.00	   CHD	   Ischaemic	  cardiomyopathy	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29421	   G344.00	   CHD	   Silent	  myocardial	  ischaemia	  
34633	   G34y.00	   CHD	   Other	  specified	  chronic	  ischaemic	  heart	  disease	  
24540	   G34y000	   CHD	   Chronic	  coronary	  insufficiency	  
23078	   G34y100	   CHD	   Chronic	  myocardial	  ischaemia	  
35713	   G34yz00	   CHD	   Other	  specified	  chronic	  ischaemic	  heart	  disease	  NOS	  
15754	   G34z.00	   CHD	   Other	  chronic	  ischaemic	  heart	  disease	  NOS	  
18889	   G34z000	   CHD	   Asymptomatic	  coronary	  heart	  disease	  
18842	   G35..00	   CHD	   Subsequent	  myocardial	  infarction	  
45809	   G350.00	   CHD	   Subsequent	  myocardial	  infarction	  of	  anterior	  wall	  
38609	   G351.00	   CHD	   Subsequent	  myocardial	  infarction	  of	  inferior	  wall	  
72562	   G353.00	   CHD	   Subsequent	  myocardial	  infarction	  of	  other	  sites	  
46166	   G35X.00	   CHD	   Subsequent	  myocardial	  infarction	  of	  unspecified	  site	  
36423	   G36..00	   CHD	   Certain	  current	  complication	  follow	  acute	  myocardial	  infarct	  
24126	   G360.00	   CHD	   Haemopericardium/current	  comp	  folow	  acut	  myocard	  infarct	  
23708	   G361.00	   CHD	   Atrial	  septal	  defect/curr	  comp	  folow	  acut	  myocardal	  infarct	  
37657	   G362.00	   CHD	   Ventric	  septal	  defect/curr	  comp	  fol	  acut	  myocardal	  infarctn	  
59189	   G363.00	   CHD	   Ruptur	  cardiac	  wall	  w'out	  haemopericard/cur	  comp	  fol	  ac	  MI	  
59940	   G364.00	   CHD	   Ruptur	  chordae	  tendinae/curr	  comp	  fol	  acute	  myocard	  infarct	  
69474	   G365.00	   CHD	   Rupture	  papillary	  muscle/curr	  comp	  fol	  acute	  myocard	  infarct	  
29553	   G366.00	   CHD	   Thrombosis	  atrium,auric	  append&vent/curr	  comp	  foll	  acute	  MI	  
8568	   G37..00	   CHD	   Cardiac	  syndrome	  X	  
32272	   G38..00	   CHD	   Postoperative	  myocardial	  infarction	  
46112	   G380.00	   CHD	   Postoperative	  transmural	  myocardial	  infarction	  anterior	  wall	  
46276	   G381.00	   CHD	   Postoperative	  transmural	  myocardial	  infarction	  inferior	  wall	  
41835	   G384.00	   CHD	   Postoperative	  subendocardial	  myocardial	  infarction	  
68748	   G38z.00	   CHD	   Postoperative	  myocardial	  infarction,	  unspecified	  
22383	   G3y..00	   CHD	   Other	  specified	  ischaemic	  heart	  disease	  
1676	   G3z..00	   CHD	   Ischaemic	  heart	  disease	  NOS	  
35119	   G501.00	   CHD	   Post	  infarction	  pericarditis	  
39546	   Gyu3000	   CHD	   [X]Other	  forms	  of	  angina	  pectoris	  
68401	   Gyu3200	   CHD	   [X]Other	  forms	  of	  acute	  ischaemic	  heart	  disease	  
47637	   Gyu3300	   CHD	   [X]Other	  forms	  of	  chronic	  ischaemic	  heart	  disease	  
96838	   Gyu3400	   CHD	   [X]Acute	  transmural	  myocardial	  infarction	  of	  unspecif	  site	  
99991	   Gyu3600	   CHD	   [X]Subsequent	  myocardial	  infarction	  of	  unspecified	  site	  
code	   type	   endpoint	   description	  
430	   ICD9	   stroke	   Subarachnoid	  hemorrhage	  
431	   ICD9	   stroke	   Intracerebral	  hemorrhage	  
432	   ICD9	   stroke	   Other	  and	  unspecified	  intracranial	  hemorrhage	  
432.9	   ICD9	   stroke	   Hemorrhage,	  intracranial,	  NOS	  
433	   ICD9	   stroke	   Occlusion	  and	  stenosis	  of	  precerebral	  arteries	  
433.0	   ICD9	   stroke	   Occlusion	  and	  stenosis	  of	  basilar	  artery	  
433.1	   ICD9	   stroke	   Occlusion	  and	  stenosis	  of	  carotid	  artery	  
433.2	   ICD9	   stroke	   Occlusion	  and	  stenosis	  of	  vertebral	  artery	  
434	   ICD9	   stroke	   Occlusion	  of	  cerebral	  arteries	  
434.0	   ICD9	   stroke	   Cerebral	  thrombosis	  
434.00	   ICD9	   stroke	   Cerebral	  thrombosis	  without	  cerebral	  infarction	  
434.01	   ICD9	   stroke	   Cerebral	  thrombosis	  with	  cerebral	  infarction	  
434.1	   ICD9	   stroke	   Cerebral	  embolism	  
434.10	   ICD9	   stroke	   Cerebral	  embolism	  without	  cerebral	  infarction	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434.11	   ICD9	   stroke	   Cerebral	  embolism	  with	  cerebral	  infarction	  
434.9	   ICD9	   stroke	   Cerebral	  artery	  occlusion,	  unspecified	  
435	   ICD9	   stroke	   Transient	  cerebral	  ischemia	  
435.0	   ICD9	   stroke	   Basilar	  artery	  syndrome	  
435.1	   ICD9	   stroke	   Vertebral	  artery	  syndrome	  
435.2	   ICD9	   stroke	   Subclavian	  steal	  syndrome	  
435.3	   ICD9	   stroke	   Vertebrobasilar	  artery	  syndrome	  
435.9	   ICD9	   stroke	   Transient	  ischemic	  attack,	  unspec.	  
436	   ICD9	   stroke	   Acute	  but	  ill-­‐defined	  cerebrovascular	  disease	  
437	   ICD9	   stroke	   Other	  and	  ill-­‐defined	  cerebrovascular	  disease	  
437.0	   ICD9	   stroke	   Cerebral	  atherosclerosis	  
437.1	   ICD9	   stroke	   Other	  generalized	  ischemic	  cerebrovascular	  disease	  
437.2	   ICD9	   stroke	   Hypertensive	  encephalopathy	  
437.3	   ICD9	   stroke	   Cerebral	  aneurysm	  nonruptured	  
437.4	   ICD9	   stroke	   Cerebral	  arteritis	  
437.5	   ICD9	   stroke	   Moyamoya	  disease	  
437.6	   ICD9	   stroke	   Nonpyogenic	  thrombosis	  of	  intracranial	  venous	  sinus	  
437.7	   ICD9	   stroke	   Transient	  global	  amnesia	  
438	   ICD9	   stroke	   Late	  effects	  of	  cerebrovascular	  disease	  
438.0	   ICD9	   stroke	   Cognitive	  deficits	  
438.1	   ICD9	   stroke	   Speech	  and	  language	  deficits	  
438.10	   ICD9	   stroke	   Speech	  and	  language	  deficits,	  unspecified	  
438.11	   ICD9	   stroke	   Aphasia	  
438.12	   ICD9	   stroke	   Dysphasia	  
438.19	   ICD9	   stroke	   Other	  speech	  and	  language	  deficits	  
438.2	   ICD9	   stroke	   Hemiplegia/hemiparesis	  
438.20	   ICD9	   stroke	   Hemiplegia	  affecting	  unspecified	  side	  
438.21	   ICD9	   stroke	   Hemiplegia	  affecting	  dominant	  side	  
438.22	   ICD9	   stroke	   Hemiplegia	  affecting	  nondominant	  side	  
438.3	   ICD9	   stroke	   Monoplegia	  of	  upper	  limb	  
438.4	   ICD9	   stroke	   Monoplegia	  of	  lower	  limb	  
438.5	   ICD9	   stroke	   Other	  paralytic	  syndrome	  
438.8	   ICD9	   stroke	   Other	  late	  effects	  of	  cerebrovascular	  disease	  
438.81	   ICD9	   stroke	   Apraxia	  cerebrovascular	  disease	  
438.82	   ICD9	   stroke	   Dysphagia	  cerebrovascular	  disease	  
438.83	   ICD9	   stroke	   Facial	  weakness	  
438.84	   ICD9	   stroke	   Ataxia	  
438.85	   ICD9	   stroke	   Vertigo	  
438.9	   ICD9	   stroke	   CVA,	  late	  effect,	  unspec.	  
G45	   ICD10	   stroke	   Transient	  cerebral	  ischaemic	  attacks	  and	  related	  syndromes	  	  	  
G45.0	   ICD10	   stroke	   Vertebro-­‐basilar	  artery	  syndrome	  	  	  
G45.1	   ICD10	   stroke	   Carotid	  artery	  syndrome	  (hemispheric)	  	  	  
G45.2	   ICD10	   stroke	   Multiple	  and	  bilateral	  precerebral	  artery	  syndromes	  	  	  
G45.4	   ICD10	   stroke	   Transient	  global	  amnesia	  	  	  
G45.8	   ICD10	   stroke	   Other	  transient	  cerebral	  ischaemic	  attacks	  and	  related	  syndromes	  	  	  
G45.9	   ICD10	   stroke	   Transient	  cerebral	  ischaemic	  attack,	  unspecified	  	  	  
I60	   ICD10	   stroke	   Subarachnoid	  haemorrhage	  
I60.0	   ICD10	   stroke	   Subarachnoid	  haemorrhage	  from	  carotid	  siphon	  and	  bifurcation	  
I60.1	   ICD10	   stroke	   Subarachnoid	  haemorrhage	  from	  middle	  cerebral	  artery	  
288 8.5 Conclusions
   
bannisterca@cardiff.ac.uk  22 
 
I60.2	   ICD10	   stroke	   Subarachnoid	  haemorrhage	  from	  anterior	  communicating	  artery	  
I60.3	   ICD10	   stroke	   Subarachnoid	  haemorrhage	  from	  posterior	  communicating	  artery	  
I60.4	   ICD10	   stroke	   Subarachnoid	  haemorrhage	  from	  basilar	  artery	  
I60.5	   ICD10	   stroke	   Subarachnoid	  haemorrhage	  from	  vertebral	  artery	  
I60.6	   ICD10	   stroke	   Subarachnoid	  haemorrhage	  from	  other	  intracranial	  arteries	  
I60.7	   ICD10	   stroke	   Subarachnoid	  haemorrhage	  from	  intracranial	  artery,	  unspecified	  
I60.8	   ICD10	   stroke	   Other	  subarachnoid	  haemorrhage	  
I60.9	   ICD10	   stroke	   Subarachnoid	  haemorrhage,	  unspecified	  
I61	   ICD10	   stroke	   Intracerebral	  haemorrhage	  
I61.0	   ICD10	   stroke	   Intracerebral	  haemorrhage	  in	  hemisphere,	  subcortical	  
I61.1	   ICD10	   stroke	   Intracerebral	  haemorrhage	  in	  hemisphere,	  cortical	  
I61.2	   ICD10	   stroke	   Intracerebral	  haemorrhage	  in	  hemisphere,	  unspecified	  
I61.3	   ICD10	   stroke	   Intracerebral	  haemorrhage	  in	  brain	  stem	  
I61.4	   ICD10	   stroke	   Intracerebral	  haemorrhage	  in	  cerebellum	  
I61.5	   ICD10	   stroke	   Intracerebral	  haemorrhage,	  intraventricular	  
I61.6	   ICD10	   stroke	   Intracerebral	  haemorrhage,	  multiple	  localized	  
I61.8	   ICD10	   stroke	   Other	  intracerebral	  haemorrhage	  
I61.9	   ICD10	   stroke	   Intracerebral	  haemorrhage,	  unspecified	  
I62	   ICD10	   stroke	   Other	  nontraumatic	  intracranial	  haemorrhage	  
I62.0	   ICD10	   stroke	   Subdural	  haemorrhage	  (acute)(nontraumatic)	  
I62.1	   ICD10	   stroke	   Nontraumatic	  extradural	  haemorrhage	  
I62.9	   ICD10	   stroke	   Intracranial	  haemorrhage	  (nontraumatic),	  unspecified	  
I63	   ICD10	   stroke	   Cerebral	  infarction	  
I63.0	   ICD10	   stroke	   Cerebral	  infarction	  due	  to	  thrombosis	  of	  precerebral	  arteries	  
I63.1	   ICD10	   stroke	   Cerebral	  infarction	  due	  to	  embolism	  of	  precerebral	  arteries	  
I63.2	   ICD10	   stroke	  
Cerebral	  infarction	  due	  to	  unspecified	  occlusion	  or	  stenosis	  of	  precerebral	  
arteries	  
I63.3	   ICD10	   stroke	   Cerebral	  infarction	  due	  to	  thrombosis	  of	  cerebral	  arteries	  
I63.4	   ICD10	   stroke	   Cerebral	  infarction	  due	  to	  embolism	  of	  cerebral	  arteries	  
I63.5	   ICD10	   stroke	  
Cerebral	  infarction	  due	  to	  unspecified	  occlusion	  or	  stenosis	  of	  cerebral	  
arteries	  
I63.6	   ICD10	   stroke	   Cerebral	  infarction	  due	  to	  cerebral	  venous	  thrombosis,	  nonpyogenic	  
I63.8	   ICD10	   stroke	   Other	  cerebral	  infarction	  
I63.9	   ICD10	   stroke	   Cerebral	  infarction,	  unspecified	  
I64	   ICD10	   stroke	   Stroke,	  not	  specified	  as	  haemorrhage	  or	  infarction	  
I65	   ICD10	   stroke	  
Occlusion	  and	  stenosis	  of	  precerebral	  arteries,	  not	  resulting	  in	  cerebral	  
infarction	  
I65.0	   ICD10	   stroke	   Occlusion	  and	  stenosis	  of	  vertebral	  artery	  
I65.1	   ICD10	   stroke	   Occlusion	  and	  stenosis	  of	  basilar	  artery	  
I65.2	   ICD10	   stroke	   Occlusion	  and	  stenosis	  of	  carotid	  artery	  
I65.3	   ICD10	   stroke	   Occlusion	  and	  stenosis	  of	  multiple	  and	  bilateral	  precerebral	  arteries	  
I65.8	   ICD10	   stroke	   Occlusion	  and	  stenosis	  of	  other	  precerebral	  artery	  
I65.9	   ICD10	   stroke	   Occlusion	  and	  stenosis	  of	  unspecified	  precerebral	  artery	  
I66	   ICD10	   stroke	  
Occlusion	  and	  stenosis	  of	  cerebral	  arteries,	  not	  resulting	  in	  cerebral	  
infarction	  
I66.0	   ICD10	   stroke	   Occlusion	  and	  stenosis	  of	  middle	  cerebral	  artery	  
I66.1	   ICD10	   stroke	   Occlusion	  and	  stenosis	  of	  anterior	  cerebral	  artery	  
I66.2	   ICD10	   stroke	   Occlusion	  and	  stenosis	  of	  posterior	  cerebral	  artery	  
I66.3	   ICD10	   stroke	   Occlusion	  and	  stenosis	  of	  cerebellar	  arteries	  
I66.4	   ICD10	   stroke	   Occlusion	  and	  stenosis	  of	  multiple	  and	  bilateral	  cerebral	  arteries	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I66.8	   ICD10	   stroke	   Occlusion	  and	  stenosis	  of	  other	  cerebral	  artery	  
I66.9	   ICD10	   stroke	   Occlusion	  and	  stenosis	  of	  unspecified	  cerebral	  artery	  
I67.1	   ICD10	   stroke	   Cerebral	  aneurysm,	  nonruptured	  
I67.2	   ICD10	   stroke	   Cerebral	  atherosclerosis	  
I67.4	   ICD10	   stroke	   Hypertensive	  encephalopathy	  
I67.5	   ICD10	   stroke	   Moyamoya	  disease	  
I67.6	   ICD10	   stroke	   Nonpyogenic	  thrombosis	  of	  intracranial	  venous	  system	  
I67.7	   ICD10	   stroke	   Cerebral	  arteritis,	  not	  elsewhere	  classified	  
I67.8	   ICD10	   stroke	   Other	  specified	  cerebrovascular	  diseases	  
I67.9	   ICD10	   stroke	   Cerebrovascular	  disease,	  unspecified	  
I68.0	   ICD10	   stroke	   Cerebral	  amyloid	  angiopathy	  
I68.2	   ICD10	   stroke	   Cerebral	  arteritis	  in	  other	  diseases	  classified	  elsewhere	  
I68.8	   ICD10	   stroke	   Other	  cerebrovascular	  disorders	  in	  diseases	  classified	  elsewhere	  
I69	   ICD10	   stroke	   Sequelae	  of	  cerebrovascular	  disease	  
I69.0	   ICD10	   stroke	   Sequelae	  of	  subarachnoid	  haemorrhage	  
I69.1	   ICD10	   stroke	   Sequelae	  of	  intracerebral	  haemorrhage	  
I69.2	   ICD10	   stroke	   Sequelae	  of	  other	  nontraumatic	  intracranial	  haemorrhage	  
I69.3	   ICD10	   stroke	   Sequelae	  of	  cerebral	  infarction	  
I69.4	   ICD10	   stroke	   Sequelae	  of	  stroke,	  not	  specified	  as	  haemorrhage	  or	  infarction	  
I69.8	   ICD10	   stroke	   Sequelae	  of	  other	  and	  unspecified	  cerebrovascular	  diseases	  
medcode	   readcode	   endpoint	   description	  
34135	   14A7.00	   stroke	   H/O:	  CVA/stroke	  
6305	   14A7.11	   stroke	   H/O:	  CVA	  
5871	   14A7.12	   stroke	   H/O:	  stroke	  
13567	   14AB.00	   stroke	   H/O:	  TIA	  
16554	   14AF.00	   stroke	   H/O	  sub-­‐arachnoid	  haemorrhage	  
66873	   14AK.00	   stroke	   H/O:	  Stroke	  in	  last	  year	  
100639	   1M4..00	   stroke	   Central	  post-­‐stroke	  pain	  
18686	   662e.00	   stroke	   Stroke/CVA	  annual	  review	  
10792	   662M.00	   stroke	   Stroke	  monitoring	  
28914	   662o.00	   stroke	   Haemorrhagic	  stroke	  monitoring	  
35916	   7A20300	   stroke	   Endarterectomy	  and	  patch	  repair	  of	  carotid	  artery	  
12733	   7A20311	   stroke	   Carotid	  endarterectomy	  and	  patch	  
2654	   7A20400	   stroke	   Endarterectomy	  of	  carotid	  artery	  NEC	  
25910	   7A22.00	   stroke	   Transluminal	  operations	  on	  carotid	  artery	  
29973	   7A22000	   stroke	   Percutaneous	  transluminal	  angioplasty	  of	  carotid	  artery	  
2659	   7A22100	   stroke	   Arteriography	  of	  carotid	  artery	  
68069	   7A22200	   stroke	   Endovascular	  repair	  of	  carotid	  artery	  
47580	   7A22300	   stroke	   Percutaneous	  transluminal	  insertion	  stent	  carotid	  artery	  
62661	   7A22y00	   stroke	   Other	  specified	  transluminal	  operation	  on	  carotid	  artery	  
41703	   7A22z00	   stroke	   Transluminal	  operation	  on	  carotid	  artery	  NOS	  
53999	   7A23.00	   stroke	   Cerebral	  artery	  and	  circle	  of	  Willis	  aneurysm	  operations	  
5365	   7A23.11	   stroke	   Cerebral	  artery	  aneurysm	  operations	  
50929	   7A23.12	   stroke	   Circle	  of	  Willis	  aneurysm	  operations	  
45897	   7A23000	   stroke	   Excision	  of	  aneurysm	  of	  cerebral	  artery	  
71034	   7A23100	   stroke	   Excision	  of	  aneurysm	  of	  circle	  of	  Willis	  
10625	   7A23200	   stroke	   Clipping	  of	  aneurysm	  of	  cerebral	  artery	  
45450	   7A23300	   stroke	   Clipping	  of	  aneurysm	  of	  circle	  of	  Willis	  
37823	   7A23400	   stroke	   Ligation	  of	  aneurysm	  of	  cerebral	  artery	  NEC	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97937	   7A23500	   stroke	   Ligation	  of	  aneurysm	  of	  circle	  of	  Willis	  NEC	  
58757	   7A23600	   stroke	   Obliteration	  of	  aneurysm	  of	  cerebral	  artery	  NEC	  
94491	   7A23700	   stroke	   Obliteration	  of	  aneurysm	  of	  circle	  of	  Willis	  NEC	  
30415	   7A23800	   stroke	   Percutaneous	  coil	  embolisation	  of	  cerebral	  artery	  aneurysm	  
63903	   7A23y00	   stroke	   Operation	  on	  cerebral	  artery/	  circle	  of	  Willis	  aneurysm	  OS	  
50260	   7A23z00	   stroke	   Operation	  on	  cerebral	  artery/	  circle	  of	  Willis	  aneurysm	  NOS	  
55351	   7P24200	   stroke	   Delivery	  of	  rehabilitation	  for	  stroke	  
13707	   8HBJ.00	   stroke	   Stroke	  /	  transient	  ischaemic	  attack	  referral	  
56458	   8HHM.00	   stroke	   Ref	  to	  multidisciplinary	  stroke	  function	  improvement	  service	  
18804	   8HTQ.00	   stroke	   Referral	  to	  stroke	  clinic	  
32959	   9N0p.00	   stroke	   Seen	  in	  stroke	  clinic	  
18687	   9N4X.00	   stroke	   DNA	  -­‐	  Did	  not	  attend	  stroke	  clinic	  
31218	   9Om..00	   stroke	   Stroke/transient	  ischaemic	  attack	  monitoring	  administration	  
28753	   9Om0.00	   stroke	   Stroke/transient	  ischaemic	  attack	  monitoring	  first	  letter	  
34245	   9Om1.00	   stroke	   Stroke/transient	  ischaemic	  attack	  monitoring	  second	  letter	  
34375	   9Om2.00	   stroke	   Stroke/transient	  ischaemic	  attack	  monitoring	  third	  letter	  
51465	   9Om3.00	   stroke	   Stroke/transient	  ischaemic	  attack	  monitoring	  verbal	  invitati	  
89913	   9Om4.00	   stroke	   Stroke/transient	  ischaemic	  attack	  monitoring	  telephone	  invte	  
54744	   F11x200	   stroke	   Cerebral	  degeneration	  due	  to	  cerebrovascular	  disease	  
2418	   G6...00	   stroke	   Cerebrovascular	  disease	  
1786	   G60..00	   stroke	   Subarachnoid	  haemorrhage	  
29939	   G600.00	   stroke	   Ruptured	  berry	  aneurysm	  
56007	   G601.00	   stroke	   Subarachnoid	  haemorrhage	  from	  carotid	  siphon	  and	  bifurcation	  
19412	   G602.00	   stroke	   Subarachnoid	  haemorrhage	  from	  middle	  cerebral	  artery	  
42331	   G603.00	   stroke	   Subarachnoid	  haemorrhage	  from	  anterior	  communicating	  artery	  
9696	   G604.00	   stroke	   Subarachnoid	  haemorrhage	  from	  posterior	  communicating	  artery	  
41910	   G605.00	   stroke	   Subarachnoid	  haemorrhage	  from	  basilar	  artery	  
60692	   G606.00	   stroke	   Subarachnoid	  haemorrhage	  from	  vertebral	  artery	  
17326	   G60X.00	   stroke	   Subarachnoid	  haemorrh	  from	  intracranial	  artery,	  unspecif	  
23580	   G60z.00	   stroke	   Subarachnoid	  haemorrhage	  NOS	  
5051	   G61..00	   stroke	   Intracerebral	  haemorrhage	  
6960	   G61..11	   stroke	   CVA	  -­‐	  cerebrovascular	  accid	  due	  to	  intracerebral	  haemorrhage	  
18604	   G61..12	   stroke	   Stroke	  due	  to	  intracerebral	  haemorrhage	  
31595	   G610.00	   stroke	   Cortical	  haemorrhage	  
40338	   G611.00	   stroke	   Internal	  capsule	  haemorrhage	  
46316	   G612.00	   stroke	   Basal	  nucleus	  haemorrhage	  
13564	   G613.00	   stroke	   Cerebellar	  haemorrhage	  
7912	   G614.00	   stroke	   Pontine	  haemorrhage	  
62342	   G615.00	   stroke	   Bulbar	  haemorrhage	  
30045	   G616.00	   stroke	   External	  capsule	  haemorrhage	  
30202	   G617.00	   stroke	   Intracerebral	  haemorrhage,	  intraventricular	  
57315	   G618.00	   stroke	   Intracerebral	  haemorrhage,	  multiple	  localized	  
31060	   G61X.00	   stroke	   Intracerebral	  haemorrhage	  in	  hemisphere,	  unspecified	  
28314	   G61X000	   stroke	   Left	  sided	  intracerebral	  haemorrhage,	  unspecified	  
19201	   G61X100	   stroke	   Right	  sided	  intracerebral	  haemorrhage,	  unspecified	  
3535	   G61z.00	   stroke	   Intracerebral	  haemorrhage	  NOS	  
31805	   G62..00	   stroke	   Other	  and	  unspecified	  intracranial	  haemorrhage	  
36178	   G620.00	   stroke	   Extradural	  haemorrhage	  -­‐	  nontraumatic	  
4273	   G621.00	   stroke	   Subdural	  haemorrhage	  -­‐	  nontraumatic	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17734	   G622.00	   stroke	   Subdural	  haematoma	  -­‐	  nontraumatic	  
18912	   G623.00	   stroke	   Subdural	  haemorrhage	  NOS	  
20284	   G62z.00	   stroke	   Intracranial	  haemorrhage	  NOS	  
45781	   G63..00	   stroke	   Precerebral	  arterial	  occlusion	  
57495	   G63..11	   stroke	   Infarction	  -­‐	  precerebral	  
63830	   G63..12	   stroke	   Stenosis	  of	  precerebral	  arteries	  
32447	   G630.00	   stroke	   Basilar	  artery	  occlusion	  
4240	   G631.00	   stroke	   Carotid	  artery	  occlusion	  
2156	   G631.11	   stroke	   Stenosis,	  carotid	  artery	  
4152	   G631.12	   stroke	   Thrombosis,	  carotid	  artery	  
40847	   G632.00	   stroke	   Vertebral	  artery	  occlusion	  
98642	   G633.00	   stroke	   Multiple	  and	  bilateral	  precerebral	  arterial	  occlusion	  
2652	   G634.00	   stroke	   Carotid	  artery	  stenosis	  
51326	   G63y.00	   stroke	   Other	  precerebral	  artery	  occlusion	  
23671	   G63y000	   stroke	   Cerebral	  infarct	  due	  to	  thrombosis	  of	  precerebral	  arteries	  
24446	   G63y100	   stroke	   Cerebral	  infarction	  due	  to	  embolism	  of	  precerebral	  arteries	  
71585	   G63z.00	   stroke	   Precerebral	  artery	  occlusion	  NOS	  
8837	   G64..00	   stroke	   Cerebral	  arterial	  occlusion	  
5363	   G64..11	   stroke	   CVA	  -­‐	  cerebral	  artery	  occlusion	  
569	   G64..12	   stroke	   Infarction	  -­‐	  cerebral	  
6155	   G64..13	   stroke	   Stroke	  due	  to	  cerebral	  arterial	  occlusion	  
16517	   G640.00	   stroke	   Cerebral	  thrombosis	  
36717	   G640000	   stroke	   Cerebral	  infarction	  due	  to	  thrombosis	  of	  cerebral	  arteries	  
15019	   G641.00	   stroke	   Cerebral	  embolism	  
34758	   G641.11	   stroke	   Cerebral	  embolus	  
27975	   G641000	   stroke	   Cerebral	  infarction	  due	  to	  embolism	  of	  cerebral	  arteries	  
3149	   G64z.00	   stroke	   Cerebral	  infarction	  NOS	  
15252	   G64z.11	   stroke	   Brainstem	  infarction	  NOS	  
5602	   G64z.12	   stroke	   Cerebellar	  infarction	  
25615	   G64z000	   stroke	   Brainstem	  infarction	  
47642	   G64z100	   stroke	   Wallenberg	  syndrome	  
5185	   G64z111	   stroke	   Lateral	  medullary	  syndrome	  
9985	   G64z200	   stroke	   Left	  sided	  cerebral	  infarction	  
10504	   G64z300	   stroke	   Right	  sided	  cerebral	  infarction	  
26424	   G64z400	   stroke	   Infarction	  of	  basal	  ganglia	  
504	   G65..00	   stroke	   Transient	  cerebral	  ischaemia	  
3132	   G65..11	   stroke	   Drop	  attack	  
1433	   G65..12	   stroke	   Transient	  ischaemic	  attack	  
2417	   G65..13	   stroke	   Vertebro-­‐basilar	  insufficiency	  
23942	   G650.00	   stroke	   Basilar	  artery	  syndrome	  
5268	   G650.11	   stroke	   Insufficiency	  -­‐	  basilar	  artery	  
33377	   G651.00	   stroke	   Vertebral	  artery	  syndrome	  
21118	   G651000	   stroke	   Vertebro-­‐basilar	  artery	  syndrome	  
23465	   G652.00	   stroke	   Subclavian	  steal	  syndrome	  
44765	   G653.00	   stroke	   Carotid	  artery	  syndrome	  hemispheric	  
50594	   G654.00	   stroke	   Multiple	  and	  bilateral	  precerebral	  artery	  syndromes	  
6489	   G655.00	   stroke	   Transient	  global	  amnesia	  
10794	   G656.00	   stroke	   Vertebrobasilar	  insufficiency	  
19354	   G65y.00	   stroke	   Other	  transient	  cerebral	  ischaemia	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1895	   G65z.00	   stroke	   Transient	  cerebral	  ischaemia	  NOS	  
55247	   G65z000	   stroke	   Impending	  cerebral	  ischaemia	  
16507	   G65z100	   stroke	   Intermittent	  cerebral	  ischaemia	  
15788	   G65zz00	   stroke	   Transient	  cerebral	  ischaemia	  NOS	  
1469	   G66..00	   stroke	   Stroke	  and	  cerebrovascular	  accident	  unspecified	  
1298	   G66..11	   stroke	   CVA	  unspecified	  
6253	   G66..12	   stroke	   Stroke	  unspecified	  
6116	   G66..13	   stroke	   CVA	  -­‐	  Cerebrovascular	  accident	  unspecified	  
18689	   G660.00	   stroke	   Middle	  cerebral	  artery	  syndrome	  
19280	   G661.00	   stroke	   Anterior	  cerebral	  artery	  syndrome	  
19260	   G662.00	   stroke	   Posterior	  cerebral	  artery	  syndrome	  
8443	   G663.00	   stroke	   Brain	  stem	  stroke	  syndrome	  
17322	   G664.00	   stroke	   Cerebellar	  stroke	  syndrome	  
33499	   G665.00	   stroke	   Pure	  motor	  lacunar	  syndrome	  
51767	   G666.00	   stroke	   Pure	  sensory	  lacunar	  syndrome	  
7780	   G667.00	   stroke	   Left	  sided	  CVA	  
12833	   G668.00	   stroke	   Right	  sided	  CVA	  
16956	   G669.00	   stroke	   Cerebral	  palsy,	  not	  congenital	  or	  infantile,	  acute	  
13577	   G67..00	   stroke	   Other	  cerebrovascular	  disease	  
11171	   G670.00	   stroke	   Cerebral	  atherosclerosis	  
5184	   G670.11	   stroke	   Precerebral	  atherosclerosis	  
40053	   G671.00	   stroke	   Generalised	  ischaemic	  cerebrovascular	  disease	  NOS	  
70536	   G671000	   stroke	   Acute	  cerebrovascular	  insufficiency	  NOS	  
24385	   G671100	   stroke	   Chronic	  cerebral	  ischaemia	  
12555	   G671z00	   stroke	   Generalised	  ischaemic	  cerebrovascular	  disease	  NOS	  
3979	   G672.00	   stroke	   Hypertensive	  encephalopathy	  
31816	   G672.11	   stroke	   Hypertensive	  crisis	  
4635	   G673.00	   stroke	   Cerebral	  aneurysm,	  nonruptured	  
22018	   G673000	   stroke	   Dissection	  of	  cerebral	  arteries,	  nonruptured	  
35059	   G673100	   stroke	   Carotico-­‐cavernous	  sinus	  fistula	  
12634	   G673200	   stroke	   Carotid	  artery	  dissection	  
97122	   G673300	   stroke	   Vertebral	  artery	  dissection	  
22400	   G674.00	   stroke	   Cerebral	  arteritis	  
10189	   G674000	   stroke	   Cerebral	  amyloid	  angiopathy	  
32310	   G675.00	   stroke	   Moyamoya	  disease	  
37947	   G676.00	   stroke	   Nonpyogenic	  venous	  sinus	  thrombosis	  
39344	   G676000	   stroke	   Cereb	  infarct	  due	  cerebral	  venous	  thrombosis,	  nonpyogenic	  
31704	   G677.00	   stroke	   Occlusion/stenosis	  cerebral	  arts	  not	  result	  cerebral	  infarct	  
51759	   G677000	   stroke	   Occlusion	  and	  stenosis	  of	  middle	  cerebral	  artery	  
57527	   G677100	   stroke	   Occlusion	  and	  stenosis	  of	  anterior	  cerebral	  artery	  
65770	   G677200	   stroke	   Occlusion	  and	  stenosis	  of	  posterior	  cerebral	  artery	  
55602	   G677300	   stroke	   Occlusion	  and	  stenosis	  of	  cerebellar	  arteries	  
71274	   G677400	   stroke	   Occlusion+stenosis	  of	  multiple	  and	  bilat	  cerebral	  arteries	  
9943	   G678.00	   stroke	   Cereb	  autosom	  dominant	  arteriop	  subcort	  infarcts	  leukoenceph	  
98188	   G679.00	   stroke	   Small	  vessel	  cerebrovascular	  disease	  
101733	   G67A.00	   stroke	   Cerebral	  vein	  thrombosis	  
34117	   G67y.00	   stroke	   Other	  cerebrovascular	  disease	  OS	  
37493	   G67z.00	   stroke	   Other	  cerebrovascular	  disease	  NOS	  
23361	   G68..00	   stroke	   Late	  effects	  of	  cerebrovascular	  disease	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44740	   G680.00	   stroke	   Sequelae	  of	  subarachnoid	  haemorrhage	  
48149	   G681.00	   stroke	   Sequelae	  of	  intracerebral	  haemorrhage	  
43451	   G682.00	   stroke	   Sequelae	  of	  other	  nontraumatic	  intracranial	  haemorrhage	  
39403	   G683.00	   stroke	   Sequelae	  of	  cerebral	  infarction	  
51138	   G68W.00	   stroke	   Sequelae/other	  +	  unspecified	  cerebrovascular	  diseases	  
6228	   G68X.00	   stroke	   Sequelae	  of	  stroke,not	  specfd	  as	  h'morrhage	  or	  infarction	  
40758	   G6W..00	   stroke	   Cereb	  infarct	  due	  unsp	  occlus/stenos	  precerebr	  arteries	  
33543	   G6X..00	   stroke	   Cerebrl	  infarctn	  due/unspcf	  occlusn	  or	  sten/cerebrl	  artrs	  
51311	   G6y..00	   stroke	   Other	  specified	  cerebrovascular	  disease	  
10062	   G6z..00	   stroke	   Cerebrovascular	  disease	  NOS	  
73901	   Gyu6.00	   stroke	   [X]Cerebrovascular	  diseases	  
65745	   Gyu6100	   stroke	   [X]Other	  subarachnoid	  haemorrhage	  
53810	   Gyu6200	   stroke	   [X]Other	  intracerebral	  haemorrhage	  
91627	   Gyu6300	   stroke	   [X]Cerebrl	  infarctn	  due/unspcf	  occlusn	  or	  sten/cerebrl	  artrs	  
53745	   Gyu6400	   stroke	   [X]Other	  cerebral	  infarction	  
90572	   Gyu6500	   stroke	   [X]Occlusion	  and	  stenosis	  of	  other	  precerebral	  arteries	  
92036	   Gyu6600	   stroke	   [X]Occlusion	  and	  stenosis	  of	  other	  cerebral	  arteries	  
96630	   Gyu6F00	   stroke	   [X]Intracerebral	  haemorrhage	  in	  hemisphere,	  unspecified	  
94482	   Gyu6G00	   stroke	   [X]Cereb	  infarct	  due	  unsp	  occlus/stenos	  precerebr	  arteries	  
42248	   ZLEP.00	   stroke	   Discharge	  from	  stroke	  serv	  
19348	   ZV12511	   stroke	   [V]Personal	  history	  of	  stroke	  
7138	   ZV12512	   stroke	   [V]Personal	  history	  of	  cerebrovascular	  accident	  (CVA)	  
code	   type	   endpoint	   description	  
G45	   ICD-­‐10	   TIA	  
Transient	  cerebral	  ischaemic	  attacks	  and	  related	  syndromes	  (excl:	  
neonatal	  cerebral	  ischaemia	  (P91.0))	  
G45.0	   ICD-­‐10	   TIA	   Vertebro-­‐basilar	  artery	  syndrome	  
G45.1	   ICD-­‐10	   TIA	   Carotid	  artery	  syndrome	  (hemispheric)	  
G45.2	   ICD-­‐10	   TIA	   Multiple	  and	  bilateral	  precerebral	  artery	  syndromes	  
G45.3	   ICD-­‐10	   TIA	   Amaurosis	  fugax	  
G45.4	   ICD-­‐10	   TIA	   Transient	  global	  amnesia	  excl.	  amnesia	  NOS	  (R41.3)	  
G45.8	   ICD-­‐10	   TIA	   Other	  transient	  cerebral	  ischaemic	  attacks	  and	  related	  syndromes	  
G45.9	   ICD-­‐10	   TIA	  
Transient	  cerebral	  ischaemic	  attack,	  unspecified	  (Spasm	  of	  cerebral	  artery,	  
Transient	  cerebral	  ischaemia	  NOS)	  
medcode	   readcode	   desc	  
21844	   G31y300	   Transient	  myocardial	  ischaemia	  
55878	   Q494.00	   Transient	  myocardial	  ischaemia	  of	  newborn	  
102326	   1JK..00	   Suspected	  transient	  ischaemic	  attack	  
1433	   G65..12	   Transient	  ischaemic	  attack	  
504	   G65..00	   Transient	  cerebral	  ischaemia	  
89913	   9Om4.00	   Stroke/transient	  ischaemic	  attack	  monitoring	  telephone	  invte	  
28753	   9Om0.00	   Stroke/transient	  ischaemic	  attack	  monitoring	  first	  letter	  
34375	   9Om2.00	   Stroke/transient	  ischaemic	  attack	  monitoring	  third	  letter	  
15788	   G65zz00	   Transient	  cerebral	  ischaemia	  NOS	  
19354	   G65y.00	   Other	  transient	  cerebral	  ischaemia	  
13707	   8HBJ.00	   Stroke	  /	  transient	  ischaemic	  attack	  referral	  
101251	   ZV12D00	   [V]Personal	  history	  of	  transient	  ischaemic	  attack	  
100015	   8CRB.00	   Transient	  ischaemic	  attack	  clinical	  management	  plan	  
31218	   9Om..00	   Stroke/transient	  ischaemic	  attack	  monitoring	  administration	  
34245	   9Om1.00	   Stroke/transient	  ischaemic	  attack	  monitoring	  second	  letter	  
51465	   9Om3.00	   Stroke/transient	  ischaemic	  attack	  monitoring	  verbal	  invitati	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1895	   G65z.00	   Transient	  cerebral	  ischaemia	  NOS	  
42720	   F580200	   Transient	  ischaemic	  deafness	  
2417	   G65..13	   Vertebro-­‐basilar	  insufficiency	  
10794	   G656.00	   Vertebrobasilar	  insufficiency	  
21118	   G651000	   Vertebro-­‐basilar	  artery	  syndrome	  
44765	   G653.00	   Carotid	  artery	  syndrome	  hemispheric	  
51326	   G63y.00	   Other	  precerebral	  artery	  occlusion	  
71585	   G63z.00	   Precerebral	  artery	  occlusion	  NOS	  
50594	   G654.00	   Multiple	  and	  bilateral	  precerebral	  artery	  syndromes	  
1195	   F423600	   Amaurosis	  fugax	  
28278	   1B1S.00	   Transient	  global	  amnesia	  
19004	   Z7CE711	   TGA	  -­‐	  Transient	  global	  amnesia	  
18996	   Z7CE700	   Transient	  global	  amnesia	  
6489	   G655.00	   Transient	  global	  amnesia	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Appendix G
Run statistics: CPRD experiments
The full range of run statistics for the 25 GP runs in the CPRD experiments in chapter 7
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Figure G.1: The full range of runs statisitcs for the 25 SSOGP runs in the CPRD
experiments in chapter 7.
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Appendix H
Final Models: CPRD experiments
The final 25 models developed by SSOGP the CPRD experiments in chapter 7, presen-
ted as a binary trees
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Appendix I
Predictor Effects: CPRD experiments
Plots of the effects of predictor values on log hazard in the ’final’ GP model in the
CPRD experiments in chapter 7
Figure I.1: Plots of the effects of predictor values on log hazard in the ’final’ GP
model in the CPRD experiments in chapter 7.
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Appendix J
Results: CPRD experiments
(secondary analysis)
Results of the additional experiments that repeat the CPRD experiments in chapter 7,
but only on the subset of covariates that were selected with a relatively high fre-
quency(> 0.5) in the main experiment.
Figure J.1: Average survival curves for the Cox regression and genetic program-
ming models. The error bars represent ±2 standard errors of the KM estimates.
330 8.5 Conclusions
Figure J.2: C-statistic estimates by model for t=1, 3 and 5 years
Table J.1: C-statistic estimates by model at t=2, 5, and 8 years
Time (years) Genetic Programming (superset) Genetic Programming (subset)
2 0.656 0.682
5 0.621 0.645
8 0.631 0.656
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Figure J.3: Calibration plots for the Cox regression and genetic programming
models, at t=1, 3, and 5 years..
Table J.2: χ2 statistic for the comparison between observed versus expected (ac-
cording to the model) number of events in groups of patients defined according to
the predicted 1− S(t) at t=2, 5, and 8 years.
Time (years) Genetic Programming (superset) Genetic Programming (subset)
t χ2 p-value χ2 p-value
2 1589 < 0.001 1590 < 0.001
5 4146 < 0.001 4256 < 0.001
8 6937 < 0.001 7129 < 0.001
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